

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

FIELD OF THE INVENTION

[0001] The invention relates to the field of medical treatment and diagnosis of disease. More particularly, this invention relates to novel sulfonylurea and related compounds and their use in treating, or identifying a disease or condition responsive to modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

BACKGROUND TO THE INVENTION

[0002] Any reference to background art herein is not to be construed as an admission that such art constitutes common general knowledge in Australia or elsewhere.

[0003] The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-associated periodic syndromes (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.

[0004] NLRP3 is an intracellular signalling molecule that senses many pathogen-derived, environmental and host-derived factors. Upon activation, NLRP3 binds to apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). ASC then polymerises to form a large aggregate known as an ASC speck. Polymerised ASC in turn interacts with the cysteine protease caspase-1 to form a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the proinflammatory cytokines IL-1 β and IL-18 to their active forms and mediates a type of inflammatory cell death known as pyroptosis. The ASC speck can also recruit

and activate caspase-8, which can process pro-IL-1 β and pro-IL-18 and trigger apoptotic cell death.

[0005] Caspase-1 cleaves pro-IL-1 β and pro-IL-18 to their active forms, which are secreted from the cell. Active caspase-1 also cleaves gasdermin-D to trigger pyroptosis. Through its control of the pyroptotic cell death pathway, caspase-1 also mediates the release of alarmin molecules such as IL-33 and high mobility group box 1 protein (HMGB1). Caspase-1 also cleaves intracellular IL-1R2 resulting in its degradation and allowing the release of IL-1 α . In human cells caspase-1 may also control the processing and secretion of IL-37. A number of other caspase-1 substrates such as components of the cytoskeleton and glycolysis pathway may contribute to caspase-1-dependent inflammation.

[0006] NLRP3-dependent ASC specks are released into the extracellular environment where they can activate caspase-1, induce processing of caspase-1 substrates and propagate inflammation.

[0007] Active cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape the immune response to infection and injury. For example, IL-1 β signalling induces the secretion of the pro-inflammatory cytokines IL-6 and TNF. IL-1 β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by $\gamma\delta$ T cells in the absence of T cell receptor engagement. IL-18 and IL-12 also synergise to induce IFN- γ production from memory T cells and NK cell driving a Th1 response.

[0008] Other intracellular pattern recognition receptors (PRRs) are also capable of forming inflammasomes. These include other NLR family members such as NLRP1 and NLRC4, as well as non-NLR PRRs such as the double-stranded DNA (dsDNA) sensors absent in melanoma 2 (AIM2) and interferon, gamma inducible protein 16 (IFI16). NLRP3-dependent IL-1 β processing can

also be activated by an indirect, non-canonical pathway downstream of caspase-11.

[0009] The inherited CAPS diseases Muckle–Wells syndrome (MWS), familial cold autoinflammatory syndrome and neonatal-onset multisystem inflammatory disease are caused by gain-of-function mutations in NLRP3, thus defining NLRP3 as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of a number of complex diseases, notably including metabolic disorders such as type 2 diabetes, atherosclerosis, obesity and gout.

[0010] A role for NLRP3 in diseases of the central nervous system is emerging, and lung diseases have also been shown to be influenced by NLRP3. Furthermore, NLRP3 has a role in the development of liver disease, kidney disease and aging. Many of these associations were defined using *Nlrp3*^{-/-} mice, but there have also been insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes, the deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1 β signaling, resulting in cell death and inflammation.

[0011] Several small molecules have been shown to inhibit the NLRP3 inflammasome. Glyburide inhibits IL-1 β production at micromolar concentrations in response to the activation of NLRP3 but not NLRC4 or NLRP1. Other previously characterised NLRP3 inhibitors include parthenolide, 3,4-methylenedioxy- β -nitrostyrene and dimethyl sulfoxide (DMSO), although these agents have limited potency and are nonspecific

[0012] Current treatments for NLRP3-related diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist anakinra, the neutralizing IL-1 β antibody canakinumab and the soluble decoy IL-1 receptor rilonacept. These approaches have proven successful in the

treatment of CAPS, and these biologic agents have been used in clinical trials for other IL-1 β -associated diseases.


[0013] Several small molecules have been shown to inhibit the NLRP3 inflammasome. Glyburide inhibits IL-1 β production at micromolar concentrations in response to the activation of NLRP3 but not NLRC4 or NLRP1. Other previously characterised NLRP3 inhibitors include parthenolide, 3,4-methylenedioxy- β -nitrostyrene and dimethyl sulfoxide (DMSO), although these agents have limited potency and are nonspecific.

[0014] Certain diarylsulfonylurea-containing compounds have been identified as cytokine release inhibitory drugs (CRIDs) (Perregaux et al.; J. Pharmacol. Exp. Ther. 299, 187-197, 2001). CRIDs are a class of diarylsulfonylurea containing compounds that inhibit the post-translational processing of IL-1 β . Post-translational processing of IL-1 β is accompanied by activation of caspase-1 and cell death. CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.

[0015] There is a need to provide compounds with improved pharmacological and/or physiological and or physicochemical properties and/or those that provide a useful alternative to known compounds.

SUMMARY OF INVENTION

[0016] According to a first aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (I)

wherein, W is selected from O, S and Se;

J is selected from S and Se;

R₁ is selected from the group consisting of cycloalkyl, aryl, heteroaryl and heterocyclyl, all of which may be optionally substituted;

R₂ is selected from the group consisting of cycloalkyl, aryl, heteroaryl and heterocyclyl, all of which may be optionally substituted; and

both R₁ is directly bonded to J and R₂ is directly bonded to the adjacent nitrogen, via a carbon atom.

[0017] According to a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

[0018] A third aspect of the invention resides in a method of treatment or prevention of a disease, disorder or condition including the step of administering an effective amount of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect to thereby treat or prevent the disease disorder or condition.

[0019] A fourth aspect of the invention provides for a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect for use in the treatment or prevention of a disease, disorder or condition.

[0020] A fifth aspect of the invention provides for use of a compound of the first aspect, or a pharmaceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition.

[0021] In one embodiment, the disease, disorder or condition is responsive to inhibition of activation of the NLRP3 inflammasome.

[0022] In particular non-limiting embodiments of the above aspects, the disease, disorder or condition is a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the respiratory system, the central nervous system, is a cancer or other malignancy and/or is caused by or associated with a pathogen.

[0023] In a sixth aspect of the invention there is provided a method of diagnosing a disease, disorder or condition in a mammal including the step of administering a labelled compound of formula (I), (Ia), (Ib), (Ic) or (II), or a pharmaceutically effective salt, solvate or prodrug thereof, to the mammal or to a biological sample obtained from the mammal to facilitate diagnosis of the disease disorder or condition in the mammal.

[0024] A seventh aspect of the invention resides in a method of modulating the activity of a biological target comprising the step of exposing the biological target to a compound of the first aspect, or a pharmaceutically acceptable salt thereof.

[0025] The biological target may be selected from the group consisting of the NLRP3 inflammasome, IL-1 β , IL-17, IL-18, IL-1 α , IL-37, IL-33 and Th17 cells.

[0026] The various features and embodiments of the present invention, referred to in individual sections above apply, as appropriate, to other sections, *mutatis mutandis*. Consequently features specified in one section may be combined with features specified in other sections as appropriate.

[0027] Further features and advantages of the present invention will become apparent from the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order that the invention may be readily understood and put into practical effect, preferred embodiments will now be described by way of example with reference to the accompanying figures wherein:

[0029] FIG 1A to 1C is a series of graphical representations of the plasma concentrations of a known sulfonylurea (MCC950) following different dosing levels in mice; and

[0030] FIG 2A to 2C is a series of graphical representations of the plasma concentrations of a sulfonylurea of the present invention (MCC7840) following different dosing levels in mice.

DETAILED DESCRIPTION

[0031] The present invention is predicated, at least in part, on the finding that certain sulfonyl ureas and related compounds have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome and/or inhibition of IL-1 β and/or IL-17 and/or IL-18, and/or IL-1 α , and/or IL-37, and/or IL-33 as well as interfere with or modulate the activity of T helper cells such as Th17. Particularly, the compounds of the invention are useful in the treatment of a wide range of disorders in which the inflammation process, or the NLRP3 inflammasome and/or IL-1 β and/or IL-17 and/or IL-18, and/or IL-1 α , and/or IL-37, and/or IL-33 and/or Th17 cells play a part.

[0032] Evidence from human CAPS patients and mouse models of CAPS has lead the present inventors to believe that NLRP3 inhibition will be a superior treatment over IL-1 biologics, as inhibition of all NLRP3-dependent processes will be more effective than inhibition of a single NLRP3-dependent process, such as IL-1 signalling.

[0033] Individuals with CAPS display dysregulated secretion of both IL-1 β and IL-18, and CAPS patients treated with anti-IL-1 biologics have residual

disease. Symptoms such as bony overgrowth and joint deformity are not prevented by IL-1 biologics. In addition, symptoms involving the central nervous system such as hearing loss are difficult to control using IL-1 biologics, which appear to poorly penetrate the central nervous system. Studies in mouse models of CAPS indicate that deficiency in either IL-1 signalling or IL-18 alone is insufficient to block systemic inflammation, particularly in older animals. In a severe model of CAPS, only a complete loss of caspase-1 signalling fully rescued the disease.

[0034] Specific inhibition of NLRP3 by sulfonyurea-containing compounds, such as those of the first aspect, may block all processes downstream of NLRP3, including ASC speck formation and caspase-8 and caspase-1 activation. Consequently, NLRP3 inhibition will block all caspase-1 dependent processes such as IL-1 β , IL-18 and IL-37 processing and secretion, gasdermin D cleavage, pyroptosis, and release of IL-1 α , IL-33 and HMGB. Furthermore, NLRP3-dependent extracellular release of the ASC speck will be blocked, and caspase-8-dependent pro-IL-1 β and pro-IL-18 cleavage and apoptotic cell death will be prevented. Thus, specific inhibition of NLRP3 by compounds of the first aspect will prevent multiple downstream inflammatory signals and should therefore prove more effective anti-inflammatory therapy than IL-1 blockade alone.

[0035] Anti-IL-1 biologics block IL-1 derived from NLRP3-independent sources, such IL-1 produced by other inflammasomes (e.g. NLRC4, NLRP1, NLRP6, AIM2) and IL-1 generated by the latter pathways may be important for host defence against pathogens. For example, patients receiving IL-1/IL-1R antagonists exhibit increased incidence of upper airway infections. Specific inhibition of NLRP3 by the present compounds may thus exert less generalised immunosuppression compared to anti-IL-1 biologics.

[0036] IL-1 β and IL-18, generated by the Nlrp3/caspase-1 axis, play critical roles in driving IL-17 production by CD4 Th17 cells and $\gamma\delta$ T cells. IL-1 β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by $\gamma\delta$ T cells in the absence of TCR engagement. IL-1-driven IL-17 has also been implicated in psoriasis, type I diabetes, rheumatoid arthritis, type 2 diabetes mellitus, atherosclerosis, obesity, gout, and recently, asthma.

[0037] In essence, each of these diseases has been shown to involve the activation of tissue macrophages, dendritic cells, or brain microglia, driven by either soluble alarmins, or the frustrated phagocytosis of metabolites that accumulate extracellularly. NLRP3 senses these events, leading to IL-1 release, triggering inflammation to clear the offensive material. Disease will result if this process becomes chronic or over-activated, which explains why so many diseases have been shown to involve NLRP3. Inhibitors that act to prevent NLRP3 activation hence can have utility in IL-17 driven, as well as IL-1 driven diseases.

[0038] In this patent specification, the terms 'comprises', 'comprising', 'includes', 'including', or similar terms are intended to mean a non-exclusive inclusion, such that a method or composition that comprises a list of elements does not include those elements solely, but may well include other elements not listed.

[0039] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as would be commonly understood by those of ordinary skill in the art to which this invention belongs.

[0040] The term "pharmaceutically acceptable salt", as used herein, refers to salts which are toxicologically safe for systemic or localised administration such as salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. The pharmaceutically acceptable salts may be selected from the group including

alkali and alkali earth, ammonium, aluminium, iron, amine, glucosamine, chloride, sulphate, sulphonate, bisulphate, nitrate, citrate, tartrate, bitartrate, phosphate, carbonate, bicarbonate, malate, maleate, napsylate, fumarate, succinate, acetate, benzoate, terephthalate, palmoate, piperazine, pectinate and S-methyl methionine salts and the like.

[0041] The term "*alkyl*" refers to a straight-chain or branched alkyl substituent containing from, for example, 1 to about 12 carbon atoms, preferably 1 to about 9 carbon atoms, more preferably 1 to about 6 carbon atoms, even more preferably from 1 to about 4 carbon atoms, still yet more preferably from 1 to 2 carbon atoms. Examples of such substituents may be selected from the group consisting of methyl, ethyl, propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, pentyl, isoamyl, 2-methylbutyl, 3-methylbutyl, hexyl, heptyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-ethylbutyl, 3-ethylbutyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The number of carbons referred to relates to the carbon backbone and carbon branching but does not include carbon atoms belonging to any substituents, for example the carbon atoms of an alkoxy substituent branching off the main carbon chain. Substituted alkyl includes alkyl substituted with one or more moieties selected from the group consisting of halo (*e.g.*, Cl, F, Br, and I); halogenated alkyl (*e.g.*, CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of 'optionally substituted'.

[0042] The term "*alkenyl*" refers to optionally substituted unsaturated linear or branched hydrocarbon groups, having 2 to 12 carbon atoms, preferably 2 to 9 carbon atoms, more preferably 2 to 6 carbon atoms and having at least one carbon-carbon double bond. Where appropriate, the alkenyl group may have a

specified number of carbon atoms, for example, C₂-C₆ alkenyl which includes alkenyl groups having 2, 3, 4, 5 or 6 carbon atoms in linear or branched arrangements. The number of carbons referred to relates to the carbon backbone and carbon branching but does not include carbon atoms belonging to any substituents. Examples of such substituents may be selected from the group consisting of ethenyl, propenyl, isopropenyl, butenyl, s- and t-butenyl, pentenyl, hexenyl, hept-1,3-diene, hex-1,3-diene, non-1,3,5-triene and the like. Substituted alkenyl includes alkenyl substituted with one or more moieties selected from the group consisting of halo (*e.g.*, Cl, F, Br, and I); halogenated alkyl (*e.g.*, CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of 'optionally substituted'.

[0043] The term "alkoxy" as used herein means straight or branched chain alkyl groups linked by an oxygen atom (*i.e.*, -O-alkyl), wherein alkyl is as described above. In particular embodiments, alkoxy refers to oxygen-linked groups comprising 1 to 10 carbon atoms ("C1-10 alkoxy"). In further embodiments, alkoxy refers to oxygen-linked groups comprising 1 to 8 carbon atoms ("C1-8 alkoxy"), 1 to 6 carbon atoms ("C1-6 alkoxy"), 1 to 4 carbon atoms ("C1-4 alkoxy") or 1 to 3 carbon atoms ("C1-3 alkoxy").

[0044] The terms "cycloalkyl" and "cycloalkenyl" refers to optionally substituted saturated and unsaturated mono-cyclic, bicyclic or tricyclic carbon groups. Where appropriate, the cycloalkyl or cycloalkenyl group may have a specified number of carbon atoms, for example, C₃-C₆ cycloalkyl or cycloalkenyl includes within its scope a carbocyclic group having 3, 4, 5 or 6 carbon atoms. Examples of such substituents may be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,

cyclohexadienyl and the like. Substituted cycloalkyl or cycloalkenyl includes substitutions with one or more moieties selected from the group consisting of halo (*e.g.*, Cl, F, Br, and I); halogenated alkyl (*e.g.*, CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate as well as those described under the definition of 'optionally substituted'.

[0045] The term "alkylthio" as used herein means a thio group with one or more alkyl substituents, where alkyl is defined as above.

[0046] The term "amino" as used herein means a moiety represented by the structure NR₂₃, and includes primary amines, and secondary and tertiary amines substituted by alkyl (*i.e.*, alkylamino). Thus, R₂₃ may represent, for example, two hydrogen atoms, two alkyl moieties, or one hydrogen atom and one alkyl moiety.

[0047] The term "aryl" refers to a stable monocyclic, bicyclic, or tricyclic carbon ring of up to 8 members in each ring, wherein at least one ring is aromatic as defined by the Hückel 4n+2 rule. The term includes polycyclic systems comprising saturated carbon rings or heteroaryl or heterocyclic groups so long as at least one ring is aryl, as described.

[0048] The terms "aralkyl" and "arylalkyl" as used herein mean an aryl group as defined above linked to the molecule through an alkyl group as defined above.

[0049] The term "heteroaryl" refers to an aryl group containing from one or more (particularly one to four) non-carbon atom(s) (particularly N, O or S) or a combination thereof, which heteroaryl group is optionally substituted at one or more carbon or nitrogen atom(s). Heteroaryl rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings. Heteroaryl

includes, but is not limited to, 5-membered heteroaryls having one hetero atom (e.g., thiophenes, pyrroles, furans); 5 membered heteroaryls having two heteroatoms in 1,2 or 1,3 positions (e.g., oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-membered heteroaryls having three heteroatoms (e.g., triazoles, thiadiazoles); 5-membered heteroaryls having four heteroatoms (e.g., tetrazoles); 6-membered heteroaryls with one heteroatom (e.g., pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine); 6-membered heteroaryls with two heteroatoms (e.g., pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines); 6-membered heretoaryls with three heteroatoms (e.g., 1,3,5- triazine); and 6-membered heteroaryls with four heteroatoms. "Substituted heteroaryl" means a heteroaryl having one or more non-interfering groups as substituents and including those defined under 'optionally substituted'.

[0050] "Heterocyclyl" as used herein refers to a non-aromatic ring having 5 to 8 atoms in the ring and of those atoms 1 to 4 are heteroatoms. Heterocyclic rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings. Heterocyclic includes partially and fully saturated heterocyclic groups. Heterocyclic systems may be attached to another moiety via any number of carbon atoms or heteroatoms of the radical and may be both saturated and unsaturated. Non-limiting examples of heterocyclic include C₄-C₆ selenocycles, pyrrolidinyl, pyrrolinyl, pyranyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolinyl, dithiolyl, oxathiolyl, dioxanyl, dioxinyl, oxazinyl, azepinyl, diazepinyl, thiazepinyl, oxepinyl and thiapinyl, imidazoliny, thiomorpholinyl, and the like.


[0051] "Optionally substituted" in reference to a substituent group refers to substituent groups optionally substituted with one or more moieties, for example, those selected from the group consisting of optionally substituted C1-10 alkyl (e.g., optionally substituted C1-6 alkyl); optionally substituted C3-6

cycloalkyl (e.g., optionally substituted cyclopropyl); optionally substituted hydroxyalkyl; optionally substituted C1-10 alkoxy (e.g., optionally substituted C1-6 alkoxy); optionally substituted C2-10 alkenyl; optionally substituted C2-10 alkynyl; optionally substituted C6-C12 aryl; aryloxy; optionally substituted heteroaryl; optionally substituted heterocyclyl; halo (e.g., Cl, F, Br, and I); hydroxyl; halogenated alkyl (e.g., CF_3 , 2-Br-ethyl, CH_2F , CH_2CF_3 , and CF_2CF_3); amino (e.g., NH_2 , NR_{12}H , and $\text{NR}_{12}\text{R}_{13}$); alkylamino; arylamino; acyl; amido; CN; NO_2 ; N_3 ; CH_2OH ; CONH_2 ; $\text{CONR}_{24}\text{R}_{25}$; CO_2R_{24} ; $\text{CH}_2\text{OR}_{24}$; NHCOR_{24} ; $\text{NHCO}_2\text{R}_{24}$; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters such as alkyl or aralkyl sulfonyl, including methanesulfonyl; phosphonic acid; phosphate; phosphonate; mono-, di-, or triphosphate esters; trityl or monomethoxytrityl; R_{24}SO ; R_{24}SO_2 ; CF_3S ; and CF_3SO_2 ; trialkylsilyl such as dimethyl-t-butylsilyl or diphenylmethylsilyl; and R_{24} and R_{25} are each independently selected from H or optionally substituted C1-10 alkyl, C1-6 alkyl or C1-4 alkyl.

[0052] Whenever a range of the number of atoms in a structure is indicated (e.g., a C₁-C₁₂, C₁-C₁₀, C₁-C₉, C₁-C₆, C₁-C₄, or C₂-C₂₀, C₂-C₁₂, C₂-C₁₀, C₂-C₉, C₂-C₈, C₂-C₆, C₂-C₄ alkyl, alkenyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1-12 carbon atoms (e.g., C₁-C₁₂), 1-9 carbon atoms (e.g., C₁-C₉), 1-6 carbon atoms (e.g., C₁-C₆), 1-4 carbon atoms (e.g., C₁-C₄), 1-3 carbon atoms (e.g., C₁-C₃), or 2-8 carbon atoms (e.g., C₂-C₈) as used with respect to any chemical group (e.g., alkyl, etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and/or 12 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 1-9 carbon atoms, 1-10 carbon atoms, 1-11 carbon atoms, 1-12 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8 carbon atoms, 2-9 carbon atoms, 2-10 carbon

atoms, 2-11 carbon atoms, 2-12 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 3-7 carbon atoms, 3-8 carbon atoms, 3-9 carbon atoms, 3-10 carbon atoms, 3-11 carbon atoms, 3-12 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7 carbon atoms, 4-8 carbon atoms, 4-9 carbon atoms, 4-10 carbon atoms, 4-11 carbon atoms, and/or 4-12 carbon atoms, etc., as appropriate).

[0053] According to a first aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (I)

wherein, W is selected from O, S and Se;

J is selected from S and Se;

R₁ is selected from the group consisting of cycloalkyl, aryl, heteroaryl and heterocyclyl, all of which may be optionally substituted;

R₂ is selected from the group consisting of cycloalkyl, aryl, heteroaryl and heterocyclyl, all of which may be optionally substituted; and

both R₁ is directly bonded to J and R₂ is directly bonded to the adjacent nitrogen, via a carbon atom.

[0054] In one preferred embodiment, W is O.

[0055] In one preferred embodiment, J is S.

[0056] In a particularly preferred embodiment, W is O and J is S.

[0057] In one embodiment, R₁ is selected from the group consisting of C₅ or C₆ cycloalkyl, 5-membered or 6-membered heteroaryl, bicyclic heteroaryl wherein at least one ring is heteroaryl, phenyl, biphenyl, phenylheterocyclyl, 5-membered or 6-membered heterocyclyl, and heterocyclylcycloalkyl, all of which may be optionally substituted.

[0058] In certain embodiments, W is O, J is S and R₁ is selected from the group consisting of pyrazole, furan, tetrahydrofuran, tetrahydropyran, pyran, pyrrolidine, pyrrole, triazole, tetrazole, imidazole, pyridine, morpholine, piperazine, piperidine, substituted phenyl, phenylheteroaryl, phenylheterocyclyl, biphenyl, quinoline, isoquinoline, naphthyl, pyrazine and pyrimidine, all of which may be optionally substituted as appropriate.


[0059] In one embodiment, when W is O, J is S and R₁ is 2-furan or 2-thiophene it is selected from unsubstituted 2-furan or 2,5-substituted furan and unsubstituted 2-thiophene or 2,5-substituted thiophene.

[0060] In one embodiment, when W is O, J is S, and R₁ is 2,5-substituted furan or 2,5-substituted thiophene then the 2,5-substituted furan or 2,5-substituted thiophene is not substituted with a tertiary alcohol group.

[0061] In certain embodiments it has been found that when R₁ is an unsubstituted furan then it has the ability to cross the blood brain barrier at levels about 10 times greater than CRID3, a prior art sulfonylurea.

[0062] In the above embodiments, reference to 2,5-substituted does not preclude the presence of further substitutions on the ring but merely indicates that the numbered substitutions must be present. For example, 2,4,5-substitutions are considered within the scope of such terms.

[0063] Reference to 2-furan and 2-thiophene means that the ring is connected to the sulfonyl sulphur at the 2-ring position, as shown below:



[0064] In one embodiment, R_1 is 5-membered heterocyclyl or heteroaryl, each of which may be optionally substituted, comprising at least one, preferably at least two ring heteroatoms selected from N, O and S.

[0065] In certain embodiments, R_1 is a nitrogen heterocyclyl or nitrogen heteroaryl, each of which may be optionally substituted.

[0066] In one embodiment, R_1 is 5-membered nitrogen heterocyclyl or 5-membered nitrogen heteroaryl, each of which may be optionally substituted.

[0067] In an embodiment, R_1 is 5-membered heterocyclyl or 5-membered heteroaryl, each comprising at least two ring nitrogen atoms and each of which rings may be optionally substituted.

[0068] In one embodiment, W is O, J is S and R_1 is selected from the group consisting of quinoline, isoquinoline, naphthyl, pyrazine, tetrazole, imidazole, pyrrolidine, pyrrole, tetrahydropyran, pyran, piperidine, piperazine, pyrazole, pyridine, pyrimidine and triazole, each of which may be optionally substituted.


[0069] In one embodiment R_1 and/or R_2 may comprise a selenocycle.


[0070] In one embodiment, R_2 may be selected from bicyclic and tricyclic hydrocarbons, 5-, 6- and 7-membered heterocycle or heteroaryl, each of which rings may be optionally substituted, and substituted phenyl.

[0071] Suitably, the tricyclic hydrocarbon may be an indacene.


[0072] In one embodiment, R_2 may be selected from 5-, 6- or 7- membered nitrogen heterocycles, 6-membered nitrogen heteroaryl and aryl with fused cycloalkyl ring.


[0073] In one embodiment of the compound of formula (I), W is O, J is S and R₁ may be selected from the group consisting of:







and for each of these R_1 groups, R_2 may be independently selected from the group consisting of:







[0074] In any embodiment of the first aspect, when J is S and W is O, and in combination with any of the R_1 groups listed above, R_2 may be selected from:



wherein, each incidence of Y is independently selected from C, N, S and O, and which may be optionally substituted, as appropriate;

R_5 , R_{11} , R_{12} , R_{13} , R_{14} and R_{15} are independently selected from the group consisting of hydrogen, halo, cyano, amide, sulphonamide, acyl, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_5 cyloalkyl, and C_1 - C_6 alkoxy, all of which groups may be optionally substituted, as appropriate, with halo, cyano or C_1 - C_6 alkoxy; and

wherein R_{11} and R_{12} may combine to form phenyl, a 5- or 6-membered oxygen heterocycle or a 5- or 6-membered nitrogen heteroaryl, each of which may be optionally substituted;

R_{12} and R_{13} may combine to form a 5- or 6-membered nitrogen heteroaryl, which may be optionally substituted; and

R_{14} and R_{15} may combine to form a 5- or 6-membered cycloalkyl ring, phenyl, a 5- or 6-membered oxygen heterocycle or a 5- or 6-membered nitrogen heteroaryl, each of which may be optionally substituted.


[0075] Suitably, each incidence of Y is a carbon and R₅ is hydrogen or halo.

[0076] In one embodiment, R₁₂ and R₁₄ are hydrogen, R₁₁ and R₁₅ are C₁-C₆ alkyl and R₁₃ is hydrogen or halo.

[0077] Preferably, R₂ is selected from a substituted or hydrogenated indacene, a 2,6-dialkylphenyl, a 2,6-dialkyl-4-halophenyl, 2,6-dicycloalkylphenyl, and a 2,6-dicycloalkyl-4-halophenyl.


[0078] In certain preferred embodiments, and in combination with any R₁ group described for any of the formulae of the first aspect, R₂ is selected from hexahydroindacene, 2,6-diisopropylphenyl 2,6-diisopropyl-4-chlorophenyl, 2,6-dicyclopropylphenyl and 2,6-dicyclopropyl-4-chlorophenyl.

[0079] In one embodiment, W is O and J is S, R₁ is heteroaryl and R₂ is



wherein each Y is CH and R₅ is H or halogen, preferably R₅ is H.

[0080] In one embodiment, W is O and J is S, R₁ is heteroaryl and R₂ is




wherein

R₁₁ and R₁₅ are C₁₋₆ alkyl, preferably isopropyl;

R₁₂ and R₁₄ are H,


R₁₃ is H or halogen, preferably H or Cl.

[0081] In one embodiment W is O and J is S, R₁ is heteroaryl and R₂ is




wherein R₁₁ and R₁₅ are isopropyl, R₁₂ and R₁₄ are H, and R₁₃ is H or Cl.


[0082] In particular embodiments, the compound of formula (I) may be selected from a compound of formula (Ia), (Ib) and (Ic), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



formula (Ia)



formula (Ib)





formula (Ic)


wherein, R_1 is as previously described for any embodiment of formula (I).

[0083] In one embodiment of the compound of formula (Ia), (Ib) and (Ic), R_1 is selected from the group consisting of pyrazole, furan, tetrahydrofuran, tetrahydropyran, pyran, pyrrolidine, pyrrole, triazole, tetrazole, imidazole, pyridine, morpholine, piperazine, piperidine, substituted phenyl, phenylheteroaryl, phenylheterocyclyl, biphenyl, quinoline, isoquinoline, naphthyl, pyrazine and pyrimidine, all of which may be optionally substituted as appropriate.


[0084] In one embodiment of the compound of formula (Ia), (Ib) and (Ic), R_1 is selected from the group consisting of:







[0085] In one embodiment, the compound of formula (I) may be selected from a compound of formula (II), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (II)

wherein, A, B, D and E are independently selected from C, N, O, S and Se but at least one thereof is C;

each dashed line may represent a bond;

R₂ is as previously defined for any embodiment of formula (I), (Ia), (Ib) or (Ic), or may be a fluorescent group;

each incidence of R₆ is independently selected from the group consisting of hydrogen, halo, cyano, C₁-C₆ alkyl, C₁-C₆ alkylamino, C₁-C₆ alkylhydroxy, C₃-C₆ cycloalkyl, alkylphenyl, phenyl, benzyl, C₁-C₆ ester, C₂-C₆ alkenyl, C₁-C₆ trifluoroalkyl and C₁-C₆ alkoxy, each of which may be optionally substituted, or R₆ may be a fluorescent group.

[0086] In one preferred embodiment of the compound of formula (II), at least one of A, B, D and E is N (i.e. nitrogen).

[0087] In a further preferred embodiment of the compound of formula (II), at least two of A, B, D and E are N.

[0088] In one embodiment of the compound of formula (II), A, B, D and E are selected from N and C.


[0089] In a further embodiment of the compound of formula (II), A is C and at least two of B, D and E are N.

[0090] In one embodiment, A, B, D and E form a ring selected from a pyrazole, an imidazole, a triazole, and a tetrazole.

[0091] Preferably, A, B, D, and E form a ring selected from a pyrazole or an imidazole ring, most preferably a pyrazole ring.

[0092] In one embodiment A, B, D and E and/or R₂ may comprise a selenocycle.

[0093] In one embodiment, the compound of formula (I) may be selected from a compound of formula (IIa), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (IIa)


wherein R₁₁ R₁₂ R₁₃ R₁₄ and R₁₅ are as previously defined;

A, B, D and E are selected from N and C and at least two of A, B, D, and

E are N;

each incidence of R_6 is independently selected from the group consisting of hydrogen, halide, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkylamino, C_1 - C_6 alkylhydroxy, C_3 - C_6 cycloalkyl, alkylphenyl, phenyl, benzyl, C_1 - C_6 ester, C_2 - C_6 alkenyl, C_1 - C_6 trifluoroalkyl and C_1 - C_6 alkoxy, each of which may be optionally substituted.

[0094] In one embodiment, the compound of formula (I) may be selected from a compound of formula (IIb), or a pharmaceutically acceptable salt, solvate or prodrug thereof:








Formula (IIb)


wherein Y and R_5 are as previously defined;

A, B, D and E are selected from N and C and at least two of A, B, D, and E are N;

each incidence of R_6 is independently selected from the group consisting of hydrogen, halide, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkylamino, C_1 - C_6 alkylhydroxy, C_3 - C_6 cycloalkyl, alkylphenyl, phenyl, benzyl, C_1 - C_6 ester, C_2 - C_6 alkenyl, C_1 - C_6 trifluoroalkyl and C_1 - C_6 alkoxy, each of which may be optionally substituted.

[0095] In one embodiment the compound of formula (II), is selected from:





wherein, R_{40} is selected from H, alkyl and halo;

R_{41} is selected from H and alkyl;

each incidence of P is independently selected from C, O or S; and


wherein each incidence of R_6 , when present, is independently selected from those groups defined for formula (II).

[0096] It will be understood that the R_6 moiety extending from the centre of each ring may represent a group bonded to the ring carbons or ring heteroatoms, as appropriate taking valency into consideration, or may not be present.


[0097] In one embodiment of formula (II), R_6 is C_1 - C_6 alkyl or C_1 - C_6 alkylhydroxy.

[0098] In certain embodiments of the compound of formula (II), for example when R_2 is hexahydrindacene and R_1 is furan, R_6 may not be a tertiary alcohol substituent.


[0099] In one embodiment, the compound of the first aspect may be selected from a compound of formula (IIIa), (IIIb) or (IIIc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (IIIa)



Formula (IIIb)



Formula (IIIc)

wherein, R_{21} is selected from H, alkyl, perhaloalkyl or hydroxylalkyl;

R_{22} is selected from H, alkyl, perhaloalkyl, C_3 - C_6 cycloalkyl, phenyl or benzyl;

R_{18} is H or halogen;

R_{16} and R_{17} are H or alkyl; or R_{16} and R_{17} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

R_{19} and R_{20} are H or alkyl; or R_{19} and R_{20} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

provided that R_{21} and R_{22} are not both H; and

provided that R_{16} , R_{17} , R_{18} , R_{19} and R_{20} are not all H.

[00100] In a preferred embodiment of compounds of formulae (IIIa), (IIIb) and (IIIc):

R_{21} is selected from H, alkyl, perhaloalkyl or hydroxylalkyl; preferably C_{1-6} perhaloalkyl or hydroxylalkyl;

R_{22} is selected from H, alkyl, perhaloalkyl, C_3 - C_6 cycloalkyl, phenyl or benzyl;

R_{16} and R_{17} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{19} and R_{20} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{18} is H or halogen, preferably R_{18} is H; and

provided that R_{21} and R_{22} are not both H.

[00101] In another preferred embodiment of the compounds of formulae (IIIa), (IIIb) and (IIIc):

R_{21} is selected from H, alkyl, perhaloalkyl or hydroxylalkyl; preferably C_{1-6} perhaloalkyl or hydroxylalkyl;

R_{22} is selected from H, alkyl, perhaloalkyl, C_3-C_6 cycloalkyl, phenyl and benzyl;


R_{16} and R_{20} are C_{1-6} alkyl, preferably isopropyl;

R_{17} and R_{19} are H,


R_{18} is H or halogen; preferably R_{18} is H or Cl; and

provided that R_{21} and R_{22} are not both H.


[00102] In one embodiment, the compound of the first aspect may be selected from a compound of formula (IVa), (IVb) or (IVc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (IVa)



Formula (IVb)



Formula (IVc)

wherein, R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C_3-C_6 cycloalkyl, phenyl and benzyl or R_{21} and R_{22} , together with the carbon atoms to which they are attached, may form a cyclopentyl or a cyclohexyl ring;

R_{18} is H or halogen;

R_{16} and R_{17} are H or alkyl; or R_{16} and R_{17} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

R_{19} and R_{20} are H or alkyl; or R_{19} and R_{20} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

provided that R_{21} and R_{22} are not both H; and

provided that R_{16} , R_{17} , R_{18} , R_{19} and R_{20} are not all H.

[00103] In a preferred embodiment of compounds of formulae (IVa), (IVb) and (IVc):

R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C_{1-6} perhaloalkyl and hydroxylalkyl;

R_{16} and R_{17} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{19} and R_{20} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{18} is H or halogen; preferably R_{18} is H; and

provided that R_{21} and R_{22} are not both H.

[00104] In another preferred embodiment of compounds of formulae (IVa), (IVb) and (IVc):

R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C_{1-6} perhaloalkyl and hydroxylalkyl;


R_{16} and R_{20} are C_{1-6} alkyl, preferably isopropyl;

R_{17} and R_{19} are H,


R_{18} is H or halogen; preferably R_{18} is H or Cl;

provided that R_{21} and R_{22} are not both H.


[00105] In one embodiment, the compound of the first aspect may be selected from a compound of formula (Va), (Vb) or (Vc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (Va)



Formula (Vb)



Formula (Vc)

wherein, R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C₃-C₆ cycloalkyl, phenyl and benzyl;

R_{18} is H or halogen;

R_{16} and R_{17} are H or alkyl; or R_{16} and R_{17} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

R_{19} and R_{20} are H or alkyl; or R_{19} and R_{20} , together with the carbon

atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

provided that R_{21} and R_{22} are not both H; and

provided that R_{16} , R_{17} , R_{18} , R_{19} and R_{20} are not all H.

[00106] In a preferred embodiment of compounds of formulae (Va), (Vb) and (Vc):

R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C_{1-6} perhaloalkyl and hydroxylalkyl;

R_{16} and R_{17} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{19} and R_{20} , together with the atoms to which they are attached, form a cyclopentyl ring;

R_{18} is H or halogen; preferably R_{18} is H; and

provided that R_{21} and R_{22} are not both H.

[00107] In another preferred embodiment of compounds of formulae (Va), (Vb) and (Vc):

R_{21} and R_{22} are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C_{1-6} perhaloalkyl and hydroxylalkyl;


R_{16} and R_{20} are C_{1-6} alkyl, preferably isopropyl;

R_{17} and R_{19} are H;


R_{18} is H or halogen; preferably R_{18} is H or Cl; and

provided that R_{21} and R_{22} are not both H.

[00108] In one embodiment, the compound of the first aspect may be selected from a compound of formula (VIa) or (VIb), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (VIa)



Formula (VIb)

wherein, R₂₂ is selected from alkyl, perhaloalkyl, hydroxylalkyl, C₃-C₆ cycloalkyl, phenyl and benzyl;

R₁₈ is H or halogen;

R₁₆ and R₁₇ are H or alkyl; or R₁₆ and R₁₇, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

R₁₉ and R₂₀ are H or alkyl; or R₁₉ and R₂₀, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S; and

provided that R₁₆, R₁₇, R₁₈, R₁₉ and R₂₀ are not all H.

[00109] In a preferred embodiment of compounds of formulae (VIa) and (VIb):

R₂₂ is selected from alkyl, perhaloalkyl, hydroxylalkyl, C₃-C₆ cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C₁₋₆ perhaloalkyl and hydroxylalkyl;

R₁₆ and R₁₇, together with the atoms to which they are attached, form a cyclopentyl ring;

R₁₉ and R₂₀, together with the atoms to which they are attached, form a cyclopentyl ring; and

R_{18} is H or halogen; preferably R_{18} is H.

[00110] In another preferred embodiment of compounds of formulae (VIa) and (VIb):


R_{22} is selected from alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, phenyl and benzyl; preferably the perhaloalkyl and hydroxylalkyl are C_{1-6} perhaloalkyl and hydroxylalkyl;

R_{16} and R_{20} are C_{1-6} alkyl, preferably isopropyl;

R_{17} and R_{19} are H; and

R_{18} is H or halogen; preferably R_{18} is H or Cl.

[00111] In one embodiment, the compound of the first aspect may be selected from a compound of formula (VII), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



Formula (VII)

wherein, Q is O or S;

each incidence of R_{30} is independently selected from alkyl, perhaloalkyl, hydroxylalkyl, C_3 - C_6 cycloalkyl, and alkylamino;

R_{18} is H or halogen;

R_{16} and R_{17} are H or alkyl; or R_{16} and R_{17} , together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising

one or two heteroatoms selected from N, O and S;

R₁₉ and R₂₀ are H or alkyl; or R₁₉ and R₂₀, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;

provided that R₁₆, R₁₇, R₁₈, R₁₉ and R₂₀ are not all H; and

provided that when Q is O and R₁₆ and R₁₇, and separately R₁₉ and R₂₀, together with the respective carbon atoms to which they are attached, form a cyclopentyl ring then R₃₀ is not C-3 hydroxylalkyl.

[00112] In a preferred embodiment of compounds of formulae (VII):

Q is O or S;

each incidence of R₃₀ is independently selected from alkyl, perhaloalkyl, hydroxylalkyl, C₃-C₆ cycloalkyl, and alkylamino; preferably C₁₋₆ alkyl, perhaloalkyl, hydroxylalkyl, and alkylamino;

R₁₆ and R₁₇, together with the atoms to which they are attached, form a cyclopentyl ring;

R₁₉ and R₂₀, together with the atoms to which they are attached, form a cyclopentyl ring; and

R₁₈ is H or halogen; preferably R₁₈ is H and

provided that when Q is O then R₃₀ is not C-3 hydroxylalkyl.

[00113] In another preferred embodiment of compounds of formulae (VII):

Q is O or S;

each incidence of R₃₀ is independently selected from alkyl, perhaloalkyl, hydroxylalkyl, C₃-C₆ cycloalkyl, and alkylamino; preferably C₁₋₆ alkyl, perhaloalkyl, hydroxylalkyl, and alkylamino;

R₁₆ and R₂₀ are C₁₋₆ alkyl, preferably isopropyl;

R₁₇ and R₁₉ are H; and

R₁₈ is H or halogen; preferably R₁₈ is H or Cl.

[00114] The compounds of the first aspect, and particularly those of formulae (II) to (VI), provide a range of unexpected benefits over those sulfonylureas of the prior art, which benefits may be selected from: Improved microsomal stability; Improved permeability; Reduced Pgp liability; Reduced plasma protein binding; Increased half-life; Improved oral bioavailability; Improved AUC; Improved C_{max}; Reduced Cyp inhibition; Improved inhibition of activation of the NLRP3 inflammasome; and Improved solubility. The solubility, and certain other, improvements may be seen particularly in an aqueous environment.

[00115] In one embodiment, the compounds of the first aspect offer improved pharmacokinetic characteristics. CRID3, a known sulfonylurea, has a half life of 3.2 hours (mouse) which may lead to substantial trough levels from QD or BD dosing when the t_{1/2} is extrapolated to man. The compounds of the first aspect may differ in, for example, their protein binding, metabolism and oral availability.

[00116] Particularly it has been found that compounds of the first aspect, especially those wherein A, B, D and E form a 5-membered nitrogen heteroaryl, for example a pyrazole ring, are less metabolically labile and/or have improved pharmacokinetic properties over otherwise structurally similar furans and thiophenes seen in the prior art.

[00117] In one embodiment, the compounds of the first aspect have a tPSA of less than 90 Å².

[00118] It is one advantage of the present compounds of the first aspect that they may demonstrate a significantly lowered polar surface area in comparison to prior art sulfonylureas, such as CRID3.


[00119] In one further embodiment, the compounds of the first aspect have a tPSA of less than 90 Å² and a molecular weight of less than 405.













[00120] The absence of a tertiary alcohol group, in some embodiments, increases plasma concentration and aids in decreasing both MW and polar surface area thereby giving an overall improvement in blood brain barrier penetration.













[00121] In any of the embodiments described for the compound of the first aspect, including the compounds of formula (I) to (VII), one or more hydrogens of the substituents or optional substitutions thereupon may be deuterated.













[00122] Deuterated analogues of the compounds of the invention may exhibit increased metabolic stability due to the kinetic isotope effect.


[00123] In one embodiment, the compound of the first aspect is selected from the group consisting of:
















,




,




,




,




,





,

















,

















,




,













,






















,




,












,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,











,




,





,





[00124] In certain embodiments, the compounds of the first aspect may exhibit improved properties compared to known anti-diabetes drugs. Examples of such compounds may include those below:






[00125] These four compounds of formula (I) may be viewed as very potent versions of current sulfonylurea anti-diabetes drugs. The IC₅₀ data presented in the experimental section reflects this view. It is believed that known drugs do not target NLRP3 to any therapeutically significant extent and so it would be necessary to use very high doses to have any significant effect on the NLRP3 inflammasome. The four compounds shown above, and others of the first aspect, show advantageously improved properties in a significant decrease in IC₅₀ versus the NLRP3 inflammasome and additionally have the benefits, not realised by existing diabetes and other drugs, associated with NLRP3 inhibition such as improved wound healing and other advantages described herein.

[00126] In any one or more embodiments of the first aspect and in relation to any one or more of the compounds of formula (I) to (VII), the compound is an inhibitor of activation of the NLRP3 inflammasome.

[00127] Therefore it will be appreciated that the present invention provides for sulfonyl urea and related drugs exhibiting significantly lower NLRP3 IC₅₀ values in cell based assay using HMDM (see experimental section for protocols) than the above comparator compounds. Currently known diabetes drugs are not potent inhibitors of the NLRP3 inflammasome at therapeutic doses and to achieve any such inhibition would require dosing outside of recommended levels. The present compounds allow lower doses to be used


and therefore limit the risk of toxic effects.


[00128] In a further embodiment, one or more of the compounds of the first aspect may be useful as photoswitchable compounds which may be applied in a range of uses including but not limited to insulin release. Such compounds may, in one embodiment, be selected from the group consisting of:



wherein, R_2 is as defined in any one or more of the embodiments of compounds of formula (I) to (VII) described previously.













[00129] In certain embodiments of the invention one or more compounds of the first aspect may be appropriate for use as probes, such as photoaffinity probes, or as reactive intermediates which can be modified either directly or by means of a linking moiety to give biotinylated, fluorescent or photoaffinity probes including, but not limited to, those shown below:






wherein, R₂ is as defined in any one or more of the embodiments described for formula (I) to (VII).

[00130] Particularly, such compounds as probes or reactive intermediates may be selected from those below:



[00131] It will be appreciated that the compounds of the first aspect may be modified or derivatised by means well understood in the art to allow linkage to a molecule such as biotin, or a fluorescent group or photoaffinity label, as shown with certain of the compounds above.

[00132] In one embodiment, the compound of formula (I) or (II) does not comprise a structure selected from the groups below shown attached to the sulfonyl moiety (i.e. as an R_1 group):



[00133] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R_2 is selected from hexahydroindacene, 2,6-diisopropylphenyl and 2,6-diisopropyl-4-chlorophenyl then R_1 is not one of 2,4-disubstituted furan, 2,4-disubstituted thiophene, 2,5-disubstituted furan and 2,5-disubstituted thiophene.

[00134] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R_1 is selected from substituted triazole, thiadiazole, 4-substituted pyridine and 1,2-disubstituted imidazole then R_2 is not unsubstituted phenyl, 2- or 4-chlorophenyl

or 3,4- substituted phenyl, substituted with one or more of halo, trifluoromethyl, nitro or thiomethyl.

[00135] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R₁ is selected from substituted triazole, thiadiazole, benzothiazole and substituted pyrimidine then R₂ is not thiophene, 3-chlorophenyl, 4-ethoxyphenyl, substituted benzimidazole or substituted benzothiazole.

[00136] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R₁ is ethoxy substituted benzothiazole, then R₂ is not 2,6-diisopropylphenyl.

[00137] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R₁ is selected from benzofuran, benzothiophene and indole then R₂ is not 3- or 3,4-halo, methyl, ethyl or trifluoromethyl substituted phenyl.

[00138] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O and R₂ is substituted pyrimidine, then R₁ is not pyrazole substituted with ester or carboxy.

[00139] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S and W as O then the carbon atom of R₂ which is directly bonded to the urea nitrogen is not a carbonyl carbon.

[00140] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S and W as O, then the carbon atom of R₂ which is directly bonded to the urea nitrogen is an aryl, heteroaryl or heterocyclic ring carbon.

[00141] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S and W as O, R₂ is a

substituted phenyl and R₁ is a pyrazole then the R₁ pyrazole is not substituted with an aryl or heteroaryl group.

[00142] In one embodiment, wherein the compound of the first aspect, including any compound of formula (I) to (VII), has J as S, W as O, and R₁ is a pyrazole and the sulfonylurea linker is branched in position 4 thereof, the pyrazole is not fused in positions 1 and 5 with a 6-membered heterocycle to form a pyrazolopyrimidine derivative.

[00143] In one embodiment, the compound of the first aspect, including any compound of formula (I) to (VII) is not a compound selected from the group consisting of:

1. 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-benzenesulfonyl]-urea;
2. 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
3. 1-(1,2,3,5,6,7-Hexahydro-4-aza-s-indacen-8-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
4. 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
5. 1-(4-[1,3]Dioxolan-2-yl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
6. 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
7. 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
8. 1-(4-Acetyl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
9. 1-(1H-Benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;

10. 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
11. 1-(8-Chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
12. 1-(4-Acetyl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
13. 1-(8-Fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
14. 1-(4-Fluoro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-benzenesulfonyl]-urea; and
15. 1-(6-Fluoro-1H-benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
16. 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(1H-indole-6-sulfonyl)-urea;
17. 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(5-fluoro-1H-indole-6-sulfonyl)-urea;
18. 1-[1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-(1H-indole-6-sulfonyl)-urea;
19. 1-(5-Fluoro-1H-indole-6-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-5-indacen-4-yl)-urea;
20. 1-[4-Chloro-2,6-diisopropyl-phenyl]-3-[2-fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)-benzenesulfonyl]-urea;
21. 3-[3-[4-Chloro-2,6-diisopropyl-phenyl]-ureidosulfonyl]-N-methyl-benzenesulfonamide;
22. 1-[2-Fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)benzenesulfonyl]-3-1,2,3,5,6,7-hexahydro-indacen-4-yl)-urea;
23. 3-[3-(1,2,3,5,6,7-Hexahydro-S-indacen-4-yl)-ureidosulfonyl]-N-methyl-benzenesulfonamide;
24. 4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonamide.

[00144] In some embodiments of the present invention, therapeutically inactive prodrugs of the compounds of the first aspect are provided. Prodrugs

are compounds which, when administered to a mammal, are converted in whole or in part to a compound of the invention. In most embodiments, the prodrugs are pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules to exert a therapeutic effect. Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, or stability of the compound or to otherwise alter the properties of the compound. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include, but are not limited to, compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, and/or dephosphorylated to produce the active compound.

[00145] A number of prodrug ligands are known. In general, alkylation, acylation, or other lipophilic modification of one or more heteroatoms of the compound, such as a free amine or carboxylic acid residue, may reduce polarity and allow for the compound's passage into cells. Examples of substituent groups that can replace one or more hydrogen atoms on a free amine and/or carboxylic acid moiety include, but are not limited to, the following: aryl; steroids; carbohydrates (including sugars); 1,2-diacylglycerol; alcohols; acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester (including alkyl or arylalkyl sulfonyl, such as methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as provided in the definition of an aryl given herein); optionally substituted arylsulfonyl; lipids (including phospholipids); phosphatidylcholine; phosphocholine; amino acid residues or derivatives; amino acid acyl residues or derivatives; peptides; cholesterol; or other pharmaceutically acceptable leaving groups which, when administered in vivo, provide the free amine. Any of these moieties can be used in combination with the disclosed active agents to achieve a desired effect.

[00146] In some embodiments, compounds with one or more chiral centers are provided. While racemic mixtures of compounds of the invention may be active, selective, and bioavailable, isolated isomers may be of interest as well.

[00147] The compounds of the first aspect may contain chiral centers, which may be either of the (R) or (S) configuration, or which may comprise a mixture thereof. Accordingly, the present invention also includes stereoisomers of the compounds described herein, where applicable, either individually or admixed in any proportions. Stereoisomers may include, but are not limited to, enantiomers, diastereomers, racemic mixtures, and combinations thereof. Such stereoisomers can be prepared and separated using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds and prodrugs of the present invention. Isomers may include geometric isomers. Examples of geometric isomers include, but are not limited to, cis isomers or trans isomers across a double bond. Other isomers are contemplated among the compounds of the present invention. The isomers may be used either in pure form or in admixture with other isomers of the compounds described herein.

[00148] Various methods are known in the art for preparing optically active forms and determining activity. Such methods include standard tests described herein and other similar tests which are well known in the art. Examples of methods that can be used to obtain optical isomers of the compounds according to the present invention include the following:

i) physical separation of crystals whereby macroscopic crystals of the individual enantiomers are manually separated. This technique may particularly be used when crystals of the separate enantiomers exist (*i.e.*, the material is a conglomerate), and the crystals are visually distinct;

ii) simultaneous crystallization whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter

is a conglomerate in the solid state;

iii) enzymatic resolutions whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;

iv) enzymatic asymmetric synthesis, a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;

v) chemical asymmetric synthesis whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (*i.e.*, chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries;

vi) diastereomer separations whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;

vii) first- and second-order asymmetric transformations whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomers;

viii) kinetic resolutions comprising partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;

x) chiral liquid chromatography whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase. The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;

xi) chiral gas chromatography whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;

xii) extraction with chiral solvents whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent; and

xiii) transport across chiral membranes whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane which allows only one enantiomer of the racemate to pass through.

[00149] The compound optionally may be provided in a composition that is enantiomerically enriched, such as a mixture of enantiomers in which one enantiomer is present in excess, in particular, to the extent of 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, including 100%.

[00150] The terms (R), (S), (R,R), (S,S), (R,S) and (S,R) as used herein mean that the composition contains a greater proportion of the named isomer of the compound in relation to other isomers. In a preferred embodiment, these terms indicate that the composition contains at least 90% by weight of the named isomer and 10% by weight or less of the one or more other isomers; or more preferably about 95% by weight of the named isomer and 5% or less of the one or more other isomers. In some embodiments, the composition may contain at least 99% by weight of the named isomer and 1% or less by weight of the one or more other isomers, or may contain 100% by weight of the named isomer and 0% by weight of the one or more other isomers. These percentages are based on the total amount of the compound of the present invention present in the composition.

[00151] The compounds of the first aspect may be utilized per se or in the form of a pharmaceutically acceptable ester, amide, salt, solvate, prodrug, or isomer, as appropriate. For example, the compound may be provided as a pharmaceutically acceptable salt. If used, a salt of the drug compound should be both pharmacologically and pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such pharmacologically and pharmaceutically acceptable salts can be prepared by reaction of the drug with an organic or inorganic acid, using standard methods detailed in the literature.

[00152] Examples of pharmaceutically acceptable salts of the compounds useful according to the invention include acid addition salts. Salts of non-pharmaceutically acceptable acids, however, may be useful, for example, in the preparation and purification of the compounds. Suitable acid addition salts according to the present invention include organic and inorganic acids. Preferred salts include those formed from hydrochloric, hydrobromic, sulfuric,

phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, benzenesulfonic, and isethionic acids. Other useful acid addition salts include propionic acid, glycolic acid, oxalic acid, malic acid, malonic acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, and the like. Particular example of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ -hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

[00153] An acid addition salt may be reconverted to the free base by treatment with a suitable base. Preparation of basic salts of acid moieties which may be present on a compound or prodrug useful according to the present invention may be prepared in a similar manner using a pharmaceutically acceptable base, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, triethylamine, or the like.

[00154] Esters of the active agent compounds according to the present invention may be prepared through functionalization of hydroxyl and/or carboxyl groups that may be present within the molecular structure of the compound. Amides and prodrugs may also be prepared using techniques known to those skilled in the art. For example, amides may be prepared from esters, using

suitable amine reactants, or they may be prepared from an anhydride or an acid chloride by reaction with ammonia or a lower alkyl amine. Moreover, esters and amides of compounds of the invention can be made by reaction with a carbonylating agent (*e.g.*, ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (*e.g.*, 4-dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a suitable organic solvent (*e.g.*, tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) at a temperature of 0 °C to 60 °C. Prodrugs are typically prepared by covalent attachment of a moiety, which results in a compound that is therapeutically inactive until modified by an individual's metabolic system. Examples of pharmaceutically acceptable solvates include, but are not limited to, compounds according to the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.

[00155] In the case of solid compositions, it is understood that the compounds used in the methods of the invention may exist in different forms. For example, the compounds may exist in stable and metastable crystalline forms and isotropic and amorphous forms, all of which are intended to be within the scope of the present invention.

[00156] If a compound useful as an active agent according to the invention is a base, the desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acids such as glucuronic acid and galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as

benzoic acid and cinnamic acid, sulfonic acids such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.

[00157] If a compound described herein as an active agent is an acid, the desired salt may be prepared by any suitable method known in the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal or alkaline earth metal hydroxide or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

[00158] According to a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (I) to (VII), or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

[00159] Suitably, the pharmaceutically acceptable carrier, diluent and/or excipient may be or include one or more of diluents, solvents, pH buffers, binders, fillers, emulsifiers, disintegrants, polymers, lubricants, oils, fats, waxes, coatings, viscosity-modifying agents, glidants and the like.

[00160] The salt forms of the compounds of the invention may be especially useful due to their improved solubility.

[00161] In one embodiment, the pharmaceutical composition includes a cyclodextrin.

[00162] The cyclodextrin may be selected from alpha, beta or gamma cyclodextrins.

[00163] In one embodiment, the cyclodextrin is selected from a methyl cyclodextrin, a hydroxypropyl cyclodextrin and a sulfobutylether cyclodextrin.

[00164] It has been found that cyclodextrins provide significant advantages in

formulation and delivery of the compounds of the invention.

[00165] Cyclodextrin formulations such as for example, one or more compounds of the invention with hydroxypropyl beta cyclodextrin or methyl beta cyclodextrin, may have uses in cholesterol sequestration/cholesterol lowering or via NLRP3 inhibition for Non-alcoholic steatohepatitis (NASH), alcoholic liver disease, atherosclerosis and also in Alzheimer's Disease (AD).

[00166] Diluents may include one or more of microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, and the like. Binders may include one or more of povidone, starch, stearic acid, gums, hydroxypropylmethyl cellulose and the like. Disintegrants may include one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate and the like. Solvents may include one or more of ethanol, methanol, isopropanol, chloroform, acetone, methylethyl ketone, methylene chloride, water and the like. Lubricants may include one or more of magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, glyceryl behenate and the like. A glidant may be one or more of colloidal silicon dioxide, talc or cornstarch and the like. Buffers may include phosphate buffers, borate buffers and carbonate buffers, although without limitation thereto. Fillers may include one or more gels inclusive of gelatin, starch and synthetic polymer gels, although without limitation thereto. Coatings may comprise one or more of film formers, solvents, plasticizers and the like. Suitable film formers may be one or more of hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, povidone, sodium carboxymethyl cellulose, polyethylene glycol, acrylates and the like. Suitable solvents may be one or more of water, ethanol, methanol, isopropanol, chloroform, acetone, methylethyl ketone, methylene chloride and the like. Plasticizers may be one or more of propylene glycol, castor oil, glycerin, polyethylene glycol, polysorbates, and the like.

[00167] Reference is made to the Handbook of Excipients 6th Edition, Eds. Rowe, Sheskey & Quinn (Pharmaceutical Press), which provides non-limiting examples of excipients which may be useful according to the invention.

[00168] It will be appreciated that the choice of pharmaceutically acceptable carriers, diluents and/or excipients will, at least in part, be dependent upon the mode of administration of the formulation. By way of example only, the composition may be in the form of a tablet, capsule, caplet, powder, an injectable liquid, a suppository, a slow release formulation, an osmotic pump formulation or any other form that is effective and safe for administration.

[00169] Suitably, the pharmaceutical composition is for the treatment or prevention of a disease, disorder or condition in a mammal.

[00170] A third aspect of the invention resides in a method of treatment or prevention of a disease, disorder or condition including the step of administering an effective amount of a compound of formula (I) to (VII), or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect to thereby treat or prevent the disease disorder or condition.

[00171] A fourth aspect of the invention provides for a compound of formula (I) to (VII), or a pharmaceutically effective salt, solvate or prodrug thereof, or the pharmaceutical composition of the second aspect for use in the treatment or prevention of a disease, disorder or condition.

[00172] A fifth aspect of the invention provides for use of a compound of formula (I) to (VII), or a pharmaceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition.

[00173] As generally used herein, the terms “administering” or “administration”, and the like, describe the introduction of the compound or composition to a mammal such as by a particular route or vehicle. Routes of

administration may include topical, parenteral and enteral which include oral, buccal, sub-lingual, nasal, anal, gastrointestinal, subcutaneous, intramuscular and intradermal routes of administration, although without limitation thereto.

[00174] By "treat", "treatment" or "treating" is meant administration of the compound or composition to a subject to at least ameliorate, reduce or suppress existing signs or symptoms of the disease, disorder or condition experienced by the subject.

[00175] By "prevent", "preventing" or "preventative" is meant prophylactically administering the formulation to a subject who does not exhibit signs or symptoms of a disease disorder or condition, but who is expected or anticipated to likely exhibit such signs or symptoms in the absence of prevention. Preventative treatment may at least lessen or partly ameliorate expected symptoms or signs.

[00176] As used herein, "effective amount" refers to the administration of an amount of the relevant compound or composition sufficient to prevent the occurrence of symptoms of the condition being treated, or to bring about a halt in the worsening of symptoms or to treat and alleviate or at least reduce the severity of the symptoms. The effective amount will vary in a manner which would be understood by a person of skill in the art with patient age, sex, weight etc. An appropriate dosage or dosage regime can be ascertained through routine trial.

[00177] As used herein, the terms "subject" or "individual" or "patient" may refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, for whom therapy is desired. Suitable vertebrate animals include, but are not restricted to, primates, avians, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes). A preferred subject is a human

in need of treatment for a disease, disorder or condition as described herein. However, it will be understood that the aforementioned terms do not imply that symptoms are necessarily present.

[00178] In one particular embodiment, the disease, disorder or condition is one which is responsive to inhibition of activation of the NLRP3 inflammasome.

[00179] According to this embodiment, the compound of the first aspect, or pharmaceutically effective salt, solvate or prodrug thereof is a specific inhibitor of NLRP3.

[00180] In a further embodiment, the disease, disorder or condition is responsive to modulation of one or more of IL-1 β , IL-17, IL-18, IL-1 α , IL-37, IL-33 and Th17 cells.

[00181] In one embodiment, the modulation is inhibition of one or more of IL-1 β , IL-17, IL-18, IL-1 α , IL-37, and IL-33.

[00130] In one embodiment, the modulation of Th17 cells, is by inhibition of production and/or secretion of IL-17.

[00182] In general embodiments, the disease, disorder or condition is a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the respiratory system, the central nervous system, is a cancer or other malignancy and/or is caused by or associated with a pathogen.

[00183] It will be appreciated that these general embodiments defined according to broad categories of diseases, disorders and conditions are not mutually exclusive. In this regard any particular disease, disorder or condition may be categorized according to more than one of the above general embodiments. A non-limiting example is Type I diabetes which is an autoimmune disease and a disease of the endocrine system.

[00184] In one embodiment, the disease, disorder or condition is of the immune system. In particular embodiments, the disease disorder or condition is an inflammatory disease disorder or condition or an autoimmune disease disorder or condition.

[00185] In one embodiment, the disease, disorder or condition is of the skin.

[00186] In one embodiment, the disease, disorder or condition is of the cardiovascular system.

[00187] In one embodiment, the disease, disorder or condition is a cancer, tumour or other malignancy. As used herein, cancers tumours and malignancies, refer to diseases disorders or conditions, or to cells or tissues associated with the diseases, disorders or conditions, characterized by aberrant or abnormal cell proliferation, differentiation and/or migration often accompanied by an aberrant or abnormal molecular phenotype that includes one or more genetic mutations or other genetic changes associated with oncogenesis, expression of tumour markers, loss of tumour suppressor expression or activity and/or aberrant or abnormal cell surface marker expression. In general embodiments, cancers, tumours and malignancies may include sarcomas, lymphomas, leukemias, solid tumours, blastomas, gliomas, carcinomas, melanomas and metastatic cancers, although without limitation thereto. A more comprehensive listing of cancers tumours and malignancies may be found at the National Cancer Institutes website <http://www.cancer.gov/cancertopics/types/alphalist>.

[00188] In one embodiment, the disease, disorder or condition is of the renal system.

[00189] In one embodiment, the disease, disorder or condition is of the gastro-intestinal tract.

[00190] In one embodiment, the disease, disorder or condition is of the respiratory system.

[00191] In a further embodiment, the disease, disorder or condition is of the endocrine system.

[00192] In one embodiment, the disease, disorder or condition is of the central nervous system (CNS).

[00193] In one embodiment, the disease, disorder or condition is caused by, or is associated with, a pathogen. The pathogen may be a virus, a bacterium, a protist, a worm or a fungus or any other organism capable of infecting a mammal, although without limitation thereto.

[00194] Non-limiting examples of viruses include influenza virus, cytomegalovirus, Epstein Barr Virus, human immunodeficiency virus (HIV), alphavirus such as Chikungunya and Ross River virus, flaviviruses such as Dengue virus, Zika virus and papillomavirus, although without limitation thereto.

[00195] Non-limiting examples of pathogenic bacteria include *Staphylococcus aureus*, *Helicobacter pylori*, *Bacillus anthracis*, *Bordetella pertussis*, *Corynebacterium diphtheriae*, *Clostridium tetani*, *Clostridium botulinum*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Listeria monocytogenes*, *Hemophilus influenzae*, *Pasteurella multocida*, *Shigella dysenteriae*, *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Mycoplasma pneumoniae*, *Mycoplasma hominis*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Rickettsia rickettsii*, *Legionella pneumophila*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Propionibacterium acnes*, *Treponema pallidum*, *Chlamydia trachomatis*, *Vibrio cholerae*, *Salmonella typhimurium*, *Salmonella typhi*, *Borrelia burgdorferi* and *Yersinia pestis*, although without limitation thereto.

[00196] Non-limiting examples of protists include Plasmodium, Babesia, Giardia, Entamoeba, Leishmania and Trypanosomes, although without limitation thereto.

[00197] Non-limiting examples of worms include helminths inclusive of schistisomes, roundworms, tapeworms and flukes, although without limitation thereto.

[00198] Non-limiting examples of fungi include Candida and Aspergillus species, although without limitation thereto.

[00199] Further relevant disease, disorder or conditions may be selected from the group consisting of those recited in the journal article found at: <http://onlinelibrary.wiley.com/store/10.1111/j.1365-2249.2011.04440.x/asset/j.1365-2249.2011.04440.x.pdf?v=1&t=i60c1phf&s=d26f50a2622926cc6b4bc855bd911ae9dc9750cf>.

[00200] In particular embodiments, the disease, disorder or condition is selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD);

Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome and Schnitzler syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma, asbestosis, silicosis and cystic fibrosis; central nervous system diseases including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudo-gout; ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy and diabetic nephropathy; liver disease including non-alcoholic steatohepatitis and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis; viral infections including alpha virus (Chikungunya, Ross River) and flavivirus (Dengue and Zika Virus), flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodysplastic syndrome, leukemia; polymyositis; stroke; myocardial infarction; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; pericarditis including Dressler's syndrome, ischaemia reperfusion injury and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

[00201] In one non-limiting example of those described, the disease, disorder or condition being treated is NASH. NLRP3 inflammasome activation is central

to inflammatory recruitment in NASH, and inhibition of NLRP3 may both prevent and reverse liver fibrosis. Compounds of the present invention, by interrupting the function of NLRP3 inflammasomes in liver tissue, can cause histological reductions in liver inflammation, decreased recruitment of macrophages and neutrophils, and suppression of NF- κ B activation. Inhibition of the NLRP3 can reduce hepatic expression of pro-IL-1 β and normalized hepatic and circulating IL-1 β , IL-6 and MCP-1 levels thereby assisting in treatment of the disease.

[00202] In a further non-limiting example of those described, the disease, disorder or condition being treated is severe steroid resistant (SSR) asthma. Respiratory infections induce an NLRP3 inflammasome/caspase-1/IL-1 β signaling axis in the lungs that promotes SSR asthma. The NLRP3 inflammasome recruits, and activates, pro-caspase-1 to induce IL-1 β responses. NLRP3 inflammasome-induced IL-1 β responses are therefore important in the control of infections, however, excessive activation results in aberrant inflammation and has been associated with the pathogenesis of SSR asthma and COPD. The administration of compounds of the first aspect that target specific disease processes, are more therapeutically attractive than non-specifically inhibiting inflammatory responses with steroids or IL-1 β . Targeting the NLRP3 inflammasome/caspase-1/IL-1 β signaling axis with the compounds of the first aspect may therefore be useful in the treatment of SSR asthma and other steroid-resistant inflammatory conditions.

[00203] In one further non-limiting example of those described, the disease, disorder or condition being treated is Parkinson's disease. Parkinson's is the most common neurodegenerative movement disorder and is characterized by a selective loss of dopaminergic neurons, accompanied by the accumulation of mis-folded α -synuclein (Syn) into Lewy bodies that are pathological hallmarks of the disease. Chronic microglial neuroinflammation is evident early in the disease, and has been proposed to drive pathology.

[00204] A central role for microglial NLRP3 is postulated in Parkinson's progression. The NLRP3 inflammasome is activated by fibrillar Syn via a Syk kinase dependent mechanism, and also occurs in the absence of Syn pathology at the early stages of dopaminergic degeneration, and drives neuronal loss. The compounds of the first aspect may block NLRP3 inflammasome activation by fibrillar Syn or mitochondrial dysfunction and thereby confer effective neuroprotection of the nigrostriatal dopaminergic system and assist with treatment of Parkinson's.

[00205] In a sixth aspect of the invention there is provided a method of diagnosing a disease, disorder or condition in a mammal including the step of administering a labelled compound of formula (I) to (VII), or a pharmaceutically effective salt, solvate or prodrug thereof, to the mammal or to a biological sample obtained from the mammal to facilitate diagnosis of the disease disorder or condition in the mammal.

[00206] Inflammasome activation, in particular that of the NLRP3 inflammasome, is known to drive initiation, progression and chronic development of a vast number of inflammatory diseases. The sulfonylureas and related compounds of the first aspect are potent and specific direct inhibitors of NLRP3. Accordingly, a chemical probe specific for NLRP3, which is present in immune cells during inflammation has potential utility in diagnosing inflammatory and other related diseases. An NLRP3 activation probe comprising a compound of the first aspect could act as an effective surrogate biomarker of inflammatory disease for *ex vivo* (blood) or *in vivo* (MRI, PET etc.) diagnostics.

[00207] The use of the compounds of the first aspect in diagnosing inflammatory and other related diseases, such as those listed above, may be achieved by near infrared fluorescent imaging and *ex vivo* characterisation of immune cells by degree of inhibition of IL-1 β , pro-caspase 1 cleavage and

IL-18 levels. In particular, peripheral blood monocytes (PMBCs), macrophages, dendritic cells, CD4⁺ T cells, Th17 cells, Th1 cells and Th2 cells are relevant. In vivo diagnostics using magnetic resonance imaging (MRI). H2 (deuterium) ¹³C, ¹⁹F, ¹⁵N labelled variants of [compound classes] given to a patient IV, IM, SC, PO, topical, IT, etc.

[00208] *In vivo* diagnostics using positron emission tomography (PET) are also appropriate. PET is a molecular imaging technique that requires specific probes radiolabelled with short-lived positron emitting radionuclides. Typical isotopes include ¹¹C, ¹³N, ¹⁵O, ¹⁸F, ⁶⁴Cu, ⁶²Cu, ¹²⁴I, ⁷⁶Br, ⁸²Rb and ⁶⁸Ga, with ¹⁸F being the most clinically utilized. In particular it is possible to produce in a simple manner a stable ⁶⁴Cu or ⁶²Cu salt of one or more of the compounds of formula (I) by simple ion exchange with a sodium (or other monovalent cation) salt of said compounds. This enables rapid preparation of a diagnostic probe for radioimaging, PET and the like whereby the intensity, location and temporal accretion of the diagnostic probe is able to identify the degree and/or the location of immune cells with activated NLRP3 as a surrogate biomarker of the patient's inflammatory state, and site of inflammation within the body. They will also be useful for application to biological samples removed from the body i.e. *in vitro* diagnosis.

[00209] A seventh aspect of the invention resides in a method of modulating the activity of a biological target comprising the step of exposing the biological target to a compound of formula (I) to (VII), or a pharmaceutically effective salt, solvate or prodrug thereof.

[00210] The biological target may be selected from the group consisting of NLRP3 inflammasome, IL-1 β , IL-17, IL-18, IL-1 α , IL-37, IL-33 and Th17 cells.


[00211] The modulation may be as described previously for the third to fifth aspects.

[00212] As generally used herein, a biological sample may include cells, tissues, fluids, molecules or other biological materials obtained, or obtainable, from a mammal. Non-limiting examples include urine, blood and fractions thereof such as serum, plasma, lymphocytes and erythrocytes, cerebrospinal fluid, PAP smears, nasal and ocular secretions, amniotic fluid, faeces, semen, tissue and/or organ biopsies and nucleic acid (e.g. DNA, RNA) or protein samples, although without limitation thereto.

[00213] The following experimental section describes in more detail the characterisation of certain of the compounds of the invention and their efficacy. The intention is to illustrate certain specific embodiments of the compounds of the invention and their efficacy without limiting the invention in any way.

EXPERIMENTAL

General Synthetic Methods



Method A:

A1: To a solution of R2 amine intermediate (1 eq.) with or without base such as, but not exclusively, triethylamine (1.2 eq.) in an anhydrous aprotic solvent such as, but not exclusively, tetrahydrofuran or dichloromethane was added triphosgene (0.4 to 1.1 eq.). The reaction was stirred at ambient temperature or, where necessary, heated at reflux until completion, typically from 2 to 18 h.

A2: To di-*t*-butyldicarbonate (1.2-1.4 eq.) in anhydrous acetonitrile or THF was added DMAP (15-100 mol%), after 5 minutes, a solution of R2 amine

intermediate (1.0 eq.) in acetonitrile was added. The reaction mixture was stirred for 30-60 min at room temperature.

Method B:

B1: The R2 carboxylic acid intermediate (1 eq.) was dissolved in an aprotic solvent such as toluene with or without 2 drops of DMF and a chlorinating agent such as thionyl chloride (2 eq.) added. The reaction mixture was heated at reflux until completion, then concentrated *in vacuo*. To give the corresponding R2 acid chloride intermediate.

Alternative methods of forming the acid chloride are also equally useful here for example the above procedure can be carried out without toluene and DMF thereby using thionyl chloride as both solvent and chlorinating agent.

The R2 acid chloride intermediate was dissolved in acetone and added drop-wise to a solution of sodium azide (1.5 eq) in a water:acetone (50:50) solution at 0 °C. Iced water was added to precipitate the resulting R2 acylazide intermediate which was dissolved in toluene and dried (MgSO₄) prior to adding the solution in a drop-wise fashion to anhydrous toluene at reflux while maintaining a constant flow of inert gas. The reaction was heated until completion, typically 2 h, to give the R2 isocyanate.

B2: The R2 acid chloride (formed as indicated in method B1) in dry CH₂Cl₂ was added NaN₃ (2.0 eq.) at 0 °C. The reaction mixture was stirred at room temperature for 1 h and extracted into EtOAc. The organic layer was washed with H₂O (15 mL), dried (MgSO₄), and carefully evaporated to give acyl azide. The acyl azide was dissolved in dry toluene and heated to 100 °C for 2 h. The solvent was removed to give crude R2 isocyanate.

Method C:

C1: R1 sulfonamide intermediate (1 eq.) was dissolved in anhydrous THF and treated with NaH (1 eq.) under reduced pressure. The mixture was heated to

reflux for 2 h then cooled to room temperature and R2 isocyanate intermediate in THF added under nitrogen atmosphere. The reaction mixture was stirred at reflux until completion.

C2: R1 sulfonamide intermediate (1 eq.) was dissolved in anhydrous THF or anhydrous methanol and treated with NaH (1 eq.) under reduced pressure. Once effervescence ceased the R2 isocyanate intermediate was added and the reaction mixture was stirred at ambient temperature overnight.


C3: To R1 sulfonamide intermediate (1 eq) in anhydrous THF (5 mL/mmol) was added NaH (1 eq) at 0 °C and stirred for 30 min to 2 h, or until completion, at ambient temperature under nitrogen atmosphere. Again cooled to 0 °C, R2 isocyanate (1.0 eq) in THF was added and stirred at ambient temperature until completion, typically 2 to 16 h.

C4: To crude R2 isocyanate (1.0 eq) in anhydrous THF or DCM (5-11 mL/mmol) was added R1 sulfonamide (1.0 eq) followed by base such as triethylamine , DIPEA, or DBU (1-2 eq) and the reaction mixture stirred at ambient temperature overnight.

C5: To R1 sulfonamide intermediate (1 eq) in anhydrous MeOH (5 mL/mmol) was added NaOMe (1 eq) [alternatively: a 1.0 mM solution of freshly prepared sodium methoxide (1 eq) was added to a 1.0 mM solution of R1 sulfonamide (1 eq) in anhydrous methanol]. The solvent was then removed *in vacuo*. The salt was suspended in anhydrous aprotic solvent such as acetonitrile or THF, the R2 isocyanate (1.0 eq) in anhydrous aprotic solvent such as acetonitrile or THF was added and the mixture stirred at ambient temperature overnight. The solution was then heated at reflux until completion, typically 90 min.

C6: R1 sulfonamide (1.0 eq.) was dissolved in anhydrous THF under a nitrogen atmosphere. Solid sodium methoxide (1.0 eq mmol) was added in one portion. This mixture was stirred at ambient temperature for 3 h. A solution of the R2

isocyanate (1.17 eq) in THF was added drop wise. The reaction mixture was stirred at room temperature overnight.



Method D:

A solution of amine (1.0 eq) in acetonitrile (7-12 mL/mmol) at 0 °C was treated with c.HCl (1.25-2.25 mL/mmol) in H₂O (0.5-1.2 mL/mmol) followed by aqueous solution of NaNO₂ (1.2 eq) dissolved in H₂O (0.3-0.5 mL/mmol of NaNO₂). The resulting solution was stirred at 0 °C for 45 min. AcOH (0.5-1.2 mL/mmol), CuCl₂·2H₂O (0.5 eq) and CuCl (0.05 eq) were sequentially added to the above mixture and purged with SO₂ gas for 20 min at 0 °C. The resulting reaction mixture was stirred at 0°C- 10°C until completion.

Method E:

E1: A solution of sulfonyl chloride (1 eq) in THF (10-20 mL/mmol) was cooled to -78 °C and ammonia gas was bubbled through the solution for 15 min, stirring was continued for a further 30 min then allowed to warm to ambient temperature and stirred for 2h or until completion.

E2: A solution of sulfonyl chloride (1 eq) in acetone (20 mL/mmol) was treated with a solution of NH₄HCO₃ (4 eq) dissolved in water 1.5 mL/mmol of NH₄HCO₃) at ambient temperature and stirred for 4 h or until completion.

E3: A solution of sulfonyl chloride (1 eq) in acetone (2.5 mL/mmol) was treated with NH₃ (3.5 mL/mmol, NH₄OH in H₂O, 28% NH₃ basis) at 0 °C and stirred for 2 h or until completion.

Method F




General Procedure for the synthesis of triazoles

Alkyne (1 eq) and azide (1.2 eq), 5 mol% CuSO₄, 10 mol% NaAsc solution in DMSO (500 μ L) were stirred at room temperature until completion, typically 12 h.


Synthesis of R1 sulfonamide intermediates:

Cyclohexanesulfonamide



To a solution of cyclohexanesulfonyl chloride (0.1 g, 0.54 mmol) in acetone (1 mL) was added aq NH₃ (2 mL, 28% NH₄OH in H₂O) at 0 °C and the reaction mixture stirred at room temperature for ~2 h. The solvent was removed *in vacuo* and MeOH/dichloromethane (1:9) (5 mL) added the NH₄Cl by-product was removed by filtration and remaining solution concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 0.2% MeOH-CH₂Cl₂ eluent to give cyclohexanesulfonamide as an off-white solid (30 mg, 34%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 6.61 (br s, 2H), 2.76-2.70 (m, 1H), 2.09-2.04 (m, 2H), 1.80-1.76 (m, 2H), 1.65-1.60 (m, 1H), 1.31-1.19 (m, 4H), 1.16-1.06 (m, 1H).


Cyclopentanesulfonamide



To a solution of cyclopentanesulfonyl chloride (0.1 g, 0.59 mmol) in acetone (1 mL) was added aq NH₃ (1 mL, 28% NH₄OH in H₂O) at 0 °C, and the reaction mixture stirred at room temperature for ~2 h. The solvent was removed *in vacuo*

and MeOH/dichloromethane(1:9) (5 mL) added the NH_4Cl by-product was removed by filtration and remaining solution concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 35% EtOAc-hexanes eluent to give cyclopentanesulfonamide as an off-white solid (72 mg, 81%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 6.69 (br s, 2H), 3.42-3.32 (m, 1H), 1.89-1.84 (m, 4H), 1.68-1.64 (m, 2H), 1.61-1.52 (m, 2H).

5-((dimethylamino)methyl)furan-2-sulfonamide



Furan-2-carboxylic acid (5 g, 44.6 mmol) was dissolved in ethanol (100 mL), $\text{c.H}_2\text{SO}_4$ (1.0 mL) was added and the solution heated to reflux overnight. The reaction mixture was concentrated *in vacuo* then partitioned between ethyl acetate (100 mL) and saturated NaHCO_3 (100 mL). The organic phase was washed using water then brine, dried (MgSO_4) and concentrated *in vacuo* to give ethyl furan-2-carboxylate (4.5 g, 80%). ^1H NMR (400 MHz, CDCl_3): δ = 7.57 (d, J = 1.2 Hz, 1H), 7.18 (d, J = 3.5 Hz, 1H), 6.51 (dd, J = 3.5, 1.2 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H).

Ethyl furan-2-carboxylate (9.0 g, 64.3 mmol) was dissolved in dichloromethane (200 mL) and chlorosulfonic acid (7.5 g, 64.3 mmol) added. The reaction was stirred at ambient temperature for 6 hours, or until completion, then pyridine (5.6 g, 70.7 mmol) and PCl_5 (14.7 g, 70.7 mmol) were added portionwise. The reaction mixture was stirred at ambient temperature for 16 hours then quenched using ice-water and stirred for 30 mins. The mixture was extracted using DCM and the combined organics washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product, ethyl 5-

(chlorosulfonyl)furan-2-carboxylate (7 g, 46%) was used directly without further purification. ^1H NMR (300 MHz, CDCl_3) δ = 7.33 (d, J = 3.9 Hz, 1H), 7.27 (d, J = 3.9 Hz, 1H), 4.44 (q, J = 7.1 Hz, 1H), 1.42 (t, J = 7.1 Hz, 2H).


The crude ethyl 5-(chlorosulfonyl)furan-2-carboxylate (7 g) was converted using general method E1 to give ethyl 5-sulfamoylfuran-2-carboxylate (5 g, 78%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ = 8.05 (s, 2H), 7.38 (d, J = 3.7 Hz, 1H), 7.09 (d, J = 3.7 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H).

Ethyl 5-sulfamoylfuran-2-carboxylate (2 g, 9.13 mmol) in dry THF (40 mL) was cooled to 0 °C and lithium aluminium hydride (1.05 g, 27.3 mmol) was added portion-wise over a period of 30 mins. The reaction was heated to 70 °C for 4 hours. The reaction was cooled to 0 °C and saturated NH_4Cl was added (20 mL) dropwise with great care over a period of 30 mins. The reaction mixture was diluted using ethyl acetate (100 mL) and filtered through a pad of celite. The organic phase was washed with water (100 mL), brine (100 mL), dried (MgSO_4) and concentrated *in vacuo* to give 5-(hydroxymethyl)furan-2-sulfonamide (1.25 g, 78%) as a pale brown liquid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.71 (s, 2H), 6.88 (d, J = 3.5 Hz, 1H), 6.44 (d, J = 3.4 Hz, 1H), 5.47 (s, 1H), 4.44 (d, J = 5.7 Hz, 2H), 3.36 (s, 7H), 2.51 (q, J = 1.8 Hz, 5H), 1.36 (s, 1H).

5-(hydroxymethyl)furan-2-sulfonamide (0.3 g, 1.7 mmol) in THF (5 mL) was cooled to 0 °C and POCl_3 (0.4 g, 2.54 mmol) added slowly. The reaction mixture was stirred at 75 °C for 2 hours then cooled to ambient temperature. The crude mixture was partitioned between ethylacetate (50 mL) and sat. aq. NaHCO_3 (50 mL) and the organic phase washed with water (50 mL), brine (50 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 30% EtOAc-hexanes eluent to give 5-(chloromethyl)furan-2-sulfonamide as a pale-brown semi-solid (0.25 g, 76%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ = 7.85 (s, 2H), 6.93 (dd, J = 3.5, 1.3 Hz, 1H), 6.69 (dd, J = 3.5, 1.3 Hz, 1H), 4.89 (d, J = 1.3 Hz, 2H).


5-(chloromethyl)furan-2-sulfonamide (0.4 g, 2.05 mmol) in THF (20 mL) was cooled to 0 °C, c.HCl (7.5 mg, 2.05 mmol) was added and the solution stirred for 20 mins at this same temperature. 5.6 M *N,N*-dimethylamine in ethanol (0.28 g, 6.15 mmol, 3 eq.) was added at 0 °C and the reaction tube sealed before stirring at room temperature overnight. The solvents were removed in vacuo and azeotroped using toluene (x2) to give 5-((dimethylamino)methyl)furan-2-sulfonamide as a gum (0.25 g, 60%). The crude product was used directly without further purification.

Furan-2-sulfonamide



Furan-2-sulfonyl chloride (0.30 g, 1.8 mmol) was added to aqueous ammonia (1.0 mL) at 0 °C and the mixture was stirred at ambient temperature for 1 h. Upon completion of the reaction, the excess aqueous ammonia was removed *in vacuo*. The residue was azeotroped with isopropanol and triturated with pentane to afford the titled compound as a light brown solid (0.21 g, 79%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.91 (s, 1H), 7.45 (br.s., 2H), 6.95 (d, *J* = 3.6 Hz, 1H), 6.63 (dd, *J* = 2.8, 1.6 Hz, 1H). LC-MS 97.4% (ELSD); *m/z* 146.11 [*M* - H]⁺.

5-methylfuran-2-sulfonamide




To a solution of 2-methylfuran (2.0 g, 24.3 mmol) in anhydrous acetonitrile (4 mL) was added SO₃•Py complex (5.0 g, 31.6 mmol) and the reaction mixture heated at 40 °C under nitrogen overnight. The reaction mixture was diluted with EtOAc (5 mL) and stirred for 2 h at 0 °C, the resulting precipitates were removed by filtration and dried to give pyridinium 5-methylfuran-2-sulfonate as

an off-white solid (2.93 g, 50%). ^1H NMR (400 MHz, DMSO): δ = 8.90 (dd, J_1 = 4 Hz, J_2 = 8 Hz, 2H), 8.57 (tt, J_1 = 1.5 Hz, J_2 = 8.1 Hz, 1H), 8.04 (dd, J_1 = 4 Hz, J_2 = 8 Hz, 2H), 6.27 (d, J = 3.0 Hz, 1H), 5.98-5.94 (m, 1H), 2.19 (s, 3H).

A slurry of pyridinium 5-methylfuran-2-sulfonate (1.0 g, 4.41 mmol) in anhydrous DME was treated with oxalyl chloride (0.53 mL, 6.21 mmol) then DMF (0.32 mL, 4.41 mmol) at 0 °C under argon and the reaction stirred at room temperature until completion. The reaction was quenched with ice-water and extracted with toluene (2 $\times$ 50 mL), the combined organics were washed with aqueous saturated NaHCO_3 (20 mL), brine (20 mL), dried (MgSO_4) and concentrated *in vacuo* to give 5-methylfuran-2-sulfonyl chloride as pale-yellow oil (350 mg, 47%). ^1H NMR (400 MHz, CDCl_3): δ = 7.23-7.21 (m, 1H), 6.27-6.25 (m, 1H), 2.47 (s, 3H).

To a solution of 5-methylfuran-2-sulfonyl chloride (0.2 g, 1.10 mmol) in acetone (1 mL) was added aq. NH_3 (1 mL, 28% NH_4OH in H_2O) at 0 °C. The reaction mixture was stirred at ambient temperature for ~2 h then concentrated *in vacuo*. The residue was suspended in dichloromethane (5 mL) the NH_4Cl by-product was removed by filtration and remaining solution concentrated *in vacuo*. The crude product purified by column chromatography on silica gel using 40% EtOAc-hexanes eluent to give 5-methylfuran-2-sulfonamide as an off-white solid (130 mg, 73%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.60 (s, 2H), 6.83-6.82 (d, J = 4.0 Hz, 1H), 6.26-6.25 (d, J = 4.0 Hz, 1H), 2.34 (s, 3H).

5-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide




To a solution of 2-ethylfuran (2.0 g, 20.8 mmol) in anhydrous acetonitrile (3 mL) was added $\text{SO}_3\cdot\text{Py}$ complex (4.30 g, 27.0 mmol). The resulting reaction mixture

was heated at 40 °C under nitrogen atmosphere for 23 h or until completion. EtOAc (5 mL) was added and the solution stirred for 2 h at 0 °C. The resulting precipitate was removed by filtration and dried to give pyridin-1-ium 5-ethylfuran-2-sulfonate as a brown coloured hygroscopic solid (3.2 g, 60%) which was used directly in the next step without purification.

To a slurry of pyridinium 5-ethylfuran-2-sulfonate (3.2 g, 12.5 mmol) in DME (15 mL) was added oxalyl chloride (1.62 mL, 27.0 mmol) and then DMF (0.97 mL, 12.5 mmol) at 0 °C under argon atmosphere, the resulting reaction mixture was stirred at room temperature until completion. The reaction mixture was quenched with ice-water and then extracted with toluene (2 × 50 mL), organic layer was washed with aqueous saturated NaHCO₃ (20 mL) and brine (20 mL), dried (MgSO₄) and concentrated *in vacuo* to give 5-ethylfuran-2-sulfonyl chloride as light brown oil (510 mg, 21%). ¹H NMR (400 MHz, CDCl₃): δ 7.23 (d, *J* = 4 Hz, 1H), 6.26 (d, *J* = 8 Hz, 1H), 2.80 (q, *J* = 8 Hz, 2H), 1.33 (t, *J* = 8 Hz, 3H).


To a solution of 5-ethylfuran-2-sulfonyl chloride in acetone (1 mL) was added aq NH₃ (1.5 mL, NH₄OH in H₂O, 28% NH₃ basis) at 0 °C, resulting reaction mixture was stirred at room temperature for 2 h or until completion. The solvent was removed in vacuo and azeotroped with toluene (x2). The residue was purified by column chromatography on silica using 1% MeOH/DCM eluant to give 5-ethylfuran-2-sulfonamide as brown coloured gum (0.36 g, 78%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.63 (bs, 2H), 6.85 (d, *J* = 4 Hz, 1H), 6.28 (d, *J* = 4 Hz, 1H), 2.70 (q, *J* = 8 Hz, 2H), 1.21 (t, *J* = 6 Hz, 3H).

4-(prop-1-en-2-yl)furan-2-sulfonamide




Synthesis of 4-(prop-1-en-2-yl)furan-2-sulfonamide was carried out from ethyl furan-3-carboxylate using procedures detailed by Urban *et.al. Synth. Commun.* **2003**, *33*(12), 2029-2043 to give the titled compound as a white solid with all spectral data consistent with the specified literature reference.

***d*₆-4-(prop-1-en-2-yl)furan-2-sulfonamide**




Modification of the procedures contained within Urban *et.al. Synth. Commun.* **2003**, *33*(12), 2029-2043 to use methyl-*d*₃-magnesium iodide in place of methyl magnesium chloride gives the corresponding *d*₆-4-(prop-1-en-2-yl)furan-2-sulfonamide.

4-(prop-1-en-2-yl)furan-2-sulfonamide



To a solution of triphenylphosphine (0.3 g, 1.16 mmol) in anhydrous THF (5.0 mL) was added iodine (1.0 eq.) and the mixture stirred at room temperature for 10 min. A solution of 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide in THF (3.0 mL) was added slowly and stirring was continued for 2 h or until completion. The solution was diluted with EtOAc (20 mL), washed with 10% aq. sodium bisulfite (20 mL), water (20 mL). The organic layer was separated, dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc:hexanes eluent to give the titled compound as a white solid (0.1 g, 58%). ¹H NMR (400 MHz, CDCl₃) δ = 7.51 (s, 1H), 7.16 (s, 1H), 5.27 (s, 2H), 2.02 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 149.3, 140.7, 140.7, 132.3, 127.8, 112.1, 111.9, 76.0, 7.7, 28.7, 19.8.

4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide




To a solution of ethyl 2-methyl-3-furoate (30 g, 0.195 M) in DCM (300 mL) at -10°C was added chlorosulfonic acid (23.8 g, 0.204 M) drop-wise over ~ 15 min. The reaction was allowed to warm to ambient temperature and stirred for 72 hours. The solution was cooled to -10°C and anhydrous pyridine (16.9 g, 0.214 M) added drop wise followed by phosphorous pentachloride (44.6 g, 0.214 M) added in ~ 10 g portions over 10 min. Stirred at $<0^{\circ}\text{C}$ for 30 min then stirred at ambient temperature overnight. The reaction mixture was added drop-wise to water (550 mL) with stirring and stirring continued for 2 hours. The organic phase was separated and the aqueous phase extracted using DCM (150 mL). The combined organics were washed using water (300 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give 44 g dark red oil. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexane eluent to give ethyl 5-(chlorosulfonyl)-2-methylfuran-3-carboxylate as an orange oil (36 g, 73%). ^1H NMR (400 MHz, CDCl_3) δ = 7.55 (s, 1H), 4.63 (q, J = 7.2 Hz, 2H), 2.75 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H).

Ethyl 5-(chlorosulfonyl)-2-methylfuran-3-carboxylate (30 g, 0.12 M) in acetone (200 mL) was added drop-wise over 15 min to a solution of ammonium bicarbonate (37.6 g, 0.475 M) in water (630 mL). The reaction mixture was stirred at ambient temperature until completion (~ 3 h). EtOAc (250 mL) was added and the pH adjusted using drop-wise addition of cHCl to pH $\sim$ 2. The organics were separated and the remaining aqueous phase saturated with sodium chloride and re-extracted using EtOAc (250 mL). The combined organics were washed with brine (300 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give a brown oily solid which was recrystallized using EtOAc-hexane to

give ethyl 2-methyl-5-sulfamoylfuran-3-carboxylate as a beige solid (11.4 g, 41%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 7.8 (s, 2H), 7.02 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 2.62 (s, 3H), 1.3 (t, J = 7.2 Hz, 3H).

Ethyl 2-methyl-5-sulfamoylfuran-3-carboxylate (10 g, 0.043 M) in anhydrous THF (400 mL) at -10°C was treated with methyl magnesium chloride solution (3.0 M in THF, 64.3 mL) drop-wise over 5 minutes with vigorous stirring. The solution was then stirred at ambient temperature for 6 hours then cooled to -5°C and treated drop-wise with a solution of ammonium chloride (51.8 g in 265 mL water). The aqueous solution was extracted using EtOAc (2 x 250 mL), the combined organics washed with brine (250 mL), dried (Na_2SO_4) and concentrated *in vacuo* to an orange oil (10 g). The crude product was purified by column chromatography on silica gel using 40% EtOAc-hexane eluent to give the titled compound as a white solid (6.1 g, 42%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 7.54 (br.s., 2H), 6.78 (s, 1H), 4.95 (s, 1H), 2.42 (s, 3H), 1.4 (s, 6H).

d_6 -4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide




Methyl 2-methyl-5-sulfamoylfuran-3-carboxylate can be prepared by modification of procedures used to synthesise ethyl 2-methyl-5-sulfamoylfuran-3-carboxylate but using methyl 2-methylfuran-3-carboxylate as starting material in place of ethyl 2-methylfuran-3-carboxylate. Methyl 2-methyl-5-sulfamoylfuran-3-carboxylate was obtained as a white solid (3 g, 29%) ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 7.89 (s, 2H), 7.03 (s, 1H), 3.79 (s, 3H), 2.61 (s, 3H).

Methyl 2-methyl-5-sulfamoylfuran-3-carboxylate (0.7 g, 3.2 mmol) in anhydrous THF (20 mL) at -10°C was treated with d_3 -methyl magnesium iodide solution

(1.0 M in Et₂O, 26 mL) drop-wise over 10 minutes with vigorous stirring. The solution was then stirred at ambient temperature for 12 h then cooled to 0 °C and treated drop-wise with a solution of sat. ammonium chloride. The aqueous solution was extracted using EtOAc (2 x 25 mL), the combined organics washed with brine (25 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using a gradient of 40-70% EtOAc-hexane eluent to give the titled compound as a white solid (0.37 g, 51%). ¹H NMR (400 MHz, DMSO-d₆) δ = 7.57 (s, 2H), 6.79 (s, 1H), 4.99 (s, 1H), 2.4 (s, 3H). ¹³C NMR (100 MHz, CD₃OD) δ = 150.3, 147.3, 128.4, 113.4, 67.3, 28.5 (multiplet), 12.2.

1-benzyl-1*H*-1,2,4-triazole-3-sulfonamide




A solution of 1*H*-1,2,4-triazole-3-thiol (1 g, 9.90 mmol) in DMF (20 mL) was treated with K₂CO₃ (4.8g, 34.7 mmol), cooled to 0 °C then benzyl bromide (4.2 g, 24.8 mmol) was added drop-wise over 5 min. The resulting reaction mixture was warmed to ambient temperature and stirred for 12 h. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 1-benzyl-3-(benzylthio)-1*H*-1,2,4-triazole as a white solid (1.5 g 54%). ¹H NMR (400 MHz, DMSO-d₆): δ = 8.67 (s, 1H), 7.39-7.32 (m, 5H), 7.27-7.21 (m, 5H), 5.36 (s, 2H), 4.29 (s, 2H).

To a solution of 1-benzyl-3-(benzylthio)-1*H*-1,2,4-triazole, **2** (0.5 g, 1.77 mmol)

in acetonitrile (5 mL) at 0 °C was added AcOH (3 mL) and H₂O (2 mL) then and Cl₂ gas was bubbled through the solution for 45 min. Stirring was continued at 0 °C for 30 min then at 20 °C for 1.5h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give a colorless liquid. The residue was diluted with THF and cooled to -78°C. Ammonia gas was bubbled through the solution for 20 min and stirring continued for a further 30 min before warming to ambient temperature and stirring for 1 h. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The residue was triturated with diethyl ether to give 1-benzyl-1*H*-1,2,4-triazole-3-sulfonamide as an off-white solid (0.25 g, 60%). ¹H NMR (400 MHz, DMSO-d₆): δ = 8.88 (s, 1H), 7.77 (s, 2H), 7.39-7.33 (m, 5H), 5.45 (s, 2H).

1-isopropyl-1*H*-1,2,3-triazole-4-sulfonamide



Sodium 1*H*-1,2,3-triazole-5-thiolate (500 mg, 4.06 mmol) was dissolved in EtOH (5 mL) and cooled to 0 °C. Benzyl bromide (0.69 g, 4.06 mmol) was added drop wise over a period of 5 min. The resulting reaction mixture was warmed to RT and stirred for 1h. Upon completion, the reaction mixture was concentrated *in vacuo* and residue obtained was diluted with saturated NaHCO₃ solution and extracted with EtOAc (2 x 20 mL). The combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The residue

obtained was stirred with n-pentane (30 mL), filtered and dried *in vacuo* to give 4-(benzylthio)-1*H*-1,2,3-triazole as a white solid (0.7 g, 90%) which was used without further purification. ^1H NMR (400 MHz, CDCl_3): δ = 7.40-7.38 (m, 1H), 7.35-7.21 (m, 5H), 4.12 (s, 2H). LCMS (m/z): 192.0 $[\text{M}+\text{H}]^+$


A solution of 4-(benzylthio)-1*H*-1,2,3-triazole (5 g, 26.1 mmol) in DMF (50 mL) was cooled to 0 °C and treated with K_2CO_3 (9.03 g, 65.4 mmol). The reaction mixture was stirred for 5 minutes at same temperature. Isopropyl iodide (8.89 g, 52.3 mmol) was added drop wise to the above mixture over 5 min. The resulting reaction mixture was warmed to RT and stirred for 2h. Upon completion, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL). The organic extract was washed with water, brine and dried over anhydrous Na_2SO_4 . The crude product was purified by column chromatography on silica using, 8% EtOAc-hexane eluent to give 5-(benzylthio)-1-isopropyl-1*H*-1,2,3-triazole **A** (0.9 g), 4-(benzylthio)-2-isopropyl-2*H*-1,2,3-triazole **B** (1 g) and the desired product 4-(benzylthio)-1-isopropyl-1*H*-1,2,3-triazole **C** (1.4 g, 23%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.29-7.18 (m, 5H), 4.78-4.71 (m, 1H), 4.09 (s, 2H), 1.4 (d, J = 6.8 Hz, 6H). LCMS (m/z): 234.30 $[\text{M}+\text{H}]^+$.

A solution of 4-(benzylthio)-1-isopropyl-1*H*-1,2,3-triazole (75 mg, 0.32 mmol) in acetic acid (2.25 mL) and H_2O (1.12 mL) was cooled to 0 °C. *N*-chlorosuccinamide (170 mg, 1.28 mmol) was added at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 1 h. Upon completion, the reaction mixture was diluted with water and extracted with ethyl acetate (2 x 10 mL). The combined organic extracts were washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica using, 8% EtOAc-hexanes eluant to give 1-isopropyl-1*H*-1,2,3-triazole-4-sulfonyl chloride (0.1 g, 100%) as a pale brown liquid used without further purification. LCMS (m/z): 210.10 $[\text{M}+\text{H}]^+$.

A solution of 1-isopropyl-1*H*-1,2,3-triazole-4-sulfonyl chloride (100 mg) in THF


(5 mL) was cooled to $-40\text{ }^{\circ}\text{C}$. Ammonia gas was purged through the aforementioned solution for 15 min. The reaction mixture was warmed to RT and stirred for 2h. Upon completion, the reaction mixture was concentrated *in vacuo* and residue obtained was diluted with ethyl acetate (25 mL) and water (10 mL). The organic extract was washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo* to give 1-isopropyl-1*H*-1,2,3-triazole-4-sulfonamide (0.07 g, 78%) as brown solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.71 (s, 1H), 7.66 (s, 2H), 4.91-4.87 (m, 1H), 1.5 (d, J =6.8 Hz, 6H). LCMS (m/z): 191.30 $[\text{M}+\text{H}]^+$.

1-methyl-1*H*-pyrazole-3-sulfonamide



1-Methyl-1*H*-pyrazol-3-amine hydrochloride was reacted to 1-methyl-1*H*-pyrazole-3-sulfonyl chloride, a pale-yellow liquid, using general method D (0.7 g, 38%). ^1H NMR (300 MHz, CDCl_3): δ = 7.51-7.50 (d, J = 2.1 Hz, 1H), 6.89-6.88 (d, J = 2.4 Hz, 1H), 4.06 (s, 3H). LCMS (m/z): 160.9 ($\text{M}-1$) $^-$. The sulfonyl chloride was converted using general method E1 to give the titled compound as an off-white solid (0.4 g, 69%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.80 (d, J = 2.1 Hz, 1H), 7.36 (s, 2H), 6.53 (d, J = 2.1 Hz, 1H), 3.88 (s, 3H). LCMS (m/z): 162.05 ($\text{M}+1$) $^+$.

1-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide




1-(trifluoromethyl)-1*H*-pyrazol-3-amine was reacted to 1-(trifluoromethyl)-1*H*-pyrazole-3-sulfonyl chloride, a brown liquid, using general method D (0.4 g, 43%). ^1H NMR (300 MHz, CDCl_3) δ = 8.02 (d, J = 2.8 Hz, 1H), 7.06 (d, J = 2.8

Hz, 1H). ^{19}F NMR (282 MHz, CDCl_3) δ = -60.46.


The sulfonyl chloride was converted using general method E1 to give the titled compound (0.22 g, 46%). ^1H NMR (300 MHz, CDCl_3) δ = 7.92 (dd, J = 2.8, 0.3 Hz, 1H), 6.91 (dd, J = 2.8, 0.7 Hz, 1H), 5.28 (s, 2H). ^{19}F NMR (282 MHz, CDCl_3) δ = -60.41.

1-isopropyl-1*H*-pyrazole-3-sulfonamide



1-Isopropyl-1*H*-pyrazol-3-amine was reacted to 1-isopropyl-1*H*-pyrazole-3-sulfonyl chloride, a brown liquid, using general method D (0.5 g, 43 %). ^1H NMR (400 MHz, CDCl_3): δ = 7.55 (s, 1H), 6.88 (s, 1H), 4.66-4.63 (m, 1H), 3.6 (br.s., 2H), 1.59 (d, J = 6.8 Hz, 6H). LCMS (m/z): 209.0 ($M+1$) $^+$. The sulfonyl chloride was converted using general method E1 to give the titled compound as yellow solid (0.45 g, 82%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 7.9 (d, J = 2.4 Hz, 1H), 7.36 (s, 2H), 6.55 (d, J = 2.1 Hz, 1H), 4.57-4.53 (m, 1H), 1.42 (d, J = 6.9 Hz, 6H). LCMS (m/z): 190.0 ($M+1$) $^+$.

1-isopropyl-1*H*-pyrazole-4-sulfonamide



A solution of 4-iodo-1*H*-pyrazole (1 g, 5.15 mmol) in DMF (20 mL) was treated with K_2CO_3 (1.42g, 10.30 mmol) and isopropyl iodide (1.05 g, 6.19 mmol) at ambient temperature under nitrogen atmosphere. The resulting reaction mixture was heated to 90 $^\circ\text{C}$ and stirred for 12 h. The mixture was cooled, diluted with water (50 mL) and extracted with diethyl ether (2 x 50 mL). The combined


organics were washed with water (2 x 50 mL), brine (50 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 4-iodo-1-isopropyl-1*H*-pyrazole as a colorless liquid (1.1 g, 92%). ^1H NMR (400 MHz, CDCl_3): δ = 7.50-7.46 (m, 2H), 4.53-4.47 (m, 1H), 1.50 (d, J = 6.8 Hz, 6H). LCMS (m/z): 237.2 ($M + 1$)⁺.

A solution of 4-iodo-1-isopropyl-1*H*-pyrazole (1 g, 4.24 mmol) in dioxane (20 mL) was treated sequentially with benzyl mercaptan (0.8g, 6.35 mmol) and DIPEA (1.1g, 8.47 mmol) under nitrogen atmosphere. The solution was degassed by purging with argon gas for 15 min. $\text{Pd}_2(\text{dba})_3$ (40 mg, 0.0423 mmol) and Xantphos (50 mg, 0.0847 mmol) were added under argon atmosphere then the resulting mixture was sealed in the reaction vessel and heated at 75 °C for 6 h. The reaction mixture was cooled, concentrated *in vacuo*, diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were washed with water (2 x 50 mL), brine (50 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 4-(benzylthio)-1-isopropyl-1*H*-pyrazole as a yellow liquid (650 mg, 66%). ^1H NMR (400 MHz, CDCl_3): δ = 7.36 (s, 1H), 7.26-7.22 (m, 4H), 7.11-7.09 (m, 2H), 4.41-4.36 (m, 1H), 3.76 (s, 2H), 1.42 (d, J = 6.8 Hz, 6H). LCMS (m/z): 233.3 ($M + 1$)⁺

To a solution of 4-(benzylthio)-1-isopropyl-1*H*-pyrazole, 3 (0.35 g, 1.508 mmol) in acetonitrile (10 mL) at 0 °C was added AcOH (0.7 mL) and H_2O (0.35 mL) then DCDMH (0.6 g, 3.017 mmol) was added portion-wise over 5 min. The solution was stirred for 30 min then warmed to ambient temperature and stirred for a further 2 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give 1-isopropyl-1*H*-pyrazole-4-sulfonyl chloride as a colorless liquid. The sulfonyl


chloride was diluted with THF and cooled to -78°C then NH_3 gas was bubbled through the solution for 15 minutes. The reaction mixture was stirred at -78°C for 1 h and at ambient temperature for 2 h. The reaction mixture was diluted with water and compound extracted with ethyl acetate (2 x 25 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The residue obtained was triturated with diethyl ether and dried under reduced pressure give 1-isopropyl-1*H*-pyrazole-4-sulfonamide as a light brown solid (0.2 g, 71%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.21 (s, 1H), 7.71 (s, 1H), 7.22 (s, 2H), 4.59-4.53 (m, 1H), 1.4 (d, J = 6.8 Hz, 6H). LCMS (m/z): 190.2 ($M + 1$) $^+$.

1-cyclopropyl-1*H*-pyrazole-3-sulfonamide



1-Cyclopropyl-1*H*-pyrazole-3-amine was reacted to 1-cyclopropyl-1*H*-pyrazole-3-sulfonyl chloride using general method D then converted using general method E1 to give the titled compound as a light brown solid (0.2 g, 33%). ^1H NMR (400 MHz, CDCl_3) δ = 7.51 (d, J = 2.4 Hz, 1H), 6.69 (d, J = 2.4 Hz, 1H), 5.04 (s, 2H), 3.67 (m, 1H), 1.28 – 1.05 (m, 4H).


1-(*tert*-butyl)-1*H*-pyrazole-3-sulfonamide



1-(*tert*-butyl)-1*H*-pyrazol-3-amine was reacted to 1-(*tert*-butyl)-1*H*-pyrazole-3-sulfonyl chloride using general method D then converted using general method E1 to give the titled compound as a light brown solid (150 mg, 26%). ^1H NMR


(400 MHz, DMSO- d_6): δ = 7.56 (d, J = 3.6 Hz, 1H), 6.7 (d, J = 3.2 Hz, 1H), 4.75 (br.s., 1H), 1.60 (s, 9H). LCMS (m/z): 204.15 ($M+1$)⁺.

1-cyclohexyl-1H-pyrazole-3-sulfonamide




1-Cyclohexyl-1H-pyrazole-3-amine was reacted to 1-cyclohexyl-1H-pyrazole-3-sulfonyl chloride using general method D then converted using general method E1 to give the titled compound as a white solid (0.35 mg, 50%). ¹H NMR (300 MHz, DMSO- d_6) δ = 7.89 (d, J = 2.3 Hz, 1H), 7.36 (s, 2H), 6.55 (d, J = 2.3 Hz, 1H), 4.28 – 4.08 (m, 1H), 2.0 1.1 (m, 6H).

1-phenyl-1H-pyrazole-3-sulfonamide




1-phenyl-1H-pyrazol-3-amine was reacted to 1-phenyl-1H-pyrazole-3-sulfonyl chloride, a yellow liquid, using general method D (0.5 g, 47 %). ¹H NMR (400 MHz, CDCl₃): δ = 8.04 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 9.2 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 7.2 Hz, 1H), 7.08 (d, J = 2.8 Hz, 1H). The sulfonyl chloride was converted using general method E1 to give the titled compound as a yellow solid (0.4 g, 87 %). ¹H NMR (400 MHz, DMSO- d_6): δ = 8.62 (d, J = 2.7 Hz, 1H), 7.86 (d, J = 8.7 Hz, 2H), 7.61 (br.s., 2H), 7.57 (t, J = 7.8 Hz, 2H), 7.41 (t, J = 7.2 Hz, 1H), 6.85 (d, J = 2.4 Hz, 1H). LCMS (m/z): 224.1 ($M+1$)⁺.

1-benzyl-1H-pyrazole-3-sulfonyl chloride




1-benzyl-1*H*-pyrazol-3-amine was reacted to 1-benzyl-1*H*-pyrazole-3-sulfonyl chloride, a light brown liquid, using general method D (0.2 g, 45%). ¹H NMR (300 MHz, CDCl₃): δ 7.42-7.38 (m, 3H), 7.33-7.28 (m, 3H), 6.8 (d, *J* = 2.4Hz, 1H), 5.42 (s, 2H). The sulfonyl chloride was converted using general method E1 to give the titled compound as a light brown liquid (0.15 g, 81%). ¹H NMR (400 MHz, CDCl₃): δ = 7.42-7.36 (m, 4H), 7.24 (d, *J* = 1.6Hz, 2H), 6.7 (d, *J* = 2.4Hz, 1H), 5.35 (s, 2H), 5.10 (s, 2H). LCMS (*m/z*): 238.10 (*M* + 1)⁺

1-(1-phenylethyl)-1*H*-pyrazole-3-sulfonamide



1-(1-phenylethyl)-1*H*-pyrazol-3-amine was reacted to 1-(1-phenylethyl)-1*H*-pyrazole-3-sulfonyl chloride using general method D then converted using general method E1 to give the titled compound as a white solid (0.25 mg, 68%). ¹H NMR (300 MHz, CDCl₃) δ = 7.43 – 7.18 (m, 6H), 6.72 (d, *J* = 2.4 Hz, 1H), 5.57 (q, *J* = 7.1 Hz, 1H), 5.02 (s, 2H), 1.92 (d, *J* = 7.1 Hz, 3H).


1-(2-(piperidin-1-yl)ethyl)-1*H*-pyrazole-3-sulfonamide



1-(2-(piperidin-1-yl)ethyl)-1*H*-pyrazol-3-amine was reacted to 1-(2-(piperidin-1-


yl)ethyl)-1*H*-pyrazole-3-sulfonyl chloride, a pale-brown liquid, using general method D then converted using general method E1 to give the titled compound as an off-white solid (0.3 g, 46%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.84 (d, *J* = 2.1 Hz, 1H), 7.36 (s, 2H), 6.54 (s, *J* = 2.4 Hz, 1H), 4.26 (t, *J* = 6.9 Hz, 2H), 2.66 (t, *J* = 6.6 Hz, 2H), 2.36 (s, 4H), 1.46-1.34 (m, 6H). LCMS (*m/z*): 259.10 (*M* + 1)⁺.

1,5-dimethyl-1*H*-pyrazole-3-sulfonamide




1,5-dimethyl-1*H*-pyrazol-3-amine was reacted to 1,5-dimethyl-1*H*-pyrazole-3-sulfonyl chloride, a yellow liquid, using general method D (0.45 g, 26%). ¹H NMR (300 MHz, CDCl₃): δ = 5.92 (s, 1H), 3.71 (s, 3H), 2.23 (s, 3H). LCMS (*m/z*): 217 (*M* + Na)⁺. The sulfonyl chloride was converted using general method E1 to give the titled compound as an off-white solid (0.25 g, 55%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.30 (s, 2H), 6.36 (s, 1H), 3.76 (s, 3H), 2.27 (s, 3H). LCMS (*m/z*): 175.9 (*M* + 1)⁺.

1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide



1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-amine was reacted to 1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonyl chloride, a pale-brown liquid, using general method D (1.1 g, 37%). ¹H NMR (300 MHz, CDCl₃): δ = 7.21 (s, 1H), 4.16 (s, 3H). The sulfonyl chloride was converted using general method E1 to give the titled compound as a yellow solid (0.45 mg, 82%). ¹H NMR (300 MHz, CDCl₃): δ = 7.06 (s, 1H), 5.02 (br.s., 2H), 4.03 (s, 3H).

1-isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide



A mixture of NaH (2.14 g, 89.3 mmol) in DMF (20 mL) was cooled to -10 °C. A solution of 1,1,1-trifluoropropan-2-one (5 g, 44.6 mmol) in DMF (80 mL) was added very carefully to the above mixture and stirred at -10 °C for 5 min. CS₂ (10.2 g, 133.9 mmol) was added drop-wise to the above mixture over 30 min then the reaction mixture was warmed to ambient temperature and stirred for 1 h. The reaction mixture was cooled to 0 °C and treated with CH₃I (7.5 mL) over 10 min. The resulting reaction mixture was warmed to ambient temperature and stirred for 12 h. The reaction mixture was diluted with cold water (50 mL) and extracted with diethyl ether (2 x 100 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give 1,1,1-trifluoro-4,4-bis(methylthio)but-3-en-2-one as a light brown solid (3.5 g, 36%). ¹H NMR (300 MHz, CDCl₃): δ = 6.24 (s, 1H), 2.57 (m, 6H). LCMS (*m/z*): 217.20 (M + 1)⁺.

A solution of 1,1,1-trifluoro-4,4-bis(methylthio)but-3-en-2-one (2.5 g, 11.6 mmol) in EtOH (25 mL) was treated with isopropyl hydrazine hydrochloride (2 g, 13.9 mmol) at 0 °C, Et₃N (2.4g, 40.98 mmol) was added and the mixture heated at 80°C for 12 h. The reaction mixture was concentrated *in vacuo*, diluted with sat. aq. NaHCO₃ solution and extracted with EtOAc (2 x 250 mL). The combined organics were washed with water (200 mL), brine (200 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 100% EtOAc eluent to give 1-isopropyl-3-


(methylthio)-5-(trifluoromethyl)-1*H*-pyrazole as a light brown liquid (1.5 g, 58%). ¹H NMR (400 MHz, CDCl₃): δ = 6.47 (s, 1H), 4.58-4.53 (m, 1H), 2.49 (s, 3H), 1.50 (d, *J* = 6.8 Hz, 6H). LCMS (*m/z*): 225.20 (*M* + 1)⁺.

A solution of 1-isopropyl-3-(methylthio)-5-(trifluoromethyl)-1*H*-pyrazole (0.5g, 2.23 mmol) in chloroform (10 mL) at 0°C was treated with mCPBA (0.38 g, 2.23 mmol) and stirred at 10 °C for 1 h. The reaction mixture was diluted with saturated NaHCO₃ solution (10 mL) and extracted with CHCl₃ (2 x 30 mL). The combined organics were washed with water (30 mL), brine (30 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The residue obtained was dissolved in CHCl₃ (10 mL) and treated with trifluoroacetic anhydride (1.4 g, 6.7 mmol) the reaction mixture was heated at 50 °C for 3 h, cooled to ambient temperature and concentrated *in vacuo*. The residue obtained was diluted with MeOH (5 mL)-THF (5 mL)-H₂O (5 mL), cooled to 0°C, treated with Na₂CO₃ (0.7 g, 6.7 mmol) and stirred for 3h. The solution was diluted with water (30 mL) and extracted with CHCl₃ (2 x 50 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue (0.2 g) containing 1-isopropyl-3-((1-isopropyl-5-(trifluoromethyl)-1*H*-imidazol-4-yl)disulfanyl)-5-(trifluoromethyl)-1*H*-pyrazole was used in the next in step without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 6.85 (s, 2H), 6.70 (s, 1H), 6.60 (s, 1H), 4.6 (m, 2H), 1.53 (m, 6H). LCMS (*m/z*): 416.75 (*M* - 1)⁻.

A solution of crude 1-isopropyl-3-((1-isopropyl-5-(trifluoromethyl)-1*H*-imidazol-4-yl)disulfanyl)-5-(trifluoromethyl)-1*H*-pyrazole (0.2 g crude, 0.478 mmol) in acetonitrile (10 mL) was cooled to 0°C and treated with AcOH (1 mL) and H₂O (1.5mL). DCDMH (0.19 g, 0.956 mmol) was added portion-wise over 5 minutes and stirred for 2h. The mixture was diluted with water (20 mL) and extracted with DCM (2 x 20 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give 1-

isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonyl chloride as a colorless liquid. The (1-isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonyl chloride) was diluted with THF, cooled to -78 °C and NH₃ gas was bubbled through the solution for 10 min then stirred for 1 h before warming to ambient temperature and stirring for a further 1 h. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 25 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The residue obtained was triturated with diethyl ether and n-pentane to give 1-isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide as a white solid (75 mg, 61%). ¹H NMR (400 MHz, CDCl₃): δ = 7.01 (s, 1H), 5.06 (s, 2H), 4.73-4.70 (m, 1H), 1.5 (d, *J* = 6.8 Hz, 6H). LCMS (*m/z*): 256.0 (M - 1)⁻.

5-isopropyl-1-methyl-1*H*-pyrazole-3-sulfonamide




A solution of 1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazol-3-amine (0.25 g, 1.824 mmol) in acetonitrile (10 mL) at 0 °C was treated with c.HCl (1.2 mL) in H₂O (0.5 mL) followed by aqueous solution of NaNO₂ (0.15 g, 2.19 mmol) dissolved in H₂O (2 mL). The resulting solution was stirred at 0 °C for 45 min. AcOH (0.25 mL), CuCl₂·2H₂O (0.15 g, 0.91 mmol) and CuCl (10 mg, 0.091 mmol) were sequentially added to the above mixture and purged with SO₂ gas for 20 min at 0 °C. The resulting reaction mixture was stirred at 0°C- 10°C for 60 min. Upon completion, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole-3-sulfonyl chloride as a colourless liquid (0.15 g, 38%). ¹H NMR (300 MHz, CDCl₃): δ =

6.77 (s, 1H), 5.51 (s, 1H), 5.28 (s, 1H), 4.02 (s, 3H), 2.11 (s, 3H).

A solution of 1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole-3-sulfonyl chloride (0.075 g, 0.34 mmol) in THF (7 mL) was cooled to -78 °C and ammonia gas was bubbled through the solution for 15 min, stirring was continued for a further 30 min then allowed to warm to ambient temperature and stirred for 2h or until completion. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through a pad of celite. The filtrate was dried (Na₂SO₄) and concentrated *in vacuo* to give 1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole-3-sulfonamide as an off-white solid used without purification 0.04 g (crude).

A solution of crude 1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole-3-sulfonamide (0.12 g, 0.6 mmol) in MeOH (10 mL) - EtOAc (4 mL) was treated with 10% palladium on carbon (30 mg) under nitrogen atmosphere. The reaction flask was evacuated, filled with hydrogen (balloon) and stirred for 4 h. The reaction mixture was diluted with ethyl acetate (25 mL), filtered through a pad of celite, dried (Na₂SO₄) and concentrated *in vacuo*. The solid obtained was further washed with diethyl ether to give 5-isopropyl-1-methyl-1*H*-pyrazole-3-sulfonamide as an off-white solid (0.11 g, 91%). ¹H NMR (400 MHz, CDCl₃): δ = 6.50 (s, 1H), 5.00 (br.s., 2H), 3.87 (s, 3H), 2.97-2.93 (m, 1H), 1.28 (d, *J* = 7.2 Hz, 6H).

5-(2-hydroxypropan-2-yl)-1-methyl-1*H*-pyrazole-3-sulfonamide




ethyl 3-amino-1-methyl-1*H*-pyrazole-5-carboxylate was reacted to ethyl 3-(chlorosulfonyl)-1-methyl-1*H*-pyrazole-5-carboxylate, a light-yellow liquid, using general method D (0.35 g, 47%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.39 (s,

1H), 4.40 (q, $J = 7.1$ Hz, 2H), 4.32 (s, 3H), 1.40 (t, $J = 7.1$ Hz, 3H).. The sulfonyl chloride was converted using general method E2 to give ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate as an off-white solid (0.3 g, 94%). ^1H NMR (300 MHz, DMSO- d_6) $\delta = 7.59$ (s, 2H), 7.09 (s, 1H), 4.33 (q, $J = 7.1$ Hz, 2H), 4.14 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 3H).

To a solution of ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate (0.25 g, 1.07 mmol) in anhydrous THF (10 mL) at 0 °C was added methyl magnesium chloride (3 M in THF, 5 equivalents) drop-wise. The resulting reaction mixture was gradually warmed to ambient temperature and stirred for 6h or until completion. The solution was cooled to 0°C, quenched with sat. aq. NH_4Cl (2.0 mL) then diluted with cold water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organics were washed with brine (50 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 50% gradient of EtOAc in hexanes eluent to give the titled compound as a white solid. (0.2 g, 87%). ^1H NMR (400 MHz, DMSO- d_6) $\delta = 7.34$ (s, 2H), 6.40 (s, 1H), 5.48 (s, 1H), 4.0 (s, 3H), 1.50 (s, 6H).

1-benzyl-5-(2-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide




Ethyl 3-amino-1-benzyl-1H-pyrazole-5-carboxylate was reacted to ethyl 1-benzyl-3-(chlorosulfonyl)-1H-pyrazole-5-carboxylate, a light-brown liquid, using method D (0.35 g, 47%). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.41$ (s, 1H), 7.34-7.26 (m, 5H), 5.87 (s, 2H), 4.37 (q, $J = 7.2$ Hz, 2H), 1.38 (t, $J = 7.2$ Hz, 3H). The sulfonyl chloride was converted using general method E2 to give ethyl 1-benzyl-3-sulfamoyl-1H-pyrazole-5-carboxylate as a white solid (0.7 g, 88%). ^1H NMR (400 MHz, DMSO- d_6): $\delta = 7.66$ (s, 2H), 7.39-7.27 (m, 3H), 7.2-7.18 (m, 3H),

5.77(s, 2H), 4.33 (q, $J = 7.2$ Hz, 2H), 1.29 (t, $J = 7.2$ Hz, 3H). LCMS (m/z): 310.05 ($M + 1$)⁺.


To a solution of ethyl 1-benzyl-3-sulfamoyl-1*H*-pyrazole-5-carboxylate (0.5 g, 1.62 mmol) in anhydrous THF (10 mL) at 0 °C was added methyl magnesium chloride (3 M in THF, 2.77 mL, 8.1 mmol) drop-wise. The resulting reaction mixture was gradually warmed to ambient temperature and stirred for 4h or until completion. The solution was cooled to 0°C, quenched with sat. aq. NH₄Cl (2.0 mL) then diluted with cold water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organics were washed with brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 70-100% gradient of EtOAc in hexanes eluent to give the titled compound as a white solid. (0.27 g, 57%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.37 (s, 2H), 7.39-7.27 (m, 3H), 7.2-7.18 (m, 2H), 6.45 (s, 1H), 5.66 (s, 2H), 5.60 (s, 1H), 1.44 (s, 6H). LCMS (m/z): 296.1 ($M + 1$)⁺.

5-(2-hydroxypropan-2-yl)-1-phenyl-1*H*-pyrazole-3-sulfonamide



2-(3-amino-1-phenyl-1*H*-pyrazol-5-yl)propan-2-ol was reacted to 5-(2-hydroxypropan-2-yl)-1-phenyl-1*H*-pyrazole-3-sulfonyl chloride, a yellow liquid, using method D (0.4 g, 36%). ¹H NMR (300 MHz, CDCl₃): δ = 7.55-7.45 (m, 5H), 6.91 (s, 1H), 1.51 (s, 6H). The sulfonyl chloride was converted using general method E2 to give the titled compound as a yellow solid (0.32 g, 87%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.5 (s, 5H), 7.47 (s, 2H), 6.65 (s, 1H), 5.41 (s, 1H), 1.30 (s, 6H).


5-(dimethylamino)naphthalene-1-sulfonamide



5-(dimethylamino)naphthalene-1-sulfonamide 3-azidobenzenesulfonamide was synthesized according to procedures contained in Satish K. Nair, Daniel Elbaum and David W. Christianson. *J. Biol. Chem.* **1996**, 271:1003-100 and Lixuan Mu, Wensheng Shi, Guangwei She, Jack C. Chang, and Shuit-Tong Lee. *Angew. Chem. Int. Ed.* **2009**, 48, 3469 –3472.

A solution of 5-(dimethylamino)naphthalene-1-sulfonyl chloride (0.12 g, 0.44 mmol) in acetone (5 mL) was added drop-wise to a solution of ammonium bicarbonate (0.17 g, 1.76 mmol) in water (1.0 mL) and the reaction stirred at ambient temperature for 2 h, or until completion. The pH was adjusted using c.HCl to pH 2.0. The organic phase was separated and the aqueous phase was saturated with NaCl and extracted with ethyl acetate. The combined organic phases were washed with brinem dried (MgSO_4) and concentrated *in vacuo* to give the titled compound as a white solid (0.075 g, 67% yield). ^1H NMR (600 MHz, CD_3OD) δ = 8.54 (d, J = 8.5 Hz, 0H), 8.36 (d, J = 8.7 Hz, 1H), 8.23 (d, J = 7.3 Hz, 1H), 7.58 (ddd, J = 17.0, 8.6, 7.4 Hz, 2H), 7.28 (d, J = 7.6 Hz, 1H), 2.89 (s, 6H). ^{13}C NMR (151 MHz, CD_3OD) δ = 151.6, 138.9, 129.7, 129.4, 129.2, 127.4, 126.6, 122.9, 119.5, 114.8, 44.4.

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydrobenzo[b]thiophene-6-sulfonamide 1,1-dioxide



m-Chloroperbenzoic acid (77%, 6.35 g, 27.9 mmol) was added portion wise to a solution of benzo[*b*]thiophene (1.50 g, 11.1 mmol) in anhydrous dichloromethane (100 mL) at room temperature with vigorous stirring, the

resulting reaction mixture was stirred for 16 h at the same temperature. A saturated aqueous NaHCO_3 solution (250 mL) was added and aqueous layer was extracted with dichloromethane (2 x 100 mL), organic layer was separated, combined organic layers dried (MgSO_4) and concentrated *in vacuo*. Crystallization from ethanol afforded benzo[b]thiophene 1,1-dioxide (1.56 g, 84%) as an off-white solid. ^1H NMR (600 MHz, CDCl_3): δ = 7.73 (d, J = 6 Hz, 1H), 7.58-7.53 (m, 2H), 7.38 (d, J = 12 Hz, 1H), 7.23 (d, J = 6 Hz, 1H), 6.73 (d, J = 6 Hz, 1H). LCMS (m/z): 167 $[\text{M} + \text{H}]^+$


A solution of benzo[b]thiophene 1,1-dioxide (0.75 g, 4.51 mmol) in ethanol (55 mL) was degassed with nitrogen for 10 minutes then 10% Pd/C (10 mg) was added and the mixture stirred under hydrogen atmosphere (1 atm) for 24 h. The reaction mixture was filtered through a Celite pad, filtrate was concentrated to give 2,3-dihydrobenzo[b]thiophene 1,1-dioxide (0.74 g, 97%) as an off-white solid. ^1H NMR (600 MHz, CDCl_3): δ = 7.75 (d, J = 6 Hz, 1H), 7.59 (t, J = 9 Hz, 1H), 7.49 (t, J = 6 Hz, 1H), 7.40 (d, J = 6 Hz, 1H), 3.51 (t, J = 6 Hz, 2H), 3.41 (t, J = 6 Hz, 2H). LCMS (m/z): 169 $[\text{M} + \text{H}]^+$

2,3-dihydrobenzo[b]thiophene 1,1-dioxide (0.75 g, 4.45 mmol) was heated in chlorosulfonic acid (1.5 mL, 22.2 mmol) at 80 °C for 4 h. Reaction mixture was poured onto crushed ice and stirred for 5 minutes. The aqueous solution was extracted with dichloromethane (2x50 mL) and the combined organics dried (MgSO_4) and concentrated *in vacuo* to give 2,3-dihydrobenzo[b]thiophene-6-sulfonyl chloride 1,1-dioxide (0.45 g, 38%) as a light brown oil. The crude product was used directly in the next step without purification. ^1H NMR (600 MHz, CDCl_3): δ = 8.42 (s, 1H), 8.25 (d, J = 12 Hz, 1H), 7.69 (d, J = 6 Hz, 1H), 3.64 (t, J = 9 Hz, 2H), 3.55 (t, J = 6 Hz, 2H).

To a solution of 2,3-dihydrobenzo[b]thiophene-6-sulfonyl chloride 1,1-dioxide (0.45 g, 1.68 mmol) in acetone (1 mL) was added aq NH_3 (2 mL, 28% NH_4OH in H_2O) at 0 °C, the resulting reaction mixture was stirred at room temperature for


2 h or until completion. The solvent was removed in vacuo and azeotroped with toluene (x2). The crude residue was purified by column chromatography on silica using 4% MeOH/CH₂Cl₂ eluent to give 2,3-dihydrobenzo[*b*]thiophene-6-sulfonamide 1,1-dioxide (0.16 mg, 39%) as an off-white solid. ¹H-NMR (DMSO-d₆): δ = 8.09 (s, 1H), 8.06 (d, *J* = 12 Hz, 1H), 7.75 (d, *J* = 6 Hz, 1H), 7.60 (bs, 2H), 3.70 (t, *J* = 6 Hz, 2H), 3.44 (t, *J* = 9 Hz, 2H).

3-azidobenzenesulfonamide



Synthesised according to procedure contained in Pawan Kumar, Navneet Chandak, Poul Nielsen, Pawan K. Sharma. *Bioorg. Med. Chem.* **2012**, 20, 3843–3849. A solution of 3-aminobenzenesulfonamide (0.3 g, 1.7 mmol) in CH₃CN (8 mL) was cooled to 0 °C. To this stirred mixture was added *t*-BuONO (250 μL, 2.1 mmol) followed by TMSN₃ (276 μL, 2.1 mmol). The resulting solution was stirred at room temperature for 1 h. The reaction mixture was concentrated *in vacuo* and the crude product purified by column chromatography on silica gel using 100% hexanes eluant to give the titled compound as a pale yellow solid (0.31 g, 91%). ¹H NMR (600 MHz, CD₃OD) δ 7.68 – 7.62 (m, 1H), 7.56 (d, *J* = 1.8 Hz, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.19 – 7.15 (m, 1H). ¹³C NMR (151 MHz, DMSO-d₆) δ 146.2, 140.8, 131.2, 122.9, 122.4, 116.5.


N-(3-Sulfamoylphenyl)pent-4-ynamide



To a solution of pent-4-ynoic acid (0.1 g, 1.02 mmol) and 3-


aminobenzenesulfonamide (0.21 g, 1.22 mmol) in dry DMF (5.0 ml) was added HBTU (0.46 g, 1.22 mmol) followed by DIPEA (212 μ L, 1.22 mmol). The reaction mixture was stirred at ambient temperature for 2 h, or until completion. The mixture was diluted with EtOAc (30 mL), washed with H₂O (20 mL), brine (20 mL) then the organics dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 100% hexanes eluant to give the titled compound as a to give the titled compound as a pale-yellow solid (0.2 g, 79%). ¹H NMR (400 MHz, CD₃OD) δ = 8.22 (dd, *J* = 2.2, 1.7 Hz, 1H), 7.75 – 7.68 (m, 1H), 7.65 – 7.58 (m, 1H), 7.51 – 7.42 (m, 2H), 2.64 – 2.59 (m, 2H), 2.58 – 2.54 (m, 2H), 2.32 – 2.25 (m, 1H). ¹³C NMR (101 MHz, CD₃OD) δ = 171.3, 143.8, 138.9, 129.2, 122.9, 121.0, 117.1, 82.1, 69.1, 35.4, 14.0.

Benzene-1,3-disulfonamide




Benzene-1,3-disulfonyl dichloride (0.50 g, 0.726 mmol) was dissolved in tetrahydrofuran (4 mL) and the solution was cooled to 0 °C. aqueous ammonia (0.4 mL) was added at 0 °C and the mixture was stirred at ambient temperature for 1 h. Upon completion of the reaction, the mixture was poured into chilled water and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated *in vacuo*. The resulting solid was triturated with pentane to afford the titled compound as a light brown solid (0.16 g, 87%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.27 (t, *J* = 2.0 Hz, 1H), 8.06 (dd, *J* = 2.0, 8.0 Hz, 2H), 7.81 (t, *J* = 8.0 Hz, 1H), 7.64 (s, 4H).

***N*¹,*N*¹-dimethylbenzene-1,3-disulfonamide**




3-amino-*N,N*-dimethylbenzenesulfonamide was converted to 3-(*N,N*-dimethylsulfamoyl)benzenesulfonyl chloride (0.45 g, 80%) using method D. ^1H NMR (300 MHz, CDCl_3) δ = 8.42 (t, J = 2.0 Hz, 1H), 8.27 (d, J = 7.9 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.85 (t, J = 7.9 Hz, 1H), 2.79 (s, 6H). The sulfonyl chloride was converted using general method E1 to give the titled compound as a yellow solid (0.45 g, 93%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.13 (m, 2H), 7.98 (d, J = 7.9 Hz, 1H), 7.87 (t, J = 7.9 Hz, 1H), 7.65 (s, 2H), 2.65 (s, 6H).

Methyl 3-sulfamoylbenzoate




Methyl 3-(chlorosulfonyl)benzoate (1.00 g, 4.26 mmol) was dissolved in anhydrous tetrahydrofuran (15 mL) and the solution was cooled to 0 °C. Aqueous ammonia (5.0 mL) was added drop-wise and the mixture stirred at ambient temperature for 2 h. Upon completion the reaction mixture was poured into chilled water and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated *in vacuo*. The resulting solid was triturated with pentane to afford the titled compound as a light brown solid (0.75 g, 82%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.40 (s, 1H), 8.19 (d, J = 8 Hz, 1H), 8.1 (d, J = 8 Hz, 1H), 7.77 (t, J = 8 Hz, 1H), 7.6 (s, 2H), 3.92 (s, 3H); m/z 214.0 $[\text{M} - \text{H}^+]^-$.

3-(4-phenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide




Ethynylbenzene (1 eq) and 3-azidobenzenesulfonamide (1.2 eq), 5 mol% CuSO₄, 10 mol% NaAsc solution in DMSO (500 μ L) were stirred at room temperature for 12 h. The crude product was purified directly from the reaction mixture using reverse phase column chromatography (Reveleris flash column chromatography, 4 g, 18 mL/min.) and freeze dried to give the product as a white solid (32 mg, 70%). ¹H NMR (400 MHz, DMSO-d₆) δ = 9.57 – 9.36 (m, 1H), 8.46 (d, *J* = 5.7 Hz, 1H), 8.20 (s, 1H), 7.98 (d, *J* = 8.1 Hz, 3H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.62 (s, 2H), 7.53 (d, *J* = 7.4 Hz, 2H), 7.42 (d, *J* = 7.5 Hz, 1H).

***N*-(prop-2-yn-1-yl)-3-(4-sulfamoylphenyl)propanamide**



To a solution of 3-(4-sulfamoylphenyl)propanoic acid (0.3 g, 1.5 mmol) and propargyl amine (0.11 g, 1.5 mmol) in dry DMF (5.0 ml) was added HBTU (0.74 g, 1.5 mmol) followed by DIPEA (342 μ L, 1.22 mmol). The reaction mixture was stirred at RT for 2 h. The reaction was monitored by LCMS and after the completion of reaction, it was diluted with EtOAc (30 mL) washed with H₂O (20 mL), brine (20 mL). The organic layer was separated; dried (MgSO₄) and evaporated to give the crude product. The crude product was purified by silica gel column chromatography (1:1, EtOAc:Hexane) to isolate the title compound as a white solid (0.22 g, 63%). ¹H NMR (400 MHz, CD₃OD) δ = 7.85 (d, *J* = 7.9 Hz, 2H), 7.38 (d, *J* = 7.9 Hz, 2H), 3.97 (t, *J* = 2.4 Hz, 2H), 3.04 (t, *J* = 7.6 Hz, 2H), 2.55 (t, *J* = 7.6 Hz, 2H), 2.33 (d, *J* = 2.8 Hz, 1H).


benzo[d][1,3]dioxole-5-sulfonamide



Sulfuryl chloride (2.18 ml, 26.7 mmol) was added to anhydrous DMF (2.10 ml, 26.7 mmol) at 0 °C under nitrogen atmosphere, then the ice bath was removed and the solution stirred for 15 minutes. The solution was cooled once more to 0 °C and benzo[d][1,3]dioxole was added. The reaction mixture was allowed to reach room temperature then heated at 100 °C for 2 h. The reaction mixture was poured onto crushed ice, stirred for 5 minutes, then extracted with dichloromethane (100 ml then 2 x 50 mL). The combined organics were dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 15% DCM-hexanes eluent to give benzo[d][1,3]dioxole-5-sulfonyl chloride as an off-white solid (1.78 g, 33%). ¹H NMR (400 MHz, CDCl₃): δ = 7.64 (d, *J* = 8.0 Hz, 1H), 7.43 (s, 1H), 6.95 (d, *J* = 8.0 Hz, 1H), 6.16 (s, 2H).

To a solution of benzo[d][1,3]dioxole-5-sulfonyl chloride (0.30 g, 1.35 mmol) in acetone (1 mL) was added aq. NH₃ (1.5 mL, 28% NH₄OH in H₂O) at 0 °C, the reaction mixture was stirred at room temperature until completion, typically 2 h, then concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 2% MeOH-DCM eluent to give the titled compound as an off-white solid (210 mg, 77%). ¹H NMR (400 MHz, DMSO-d₆): δ = 7.32 (d, *J* = 8.0 Hz, 1H), 7.25 (s, 1H), 7.21 (bs, 2H), 7.02 (d, *J* = 8.0 Hz, 1H), 6.11 (s, 2H).


Pyridine-4-sulfonamide



Pyridine-4-sulfonyl chloride was converted using general method E3 to give the


titled compound as a pale-yellow solid (50 mg, 56%). ^1H NMR (300 MHz, DMSO- d_6): δ = 8.56 (d, J = 4.5 Hz, 1H), 7.49 (d, J = 4.5 Hz, 1H), 7.24 (br.s., 2H).

Pyridine-3-sulfonamide



Pyridine-3-sulfonyl chloride was converted using general method E3 to give the titled compound as a pale-yellow solid (0.7 g, 79%). ^1H NMR (300 MHz, DMSO- d_6) δ = 8.96 (dd, J = 2.5, 0.9 Hz, 1H), 8.77 (dd, J = 4.8, 1.6 Hz, 1H), 8.17 (ddd, J = 8.0, 2.4, 1.6 Hz, 1H), 7.67 – 7.56 (m, 3H).


Pyridine-2-sulfonamide



A 1.0 M solution of HCl (45 mL) and DCM (45 mL) was cooled to -10 °C and pyridine-2-thiol (1.0 g, 9.0 mmol) added. After 10 min, NaOCl (6% solution, 47 mL, 3.3 eq.) was added drop-wise over 5 min and stirring continued at -10 °C for 10 min. The organic phase was separated, dried using Na_2SO_4 and filtered. The resulting solution was added drop-wise to a pre-cooled solution of sat. methanolic ammonia and DCM (1:1, 40 mL) at 0 °C then allowed to warm to ambient temperature and stirred until completion, typically 2 h. The solvent was removed *in vacuo* to give a white solid which was dissolved in hot EtOAc and filtered to remove solid impurities. The solvent was removed *in vacuo* and recrystallized with EtOAc-hexanes to give the titled compound as a yellow solid (0.5 g, 35%). ^1H NMR (300 MHz, DMSO- d_6) δ = 8.70 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.05 (td, J = 7.7, 1.7 Hz, 1H), 7.91 (dt, J = 7.9, 1.1 Hz, 1H), 7.62 (ddd, J =


7.6, 4.7, 1.2 Hz, 1H), 7.45 (s, 2H).

4-(trifluoromethyl)pyridine-2-sulfonamide



4-(trifluoromethyl)pyridine-2-sulfonamide was synthesized according to the procedures used to synthesise pyridine-2-sulfonamide but using 4-(trifluoromethyl)pyridine-2-thiol in place of pyridine-2-thiol. The product 4-(trifluoromethyl)pyridine-2-sulfonamide was given as a solid (0.7 g, 56%). ^1H NMR (300 MHz, DMSO- d_6) δ = 9.02 (d, J = 5.0 Hz, 1H), 8.16 (s, 1H), 8.07 (d, J = 5.0 Hz, 1H), 7.68 (s, 2H).


3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonamide



3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)aniline was converted using general method D to 3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonyl chloride, a yellow liquid (1.1 g, 52%). ^1H NMR (300 MHz, CDCl_3) δ = 8.15 – 8.08 (m, 1H), 7.82 – 7.77 (m, 1H), 7.76 – 7.68 (m, 1H), 7.68 – 7.61 (m, 1H). ^{19}F NMR (282 MHz, CDCl_3) δ -65.06.

3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonyl chloride was converted using general method E2 to the titled compound as a white solid (0.6 g, 60%). ^1H NMR (300 MHz, CDCl_3) δ = 7.99 (dt, J = 7.9, 1.5 Hz, 1H), 7.71 (t, J = 2.0 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 4.87 (s, 2H). ^{19}F NMR (282 MHz, CDCl_3) δ -65.13.


2-(methyl(7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)-*N*-(4-sulfamoylphenethyl)acetamide



2-(Methylamino)acetic acid (0.24 g, 2.75 mmol) and sodium hydrogencarbonate (0.694 g, 8.26 mmol) were dissolved in a mixture of water (10 mL) and MeOH (20 mL). Then, 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole (0.50 g, 2.50 mmol) was added and the mixture stirred at 60 °C for 2 h. Upon completion of the reaction, volatiles were removed under reduced pressure and the crude residue obtained was purified by column chromatography on silica gel using 0-5% gradient of methanol in dichloromethane to obtain 2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)acetic acid as a brick-red solid (1.10 g, 87%).


2-(Methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)acetic acid (1.00 g, 3.96 mmol) was dissolved in anhydrous tetrahydrofuran (25 mL) under nitrogen atmosphere and the solution was cooled to 0 °C. Diisopropylethylamine (0.76 g, 5.55 mmol) and 1,1'-carbonyldiimidazole (0.90 g, 4.75 mmol) were added and the mixture stirred at 50 °C until all of the 2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)acetic acid had reacted. The reaction mixture was then cooled to 0 °C, 4-(2-aminoethyl)benzenesulfonamide (0.95 g, 4.75 mmol) was added and stirred at ambient temperature until completion, typically 6 h. The solvents were removed in vacuo and the residue was purified by reverse phase preparative HPLC to afford the titled compound as a brick-red solid (1.20 g, 70%). LCMS (m/z): 435.4 ($M + 1$)⁺.

4-(2-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)ethyl)benzenesulfonamide



4-(2-aminoethyl)benzenesulfonamide (0.55 g, 2.75 mmol) and diisopropylethylamine (0.64 g, 2.75 mmol) were dissolved in ethanol (20 mL) and the solution cooled to 0 °C. 4-Chloro-7-nitrobenzo[c][1,2,5]oxadiazole (0.50 g, 2.50 mmol) was added at 0 °C and the mixture was stirred at ambient temperature for 16 h. Upon completion of the reaction, the reaction mass was poured into brine and extracted with ethyl acetate. Solvents evaporated from the combined organic extract under reduced pressure and the crude obtained was purified by reverse phase prep HPLC to afford the titled product as a dark yellow solid (0.250 g, 7%). ¹H NMR (400 MHz, CD₃OD) δ= 8.5 (d, *J* = 8.8 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 6.35 (d, *J* = 8.8 Hz, 1H), 3.83 (m, 2H), 3.15 (t, *J* = 7.6 Hz, 2H).

2-(7-(Dimethylamino)-2-oxo-2*H*-chromen-4-yl)-*N*-(4-sulfamoylphenethyl)acetamide (17l):




Molecular Weight: 429.49

2-(7-(dimethylamino)-2-oxo-2*H*-chromen-4-yl)acetic acid (0.50 g, 2.02 mmol), EDC·HCl (0.47 g, 3.03 mmol), HOBt (0.464 g, 3.03 mmol) and *N*-methylmorpholine (0.409 g, 4.04 mmol) were mixed in anhydrous tetrahydrofuran (5 mL) and stirred at 0 °C for 30 min. 4-(2-

Aminoethyl)benzenesulfonamide (0.445 g, 2.224 mmol) was added and stirring continued at ambient temperature for 18 h. Upon completion, the reaction was poured onto chilled water and extracted with ethyl acetate. The solvent was removed *in vacuo* and the residue was purified by column chromatography on silica gel using a gradient of 0-5% methanol in dichloromethane to give 2-(7-(dimethylamino)-2-oxo-2*H*-chromen-4-yl)-*N*-(4-sulfamoylphenethyl)acetamide as a greenish-yellow solid (0.25 g, 29%). LCMS (m/z): 430.2 ($M + 1$)⁺.

6,7-dihydro-5H-pyrrolo[1,2-*a*]imidazole-2-sulfonamide



A solution of 3-chlorobutanenitrile (20 g, 193.1 mmol) in diethyl ether (100 mL) was treated with MeOH (7.41g, 231.7 mmol) and cooled to 0 °C. HCl gas was bubbled into the reaction mixture for 4 h at 0 °C. The reaction mixture was stirred at -20 °C for 24 h and reaction mixture was concentrated *in vacuo*. The solid residue obtained was washed with diethyl ether (3 x 100 mL), *n*-pentane (2 x 100 mL) and dried *in vacuo* at 45 °C to give methyl 4-chlorobutanimidate hydrochloride as a white solid.

Methyl 4-chlorobutanimidate hydrochloride (25 g, 146.1 mmol) was dissolved in DCM (250 mL) treated with Et₃N (44.3 g, 4.38 mmol) and resulting solution was cooled to 0 °C. 2,2-Dimethoxyethan-1-amine (12.2 g, 116.9 mmol) was added dropwise to the above mixture over a period of 5 min. The resulting reaction

mixture was warmed to 60 °C and stirred for 3 h. The reaction mixture was concentrated *in vacuo* and residue obtained was treated with formic acid (150 mL) and heated at 80 °C for 24 h. Upon completion, the reaction mixture was concentrated *in vacuo* and residue obtained azeotroped with toluene (2 x 100 mL). The crude mixture was basified with saturated NaHCO₃ solution and extracted with DCM (3 x 200 mL). The combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give 6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole (8 g, 39% over 3 steps) as a low melting dark solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.0 (s, 1H), 6.83 (s, 1H), 3.95 (t, *J*=7.2 Hz, 2H), 2.84 (t, *J*=7.2 Hz, 2H), 2.61-2.51 (m, 2H).

A solution of 6, 7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole (4 g, 37.0 mmol) in acetonitrile (120 mL) was cooled to 0 °C. *N*-Iodosuccinimide (9.16g, 40.7 mmol) was added portion wise at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 12h. Upon completion, the reaction mixture was diluted with saturated Na₂S₂O₃ solution and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 4-40% EtOAc-hexanes eluant to give 2-iodo-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole (1.0 g, 19%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.03 (s, 1H), 3.89 (t, *J*=7.2 Hz, 2H), 3.02 (t, *J*=7.2 Hz, 2H), 2.65-2.55 (m, 2H). LCMS (*m/z*): 235 [M+H]⁺.


In a 50 mL re-sealable reaction tube, a solution of 2-iodo-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole (0.3 g, 1.28 mmol) and phenylmethane thiol (0.24 g, 1.92 mmol) in 1,4-dioxane (10 mL) was treated with DIPEA (0.41 g, 3.20 mmol) at RT under nitrogen atmosphere. Nitrogen gas was purged through the solution for 5 minutes. Xantphos (74mg, 0.128mmol) and Pd₂(dba)₃ (60 mg, 0.064 mmol) were sequentially added to the aforementioned solution and the vessel purged with nitrogen gas for 5 minutes. The resulting mixture was stirred

at 110 °C for 12h. Upon completion, the mixture was cooled to RT, diluted with EtOAc (25 mL) and filtered through celite. The filtrate was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 50-70% EtOAc-hexanes eluant to give 2-(benzylthio)-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole, (0.15 g, 51%) as a brown liquid. ¹H NMR (300 MHz, CDCl₃): δ = 7.26-7.22 (m, 3H), 7.12 (s, 1H), 7.05-7.02 (m, 2H), 3.73 (s, 2H), 3.14 (t, *J* = 6.9 Hz, 2H), 2.81 (t, *J* = 7.2 Hz, 2H), 2.32-2.27 (m, 2H). LCMS (*m/z*): 231.3 [M+H]⁺.

A solution of 2-(benzylthio)-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole (250 mg, 1.08 mmol) in acetonitrile (2.5 mL), acetic acid (0.5 mL) and H₂O (1.2 mL) was cooled to 0 °C. DCDMH (170 mg, 0.869 mmol) was added at 0 °C and resulting reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 20 mL). The combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give 6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonyl chloride as a pale brown liquid used directly in the next step.


A solution of 6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonyl chloride (300 mg) in THF (15 mL) was cooled to -40 °C. Ammonia gas was purged through the aforementioned solution for 15 min and solution was stirred at -40 °C for 1 h. The reaction mixture was warmed to RT, stirred for 1 h then, upon completion, concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 10% MeOH-CHCl₃ eluant to give 6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonamide (117 mg, 88%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.54 (bs, 2H), 7.26 (s, 1H), 4.06 (s, 2H), 2.80 (s, 2H), 2.32 (s, 2H). LCMS (*m/z*): 187.95 [M+H]⁺.

4-Nitrobenzenesulfonamide




4-Nitrobenzenesulfonyl chloride (1.0 eq.) dissolved in acetone (0.8 mL/mmol) was added drop-wise to Ammonium bicarbonate (4.0 eq) dissolved in water (0.8 mL/mmol). The reaction mixture was stirred at room temperature for 2 h before acidification with 1 M HCl (pH ~2). The mixture was extracted with ethyl acetate (3 x 10 mL), dried (MgSO₄) and concentrated *in vacuo* to give the titled compound as a pale orange solid (157 mg, 57%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 8.42 (d, *J* = 8.8 Hz, 2H), 8.06 (d, *J* = 8.8 Hz, 2H), 7.74 (s, 2H). HRMS calculated for C₆H₅N₂O₄S₁ [M-H]⁻ 200.9976, found 200.9984.

5-Methyl-*N*-(4-sulfamoylphenethyl)isoxazole-3-carboxamide



5-Methylisoxazole-3-carbonyl chloride (1.0 eq) (prepared using general method B1) was dissolved in anhydrous THF (4 mL/mmol) and treated with triethylamine (1.0 eq). After stirring for 5 minutes 4-(2-aminoethyl)benzenesulfonamide (1.0 eq) was added to the acid chloride solution. The reaction was stirred at room temperature, under an argon atmosphere overnight. The solvent was removed *in vacuo*, and the residue purified by reverse phase column chromatography using acetonitrile/10 mM ammonium bicarbonate (aq) as mobile phase to give the titled compound as a white solid (205 mg, 48%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 8.79 (t, *J* = 5.8 Hz, 1H), 7.74 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.3 Hz, 2H), 7.30 (s, 2H), 6.50 (q, *J* = 0.6 Hz, 1H), 3.52 – 3.46 (m, 2H), 2.91 (t, *J* = 7.2 Hz, 2H), 2.45 (d, *J* = 0.6 Hz, 3H). HRMS calculated for C₁₃H₁₄N₃O₄S₁ [M-H]⁻ 308.0711, found 308.0708.


4-(2-(7-Methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)benzenesulfonamide



N-(cyclohexylcarbamoyl)-4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)benzenesulfonamide (1.0 eq) dissolved in anhydrous pyridine (8 mL/mmol) was treated with phthalic anhydride (1 eq.) and DMAP (0.1 eq) and heated to reflux under an inert atmosphere for 4 hours. The solvent was removed *in vacuo*, and the residue purified by reverse phase column chromatography using acetonitrile/10 mM ammonium bicarbonate (aq) as mobile phase to give the titled compound as a white solid (291 mg, 75%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 7.72 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 8.7 Hz, 1H), 7.53 (d, *J* = 2.8 Hz, 1H), 7.40 (d, *J* = 8.2 Hz, 2H), 7.33 – 7.25 (m, 3H), 4.13 (d, *J* = 7.5 Hz, 2H), 3.83 (s, 3H), 2.93 (t, *J* = 7.3 Hz, 2H), 1.45 (s, 6H). HRMS calculated for C₂₀H₂₁N₂O₅S₁ [M-H]⁻ 401.1177, found 401.1174.

Synthesis of R1 and R2 amine intermediates:


1-methyl-1*H*-pyrazol-3-amine HCl



In a 20 mL microwave vial, a solution of 2-chloroacrylonitrile (2 g, 22.85 mmol) in EtOH (10 mL) was treated with methyl hydrazine (1.93g, 41.13 mmol). The

resulting reaction mixture was heated at 100 °C for 10 minutes in a Biotage microwave synthesizer. The reaction mixture was left at < 5 °C for 12 h during this time a solid precipitated. The precipitate was removed by filtration and dried *in vacuo* to give the titled compound as white solid (0.12 g, 55%). ¹H NMR (400 MHz, DMSO-d₆): δ 7.76 (s, 1H), 6.13 (s, 1H), 3.80 (s, 3H), 2.58 (s, 2H). LCMS (*m/z*): 98.3 (M + 1)⁺.

1-(trifluoromethyl)-1H-pyrazol-3-amine




3-Nitro-1H-pyrazole (5 g, 44 mmol) was dissolved in *N,N*-dimethylformamide (100 mL), cooled to -5 °C and NaH (3.8 g, 93.6 mmol) added portionwise. The reaction mixture was stirred for 15 mins before adding dibromodifluoromethane (8.6 g, 44 mmol) and allowing to warm to ambient temperature overnight. The reaction mixture was quenched using ice-water and extracted using ethyl acetate. The organic phase was washed using water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give 3-nitro-1-(trifluoromethyl)-1H-pyrazole (2.1 g, 22%) which was used without further purification. ¹⁹F NMR (282 MHz, CDCl₃) δ = -34.20.

1-(bromodifluoromethyl)-3-nitro-1H-pyrazole (2.1 g, 9.76 mmol) was dissolved in DCM (50 mL) and cooled to -78 °C before adding AgBF₄ (5.7 g, 28.3, 3 equivalents). The reaction mixture was allowed to warm to ambient temperature overnight then cooled to 0 °C and quenched by addition of sat. aq. NaHCO₃ (50 mL). The aqueous phase was extracted using DCM and the combined organics washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give 3-nitro-1-(trifluoromethyl)-1H-pyrazole (0.9 g, 51%). ¹⁹F NMR (282 MHz, CDCl₃) δ = -60.96.


3-nitro-1-(trifluoromethyl)-1H-pyrazole (1.0 g) was dissolved in THF:EtOAc (1:1, 50 mL), Pd/C (200 mg) was added and the mixture stirred under a hydrogen atmosphere (balloon) overnight. The mixture was filtered through celite and washed through using ethyl acetate. The solvent was removed in vacuo and the residue purified by column chromatography on silica gel using 40% EtOAc in hexanes eluant to give the titled product (0.75 g, 87%). ^1H NMR (300 MHz, CDCl_3) δ = 7.54 (d, J = 2.7 Hz, 1H), 5.84 (d, J = 2.7 Hz, 1H). ^{19}F NMR (282 MHz, CDCl_3) δ = -61.13.

1-isopropyl-1H-pyrazol-3-amine



Isopropyl hydrazine hydrochloride (5 g, 45.45 mmol) in water (40 mL) was treated sequentially with K_2CO_3 (12.5 g, 91 mmol) and 2-chloroacrylonitrile (4 g, 45.45 mmol). The resulting reaction mixture was stirred at 50 °C for 1 h, cooled to RT and extracted with ethyl acetate (50 mL). The organic extract was washed with water (40 mL), brine (40 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give the titled compound as a yellow solid (3.5 g, 62%). ^1H NMR (400 MHz, CDCl_3): δ = 7.15 (s, 1H), 5.56 (s, 1H), 4.27-4.23 (m, 1H), 3.6 (br.s., 2H), 1.43 (d, J = 6.4 Hz, 6H). LCMS (m/z): 126.0 ($\text{M}+1$) $^+$.

1-cyclopropyl-1H-pyrazol-3-amine




A solution of 1*H*-pyrazol-3-amine (2 g, 24.1 mmol,) in AcOH (20 mL) was treated with 2,5-hexane dione (5.7 g, 50.6 mmol) at ambient temperature under nitrogen atmosphere. The resulting reaction mixture was heated to 100 °C for 6 h. The reaction mixture was concentrated under reduced pressure and azeotroped with toluene. The crude product was purified by column chromatography on silica gel using a gradient of 50-100% EtOAc-hexanes eluent to give 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1*H*-pyrazole as a red solid (2.25 g, 59%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.92 (s, 1H), 7.85 (t, *J* = 1.8 Hz, 1H), 6.28 (t, *J* = 2.1 Hz, 1H), 5.75 (s, 2H), 2.00 (s, 6H).

Copper (II) acetate (0.56 g, 3.1 mmol), 2, 2'-bipyridine (0.48 g, 3.1 mmol) and dichloroethane (10 mL) were heated to 75 °C for 20 min. 5 mL of this pre-prepared solution was added to a mixture of 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1*H*-pyrazole (0.5 g, 3.1 mmol), potassium cyclopropyltrifluoroborate (2 eq) and sodium carbonate (2eq.), in dichloroethane (5 mL) then the reaction stirred at 75 °C for 6 h. The reaction mixture was diluted using DCM, washed using water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 1-cyclopropyl-3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1*H*-pyrazole as a yellow liquid (0.2 g, 32%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.48 (dd, *J* = 2.3, 0.5 Hz, 1H), 6.12 (d, *J* = 2.3 Hz, 1H), 5.84 (s, 2H), 3.61 (tt, *J* = 7.3, 3.6 Hz, 1H), 2.09 (s, 6H), 1.22 – 0.95 (m, 4H).

To a solution of ammonium hydroxide hydrochloride (1.64 g, 11.8 mmol) in ethanol ((10 mL) was added a solution of potassium hydroxide (0.66 g) in water (10 mL) at 0 °C. After 10 min stirring a solution of 1-cyclopropyl-3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1*H*-pyrazole (0.95 g) in ethanol (10 mL) was added and the reaction heated at 100 °C for 20 h. The solvent was removed *in vacuo* and the residue partitioned between ethyl acetate and water. The organic phase was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude


product was purified by column chromatography on silica gel using a gradient of 70-100% EtOAc-hexanes eluent to give the titled product as a brown solid (0.4 g, 69%). ^1H NMR (400 MHz, CDCl_3) δ = 7.51 (d, J = 2.4 Hz, 1H), 6.69 (d, J = 2.4 Hz, 1H), 5.04 (s, 2H), 3.67 (m, 1H), 1.19 (m, 2H), 1.12 (m, 2H).

1-(*tert*-butyl)-1*H*-pyrazol-3-amine



Isopropyl hydrazine hydrochloride (1.42 g, 11.4 mmol) in water (25 mL) at 0 °C was treated sequentially with K_2CO_3 (1.57 g, 11.4 mmol), NaHCO_3 (1.91 g, 22.9 mmol) and 2-chloroacrylonitrile (1 g, 11.4 mmol) then warmed to ambient temperature and stirred for 12h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organics were washed with water (30 mL), brine (30 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give the titled compound as a brown liquid (0.9 g, 60%). ^1H NMR (400 MHz, DMSO-d_6): δ = 7.34 (s, 1H), 5.35 (s, 1H), 4.51 (br.s., 2H), 1.40 (s, 9H). LCMS (m/z): 140.10 ($\text{M}+1$) $^+$.

1-cyclohexyl-1*H*-pyrazol-3-amine




3-nitro-1*H*-pyrazole (1 g, 8.85 mmol) was dissolved in *N,N*-dimethylformamide (20 mL) and treated with potassium carbonate (1.47 g, 10.62 mmol) and bromocyclohexane (1.8 g, 10.62 mmol). The mixture was heated to 100 °C for 16 hours (or until completion) then cooled to ambient temperature diluted using

water (100 mL) and extracted using ethyl acetate (2 x 75 mL). The combined organics were washed using water (100 mL), brine (100 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using a gradient of 10% EtOAc-hexanes eluent to give 1-cyclohexyl-3-nitro-1*H*-pyrazole as a colourless liquid (1.3 g, 76%). ^1H NMR (300 MHz, CDCl_3) δ = 7.47 (d, J = 2.5 Hz, 1H), 6.88 (d, J = 2.5 Hz, 1H), 4.26 – 4.11 (m, 1H), 2.18 (m, 2H), 1.93 (m, 2H), 1.82 - 1.20 (m, 6H).

In a 100 mL Parr shaker reaction vessel, a solution of 1,5-dimethyl-3-nitro-1*H*-pyrazole (0.65 g, 3.3 mmol) in MeOH (4 mL) and EtOAc (20 mL) was treated with 10% palladium on carbon (200 mg) under nitrogen atmosphere. The flask was evacuated then filled with hydrogen gas (60 psi) and stirred at ambient temperature for 12h. The reaction mixture was diluted with ethyl acetate (50 mL) and filtered through a bed of Celite. The filtrate was dried (Na_2SO_4) and concentrated *in vacuo* to give 1-cyclohexyl-1*H*-pyrazol-3-amine as a light brown solid (0.3 g 55%). ^1H NMR (300 MHz, CDCl_3) δ = 7.15 (d, J = 2.3 Hz, 1H), 5.56 (d, J = 2.3 Hz, 1H), 3.85 (m, 1H), 3.62 (s, 1H), 2.1 (m, 2H), 1.8 (m, 2H), 1.77 – 1.10 (m, 6H).


1-phenyl-1*H*-pyrazol-3-amine



Potassium *tert*-butoxide (11.9 g, 106.3 mmol) was dissolved in *t*BuOH (100mL) and the solution was heated to 100 °C. Phenyl hydrazine (5 g, 46.2 mmol) and 3-ethoxy acrylonitrile (4.5 g, 46.2 mmol) were sequentially added and heating continued for 16 h. The mixture was concentrated *in vacuo*. The residue obtained was partitioned between water (500 mL) and ethyl acetate (500 mL). The organic extract was washed with water (250 mL), brine (250 mL), dried

(Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 25% EtOAc-hexanes eluent to give 1-phenyl-1*H*-pyrazol-3-amine as a pale brown solid (3.5 g, 48%). ¹H NMR (400 MHz, CDCl₃): δ = 7.69 (s, 1H), 7.57 (d, *J* = 8.0 Hz, 2H), 7.41 (d, *J* = 8.0 Hz, 2H), 7.2 (t, *J* = 7.6 Hz, 1H), 5.85 (s, 1H), 3.83 (br.s., 2H). LCMS (*m/z*): 160.3 (M+1)⁺.

1-benzyl-1*H*-pyrazol-3-amine




A solution of 3-nitro-1*H*-pyrazole (1 g, 8.85 mmol) in THF (20 mL) was cooled to 0 °C and NaH (0.53 g, 13.27 mmol) was added. The suspension was stirred for 20 min then benzyl bromide (1.5 g, 8.85 mmol) was added drop-wise. The reaction was stirred until completion ~6 h, diluted with saturated NaHCO₃ solution (20 mL) and extracted with EtOAc (2 x 50 mL). The organics were washed with water (30 mL), brine (30 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give 1-benzyl-3-nitro-1*H*-pyrazole as a white solid (1.5 g, 84%). ¹H NMR (300 MHz, CDCl₃): δ = 7.40-7.36 (m, 4H), 7.31-7.27 (m, 2H), 6.90 (d, *J* = 2.7 Hz, 1H), 5.37 (s, 2H). LCMS (*m/z*): 204.20 (M + 1)⁺.

A solution of 1-benzyl-3-nitro-1*H*-pyrazole (1.5 g, 7.39 mmol) in THF (20 mL) and MeOH (5 mL) was cooled to 0 °C. Zinc powder (2.4 g, 36.9 mmol) and NH₄Cl solution (1.97 g, 36.94 mmol; in 5 mL of water) was added. The resulting reaction mixture was heated at 70 °C for 12 h. The reaction mixture was cooled to ambient temperature, diluted with EtOAc (50 mL) and filtered through a bed of Celite. The filtrate was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 50% EtOAc-hexanes eluent to give 1-benzyl-1*H*-pyrazol-3-amine as light brown liquid (0.85 g, 67%). ¹H NMR (300 MHz, CDCl₃): δ = 7.34-7.26 (m, 3H), 7.14-7.11 (m, 2H),

7.05 (d, $J=2.4$ Hz, 1H), 5.59 (d, $J=2.4$ Hz, 1H), 5.14(s, 2H). LCMS (m/z): 174.10 ($M+1$)⁺

1-(1-phenylethyl)-1H-pyrazol-3-amine




A solution of 3-nitro-1H-pyrazole (1 g, 8.85 mmol) in THF (20 mL) was cooled to 0 °C and NaH (0.7 g, 17.7 mmol) was added. The suspension was stirred for 30 min then (1-bromoethyl)benzene (1.96 g, 10.6 mmol) was added drop-wise. The reaction was heated to 80 °C overnight or until completion, cooled to ambient temperature, diluted using water (40 mL) and extracted with EtOAc (2 x 50 mL). The organics were washed with water (30 mL), brine (30 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 3-nitro-1-(1-phenylethyl)-1H-pyrazole as a yellow liquid (1.2 g, 63%). ¹H NMR (300 MHz, CDCl_3) δ 7.46 – 7.18 (m, 6H), 6.88 (d, $J = 2.5$ Hz, 1H), 5.59 (q, $J = 7.1$ Hz, 1H), 1.96 (d, $J = 7.1$ Hz, 3H).

A solution of 3-nitro-1-(1-phenylethyl)-1H-pyrazole (1 g, 4.6 mmol) in THF (20 mL) and MeOH (5 mL) was cooled to 0 °C. Zinc powder (1.49 g, 23.04 mmol) and NH_4Cl solution (1.23 g, 23.04 mmol; in 5 mL of water) was added. The resulting reaction mixture was stirred for 30 mins then heated at 80 °C for 6 h. The reaction mixture was cooled to ambient temperature, diluted with EtOAc (50 mL) and filtered through a bed of Celite. The organic phase was washed using water (20 mL), brine (20 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 50% EtOAc-hexanes eluent to give 1-(1-phenylethyl)-1H-pyrazol-3-amine as a yellow liquid (0.85 g, 67%). ¹H NMR (300 MHz, CDCl_3) δ = 7.39 – 7.04 (m, 6H),

5.59 (d, $J = 2.4$ Hz, 1H), 5.35 (q, $J = 7.1$ Hz, 1H), 3.83 (s, 2H), 1.78 (d, $J = 7.1$ Hz, 3H).

1-(2-(piperidin-1-yl)ethyl)-1H-pyrazol-3-amine




A solution of 3-nitro-1H-pyrazole (2 g, 17.7 mmol) in DMF (20 mL) was treated with 1-(2-chloroethyl)piperidine hydrochloride (4.8 g, 26.5 mmol) at ambient temperature. The solution was cooled to 0 °C, and treated with K₂CO₃ (6.1 g, 44.27 mmol) in portions over a period of 5 min. The resulting reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 40 mL). The combined organics were washed with water (40 mL), brine (40 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 25% EtOAc-hexanes eluent to give 1-(2-(3-nitro-1H-pyrazol-1-yl)ethyl)piperidine as a pale yellow solid (2.5 g, 64%). ¹H NMR (400 MHz, CDCl₃): δ = 7.60 (d, $J = 2.4$ Hz, 1H), 6.81 (d, $J = 2.4$ Hz, 1H), 4.29 (t, $J = 6.4$ Hz, 2H), 2.78 (t, $J = 6.4$ Hz, 2H), 2.41 (s, 4H), 1.57-1.53 (m, 4H), 1.45 (t, $J = 6$ Hz, 2H). LCMS (m/z): 225.10 (M + 1)⁺.

A solution of 1-(2-(3-nitro-1H-pyrazol-1-yl)ethyl)piperidine **3** (2.5 g, 11.16 mmol) in THF (20 mL) and MeOH (5 mL) was cooled to 0 °C. The solution was sequentially treated with zinc powder (3.6 g, 55.8 mmol) and aqueous NH₄Cl (3 g, 55.8 mmol) solution then warmed to ambient temperature and stirred for 5 h. The reaction mixture was diluted with ethyl acetate (50 mL), filtered through a bed of Celite and concentrated *in vacuo*. The residue was diluted with ethyl acetate (60 mL) and washed with water (40 mL), brine (40 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give 1-(2-(piperidin-1-yl)ethyl)-1H-pyrazol-3-amine

as light yellow liquid (1.75 g, 81%). ^1H NMR (400 MHz, DMSO- d_6): δ = 7.28 (d, J = 2 Hz, 1H), 5.30 (s, J = 2 Hz, 1H), 4.50 (s, 2H), 3.90 (t, J = 6.8 Hz, 2H), 2.5-2.53 (m, 4H), 2.39-2.33 (m, 6H), 1.2 (s, 2H). LCMS (m/z): 195.10 ($M + 1$) $^+$.


1,5-dimethyl-1*H*-pyrazol-3-amine



A solution of 5-methyl-3-nitro-1*H*-pyrazole (2 g, 15.7 mmol) in THF (20 mL) was cooled to 0 °C. NaH (0.7 g, 17.32 mmol) was added portion-wise over 10 min under nitrogen atmosphere. The resulting suspension was stirred for 10 min then treated with MeI (2.2 g, 15.7 mmol), warmed to ambient temperature and stirred for 4h. The reaction mixture was diluted with saturated NH_4Cl solution (20 mL) and extracted with EtOAc (2 x 30 mL). The organics were washed with water (30 mL), brine (30 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give 1,5-dimethyl-3-nitro-1*H*-pyrazole as a white solid (2 g, 91%). ^1H NMR (300 MHz, CDCl_3): δ = 6.71 (s, 1H), 3.87 (s, 3H), 2.34 (s, 3H).

In a 100 mL Parr shaker reaction vessel, a solution of 1,5-dimethyl-3-nitro-1*H*-pyrazole (2 g, 14.18 mmol) in MeOH (4 mL) and EtOAc (20 mL) was treated with 10% palladium on carbon (400 mg) under nitrogen atmosphere. The flask was evacuated then filled with hydrogen gas (60 psi) and stirred at ambient temperature for 12h. The reaction mixture was diluted with ethyl acetate (50 mL) and filtered through a bed of Celite. The filtrate was dried (Na_2SO_4) and concentrated *in vacuo* to give 1,5-dimethyl-1*H*-pyrazol-3-amine as a light brown solid (1.36 g 87%). ^1H NMR (400 MHz, DMSO- d_6): δ = 5.19 (s, 1H), 4.33 (br.s., 2H), 3.43 (s, 3H), 2.07 (s, 3H). LCMS (m/z): 112.3 ($M + 1$) $^+$

1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-amine




A solution of 1,1,1-triethoxyethane (20 g, 123 mmol) in DCM (250 mL) and pyridine (20.5g, 259 mmol) was cooled to 0 °C. A solution of trifluoroacetic anhydride (52 g, 246 mmol) in DCM (50 mL) was added drop-wise over a period of 30 min. The reaction mixture was warmed to ambient temperature, stirred for 12h, then diluted with sat. aq. NaHCO₃ solution and extracted with DCM (2 x 250 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give 4,4-diethoxy-1,1,1-trifluorobut-3-en-2-one as a pale brown liquid (20 g, 76%). ¹H NMR (400 MHz, CDCl₃): δ = 4.93 (s, 1H), 4.39 (q, *J* = 7.2 Hz, 2H), 4.18 (q, *J* = 7.2 Hz, 4H), 1.46-1.40 (m, 6H).

A solution of 4,4-diethoxy-1,1,1-trifluorobut-3-en-2-one (10 g, 47.16 mmol) in acetonitrile (100 mL) was treated with aqueous NH₃ solution (15 mL) at 0 °C then stirred at RT for 12 h. The reaction mixture was concentrated *in vacuo* then the residue was treated with water (250 mL) and extracted with DCM (2 x 250 mL). The combined organics were washed with water (250 mL), brine (250 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give (*E*)-4-amino-4-ethoxy-1,1,1-trifluorobut-3-en-2-one as an off white solid (7.5 g, 87%). ¹H NMR (300 MHz, CDCl₃): δ = 5.6 (br.s., 1H), 4.17 (q, *J* = 7.2 Hz, 2H), 1.42 (t, *J* = 7.2 Hz, 3H).

A solution of (*E*)-4-amino-4-ethoxy-1,1,1-trifluorobut-3-en-2-one (5 g, 27.3 mmol) in EtOH (30 mL) was treated with methylhydrazine sulphate (4.72 g, 32.8 mmol) and Et₃N (4.1 g, 41.0 mmol) at ambient temperature. The resulting reaction mixture was heated at 85 °C for 12 h then cooled to ambient temperature and concentrated *in vacuo*. The residue obtained was diluted with sat. aq. NaHCO₃ solution (250 mL) and extracted with EtOAc (2 x 250 mL). The

combined organics were washed with water (250 mL), brine (250 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-amine as a pale brown liquid (0.17 g, 38%). ^1H NMR (400 MHz, CDCl_3): δ = 5.93 (s, 1H), 3.79 (s, 3H), 3.68 (br.s., 2H).

1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazol-3-amine



A solution of 1-methyl-1*H*-pyrazol-3-amine (2 g, 20.6 mmol,) in AcOH (50 mL) was treated with 2,5-hexane dione (4.9 g, 43.29 mmol) at ambient temperature under nitrogen atmosphere. The resulting reaction mixture was heated to 100 °C for 1 h then stirred at ambient temperature for 5 h. The reaction mixture was concentrated under reduced pressure and azeotroped with toluene. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1-methyl-1*H*-pyrazole as a liquid (2.5 g, 69%). ^1H NMR (300 MHz, CDCl_3): δ = 7.39 (d, J = 2.1 Hz, 1H), 6.15 (d, J = 2.4 Hz, 1H), 5.84 (s, 2H), 3.92 (s, 3H), 2.10 (s, 6H).

A solution of 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1-methyl-1*H*-pyrazole (1 g, 5.71 mmol) in dry THF (10 mL) was cooled to -78 °C under nitrogen atmosphere, *n*-BuLi (1.6 M in hexanes, 4.4 mL, 6.86 mmol) was added drop-wise to the above solution over a period of 10 minutes then stirred at -78 °C for 1 h before treating with a solution of I_2 (1.54g, 5.71 mmol) in THF (5 mL) at -78 °C stirring was continued at this temperature until completion (2 h). The reaction mixture was quenched with sat. aq. NH_4Cl solution and extracted with ethyl acetate (2 x 25 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by


column chromatography on silica gel using 50% EtOAc-hexanes eluent to give 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-5-iodo-1-methyl-1*H*-pyrazole as an off-white solid (0.75g, 43.6%). ¹H NMR (400 MHz, CDCl₃): δ = 6.33 (s, 1H), 5.84 (s, 2H), 3.95 (s, 3H), 2.09 (s, 6H).

A solution of 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-5-iodo-1-methyl-1*H*-pyrazole (1g, 3.32 mmol) in DME:water (8:2, 10 mL) was treated with 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (0.67g, 3.98 mmol) and Na₂CO₃ (0.52g, 4.98 mmol) at ambient temperature under nitrogen atmosphere. The resulting solution was degassed by purging with argon for 15 min then treated with Pd(PPh₃)₄ (190 mg, 0.166 mmol) under argon atmosphere. The resulting mixture was heated at 90 °C for 24 h then cooled to ambient temperature and concentrated *in vacuo*. The residue obtained was diluted with cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole as a pale-yellow liquid (0.765 g, 92%). ¹H NMR (300 MHz, CDCl₃): δ = 6.08 (s, 1H), 5.84 (s, 2H), 5.39 (s, 1H), 5.23 (s, 1H), 3.92 (s, 3H), 2.12 (s, 9H).

A solution of 3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1-methyl-5-(prop-1-en-2-yl)-1*H*-pyrazole (0.7 g, 3.25 mmol) in EtOH-H₂O (8:2, 12 mL) was treated with NH₂OH.HCl (2.26 g, 32.55 mmol) and KOH (1.8 g, 32.55 mmol). The resulting reaction mixture was heated at 100 °C for 48 h. The reaction mixture was cooled and concentrated *in vacuo*. The residue was treated with saturated NaHCO₃ to give a solution of pH~8 then extracted with EtOAc (2 x 50 mL). The combined organics were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 100% EtOAc eluent to give 1-methyl-5-

(prop-1-en-2-yl)-1*H*-pyrazol-3-amine as a light brown liquid (0.4 g, 91%). ¹H NMR (400 MHz, CDCl₃): δ = 5.54 (s, 1H), 5.27 (s, 1H), 5.08 (s, 1H), 3.71 (s, 3H), 2.41 (s, 2H), 1.92 (s, 3H).

Ethyl 1-benzyl-3-nitro-1*H*-pyrazole-5-carboxylate




A solution of 3-nitro-1*H*-pyrazole-5-carboxylic acid (5 g, 31.8 mmol) in ethanol (50 mL) was treated with thionyl chloride (4.5 g, 38.2 mmol) drop wise over a period of 10 min at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred at 80 °C for 6 h then cooled to ambient temperature and concentrated *in vacuo*. The residue obtained was basified to pH 8 with saturated NaHCO₃ solution before extracting with ethyl acetate (2 x 100 mL). The combined organics were washed with water (100 mL), brine (100 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was triturated with diethyl ether, filtered and dried under reduced pressure to give ethyl 3-nitro-1*H*-pyrazole-5-carboxylate as a white solid (5 g, 85%). ¹H NMR (400 MHz, DMSO-d₆): δ = 7.44 (s, 1H), 4.36 (q, *J* = 6.8 Hz, 2H), 1.33 (t, *J* = 7.2 Hz, 3H). LCMS (*m/z*): 184 (M-1)⁻.

Ethyl 3-nitro-1*H*-pyrazole-5-carboxylate (1 g, 5.4 mmol) was dissolved in DMF (10 mL) at ambient temperature and treated with K₂CO₃ (1.34 g, 9.7 mmol). The resulting mixture was cooled to 0 °C and methyl iodide (1.15 g, 8.1 mmol) was added drop-wise, the reaction mixture was sealed, allowed to warm to ambient temperature and stirred for 12 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organics were washed with water (30 mL), brine (30 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel

using 5% EtOAc-hexanes eluent to give ethyl 1-methyl-3-nitro-1*H*-pyrazole-5-carboxylate as a white solid (0.65 g, 61%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 7.54 (s, *J* = 1.1 Hz, 1H), 4.35 (q, *J* = 7.1 Hz, 2H), 4.19 (d, *J* = 1.2 Hz, 3H), 1.33 (t, *J* = 7.1 Hz, 3H).

Ethyl 1-methyl-3-nitro-1*H*-pyrazole-5-carboxylate (0.65 g, 3.3 mmol) was dissolved in THF (20 mL) and MeOH (5 mL) at 0 °C. Zinc powder (1.0 g, 16.3 mmol) and aqueous NH₄Cl (0.87 g, 16.3 mmol) were added sequentially. The resulting reaction mixture was stirred at ambient temperature for 4h, then heated to 70 °C for 1 hour. The solvents were removed *in vacuo*. The residue obtained was dissolved in EtOAc (30 mL) and filtered through a bed of Celite. The filtrate was washed with water (30 mL), brine (30 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give ethyl 3-amino-1-methyl-1*H*-pyrazole-5-carboxylate as a white solid (0.5 g, 91%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 5.95 (s, 1H), 4.24 (q, *J* = 7.1 Hz, 2H), 3.83 (s, 3H), 3.41 (s, 2H), 1.27 (t, *J* = 7.1 Hz, 4H).

Ethyl 1-benzyl-3-nitro-1*H*-pyrazole-5-carboxylate




A solution of 3-nitro-1*H*-pyrazole-5-carboxylic acid (5 g, 31.8 mmol) in ethanol (50 mL) was treated with thionyl chloride (4.5 g, 38.2 mmol) drop wise over a period of 10 min at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred at 80 °C for 6 h then cooled to ambient temperature and concentrated *in vacuo*. The residue obtained was basified to pH 8 with saturated NaHCO₃ solution before extracting with ethyl acetate (2 x 100 mL). The combined organics were washed with water (100 mL), brine (100 mL),

dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was triturated with diethyl ether, filtered and dried under reduced pressure to give ethyl 3-nitro-1*H*-pyrazole-5-carboxylate as a white solid (5 g, 85%). ^1H NMR (400 MHz, DMSO-d_6): δ = 7.44 (s, 1H), 4.36 (q, J = 6.8 Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H). LCMS (m/z): 184 ($\text{M}-1$)⁻.

Ethyl 3-nitro-1*H*-pyrazole-5-carboxylate (2 g, 10.8 mmol) was dissolved in DMF (10 mL) at ambient temperature and treated with K_2CO_3 (3 g, 21.6 mmol). The resulting mixture was cooled to 0 °C and benzyl bromide (2.7 g, 16.2 mmol) was added drop-wise, the reaction mixture was allowed to warm to ambient temperature and stirred for 2 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organics were washed with water (30 mL), brine (30 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give ethyl 1-benzyl-3-nitro-1*H*-pyrazole-5-carboxylate as a white solid (1.2 g, 40%). ^1H NMR (400 MHz, CDCl_3): δ = 7.44 (s, 1H), 7.34-7.31 (m, 5H), 5.83 (s, 2H), 4.39 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H). LCMS (m/z): 276.15 ($\text{M}+1$)⁺.

Ethyl 1-benzyl-3-nitro-1*H*-pyrazole-5-carboxylate (1.2 g, 4.36 mmol) was dissolved in THF (20 mL) and MeOH (5 mL) at 0 °C. Zinc powder (1.4 g, 21.8 mmol) and aqueous NH_4Cl (1.16 g, 21.8 mmol) were added sequentially. The resulting reaction mixture was stirred at ambient temperature for 4h, then concentrated *in vacuo*. The residue obtained was dissolved in EtOAc (30 mL) and filtered through a bed of Celite. The filtrate was washed with water (30 mL), brine (30 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give ethyl 3-amino-1-benzyl-1*H*-pyrazole-5-carboxylate as a white solid (1 g, 94%). ^1H NMR (300 MHz, DMSO-d_6): δ = 7.30-7.19 (m, 3H), 7.11-7.08 (m, 2H), 6.00 (s, 1H), 5.43 (s, 2H), 4.91 (s, 2H), 4.23 (q, J = 7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). LCMS (m/z): 245.9 ($\text{M}+1$)⁺.

3-(2,5-dimethyl-1H-pyrrol-1-yl)-1-phenyl-1H-pyrazole




A solution of 1-phenyl-1H-pyrazol-3-amine (3.5 g, 21.9 mmol) in acetic acid (20 mL) was treated with 2,5-hexadione (5.2 g, 45.9 mmol) and heated to 100 °C for 4 h. The mixture was cooled and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give 3-(2,5-dimethyl-1H-pyrrol-1-yl)-1-phenyl-1H-pyrazole as a colorless liquid (2.8 g, 54%). ¹H NMR (400 MHz, CDCl₃): δ = 7.98 (s, 1H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 1H), 6.39 (s, 1H), 5.9 (s, 2H), 2.19 (s, 6H).

A solution of 3-(2,5-dimethyl-1H-pyrrol-1-yl)-1-phenyl-1H-pyrazole (2.7 g, 11.4 mmol) in THF (70 mL) at -78 °C was treated drop-wise with n-BuLi (1.6 M in THF, 10 mL, 23.91 mmol) over 10 min. The reaction mixture was stirred at -78 °C for 1.5 h then treated with freshly dried acetone (1 g, 17.0 mmol) and stirring continued at -78 °C for 1.5 h. The reaction mixture was quenched with sat. ammonium chloride (2 mL), concentrated *in vacuo* then partitioned between water (100 mL) and ethyl acetate (100 mL). The organic extract was washed with water (100 mL), brine (100 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 2-(3-(2,5-dimethyl-1H-pyrrol-1-yl)-1-phenyl-1H-pyrazol-5-yl)propan-2-ol as an off white solid (1.4 g, 42%). ¹H NMR (400 MHz, CDCl₃): δ = 7.57-7.56 (m, 2H), 7.47-7.46 (m, 3H), 6.23 (s, 1H), 5.85 (s, 2H), 2.19 (s, 6H), 1.52 (s, 6H). LCMS (*m/z*): 296.1 (M+1)⁺.


In an 100 mL re-sealable reaction tube, 2-(3-(2,5-dimethyl-1*H*-pyrrol-1-yl)-1-phenyl-1*H*-pyrazol-5-yl)propan-2-ol (1.4 g, 4.74 mmol) was dissolved in EtOH-H₂O (1:1, 50 mL) at ambient temperature. Hydroxyl amine hydrochloride (3.3 g, 47.45 mmol), and KOH (2.6 g, 47.45 mmol) were added sequentially and resulting reaction mixture was heated at 120 °C for 16 h. The reaction mixture was concentrated *in vacuo*, diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic extracts were washed with water (50 mL), brine (50 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 50% EtOAc-hexanes eluent to give 2-(3-amino-1-phenyl-1*H*-pyrazol-5-yl)propan-2-ol as a colorless liquid (0.8 g, 78%). LCMS (*m/z*): 218.1 (M+1)⁺.

8-bromo-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine




N-Bromosuccinimide (1.02 g, 5.78 mmol) was added portion-wise to a solution of 1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine (1 g, 5.78 mmol) in DCM (20 mL) at 0 °C. The solution was gradually warmed to ambient temperature and stirred for 12 h. The reaction mixture was diluted with sat. aqueous Na₂S₂O₃ (50 mL) and extracted with DCM (2 x 25 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexane eluent to give 8-bromo-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine as a brown solid (1.2 g, 83%). ¹H NMR (300 MHz, CDCl₃): δ = 3.45 (br.s., 2H), 2.92-2.88 (m, 4H), 2.81-2.77 (m, 4H), 2.16-2.09 (m, 4H); LC-MS 94% (210 nM); *m/z* 252.15 [M + H]⁺.

8-chloro-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine



N-Chlorosuccinimide (0.46 g, 3.46 mmol) was added portion-wise to a solution of 1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine, **1** (0.6 g, 3.46 mmol) in CHCl_3 (10 mL) at 0 °C. The solution was gradually warmed to ambient temperature and stirred for 10 h. The reaction mixture was diluted with sat. aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (50 mL) and extracted with DCM (2 x 25 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexane eluent to give 8-chloro-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine as a brown solid (0.45 g, 63%). ^1H NMR (300 MHz, CDCl_3): δ = 2.94 (t, J = 7.2 Hz, 4H), 2.77 (t, J = 8.1 Hz, 4H), 2.18 (m, 4H); m/z 207.8 [$\text{M} + \text{H}$] $^+$.


8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine



8-Bromo-1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine (400 mg, 1.59 mmol) was dissolved in 1,4-dioxane-water (8:2, 10 mL) and the reaction flask purged with argon gas for 15 min. K_2CO_3 (650 mg, 4.78 mmol), methyl boronic acid (100 mg, 1.75 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (100 mg, 0.079 mmol) were sequentially added under argon atmosphere. The resulting mixture was sealed and heated at 100 °C for 2 h. The reaction mixture was cooled, diluted with water and extracted using EtOAc (2 x 20 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The

crude product was purified by column chromatography on silica gel using 5% EtOAc-hexane eluent to give 8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine as a colorless liquid (0.220 g, 76%). ^1H NMR (400 MHz, CDCl_3): δ = 3.41 (br.s., 2H), 2.88-2.8 (m, J = 7.5 Hz, 4H), 2.75-2.67 (m, 4H), 2.18-2.09 (m, 7H); m/z 188.2 $[\text{M} + \text{H}]^+$.

3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine



A solution of 2,3-dihydrobenzofuran-5-carbaldehyde (10 g, 67.6 mmol), malonic acid (10.5 g, 101.35 mmol) and piperidine (0.47 mL, 4.73 mmol, 0.07 eq) was heated in pyridine (60 mL) at 100 °C for 5 h. The reaction mixture was acidified to ~pH 3 using 1N HCl and the product extracted using 10% IPA/chloroform (2 x 250 mL). The combined organic extracts were washed with water (250 mL), brine (250 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was triturated using diethyl ether to give (E)-3-(2,3-dihydrobenzofuran-5-yl)acrylic acid as a yellow solid (10 g, 78%). ^1H NMR (300 MHz, Chloroform- d) δ = 7.73 (d, J = 15.9 Hz, 1H), 7.43 (s, 1H), 7.33 (dd, J = 8.1, 1.8 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 6.29 (d, J = 15.9 Hz, 1H), 4.64 (t, J = 8.7 Hz, 2H), 3.24 (t, J = 8.7 Hz, 2H).

A solution of (E)-3-(2,3-dihydrobenzofuran-5-yl)acrylic acid (8.0 g, 42.1 mmol) in acetic acid (80 mL) and water (1.0 mL) was treated with 10% palladium on carbon (1.0 g) in two portions. The reaction mixture was stirred under an atmosphere of hydrogen gas (balloon) until completion, typically 4 h. The

mixture was diluted using ethyl acetate (100 mL) and filtered through a bed of celite washing through with further ethyl acetate. The solvents were removed in vacuo and the crude residue azeotroped using toluene (2 x 50 mL) to give an off white solid which was triturated using diethyl ether (50 mL) to give 3-(2,3-dihydrobenzofuran-5-yl)propanoic acid as a white solid (6.5 g, 80%). ¹H NMR (400 MHz, CDCl₃) δ = 7.04 (s, 1H), 6.93 (d, *J* = 8.4, 1H), 6.7 (d, *J* = 8.4 Hz, 1H), 4.55 (t, *J* = 8.4 Hz, 2H), 3.18 (t, *J* = 8.4 Hz, 2H), 2.89 (t, *J* = 7.6 Hz, 2H), 2.64 (t, *J* = 7.6 Hz, 2H).


A solution of 3-(2,3-dihydrobenzofuran-5-yl)propanoic acid (6.0 g, 31 mmol) in thionyl chloride (8 mL) was heated at 80 °C for 1 h. On completion of the reaction the thionyl chloride was removed *in vacuo* and the crude 3-(2,3-dihydrobenzofuran-5-yl)propanoyl chloride dissolved in anhydrous 1,2-dichloroethane (30 mL). In a separate flask aluminium trichloride (2 g, 15 mmol) was added to anhydrous 1,2-dichloroethane (40 mL) at 0 °C followed by the acid chloride solution (10 mL) drop-wise over 5 min and the resulting solution was stirred for 30 min at 0 °C. A further portion of aluminium trichloride (3 g, 22.5 mmol) was added followed by drop-wise addition of the remaining acid chloride solution (20 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h or until completion, diluted with water and extracted using EtOAc (2 x 50 mL). The combined organic extracts were washed with 1N HCl (50 mL), 1N NaOH (50 mL), water (25 mL), brine (25 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 2,3,5,6-tetrahydro-7*H*-indeno[5,6-*b*]furan-7-one as a white solid (3.8 g, 70%). ¹H NMR (300 MHz, CD₃OD) δ = 7.36 (s, 1H), 6.91 (s, 1H), 4.61 (t, *J* = 8.6 Hz, 3H), 3.26 (t, *J* = 8.6 Hz, 2H), 3.05 (t, *J* = 5.5 Hz, 3H), 2.68 (t, *J* = 5.5 Hz, 2H).

2,3,5,6-tetrahydro-7*H*-indeno[5,6-*b*]furan-7-one (1.5 g, 8.61 mmol) was dissolved in c.H₂SO₄ (6.0 mL) at 0 °C followed by drop-wise addition of

f.HNO₃:c.H₂SO₄, 1:1 (1.2 mL) stirring was continued at 0 °C for 1 h. The reaction mixture was added to ice-cold water (60 mL) and stirred for 10 min, the resulting light brown ppt was removed by filtration, washed with ice cold water (20 mL) and dried *in vacuo* to give 8-nitro-2,3,5,6-tetrahydro-7H-indeno[5,6-b]furan-7-one (1.2 g, 64%). ¹H NMR (300 MHz, CD₃OD) δ = 7.54 (s, 1H), 4.80 (t, *J* = 8.6 Hz, 2H), 3.42 (t, *J* = 8.6 Hz, 2H), 3.09 (t, *J* = 5.6 Hz, 2H), 2.74 (t, *J* = 5.6 Hz, 2H).

A solution of 8-nitro-2,3,5,6-tetrahydro-7H-indeno[5,6-b]furan-7-one (1.0 g, 4.57 mmol) in methanol (20 mL) 0 °C was treated with methane sulfonic acid (0.2 mL) followed by 20% palladium hydroxide (0.5 g). The reaction mixture was stirred under an atmosphere of hydrogen gas at 60 psi until completion. The reaction mixture was filtered through a bed of celite washing through with methanol (50 mL) and concentrated *in vacuo*. The residue was diluted with ethyl acetate (50 mL) and washed using sat. aq. NaHCO₃ (50 mL), water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine as a white solid (0.5 g, 63%). ¹H NMR (300 MHz, CDCl₃) δ = 6.54 (s, 1H), 5.30 (s, 2H), 4.61 (t, *J* = 8.7 Hz, 2H), 3.21 (t, *J* = 8.7 Hz, 2H), 2.95 (t, *J* = 5.5 Hz, 2H), 2.66 (t, *J* = 5.5 Hz, 2H).

4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine




3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine (0.5 g, 2.86 mmol) and triethylamine (0.51 mL, 3.71 mmol) in dichloromethane (6.0 mL) at 0 °C was treated drop-wise with a solution of pivoyl chloride (0.41 g, 3.43 mmol) in DCM

(4.0 mL). The reaction was stirred at ambient temperature for 6 h. The reaction mixture was added to sat. aq. NaHCO_3 (30 mL), and extracted using DCM (2 x 25 mL). The combined organics were washed with water (25 mL), brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo* to give N-(3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)pivalamide as a white solid (0.55 g, 74%). ^1H NMR (300 MHz, Chloroform-*d*) δ = 6.91 (s, 1H), 4.56 (t, J = 8.6 Hz, 2H), 3.17 (t, J = 8.6 Hz, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.4 Hz, 2H), 1.32 (s, 9H).

N-(3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)pivalamide (0.55 g, 2.12 mmol) in acetic acid (10 mL) was treated drop-wise with a solution of bromine (0.4 g, 2.55 mmol) in acetic acid (2.0 mL) and the reaction stirred at ambient temperature for 3 h. Ice cold water was added to the reaction mixture and stirred for 10 min. The resulting precipitate was removed by filtration, washed with water (20 mL) and dried *in vacuo* to give N-(4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)pivalamide as a pale-brown solid (0.65 g, 91%). ^1H NMR (300 MHz, Chloroform-*d*) δ = 6.94 (s, 1H), 4.61 (t, J = 8.7 Hz, 2H), 3.18 (t, J = 8.7 Hz, 2H), 2.92 – 2.80 (m, 4H), 2.06 (p, J = 7.4 Hz, 2H), 1.31 (s, 9H).

N-(4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)pivalamide (0.6 g, 1.78 mmol) in EtOH (10 mL) and CHCl_3 (15 mL) was heated at 90 °C for 36 h. The solution was concentrated *in vacuo* then basified using aq NH_4OH solution. The aqueous phase was extracted using ethyl acetate (2 x 20 mL) and the combined organics dried (Na_2SO_4) and concentrated *in vacuo* to give 4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine as a brown solid (0.3 g, 67%). ^1H NMR (400 MHz, Chloroform-*d*) δ = 4.61 (t, J = 8.6 Hz, 2H), 3.49 (s, 2H), 3.17 (t, J = 8.6 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.78 (t, J = 7.4 Hz, 2H), 2.12 (p, J = 7.4 Hz, 2H).


3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-4-amine



3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-amine (0.5 g, 1.98 mmol) in ethanol (10 mL) and acetic acid (1.5 mL) was treated with a solution of sodium nitrate (1.3 g, 19.8 mmol) in water (3.0 mL) and the reaction stirred at ambient temperature for 4 h. The ethanol was removed *in vacuo* then the residue diluted with water (30 mL), extracted using 10% IPA/chloroform (2 x 25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give 4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan as a yellow solid (0.28 g, 60%).


4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan (0.28 g, 1.18 mmol) in DMSO (10 mL) was treated with copper iodide (0.22 g, 1.18 mmol), L-proline (0.21 g, 1.88 mmol) and sodium azide (0.19 g, 2.94 mmol). The reaction mixture was heated in a sealed tube at 135 °C for 36 h. The reaction mixture was cooled, diluted with water and extracted using EtOAc (2 x 25 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-4-amine as a grey solid (0.17 g, 85%). ^1H NMR (300 MHz, Chloroform-*d*) δ = 6.21 (s, 1H), 4.59 (t, J = 8.5 Hz, 2H), 3.51 (s, 1H), 2.98 (t, J = 8.5 Hz, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.64 (t, J = 7.5 Hz, 2H), 2.10 (p, J = 7.5 Hz, 2H).

benzo[1,2-b:4,5-b']difuran-4-amine



2,3,6,7-tetrahydrobenzo[1,2-*b*:4,5-*b'*]difuran-4-carboxylic acid (0.8 g, 3.88 mmol), 2, 3-dichloro-5,6-dicyanobenzoquinone (2.64 g, 11.65 mmol) in anhydrous dioxane (20 mL) was heated in a sealed tube at 120 °C for 18 h. The reaction mixture was cooled to room temperature and sat. aq. Na₂S₂O₃ (30 mL) added before extraction with ethyl acetate (2 x 25 mL). The combined organics dried (Na₂SO₄) and concentrated *in vacuo* to give the crude benzo[1,2-*b*:4,5-*b'*]difuran-4-carboxylic acid (1.5 g). The crude acid (1.5 g), triethylamine (2.05 mL) and diphenylphosphoryl azide (4.08 g, 14.85 mmol) in tertiary butanol (20 mL) was heated in a sealed tube at 90 °C for 12 h. The solution was cooled to room temperature, diluted with water (50 mL) and extracted using EtOAc (2 x 50 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give tert-butyl benzo[1,2-*b*:4,5-*b'*]difuran-4-ylcarbamate (0.75 g) with minor impurities from the phosphine reagent, the product was dissolved in DCM (10 mL) and TFA (3.0 mL) added drop-wise over 5 min at 0 °C. The reaction was stirred at ambient temperature for 2 h then added carefully to sat. aq. NaHCO₃ (50 mL). The aqueous phase was extracted using DCM (2 x 30 mL) and the combined organic extracts were washed with water (25 mL), brine (25 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give benzo[1,2-*b*:4,5-*b'*]difuran-4-amine as an off-white solid (0.2 g, 30% over three steps). ¹H NMR (400 MHz, CDCl₃): δ = 7.6 (d, *J* = 2.2 Hz, 1H), 7.53 (d, *J* = 2.2 Hz, 1H), 7.12 (s, 1H), 6.78 (m, 2H), 4.17 (br.s., 1H).

3-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline



To a solution of 2,2,2-trifluoro-1-phenylethan-1-one (5 g, 28.7 mmol) in c.H₂SO₄ (10 mL) at -5 °C was added a solution of c.H₂SO₄ and f.HNO₃ (1:1, 16 mL) and the reaction mixture was stirred for 3 hours. The resulting solution was poured onto ice/water (100 mL) and extracted using ethyl acetate (2 x 100 mL). The combined organics were washed with water (100 mL), brine (100 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20% EtOAc-hexanes eluent to give 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one as a yellow liquid (4.2 g, 67%). ¹H NMR (400 MHz, CDCl₃) δ = 8.92 (s, 1H), 8.59 (dd, *J* = 8.1, 1.4 Hz, 1H), 8.41 (d, *J* = 7.8 Hz, 1H), 7.82 (t, *J* = 8.1 Hz, 1H). ¹⁹F NMR (233.33 MHz, CDCl₃): -71.82 (s, 3F).

A solution of 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one (4.2 g, 19.2 mmol), hydroxylamine hydrochloride (4.0 g, 57.5 mmol) and pyridine (25 mL) in ethanol (25 mL) were heated at reflux for 3 h. or until completion. The solvent was removed *in vacuo* and the crude product was purified by column chromatography on silica gel using 40% EtOAc-hexanes eluent to give 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one oxime as a colourless liquid (4.0 g, 89%). ¹⁹F NMR (233.33 MHz, CDCl₃): -66.42 and 62.28 (E and Z oxime).

To a solution of 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one oxime (4.0 g, 17.1 mmol) in dichloromethane (20 mL) was cooled to 0 °C treated with triethylamine (1.5 eq), *N,N*-dimethylamine pyridine (0.5 eq), tosylchloride (1.1 eq) and stirred at ambient temperature until completion, typically 16 h. The reaction mixture

was diluted using dichloromethane (50 mL), washed with sat. aq. NH_4Cl (100 mL), water (100 mL), brine (100 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 5% EtOAc-hexanes eluent to give 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one *O*-tosyl oxime as a white solid (4.0 g, 60%). ^1H NMR (300 MHz, CDCl_3) δ = 8.41 (ddd, J = 5.6, 3.5, 2.2 Hz, 1H), 8.21 (t, J = 1.5 Hz, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.81 – 7.65 (m, 2H), 7.42 (d, J = 7.8 Hz, 2H), 2.50 (s, 3H). ^{19}F NMR (282 MHz, cdcl_3) δ -61.55, -66.90.


A solution of 2,2,2-trifluoro-1-(3-nitrophenyl)ethan-1-one *O*-tosyl oxime (4.0 g, 10.3 mmol) in diethyl ether was cooled to -78°C and a solution of ammonia gas was bubbled through for 30 min. The reaction mixture was sealed, allowed to warm to ambient temperature then stirred for 16 h. The mixture was filtered through a pad of celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 7% EtOAc-hexanes eluent to give 3-(3-nitrophenyl)-3-(trifluoromethyl)diaziridine as a colourless liquid (2.4 g, 100%). ^1H NMR (300 MHz, CDCl_3) δ = 8.52 (t, J = 2.0 Hz, 1H), 8.33 (ddd, J = 8.3, 2.3, 1.1 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.65 (tt, J = 7.8, 0.4 Hz, 1H), 2.95 (d, J = 8.8 Hz, 1H), 2.31 (d, J = 8.9 Hz, 1H). ^{19}F NMR (282 MHz, CDCl_3) δ = -75.10.

A solution of 3-(3-nitrophenyl)-3-(trifluoromethyl)diaziridine (2.4 g, 10.3 mmol) in methanol (30 mL) was treated with triethylamine (2 eq.) and iodine (1 eq.) and the reaction mixture stirred until completion, typically 2 h. The solution was diluted using diethyl ether, washed with 10% aq citric acid, water, aq. sodium thiosulfate, brine then dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-hexanes eluent to give 3-(3-nitrophenyl)-3-(trifluoromethyl)-3H-diazirine as a colourless liquid (2.1 g, 88%). ^1H NMR (300 MHz, CDCl_3) δ 8.30 (ddd, J = 7.9, 2.2, 1.4 Hz, 1H), 8.09 – 8.01 (m, 1H), 7.70 – 7.54 (m, 2H). ^{19}F NMR (282 MHz,

CDCl_3) $\delta = -65.14$.

3-(3-nitrophenyl)-3-(trifluoromethyl)-3H-diazirine (3.0 g, 13 mmol) in THF (70 mL) was treated with a solution of sodium dithionate (10 eq.) in water (30 mL) and the mixture was stirred at ambient temperature until completion, typically overnight. The solution was diluted using water, extracted using ethyl acetate (x2), washed with water, brine then dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 40% EtOAc-hexanes eluent to give the titled compound, 3-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline, as a yellow solid (1.5 g, 58%). ^1H NMR (300 MHz, CDCl_3) $\delta = 7.16$ (t, $J = 7.9$ Hz, 1H), 6.70 (ddd, $J = 8.1, 2.3, 0.9$ Hz, 1H), 6.52 (ddt, $J = 7.9, 1.9, 0.9$ Hz, 1H), 6.45 br.(s, 1H), 3.77 (s, 2H). ^{19}F NMR (282 MHz, CDCl_3) $\delta -65.07$.

4,6-di-*tert*-butylpyrimidin-2-amine




2,4,6-Trichloropyrimidine (2.7 g, 14.7 mmol) was dissolved in anhydrous THF (30 mL) at 0 °C under nitrogen atmosphere. CuI (280 mg, 1.47 mmol) was added to the aforementioned solution and subsequently treated with 2M *tert*-butylmagnesium chloride in THF (3.78 g, 16.15 mL, 32.3 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 3 h. Upon completion, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with EtOAc (2 x 50 mL). The combined organic extract was washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 100% hexanes eluant to give 4,6-di-*tert*-butyl-2-chloropyrimidine (1.3 g, 39%) as a pale brown liquid. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.20$ (s, 1H), 1.33 (s, 18H).

LCMS (m/z): 227.3 $[M+H]^+$


In a 100 mL re-sealable reaction tube, a solution of 4,6-di-*tert*-butyl-2-chloropyrimidine (1.3 g) in EtOH (15 mL) was cooled to -50 °C. Ammonia gas was purged through the aforementioned solution for 15 min. The reaction mixture was warmed to 70 °C and stirred for 12 h. Upon completion, the reaction mixture was concentrated *in vacuo* and the residue obtained was diluted with water and extracted with ethyl acetate (50 mL). The organic extract was washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo* to give 4,6-di-*tert*-butylpyrimidin-2-amine (0.7 g, 59%) as a white solid. ^1H NMR (300 MHz, CDCl_3): δ = 6.64 (s, 1H), 4.83 (s, 2H), 1.26 (s, 18H). LCMS (m/z): 208.4 $[M+H]^+$

4-chloro-2,6-diisopropylaniline




2,6-Diisopropylaniline (5.0 g, 28.2 mmol) in DMF (100 mL) was treated with *N*-chlorosuccinimide (3.97 g, 29.7 mmol) and the reaction mixture stirred at room temperature overnight. The solution was poured onto water (500 mL) and extracted using diethyl ether (2 x 150 mL). The combined organics were washed with water (2 x 200 mL), brine (200 mL), dried (MgSO_4) and concentrated *in vacuo*. The product was purified by short path distillation to give the titled compound as a red oil (3.0 g, 50%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ = 6.84 (s, 2H), 4.75 (s, 2H), 3.01 (hept, J = 6.8 Hz, 2H), 1.13 (d, J = 6.8 Hz, 12H). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$): δ = 141.1, 133.8, 122.5, 120.5, 27.2, 22.8.

4-chloro-2,6-dicyclopropylaniline



In a 50 mL re-sealable reaction tube, a solution of 2,6-dibromo-4-chloroaniline (0.25 g, 0.88 mmol) and cyclopropyl boronic acid (0.22 g, 2.62 mmol) along with K₃PO₄ (0.74 g, 3.50 mmol) was dissolved in toluene:water (10 mL:1 mL). The resulting solution was degassed by purging with nitrogen gas for 5 minutes. Pd(OAc)₂ (20mg, 0.087 mmol) and tricyclohexylphosphine (25 mg, 0.087 mmol) were added and the solution was purged with nitrogen gas for another 5 minutes. The resulting mixture was stirred at 100 °C for 12 h. Upon completion of reaction the mixture was diluted with water (25 mL), extracted with EtOAc (2 x 25 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 5% EtOAc-hexanes eluant to give 4-chloro-2,6-dicyclopropylaniline (150 mg, 83%) as brown liquid. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 6.69 (s, 2H), 4.98 (s, 2H), 1.74-1.64 (m, 2H), 0.90-0.84 (m, 4H), 0.52 -0.47 (m, 4H). LCMS (*m/z*): 208.30 [M+H]⁺.


Synthesis of 4-chloro-2-methyl-6-(trifluoromethyl)aniline



A solution of 2-methyl-6-(trifluoromethyl)aniline (0.4g, 2.20 mmol) in acetonitrile (4 mL) and AcOH (0.3 mL) was cooled to 0 °C. *N*-Chlorosuccinimide (0.36g, 2.70 mmol) was added at 0 °C and the solution then allowed to warm to RT and stirred for 12 h. Upon completion of reaction the reaction mixture was diluted with ice cold water and the resulting precipitate removed by filtration and


washed sequentially with saturated NaHCO_3 , $\text{Na}_2\text{S}_2\text{O}_3$ solution, n-pentane and dried *in vacuo* to give 4-chloro-2-methyl-6-(trifluoromethyl)aniline (0.25 g, 52%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.30 (d, J = 2.4 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 2.17 (s, 3H). ^{19}F NMR (400 MHz, CDCl_3): δ = -63.03

4-chloro-2,6-diethylaniline




A solution of 2,6-dibromo-4-chloroaniline (0.5 g, 1.75 mmol) and ethyl boronic acid (0.4 g, 5.25 mmol) in toluene (15 mL) and water (4 mL) was treated with K_3PO_4 (1.5 g, 7.0 mmol) at RT under argon atmosphere. Argon gas was used to purge the solution for 5 minutes before treating with $\text{Pd}(\text{OAc})_2$ (40 mg, 0.175 mmol) and tricyclohexyl phosphine (50 mg, 0.175 mmol). The reaction mixture was again purged with argon for 5 minutes. The resulting mixture was stirred at 100 °C for 12 h. Upon completion the reaction mixture diluted with water extracted with EtOAc (2 x 25 mL) and the combined organic extract washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 8% EtOAc-hexanes eluant to give 4-chloro-2,6-dicyclopropylaniline (100 mg, 31%) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ = 6.94 (s, 2H), 3.61 (s, 2H), 2.53 (q, J = 7.5 Hz, 4H), 1.27 (t, J = 7.5 Hz, 6H). LCMS (m/z): 184.00 $[\text{M}+\text{H}]^+$.

4-chloro-2,6-dimethoxyaniline



2,6-dibromo-4-chloroaniline (4 g, 14.0 mmol) was dissolved in 25% NaOMe soln in MeOH (48 mL) and treated with CuI (2.9g, 15.4 mmol) at RT under nitrogen atmosphere. The resulting mixture was stirred at 70 °C for 12 h under nitrogen atmosphere. Upon completion, the reaction mixture was cooled to RT and concentrated *in vacuo*. The residue obtained was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 1% EtOAc-hexanes to give 4-chloro-2,6-dimethoxyaniline (1.0 g, 38%) as a pale brown liquid. ¹H NMR (300 MHz, CDCl₃): δ = 6.52 (s, 2H), 3.83 (s, 6H). LCMS (*m/z*): 187.9 [M+H]⁺

2-amino-5-chloro-3-cyclopropyl-N,N-dimethylbenzamide




In a 50 mL resealable reaction tube, 2-amino-3-bromobenzoic acid (2.0 g, 9.25 mmol) was dissolved in DMF (20 mL) and cooled to 0 °C. EDC-HCl (2.1 g, 11.0 mmol), HOBT (1.49 g, 11.0 mmol), DIPEA (2.8 mL, 27.7 mmol) and dimethylamine hydrochloride (1.13 g, 13.8 mmol) were sequentially added at 0 °C. The reaction mixture was warmed to 70 °C and stirred for 12 h. Upon completion the reaction mixture was diluted with water extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give 2-amino-3-bromo-N,N-dimethylbenzamide (2.0 g, 89%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.44 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.06 (dd, *J* = 7.8, 1.5 Hz, 1H), 6.61 (t, *J* = 7.8 Hz, 1H), 4.82 (bs, 2H), 3.05 (s, 6H). LCMS (*m/z*): 243.10, 245.10 [M+H]⁺.

In a 50 mL resealable reaction tube, a solution of 2-amino-3-bromo-N,N-dimethylbenzamide (2 g, 8.23 mmol), cyclopropyl boronic acid (850 mg, 9.87

mmol) and K_3PO_4 (5.23 g, 24.06 mmol) were dissolved in toluene (30 mL) and water (3 mL). The solution was degassed by purging with nitrogen gas for 5 minutes then $Pd(OAc)_2$ (184 mg, 0.823 mmol) and tricyclohexylphosphine (230 mg, 0.823 mmol) were added and solution was once again purged with nitrogen gas for 5 minutes. The resulting mixture was stirred at 100 °C for 12 h. Upon completion the reaction mixture was diluted with saturated NH_4Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 20% EtOAc-hexanes to give 2-amino-3-cyclopropyl-*N,N*-dimethylbenzamide (1.0 g, 60%) as light brown color solid. ^1H NMR (300 MHz, $CDCl_3$): δ = 7.06 (d, J = 7.5 Hz, 1H), 6.99 (dd, J = 7.8, 1.5 Hz, 1H), 6.66 (t, J = 7.8 Hz, 1H), 4.70 (bs, 2H), 3.05 (s, 6H), 1.68-1.61 (m, 1H), 0.94-0.88 (m, 2H), 0.62-0.57 (m, 2H). LCMS (m/z): 205.3 $[M+H]^+$.

A solution of 2-amino-3-cyclopropyl-*N,N*-dimethylbenzamide (0.5g, 2.44 mmol) in acetonitrile (10 mL) and AcOH (0.3 mL) was cooled to 0 °C. *N*-Chlorosuccinimide (0.5 g, 3.67 mmol) was added at 0 °C and the resulting reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with saturated $Na_2S_2O_3$ solution and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with $NaHCO_3$ solution, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 25% EtOAc-hexanes eluant to give 2-amino-5-chloro-3-cyclopropyl-*N,N*-dimethylbenzamide (0.2 g, 34%) as a brown solid. ^1H NMR (300 MHz, $CDCl_3$): δ = 7.02 (d, J = 1.5 Hz, 1H), 6.96 (d, J = 2.7 Hz, 1H), 4.66 (bs, 2H), 3.05 (s, 6H), 1.68-1.61 (m, 1H), 0.94-0.88 (m, 2H), 0.62-0.57 (m, 2H). LCMS (m/z): 239.0 $[M+H]^+$.

4-chloro-2-methoxy-6-(trifluoromethyl)aniline




In a 50 mL resealable reaction tube, a solution of 2-bromo-4-chloro-6-(trifluoromethyl)aniline (0.5 g, 1.82 mmol), bis(pinacolato diborane) (0.92 g, 3.64 mmol) and KOAc (0.44 g, 4.55 mmol) in 1,4-dioxane (10 mL) was degassed by purging with nitrogen gas for 5 minutes. Pd(dppf)Cl₂ (0.15 g, 0.182 mmol) was added and the solution purged again with nitrogen gas for 5 minutes. The resulting mixture was stirred at 110 °C for 12 h. Upon completion, the reaction mixture diluted with water, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 2% EtOAc-hexanes eluant to give 4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)aniline (0.5 g, 85%). LCMS (m/z): 324.10 [M+H]⁺.

4-Chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)aniline (500 mg, 1.55 mmol) was dissolved in THF (5 mL) and H₂O (2 mL) at RT. NaBO₃·H₂O (0.62 g, 6.23 mmol) was added portion-wise and the reaction stirred at RT for 4 h. Upon completion the reaction mixture was diluted with water extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 15% EtOAc-hexanes eluant to give 2-amino-5-chloro-3-(trifluoromethyl)phenol (0.5 g, 100%) as a yellow liquid. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 10.50 (s, 1H), 6.85 (s, 2H), 5.12 (bs, 2H). ¹⁹F NMR (300 MHz, DMSO-*d*₆): δ = -61.46. LCMS (m/z): 211.6 [M+H]⁺.

2-amino-5-chloro-3-(trifluoromethyl)phenol (250 mg, 1.18 mmol) was dissolved

in anhydrous DMF (5 mL) and treated with K_2CO_3 (240 mg, 1.77 mmol). The resulting mixture was stirred at RT for 30 minutes. Methyl iodide (185mg, 1.303 mmol) was added dropwise and the reaction stirred at RT for 2 h. Upon completion the reaction mixture was diluted with water extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 10% EtOAc-hexanes eluant to give 4-chloro-2-methoxy-6-(trifluoromethyl)aniline (0.2 g, 75%) as a pale brown solid. ^1H NMR (400 MHz, $DMSO-d_6$): δ = 7.10 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 2.0 Hz, 1H), 5.34 (bs, 2H) 3.85 (s, 3H). ^{19}F NMR (400 MHz, $DMSO-d_6$): δ = -61.45.

7-chloro-5-cyclopropyl-2,3-dihydro-1H-inden-4-amine



A solution of 2,3-dihydro-1*H*-inden-4-amine, **1** (500 mg, 3.75 mmol) in EtOH (5 mL) was cooled to 0 °C and treated dropwise with acetic anhydride (0.95 g, 9.37 mmol) under nitrogen atmosphere. The resulting reaction mixture was warmed to RT and stirred for 3h. Upon completion of reaction, (TLC, 30% ethyl acetate-hexanes, R_f , 0.2), the reaction mixture was concentrated *in vacuo*. The residue obtained was diluted with diethyl ether, filtered and dried *in vacuo* to give *N*-(2,3-dihydro-1*H*-inden-4-yl)acetamide (0.3 g, 45%) as a white solid. ^1H NMR (400 MHz, $DMSO-d_6$): δ = 9.29 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 6.8 Hz, 1H), 2.87 (t, J = 7.2 Hz, 2H), 2.80 (t, J = 7.2 Hz, 2H), 2.04 (s, 3H), 1.99-1.95 (m, 2H). LCMS (m/z): 176.40 $[M+H]^+$

N-(2,3-dihydro-1*H*-inden-4-yl)acetamide (200 mg, 1.11 mmol) was dissolved in AcOH (5 mL) and cooled to 0 °C. *N*-Chlorosuccinimide (220 mg, 1.69 mmol)


was added then the reaction mixture was warmed to RT and stirred overnight. Upon completion the reaction mixture was diluted with ice cold water and the solid formed removed by filtration, washed saturated NaHCO_3 , $\text{Na}_2\text{S}_2\text{O}_3$ solution and dried *in vacuo* to give N-(7-chloro-2,3-dihydro-1*H*-inden-4-yl)acetamide (0.12 g, 50%) as a white solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.73 (d, J = 8.4 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 3.02-2.85 (m, 4H), 2.19 (s, 3H), 1.99 (m, 2H). LCMS (m/z): 209.80 $[\text{M}+\text{H}]^+$

N-(7-chloro-2,3-dihydro-1*H*-inden-4-yl)acetamide (120 mg, 0.57 mmol) was dissolved in 3 M HCl (5 mL) and warmed to 90 °C for 4 h. Upon completion the reaction mixture was cooled to RT and basified (pH ~8) with saturated NaHCO_3 solution before extracting with EtOAc (2 x 20 mL). The combined organic extracts were washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo* to give 7-chloro-2,3-dihydro-1*H*-inden-4-amine (70 mg, 74%) as a white solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 6.85 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 8.4 Hz, 1H), 4.97(s, 2H), 2.82 (t, J = 8.1 Hz, 2H), 2.71 (t, J = 7.5 Hz, 2H), 2.01-1.96 (m, 2H). LCMS (m/z): 168.20 $[\text{M}+\text{H}]^+$.

A solution of 7-chloro-2,3-dihydro-1*H*-inden-4-amine (0.8g, 4.79 mmol) in acetonitrile (10 mL) was cooled to 0 °C and treated with *N*-iodosuccinimide (1.61 g, 7.18 mmol) at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with saturated $\text{Na}_2\text{S}_2\text{O}_3$ solution and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 4-5% EtOAc-hexanes eluant to give 7-chloro-5-iodo-2,3-dihydro-1*H*-inden-4-amine (0.45 g, 32%) as a pale brown solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 7.36 (s, 1H), 5.04 (s, 2H), 2.82-2.72 (m, 4H), 2.03-1.98 (m, 2H). LCMS (m/z): 293.7 $[\text{M}+\text{H}]^+$.

In a 50 mL resealable reaction tube, a solution of 7-chloro-5-iodo-2,3-dihydro-

2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carboxylic acid




Synthesis of 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carboxylic acid was carried out from hydroquinone using procedures detailed by Monte et.al. *J.Med.Chem.* **1996**, 39, 2953-2961 to give the 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carbaldehyde as a bright yellow solid; ¹H NMR (400 MHz,

CDCl_3): δ = 10.27 (s, 1H), 6.87 (s, 1H), 4.67 (t, J = 8.8 Hz, 2H), 4.59 (t, J = 8.8 Hz, 2H), 4.59 (t, J = 8.8 Hz, 2H), 3.46 (t, J = 8.8 Hz, 2H), 3.18 (t, J = 8.8 Hz, 2H).

The aldehyde (0.68 g, 3.58 mmol) was oxidized using silver (I) oxide (1.5 eq.) in 5% aqueous sodium hydroxide at rt for 20 days. The crude reaction mixture was filtered through celite, extracted using diethyl ether (2 x 50 mL) to remove unreacted aldehyde then the aqueous phase was acidified to pH 1 using 3.0 M aqueous HCl drop-wise at 0 °C. The product was extracted using dichloromethane (2 x 50 mL) and the combined organics washed using brine (50 mL), dried (MgSO_4) and concentrated *in vacuo* to give 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carboxylic acid as a white solid (0.44 g; 60%).

Alternatively, the aldehyde (0.5 g, 2.77 mmol) in acetone (5.0 mL) was treated with sulfamic acid (0.4 g, 4.17 mmol) in two portions at 0 °C. After 2 min a solution of sodium chlorite (0.32 g, 3.6 mmol) in water (1.0 mL) was added drop-wise and stirring continued at 0 °C for 4 h. The reaction mixture was diluted with water (20 mL) and extracted using 10% IPA/chloroform (2 x 20 mL). The combined organics were washed with water (25 mL), brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude solid was triturated with diethyl ether to give 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-carboxylic acid (0.4 g; 70%). ^1H NMR (400 MHz, DMSO-d_6): δ = 6.86 (s, 1H), 4.52 (t, J = 8.8 Hz, 2H), 4.47 (t, J = 8.8 Hz, 2H), 3.30 (t, J = 8.8 Hz, 2H), 3.10 (t, J = 8.8 Hz, 2H). ^{13}C (100 MHz, DMSO-d_6): δ = 166.4, 154.2, 153.9, 128.9, 127.2, 111.4, 110.43, 71.9, 71.6, 31.5, 29.5.

Benzo[*d*][1,3]dioxole-4-carboxylic acid



Synthesised using procedures modified from Plé et.al. *J.Med.Chem.* **2004**, *47*, 871-887 as follows:

2,3-Dihydroxybenzoic acid (5.0 g, 32.4 mmol) in anhydrous methanol (50 mL) was treated with concentrated sulfuric acid (10 drops) and heated at reflux overnight. The reaction mixture was concentrated *in vacuo*, diluted using EtOAc (100 mL) washed using sat. aqueous NaHCO₃ (2 x 50 mL), brine (50 mL) then dried (MgSO₄) and concentrated *in vacuo* to give methyl 2,3-dihydroxybenzoate (2.92 g; 54%). ¹H NMR (400 MHz, CDCl₃): δ = 10.9 (s, 1H), 7.32 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.09 (m, 1H), 6.78 (t, *J* = 8.0 Hz, 1H), 5.65 (s, 3H). ¹³C NMR (100 Hz, CDCl₃) 170.7, 148.8, 145.0, 120.5, 119.8, 119.2, 112.4, 52.4.

Methyl 2,3-dihydroxybenzoate (1.0 g, 5.95 mmol) in DMF (16 mL) was treated with KF (1.79 g, 30.9 mmol) and stirred at ambient temperature for 30 minutes. Diiodomethane (1.79 g, 6.7 mmol) was added and the reaction heated at 100 °C for 5 hours. The reaction mixture was cooled to rt, poured onto water (100 mL) and extracted using diethyl ether (2 x 50 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 10% EtOAc-petroleum ether eluent to give methyl benzo[d][1,3]dioxole-4-carboxylate as a white crystalline solid (0.56 g; 52%); ¹H NMR (400 MHz, CDCl₃): δ = 7.41 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.97 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.86 (t, *J* = 8.0 Hz, 1H), 6.1 (s, 2H), 3.93 (s, 3H).


A solution of methyl benzo[d][1,3]dioxole-4-carboxylate (0.4 g, 2.22 mmol) in methanol (8.0 mL) was treated with 2.0 M aqueous KOH (2.2 mL) and the solution stirred at rt for 3 hours. The mixture was concentrated to ~3 mL volume, diluted with water (5 mL) and acidified to pH ~3 using 2.0 M HCl. The resulting precipitate was removed by filtration, washed with water then diethyl ether and dried *in vacuo* to give benzo[d][1,3]dioxole-4-carboxylic acid as a beige solid (0.38 g, 97%). ¹H NMR (400 MHz, DMSO-d₆): δ = 7.28 (dd, *J* = 8.0,

1.2 Hz, 1H), 6.97 (dd, $J = 8.0, 1.2$ Hz, 1H), 6.89 (t, $J = 8.0$ Hz, 1H), 6.12 (s, 2H); ^{13}C NMR (100 Hz, DMSO- d_6) 165.5, 148.9, 148.5, 122.9, 121.6, 113.8, 112.5, 102.1.

Synthesised Compounds by Substituent Class


ALIPHATICS

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)cyclohexanesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and cyclohexanesulfonamide were used in general method C3 to give the titled compound as a white solid (12 mg, 41%). ^1H NMR (400 MHz, CD_3OD): $\delta = 6.97$ (s, 1H), 3.50-3.43 (m, 1H), 2.87 (t, 4H, $J = 8.0$ Hz), 2.78 (t, 4H, $J = 8.0$ Hz), 2.22-2.18 (m, 2H), 2.10-2.02 (m, 4H), 1.94-1.71 (m, 2H), 1.63-1.59 (m, 1H), 1.64-1.53 (m, 2H); 1.41-1.21 (m, 3H); ^{13}C NMR (100 MHz, CD_3OD): $\delta = 143.7, 137.8, 126.4, 118.4, 110.2, 59.9, 35.5, 30.0, 28.5, 25.8, 25.1, 24.8$; LCMS Purity: >95%; LCMS (m/z): 363 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$: 363.1737, found 363.1729.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)cyclopentanesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and cyclopentanesulfonamide were used in general method C3 to give the titled compound as a white solid (26 mg, 42%) ^1H NMR (400 MHz, CD_3OD): δ = 6.97 (s, 1H), 4.08-4.02 (m, 1H), 2.83 (t, J = 8.0 Hz, 4H), 2.80 (t, J = 8.0 Hz, 4H), 2.13-2.01 (m, 8H), 1.84-1.77 (m, 2H), 1.71-1.65 (m, 2H); ^{13}C NMR (100 MHz, CD_3OD): δ = 145.1, 139.2, 127.8, 119.8, 111.7, 62.2, 33.9, 31.4, 29.9, 28.6, 26.9; LCMS Purity: >95%; LCMS (m/z): 349 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_3\text{S}$: 349.1580, found 349.1588.

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydro-2H-pyran-4-sulfonamide.**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and tetrahydro-2H-pyran-4-sulfonamide were used in general method C2 to give the titled compound as a white solid (12 mg, 57%). ^1H NMR (400 MHz, CD_3OD): δ = 7.00 (s, 1H), 4.09 (dd, J_1 = 4 Hz, J_2 = 12 Hz, 2H), 3.82-3.76 (m, 1H), 3.49-3.43, (m, 2H), 2.89 (t, J = 8 Hz, 4H), 2.81 (t, J = 8 Hz, 4H), 2.12-2.05 (m, 6H), 1.98-1.87 (m, 2H); ^{13}C NMR (100 MHz, CD_3OD): δ = 154.0, 143.1, 137.7, 126.5, 110.4, 66.0, 57.0, 32.5, 28.5, 25.9, 25.1; LCMS Purity: >95%; LCMS (m/z): 365 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_4\text{S}$, 365.1530, found 365.1541.


***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydrofuran-3-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and tetrahydrofuran-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (12 mg, 60%). ^1H NMR (400 MHz, DMSO- d_6): δ = 8.04 (s, 1H), 6.93 (s, 1H), 4.33-4.27 (m, 1H), 4.04-4.00 (m, 1H), 3.91-3.89 (m, 1H), 3.85-3.79 (m, 1H), 3.72-3.66 (m, 1H), 2.80 (t, J = 16.0 Hz, 4H), 2.70 (t, J = 16.0 Hz, 4H), 2.24-2.17 (m, 2H), 1.99 -1.95 (m, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 142.4, 139.6, 136.6, 124.7, 108.2, 68.7, 61.7, 32.5, 30.3, 28.8, 28.1, 24.9; LCMS Purity: >95%; LCMS (m/z): 351 [$M + H$] $^+$; HRMS calculated for $\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$ 351.1373, found 351.1389.

FURANS


***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and furan-2-sulfonamide were used in general method C4 to give the titled compound as a white solid (75 mg, 16%). ^1H NMR (400 MHz, DMSO- d_6): δ = 11.08 (br.s, 1H), 8.08 (s, 1H), 8.02 (s, 1H), 7.22 (q, J = 2.0 Hz, 1H), 6.94 (s, 1H), 6.71 (q, J = 2.0 Hz, 1H), 2.78 (t, J = 7.2 Hz, 4H), 2.59 (t, J = 7.2 Hz, 4H), 1.94 (quin, J = 7.2 Hz, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 148.9, 147.9, 147.3, 143.1, 137.3, 128.7, 118.0, 117.5, 111.7, 54.9, 32.5, 30.1, 25.1. LCMS, Purity: 96.26%; m/z 345.1 ($M - H^+$). HRMS (FAB $^-$) calcd for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_4\text{S}$


$[M-H]^-$: 345.0987, found: 345.0866.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-methylfuran-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 5-methylfuran-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (28 mg, 53%). ^1H NMR (400 MHz, DMSO- d_6): δ = 7.96 (s, 1H), 7.00-6.99 (d, J = 4.0 Hz, 1H), 6.91 (s, 1H), 6.29-6.28 (d, J = 4.0 Hz, 1H), 1H), 2.78 (t, J = 8.0 Hz, 4H), 2.61 (t, J = 8.0 Hz, 4H), 2.34 (s, 3H), 2 (t, J = 8.0 Hz, 4H), 1.98-1.90 (m, 4H); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 143.3, 137.6, 129.9, 125.2, 118.0, 114.6, 108.7, 108.2, 107.8, 32.9, 30.6, 25.4, 13.8; LCMS Purity: >95%; LCMS (m/z): 361 $[M+H]^+$; HRMS calculated for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_4\text{S}$ $[M+H]^+$ 361.1216, found 361.1217.


5-ethyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)furan-2-sulfonamide



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 5-ethylfuran-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (51 mg, 47%). ^1H NMR (400 MHz, DMSO- d_6): δ = 7.97 (bs, 1H), 7.02 (s, 1H), 6.91 (d, J = 4.0 Hz, 1H), 6.31 (d, J = 4.0 Hz, 1H), 2.78 (t, J = 8.0 Hz, 4H), 2.68 (q, J = 8.0 Hz, 2H), 2.59 (t, J = 6.0 Hz, 4H), 1.97-1.90 (m, 4H), 1.19 (t, J = 8.0 Hz, 3H). ^{13}C NMR (150 MHz, DMSO- d_6):


δ = 143.5, 143.3, 142.9, 137.6, 129.8, 118.0, 108.7, 106.8, 106.3, 32.9, 30.5, 25.4, 21.3, 12.1; LCMS Purity: >95%; LCMS (m/z): 375 [$M + H$] $^+$; HRMS calculated for $C_{19}H_{22}N_2O_4S$ [$M + H$] $^+$ 375.13730, found 375.13910.

5-((dimethylamino)methyl)-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)furan-2-sulfonamide



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 5-((dimethylamino)methyl)furan-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (25 mg, 6%). ^1H NMR (400 MHz, CD_3OD) δ = 7.17 (d, J = 3.5 Hz, 1H), 6.96 (s, 1H), 6.86 (d, J = 3.5 Hz, 1H), 4.43 (s, 2H), 2.86 (s, 3H), 2.86 (t, J = 7.4 Hz, 4H), 2.73 (t, J = 7.4 Hz, 4H), 2.04 (p, J = 7.4 Hz, 4H).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C5 to give the titled compound as a white solid (2.5 g, 63%). ^1H NMR (600 MHz, $DMSO-d_6$): δ = 7.61 (br.s., 1H), 7.37 (d, J = 0.9 Hz, 1H), 6.77 (s, 1H), 6.58 (d, J = 0.9 Hz, 1H), 2.74 (t, J = 7.3 Hz, 4H), 2.65 (t, J = 7.3 Hz, 4H), 1.89 (tt, J = 7.3, 7.3 Hz, 4H), 1.34 (s, 6H). ^{13}C NMR (101 Hz, $DMSO-d_6$): δ


= 157.4, 155.7, 142.2, 137.3, 136.7, 135.7, 132.4, 115.7, 109.3, 66.6, 32.6, 31.1, 30.6, 25.1.

***N*-((8-bromo-1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



4-Bromo-8-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (40 mg, 7%). ¹H NMR (400 MHz, CD₃OD): δ = 7.68 (s, 1H), 7.23 (s, 1H), 2.91 (t, *J* = 7.6 Hz, 4H), 2.85 (t, *J* = 7.6 Hz, 4H), 2.11 (m, 4H), 1.51 (s, 6H). LCMS (*m/z*): 482.9 [M-H]⁻; 97.64% (210 nm), 99% (254 nm). HPLC: 96.70% (210nm), 97.22% (254nm).


***N*-((8-chloro-1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



4-Chloro-8-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (50 mg, 16%). ¹H NMR (400 MHz, CD₃OD) δ = 7.55 (s, 1H), 7.02 (s, 1H), 2.91 (t, *J* = 7.2 Hz, 4H), 2.85 (t, *J* = 7.2 Hz, 4H), 2.09 (m, 4H), 1.5 (s, 6H). LCMS (*m/z*): 460.9


(M +Na)⁺; 95.16% (210 nm), 95.07% (254 nm). HPLC: 97.91% (210 nm), 98.04% (254 nm).

4-(2-hydroxypropan-2-yl)-N-((8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (15 mg, 3%). ¹H NMR (400 MHz, CD₃OD): δ = 7.58 (s, 1H), 7.07 (s, 1H), 6.46 (s, 1H), 2.82-2.73 (m, *J* = 7.5 Hz, 8H), 2.12 (s, 3H), 2.05-2.02 (m, 4H), 1.508 (s, 6H). LCMS(*m/z*): 417.10 (M -1)⁻; 99.59% (210 nm), 99.33% (254 nm). HPLC: 97.92% (210nm), 97.53% (254nm).


5-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)furan-3-carboxylic acid



Ethyl 5-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)furan-3-carboxylate (0.1 g, 0.24 mmol) in THF (8 mL) at 0 °C was treated with a solution of LiOH (0.1 g, 2.4 mmol) in water (2 mL). The cooling bath was removed and the reaction mixture stirred for 3 h. The solution was acidified using 10% citric acid and immediately extracted using ethyl acetate (2 x 25 mL). The organics were washed using water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reversed phase


HPLC to give the titled compound as a white solid (5.0 mg, 5%). ^1H NMR (400 MHz, CD_3OD): δ = 8.14 (s, 1H), 7.28 (s, 1H), 6.93 (s, 1H), 2.85 (t, J = 7.6 Hz, 4H), 2.74 (t, J = 7.6 Hz, 4H), 2.04 (quin, J = 7.6 Hz, 4H).

Ethyl 5-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)furan-3-carboxylate



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and ethyl 5-sulfamoylfuran-3-carboxylate were used in general method C3. The reaction mixture was quenched using water (50 mL), extracted using ethyl acetate (2 x 25 mL) and the organics washed with brine (25 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 50% EtOAc-hexanes eluent to give the titled compound as a white solid (0.45 g, 63%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ = 8.31 (s, 1H), 7.59 (s, 1H), 6.77 (s, 1H), 4.22 (q, J = 7.2 Hz, 2H), 2.75 (t, J = 7.3 Hz, 4H), 2.65 (t, J = 7.3 Hz, 4H) 1.90 (pent, J = 7.6 Hz, 4H), 1.26 (t, J = 7.2 Hz, 3H).


***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4-(prop-1-en-2-yl)furan-2-sulfonamide were used in general

method C6 to give the titled compound as a white solid (85 mg, 51%). ^1H NMR (400 MHz, CDCl_3) δ 7.54 (s, 1H), 7.28 (s, 1H), 7.00 (s, 1H), 5.26 (s, 1H), 5.05 (s, 1H), 2.86 (t, J = 7.4 Hz, 4H), 2.69 (t, J = 7.5 Hz, 4H), 2.09 – 1.98 (m, 7H). ^{13}C NMR (101 MHz, CDCl_3) δ 144.4, 142.8, 137.8, 132.8, 129.2, 127.2, 119.4, 115.4, 113.6, 32.9, 30.5, 25.5, 20.9. HRMS (ESI) calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]$ 387.1373, found 387.1379.

4-(2-hydroxypropan-2-yl)-*N*-((3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan-8-yl)carbamoyl)furan-2-sulfonamide




8-isocyanato-3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan (prepared using general method A1) and ethyl 5-sulfamoylfuran-3-carboxylate were used in general method C3 to give ethyl 5-(*N*-((3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan-8-yl)carbamoyl)sulfamoyl)furan-3-carboxylate as a pale-brown solid (0.25 g, 50%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.32 (s, 1H), 7.17 (s, 1H), 6.77 (d, J = 5.2 Hz, 1H), 4.43 (t, J = 8.6 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.07 (t, J = 8.6 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.63 (t, J = 7.3 Hz, 2H), 1.89 (p, J = 7.4 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H).

Ethyl 5-(*N*-((3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan-8-yl)carbamoyl)sulfamoyl)furan-3-carboxylate (0.25 g, 0.6 mmol) in anhydrous THF (10 mL) at 0 °C was treated with methyl magnesium chloride solution (3.0 M in Et_2O , 6 eq.) drop-wise over 5 minutes with vigorous stirring. The solution was then stirred at 0 °C for 30 min then at ambient temperature for 4 h before being quenched drop-wise with a solution of sat. ammonium chloride. The aqueous solution was extracted using EtOAc (2 x 25 mL), the combined organics washed with brine (20 mL), dried (Na_2SO_4) and concentrated *in vacuo*.


The crude product was triturated with diethyl ether then purified by reverse phase preparative HPLC to give the titled compound as a white solid (32 mg, 13%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.58 (s, 1H), 7.08 (s, 1H), 6.84 (s, 1H), 5.02 (s, 1H), 4.47 (t, J = 8.6 Hz, 2H), 3.10 (t, J = 8.6 Hz, 2H), 2.73 (t, J = 7.3 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 1.90 (d, J = 7.4 Hz, 2H), 1.36 (s, 6H).

***N*-((4-bromo-3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan-8-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



4-bromo-8-isocyanato-3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan (prepared using general method A1) and 4-(prop-1-en-2-yl)furan-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (20 mg, 9%). ^1H NMR (400 MHz, CD_3OD) δ = 7.48 (d, J = 1.2 Hz, 1H), 6.93 (d, J = 1.2 Hz, 1H), 4.60 (t, J = 8.7 Hz, 2H), 3.16 (t, J = 8.6 Hz, 2H), 2.85 (m, 4H), 2.03 (p, J = 7.5 Hz, 2H), 1.50 (s, 6H).


4-(2-hydroxypropan-2-yl)-*N*-((3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan-4-yl)carbamoyl)furan-2-sulfonamide



4-isocyanato-3,5,6,7-tetrahydro-2*H*-indeno[5,6-*b*]furan (prepared using general method A1) and 4-(prop-1-en-2-yl)furan-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (20 mg, 9%). ^1H NMR (400 MHz, CD_3OD) δ = 7.58 (s, 1H), 7.07 (s, 1H), 6.46 (s, 1H), 4.49 (d, J = 8.9


Hz, 2H), 3.05 (t, $J = 8.7$ Hz, 2H), 2.82 (t, $J = 7.4$ Hz, 2H), 2.70 (t, $J = 7.4$ Hz, 2H), 2.04 (p, $J = 7.4$ Hz, 2H), 1.51 (d, $J = 1.9$ Hz, 6H).

4-(2-hydroxypropan-2-yl)-*N*-((2,3,6,7-tetrahydrobenzo[1,2-*b*:4,5-*b'*]difuran-4-yl)carbamoyl)furan-2-sulfonamide



4-isocyanato-2,3,6,7-tetrahydrobenzo[1,2-*b*:4,5-*b'*]difuran (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C6 to give the titled compound as a white solid (285 mg, 96%). ^1H NMR (600 MHz, DMSO- d_6) δ 7.76 (s, 1H), 7.66 (s, 1H), 7.01 (s, 1H), 6.45 (s, 1H), 5.04 (s, 1H), 4.46 (t, $J = 8.6$ Hz, 2H), 4.39 (t, $J = 8.6$ Hz, 2H), 3.08 (t, $J = 8.6$ Hz, 2H), 2.94 (t, $J = 8.6$ Hz, 2H), 1.37 (s, 6H).


***N*-(benzo[1,2-*b*:4,5-*b'*]difuran-4-ylcarbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



4-isocyanatobenzo[1,2-*b*:4,5-*b'*]difuran (prepared using general method A1) and ethyl 5-sulfamoylfuran-3-carboxylate were used in general method C3 to give ethyl 5-(*N*-(benzo[1,2-*b*:4,5-*b'*]difuran-4-ylcarbamoyl)sulfamoyl)furan-3-carboxylate as a white solid (0.05 g, 53%). ^1H NMR (300 MHz, CD $_3$ OD) δ = 8.25 (s, 1H), 7.72 (d, J 2.1 Hz, 1H), 7.63 (d, J 2.1 Hz, 1H), 7.46 (s, 1H), 7.27 (s, 1H), 6.93 (s, 1H), 6.89 (d, J 2.1 Hz, 1H), 6.86 (d, J 2.1 Hz, 1H), 4.30 (q, J 6.9 Hz, 2H), 1.4 (t, J 6.9 Hz, 3H).


Ethyl 5-(N-(benzo[1,2-b:4,5-b']difuran-4-ylcarbamoyl)sulfamoyl)furan-3-carboxylate (0.25 g, 0.6 mmol) in anhydrous THF (10 mL) at 0 °C was treated with methyl magnesium chloride solution (3.0 M in Et₂O, 10 eq.) drop-wise over 10 minutes with vigorous stirring. The solution was then stirred at 0-10 °C for 3 h then quenched drop-wise with a solution of sat. ammonium chloride. The aqueous solution was extracted using EtOAc (2 x 20 mL), the combined organics washed with brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was triturated with diethyl ether then purified by reverse phase preparative HPLC to give the titled compound as a white solid (15 mg, 6%). ¹H NMR (400 MHz, CD₃OD) δ = 7.76 (d, *J* 2.0 Hz, 1H), 7.65 (d, *J* 2.4 Hz, 1H), 7.55 (s, 1H), 7.47 (s, 1H), 7.05 (s, 1H), 6.93 (d, *J* 2.0 Hz, 1H), 6.89 (d, *J* 2.4 Hz, 1H), 1.5 (s, 6H).

***N*-(anthracen-9-ylcarbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



9-isocyanatoanthracene (prepared using general method B2) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C6 to give the titled compound as a white solid (24 mg, 23%). ¹H NMR (400 MHz, CD₃OD) δ = 8.49 (s, 1H), 8.07 – 7.98 (m, 4H), 7.75 (s, 1H), 7.55 – 7.44 (m, 4H), 7.27 – 7.22 (m, 1H), 1.49 (s, 6H). ¹³C NMR (101 MHz, CD₃OD) δ = 153.8, 149.4, 141.4, 136.6, 131.7, 128.8, 128.2, 127.4, 126.4, 125.9, 124.9, 122.8, 115.2, 111.1, 67.2, 29.6.


4-(2-hydroxypropan-2-yl)-*N*-(quinolin-8-ylcarbamoyl)furan-2-sulfonamide



Phenyl chloroformate (1.5 eq) was added slowly to a solution of quinolin-8-amine (1 g, 6.9 mmol) in THF (10 mL) and triethylamine (2 eq.) to 0 °C. The solution was stirred at room temperature for 2 h or until completion. The solution was diluted using sat.aq. NaHCO₃ solution, extracted using ethyl acetate (2 x 50 mL), washed with water, brine then dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica using 10% EtOAc-hexanes to give phenyl quinolin-8-ylcarbamate (1.5 g, 83%) as a white solid which was used directly in the next reaction step.


4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (0.2 g, 0.98 mmol) in THF (5 mL) at 0 °C was treated portion-wise with sodium hydride (3 eq.) and the suspension stirred at ambient temperature for 45 minutes (until effervescence ceased). The crude phenyl quinolin-8-ylcarbamate was dissolved in THF (5 mL) then added slowly to the reaction and the solution stirred at ambient temperature until completion, typically 4 h. The reaction was quenched with sat.aq. NH₄Cl, extracted with ethyl acetate (x2), washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified using reverse phase HPLC to give the titled compound, 4-(2-hydroxypropan-2-yl)-N-(quinolin-8-ylcarbamoyl)furan-2-sulfonamide as a white solid (40 mg, 11%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 8.89 (d, *J* = 4.3 Hz, 1H), 8.37 (m, 2H), 7.80 – 6.76 (m, 5H), 5.09 (s, 1H), 1.38 (s, 6H).

4-(2-hydroxypropan-2-yl)-N-((6-methoxyquinolin-8-yl)carbamoyl)furan-2-sulfonamide




4-(2-hydroxypropan-2-yl)-*N*-((6-methoxyquinolin-8-yl)carbamoyl)furan-2-sulfonamide was synthesised using modification of the procedures used to make 4-(2-hydroxypropan-2-yl)-*N*-(quinolin-8-ylcarbamoyl)furan-2-sulfonamide but using 6-methoxyquinolin-8-amine in place of quinolin-8-amine. The titled compound was obtained as an off-white solid (75 mg, 38%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.79 (s, 1H), 8.63 (m, 1H), 8.17 (m, 1H), 8.09 (d, *J* = 2.7 Hz, 1H), 7.49 (dd, *J* = 8.3, 4.2 Hz, 1H), 7.40 (s, 1H), 6.79 (d, *J* = 2.8 Hz, 1H), 6.69 (s, 1H), 4.96 (s, 1H), 3.84 (s, 3H), 1.36 (s, 6H).

***N*-((2,3-dihydrobenzo[*b*][1,4]dioxin-5-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




5-Isocyanato-2,3-dihydrobenzo[*b*][1,4]dioxine (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C6 to give the titled compound as a white solid (49 mg, 39%). ¹H NMR (600 MHz, Acetonitrile-*d*₃) δ = 7.56 (dd, *J* = 8.4, 1.5 Hz, 1H), 7.45 (d, *J* = 1.0 Hz, 1H), 6.98 (d, *J* = 1.0 Hz, 1H), 6.7 (t, *J* = 8.4 Hz, 1H), 6.48 (dd, *J* = 8.4, 1.5 Hz, 1H), 4.22 (m, 4H), 1.43 (s, 6H).

***N*-((2,3-dihydrobenzofuran-7-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




7-Isocyanato-2,3-dihydrobenzofuran (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C6 to give the titled compound as a white solid (32 mg, 39%). ^1H NMR (600 MHz, Acetonitrile- d_3) δ 7.64 (d, J = 7.7 Hz, 1H), 7.48 (d, J = 1.1 Hz, 1H), 7.00 (d, J = 1.1 Hz, 1H), 6.89 (m, 1H), 6.74 (t, J = 7.7 Hz, 1H), 4.56 (t, J = 8.7 Hz, 1H), 3.2 (t, J = 8.7 Hz, 1H), 1.43 (s, 6H).

***N*-((2,4-bis(trifluoromethyl)phenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




1-Isocyanato-2,4-bis(trifluoromethyl)benzene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C4 to give the titled compound as an off white solid (0.12 g, 33%). ^1H NMR (400 MHz, DMSO- d_6): δ = 8.59 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.81 (s, 1H), 7.67 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 4.94 (s, 1H), 1.36 (s, 6H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 156.0, 154.4, 142.5, 138.1, 135.8, 129.9, 125.2, 124.9, 123.0, 122.5, 121.3, 120.7, 120.4, 115.5, 115.2, 110.2, 66.5, 31.0. LCMS, Purity: 90.47%, t_r = 3.84 min, m/z 459.25 ($\text{M}-\text{H}^+$). HRMS (FAB $^+$) calcd for $\text{C}_{16}\text{H}_{14}\text{F}_6\text{N}_2\text{O}_5\text{S}$ [$\text{M}-\text{H}$] $^-$: 459.0528, found: 459.0512.

***N*-((2,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




2-Isocyanato-1,4-bis(trifluoromethyl)benzene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C4 to give the titled compound as an off white solid (55 mg, 12%). ^1H NMR (400 MHz, CD_3OD): δ = 8.61 (s, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.48 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 1.41 (s, 6H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 156.4, 154.5, 139.7, 138.1, 132.9, 127.2, 124.9, 122.3, 118.9, 117.6, 117.0, 110.0, 66.5, 31.0. LCMS, Purity: 95.02%, t_r = 2.09 min, m/z 558.94 ($\text{M}-\text{H}^+$). HRMS (FAB $^-$) calcd for $\text{C}_{16}\text{H}_{14}\text{F}_6\text{N}_2\text{O}_5\text{S}$ [$\text{M}-\text{H}$] $^-$: 459.0528, found: 459.0224.

4-(2-hydroxypropan-2-yl)-*N*-((2-methoxyphenyl)carbamoyl)furan-2-sulfonamide




1-isocyanato-2-methoxybenzene (prepared using general method A2) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C2 to give the titled compound as an off white solid (30 mg, 38%).

***N*-((2,5-dimethoxyphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



2-isocyanato-1,4-dimethoxybenzene and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C2 to give the titled compound as an off white solid (52 mg, 55%).

N-((4-chloro-2,6-dimethylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide




4-chloro-2,6-dimethylaniline, **1** (300 mg, 1.92 mmol) was dissolved in THF (50 mL) and cooled to 0 °C. NaH (100 mg, 2.49 mmol) was added in portions to the aforementioned solution under nitrogen atmosphere and stirred the mixture for 15 min. Phenyl chloroformate (0.33 mL, 0.72 mmol) was added dropwise to the aforementioned solution at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion, the reaction mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 30% EtOAc-hexanes eluant to give phenyl (4-chloro-2,6-dimethylphenyl)carbamate (0.2 g, 85%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.41-7.36 (m, 2H), 7.21-7.19 (m, 2H), 7.11-7.10 (m, 3H), 6.30 (bs, 1H), 2.33 (s, 6H).

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (133 mg, 0.64 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (65 mg, 1.63 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 45 min then treated with a solution of phenyl (4-chloro-2,6-dimethylphenyl)carbamate (200 mg, 0.73 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 2 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*.

The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give *N*-((4-chloro-2,6-dimethylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (20 mg, 31%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.83 (s, 1H), 7.56 (s, 1H), 7.19 (s, 1H), 7.10-7.05 (m, 2H), 2.16 (s, 6H), 1.55 (s, 6H). LCMS (m/z): 385.05 $[\text{M}-\text{H}]^-$, 94.12% (210 nm). HPLC: 92.60% (210nm). HRMS calculated for $\text{C}_{16}\text{H}_{18}\text{Cl}_1\text{N}_2\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^-$ 385.0630, found 365.0621.

***N*-((2,4-dimethyl-6-(trifluoromethyl)phenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




4-Chloro-2-methyl-6-(trifluoromethyl)aniline (230 mg, 1.1 mmol) was dissolved in anhydrous THF (20 mL) and treated with Et_3N (0.17 mL, 1.32 mmol) at RT. The solution was treated with triphosgene (130 mg, 0.44 mmol) and the resulting mixture stirred at 60°C for 4 h then concentrated *in vacuo*. The residue obtained was stirred with *n*-pentane (20 mL) for 10 min, filtered through a Celite pad and concentrated *in vacuo* to give 5-chloro-2-isocyanato-1-methyl-3-(trifluoromethyl)benzene (0.2 g) as a white solid. The product was used in the next step without further purification.

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide, **3** (150 mg, 0.731 mmol) was dissolved in anhydrous THF (50 mL) and treated carefully with NaH (44 mg, 1.096 mmol) at 0°C under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 30 minutes and treated with solution of 5-chloro-2-isocyanato-1-methyl-3-(trifluoromethyl)benzene (0.2 g) in THF (30 mL) under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 2 h. Upon completion, the reaction mixture was diluted with saturated NH_4Cl


solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluent. The product was then triturated with diethyl ether and n-pentane to give *N*-((2,4-dimethyl-6-(trifluoromethyl)phenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (15 mg, 5%) as a white solid. ¹H NMR (400 MHz, CD₃OD): δ = 7.52-7.48 (m, 3H), 6.99 (s, 1H), 2.19 (s, 3H), 1.47 (s, 6H). ¹⁹F NMR (400 MHz, CD₃OD): δ = -63.09. LCMS (*m/z*): 439.05 [M-H]⁻; 94.86% (210 nm), 96.92% (254 nm). HPLC: 98.90% (210nm). HRMS calculated for C₁₆H₁₅ClF₃N₂O₅S₁ [M-H]⁻ 439.0348, found 439.0339.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**



5-chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (161 mg, 34%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 7.82 (s, 1H), 7.61 (s, 1H), 7.09 (s, 2H), 6.93 (s, 1H), 5.04 (s, 1H), 3.05 – 2.99 (m, 2H), 1.35 (s, 6H), 1.05 (d, *J* = 6.9 Hz, 12H). HRMS calculated for C₂₀H₂₆ClN₂O₅S₁ [M-H]⁻ 441.1256, found 441.1264.

***N*-((4-chloro-2,6-dicyclopropylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




4-Chloro-2,6-dicyclopropylaniline, **1** (250 mg, 1.20 mmol) was dissolved in THF (50 mL) and cooled to 0 °C. NaH (72 mg, 1.80 mmol) was added in portions and the resulting mixture stirred for 20 min under nitrogen atmosphere. Phenyl chloroformate (370 mg, 2.40 mmol) was added dropwise at 0 °C then the reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 8% EtOAc-hexanes eluant to give phenyl (4-chloro-2,6-dicyclopropyl phenyl)carbamate (0.2 g, 51%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.38-7.35 (m, 2H), 7.21-7.19 (m, 3H), 6.84-6.83 (m, 2H), 2.06-2.04 (m, 2H), 1.04-1.02 (m, 4H), 0.69-0.68 (m, 4H).

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (75 mg, 0.365 mmol) was dissolved in anhydrous THF (50 mL) and treated carefully with NaH (36 mg, 0.914 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 30 min then treated with a solution of phenyl (4-chloro-2,6-dicyclopropyl phenyl)carbamate (135 mg, 0.402 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 4 h. Upon completion the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 50-100% EtOAc-hexanes to give *N*-((4-chloro-2,6-dicyclopropylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide

(10 mg, 6%) as a white solid. ^1H NMR (400 MHz, CD_3OD): δ = 7.59 (s, 1H), 7.13 (s, 1H), 6.76 (s, 2H), 1.88-1.86 (m, 2H), 1.47 (s, 6H), 0.89-0.84 (m, 4H), 0.55-0.54 (m, 4H). LCMS (m/z): 436.95 $[\text{M}-\text{H}]^-$; 96.29% (210 nm). HPLC: 98.29% (210nm). HRMS calculated for $\text{C}_{20}\text{H}_{22}\text{Cl}_1\text{N}_2\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^-$ 437.0943, found 437.0945. HRMS calculated for $\text{C}_{20}\text{H}_{22}\text{Cl}_1\text{N}_2\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^-$ 437.0943, found 437.0945.

4-(2-hydroxypropan-2-yl)-N-((5-methoxy-2,3-dihydro-1*H*-inden-4-yl)carbamoyl)furan-2-sulfonamide




5-methoxy-2,3-dihydro-1*H*-inden-4-amine (150 mg, 0.59 mmol) was dissolved in THF (15 mL) and cooled to 0 °C. NaH (35 mg, 0.89 mmol) was added to the aforementioned solution and stirred for 20 min. Phenyl chloroformate (150 mg, 0.932 mmol) was added dropwise at 0 °C then the solution allowed to warm to RT overnight. Upon completion, the reaction mixture was diluted with saturated NaHCO_3 and extracted with EtOAc (30 mL) The organic extract was washed with water, brine dried (Na_2SO_4) and concentrated *in vacuo* to give phenyl (5-methoxy-2,3-dihydro-1*H*-inden-4-yl)carbamate (100 mg, 59%) as a white solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.40-7.35 (m, 2H), 7.22-7.18 (m, 3H), 7.06 (d, J = 8.1 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.86 (s, 3H), 2.98-2.84 (m, 4H), 2.08 (t, J = 7.5 Hz, 2H). LCMS (m/z): 284.3 $[\text{M}+\text{H}]^+$

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (87 mg, 0.424 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (44 mg, 1.097 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 1 h then treated with a solution of phenyl (5-methoxy-2,3-dihydro-1*H*-inden-4-yl)carbamate (120 mg, 0.424 mmol) in THF (5 mL) under

nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 6 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution and extracted with EtOAc (2 x 30 mL). The combined organic extract was washed with water, brine dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: X bridge (150 mm x 19 mm particle size 5µm); flow: 15 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/10, 2/10, 9/70]. The fractions were lyophilized to give 4-(2-hydroxypropan-2-yl)-N-((5-methoxy-2,3-dihydro-1*H*-inden-4-yl)carbamoyl) furan-2-sulfonamide (45 mg, 17%) as a white solid. ¹H NMR (400 MHz, CD₃OD): δ = 7.67 (s, 1H), 7.21 (s, 1H), 7.04 (d, *J* = 8 Hz, 1H), 6.77 (d, *J* = 8 Hz, 1H), 3.79 (s, 3H), 2.84 (t, *J* = 7.2 Hz, 2H), 2.69 (t, *J* = 7.2 Hz, 2H), 2.01-1.97 (m, 2H), 1.49 (s, 6H). LCMS (*m/z*): 393.10 [M-H]⁻; 98.97% (210 nm), 99.47% (254 nm). HPLC: 92.07% (210nm), 93.87% (254nm). HRMS calculated for C₁₈H₂₁N₂O₆S₁ [M-H]⁺ 393.1126, found 392.1113.

N-((7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide




7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-amine, **6** (70mg, 0.33 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. NaH (20 mg, 0.505 mmol) was added to the aforementioned solution under nitrogen atmosphere and stirred for 15 min before phenyl chloroformate (100 mg, 0.674 mmol) was added dropwise at 0°C. The reaction mixture was warmed to RT and stirred for 12h. Upon completion the reaction mixture was diluted with EtOAc, filtered through celite

and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using, 10% EtOAc-hexanes eluent to give phenyl (7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamate (80 mg, 73%) as a brown solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.39-7.37 (m, 3H), 7.25-7.24 (m, 2H), 6.85(s, 1H), 3.0-2.94 (m, 4H), 2.12-2.10 (m, 2H), 1.34 (m, 1H), 0.96-0.95 (m, 2H), 0.59-0.57 (m, 2H). LCMS (*m/z*): 328.30 [M+H]⁺.

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (56 mg, 0.274 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (27 mg, 0.685 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 15 min and was treated with a solution of phenyl (7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamate (100 mg, 0.244 mmol) in THF (2 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 3 h. Upon completion the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract washed with water, brine dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: Gemini NX C18 (21.2 mm x 150 mm particle size 5µm); flow: 18 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/20, 2/30, 10/50]. The fractions were lyophilized to give N-((7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (45 mg, 38%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.95 (d, *J* = 2.4 Hz, 1H), 6.74 (s, 1H), 6.69(d, *J* = 2.4 Hz, 1H), 4.49 (m, 1H), 2.84 (t, *J* = 7.6 Hz, 2H), 2.66 (t, *J* = 7.6 Hz, 2H), 1.95 (m, 2H), 1.78 (m, 1H), 1.41 (d, *J* = 6.4 Hz, 6H), 0.82 (m, 2H), 0.54 (m, 2H). LCMS (*m/z*): 437.0 [M-H]⁻, 97.99% (210 nm). HPLC: 98.26% (210 nm). HRMS calculated for C₂₀H₂₂ClN₂O₅S₁ [M-H]⁺ 437.0943, found 437.0927.

4-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide



A solution of 8-nitro-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (200 mg, 0.92 mmol) in MeOH (5 mL) was degassed with nitrogen for 5 minutes, 10% Pd/C (20 mg, 10% wt/wt) was added and the mixture stirred under hydrogen atmosphere at room temperature for 2 h. The reaction mixture was filtered through Celite and the filtrate was concentrated in *vacuo* to give 8-amino-3,5,6,7-tetrahydro-s-indacen-1(2H)-one as off a white solid (160 mg, 93%). ^1H NMR (600 MHz, DMSO- d_6) δ 6.49 (s, 1H), 6.34 (s, 2H), 2.90-2.84 (m, 2H), 2.80 (t, J = 7.5 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H), 2.56-2.51 (m, 2H), 2.04-1.99 (m, 2H). ^{13}C NMR (150 MHz, DMSO- d_6): 206.6, 155.4, 153.7, 144.1, 125.3, 118.6, 109.4, 36.8, 33.7, 28.6, 25.0, 24.9. LCMS (m/z): 188 $[\text{M}+\text{H}]^+$. HRMS calculated for $\text{C}_{22}\text{H}_{14}\text{N}_1\text{O}_1[\text{M}+\text{H}]^+$ 188.1070, found 188.1077.


To di-*t*-butyldicarbonate (163 mg, 0.74 mmol) in anhydrous acetonitrile (1 mL) was added DMAP (26.1 mg, 0.21 mmol) at room temperature, stirred for 5 minutes, a solution of 8-amino-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (100 mg, 0.53 mmol) in acetonitrile was added. The reaction mixture was stirred for 30 minutes at room temperature. Reaction mixture was used directly in the next step without workup.

To 4-(2-hydroxypropan-2-yl) furan-2-sulfonamide intermediate (100 mg, 0.48 mmol) in anhydrous THF (1 mL) was added NaH (18.3 mg, 0.48 mmol) at 0 °C

and stirred for 30 minutes at ambient temperature under nitrogen atmosphere. Again cooled to 0 °C, 8-isocyanato-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (previous step reaction mixture) was added and stirred at ambient temperature for 16 h. To the reaction mixture added 0.5 mL of H₂O, loaded directly on C18 column for purification using aqueous 10 mM (NH₄)HCO₃ solution and acetonitrile as mobile phase, to give 4-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl) furan-2-sulfonamide as a white solid (150 mg, 67%). ¹H NMR (600 MHz, DMSO-*d*₆): δ 8.79 (s, 1H), 7.37 (s, 1H), 6.94 (s, 1H), 6.61 (s, 1H), 4.92 (s, 1H), 2.92 (t, J = 5.6 Hz, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.75 (t, J = 7.5 Hz, 2H), 2.63-2.57 (m, 2H), 1.97-1.80 (m, 2H), 1.34 (s, 6H); LCMS (m/z): 417 [M-H]⁻. HRMS calculated for C₂₀H₂₃N₂O₆S₁ [M+H]⁺ 419.1271, found 419.1291

To a solution of 4-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide (70 mg, 0.16 mmol) in MeOH (2 mL) was added NaBH₄ (63 mg, 1.67 mmol) at 0 °C under nitrogen atmosphere, resulting reaction mixture was stirred at room temperature for 3 h. Reaction mixture was quenched with H₂O (2 mL, distilled out MeOH, aqueous layer was directly loaded on C18 column for purification using aqueous 10 mM (NH₄)HCO₃ solution and acetonitrile as mobile phase, to give N-((3-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide as off-white solid (60 mg, 86%). ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.73 (bs, 1H), 7.38 (s, 1H), 6.81 (s, 1H), 6.60 (s, 1H), 5.63 (bs, 1H), 4.92 (bs, 1H), 4.87 (d, J = 6.0 Hz, 1H), 3.00-2.84 (m, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.64-2.53 (m, 2H), 2.07-2.00 (m, 1H), 1.97-1.92 (m, 1H), 1.91-1.81 (m, 2H), 1.35 (s, 6H); ¹³C NMR (150 MHz, DMSO-*d*₆): 159.5, 156.0, 144.9, 143.3, 138.3, 137.7, 136.8, 136.0, 133.0, 72.6, 67.0, 35.4, 33.1, 31.5, 31.4, 31.0, 30.4, 25.5; LCMS (m/z): 419 [M-H]⁻; HRMS calculated for C₂₀H₂₃N₂O₆S₁ [M-H]⁻ 419.1282, found 419.1263.

***N*-((1-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl) furan-2-sulfonamide**



A solution of 4-nitro-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (110 mg, 0.50 mmol) in MeOH (5 mL) was degassed with nitrogen for 5 minutes, added 10% Pd/C (11 mg, 10% wt/wt), stirred under hydrogen atmosphere at room temperature for about 2 h. Reaction mixture was filtered through Celite pad, filtrate was concentrated to give 4-amino-3,5,6,7-tetrahydro-s-indacen-1(2H)-one as an off white solid (75 mg, 80%). ^1H NMR (600 MHz, DMSO- d_6) δ 6.72 (s, 1H), 5.11 (s, 2H), 2.87 -2.74 (m, 4H), 2.70 (t, J = 7.4 Hz, 2H), 2.62-2.54 (m, 2H), 2.06-1.99 (m, 2H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 206.7, 144.6, 141.7, 139.9, 136.9, 136.8, 104.2, 39.9, 36.7, 30.6, 30.5, 24.5, 23.7. LCMS (m/z): 188 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{12}\text{H}_{14}\text{N}_1\text{O}_1$ $[\text{M}+\text{H}]^+$ 188.1070, found 188.1074.


To di-*t*-butyldicarbonate (81.6 mg, 0.37 mmol) in anhydrous acetonitrile (1 mL) was added DMAP (13.0 mg, 0.04 mmol) at room temperature, stirred for 5 minutes, a solution of 4-amino-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (50 mg, 0.26 mmol) in acetonitrile (1 mL) was added. The reaction mixture was stirred for 30 minutes at room temperature. Reaction mixture was used directly in the next step without workup.

To 4-(2-hydroxypropan-2-yl) furan-2-sulfonamide intermediate (50 mg, 0.24 mmol) in anhydrous THF (1 mL) was added NaH (9.3 mg, 0.24 mmol) at 0 °C and stirred for 30 minutes at ambient temperature under nitrogen atmosphere. Again cooled to 0 °C, 4-isocyanato-3,5,6,7-tetrahydro-s-indacen-1(2H)-one (previous step reaction mixture) was added and stirred at ambient temperature for 16 h. To the reaction mixture added 0.5 mL of H₂O, loaded directly on C18 column for purification using aqueous 10 mM (NH₄)HCO₃ solution and acetonitrile as mobile phase, to give 4-(2-hydroxypropan-2-yl)-N-((1-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl) furan-2-sulfonamide (70 mg, 63%). ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.94 (s, 1H), 7.38 (s, 1H), 7.17 (s, 1H), 6.60 (s, 1H), 4.92 (s, 1H), 2.94-2.89 (m, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.80 (t, J = 7.4 Hz, 2H), 2.56-2.52 (m, 2H), 2.00-1.94 (m, 2H), 1.35 (s, 6H); LCMS (m/z): 417 [M-H]⁻; HRMS calculated for C₂₀H₂₁N₂O₆S₁ [M-H]⁻ 417.1126, found 417.1113.

To a solution of 4-(2-hydroxypropan-2-yl)-N-((1-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide (50 mg, 0.11 mmol) in MeOH (2 mL) was added NaBH₄ (45 mg, 1.19 mmol) at 0 °C under nitrogen atmosphere, resulting reaction mixture was stirred at room temperature for 3 h. Reaction mixture was quenched with H₂O (1 mL), distilled out MeOH, aqueous layer was loaded directly on C18 column for purification using aqueous 10 mM (NH₄)HCO₃ solution and acetonitrile as mobile phase, to give N-((1-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (20 mg, 40%). ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.77 (s, 1H), 7.51 (s, 1H), 6.93 (s, 1H), 6.79 (s, 1H), 6.55 (s, 1H), 5.05 (d, J = 5.8 Hz, 1H), 4.99 (s, 1H), 4.94 (q, J = 6.4 Hz, 1H), 2.79 (t, J = 7.5 Hz, 2H), 2.70-2.61 (m, 3H), 2.52-2.49 (m, 1H), 2.2-2.21 (m, 1H), 1.95-1.90 (m, 2H), 1.74-1.59 (m, 1H), 1.36 (s, 6H); ¹³C NMR (150 MHz, DMSO-*d*₆): 163.5, 146.0, 143.1, 140.6, 138.5, 136.5, 136.2, 122.0, 116.5, 112.5, 108.5, 74.9, 67.0, 36.0, 33.0, 31.5, 30.9, 27.8, 25.6; LCMS (m/z): 419 [M-H]⁻. HRMS calculated for C₂₀H₂₃N₂O₆S₁

[M-H]⁻ 419.1282, found 419.1265.

***N*-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**




A solution of 4,6-dimethylpyrimidin-2-amine (200 mg, 1.62 mmol) in THF (5 mL) was cooled to 0 °C and treated with NaH (130 mg, 3.24 mmol) under nitrogen atmosphere. The reaction mixture was stirred for 15 min and treated with phenyl chloroformate (380 mg, 2.43 mmol) at 0 °C under nitrogen atmosphere. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give phenyl (4,6-dimethylpyrimidin-2-yl)carbamate (200 mg, 51%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.91 (s, 1H), 7.40-7.35 (m, 2H), 7.24-7.19 (m, 3H), 6.78(s, 1H), 2.41(s, 6H). LCMS (*m/z*): 244.20 [M+H]⁺.

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (150 mg, 0.731 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (75 mg, 1.83 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was warmed to 60 °C and stirred for 2 h. The solution was cooled to 0 °C and treated with a solution of phenyl (4,6-dimethylpyrimidin-2-yl)carbamate (195 mg, 0.804 mmol) in THF (5 mL) under nitrogen atmosphere at 0 °C. The reaction mixture was warmed to 50 °C for 4 h and then stirred at RT for 4 h. Upon completion the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract washed with water, brine,

dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: X-bridge (150 mm x 19 mm particle size 5 μm); flow: 15 mL/min; eluent: 10 mM ammonium acetate in 0.1% AcOH in water (A) & MeCN (B); gradient: T/% B= 0/15, 2/25, 8/40]. The fractions were lyophilized to give N-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (25 mg, 7%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 8.18 (s, 1H), 7.51 (d, J = 0.8 Hz, 1H), 7.40 (d, J = 1.2 Hz, 1H), 6.78 (s, 1H), 2.48 (s, 6H), 1.57 (s, 6H). LCMS (m/z): 355.0 $[\text{M}+\text{H}]^+$, 100% (210 nm), 100% (254 nm). HPLC: 96.49% (210 nm), 98.76% (254 nm). HRMS calculated for $\text{C}_{14}\text{H}_{17}\text{N}_4\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^-$ 353.0925, found 353.0921.

N-((4-cyclopropyl-6-methylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide




4-cyclopropyl-6-methylpyrimidin-2-amine (50mg, 0.33 mmol) was dissolved in THF (2 mL) and cooled to 0 °C. NaH (16 mg, 0.40 mmol) was added carefully to aforementioned solution and stirred for 20 min. Phenyl chloroformate (80 mg, 0.503 mmol) was added dropwise at 0 °C. The reaction mixture was warmed to RT and stirred at RT for 12 h. Upon completion of reaction (TLC, 50% ethyl acetate-hexanes, R_f , 0.4), the reaction mixture was diluted with EtOAc and filtered through a celite pad. The filtrate was concentrated *in vacuo* and crude product was purified by column chromatography on silica gel (60-120 mesh) using 30% EtOAc-hexanes eluant to give phenyl (4-cyclopropyl-6-methylpyrimidin-2-yl)carbamate (40 mg, 44%) as an off white solid. ^1H NMR (300 MHz, CDCl_3): δ = 8.06 (s, 1H), 7.40-7.37 (m, 2H), 7.24-7.15 (m, 3H), 6.73 (s, 1H), 2.4 (s, 3H), 1.94-1.86 (m, 1H), 1.15-1.1 (m, 2H), 1.0-0.99 (m, 2H).

LCMS (m/z): 270.3 $[M+H]^+$

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (150 mg, 0.731 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (73 mg, 1.829 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 1 h and treated with a solution of phenyl (4-cyclopropyl-6-methylpyrimidin-2-yl)carbamate (190 mg, 0.731 mmol) in THF (5 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred at RT for 6 h. Upon completion, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with EtOAc (2 x 30 mL). The combined organic extract was washed with water, brine dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: X bridge (150 mm x 19 mm particle size 5 μm); flow: 15 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/15, 2/25, 8/40]. The fractions were lyophilized to give N-((4-cyclopropyl-6-methylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (30 mg, 11%) as a white solid. ^1H NMR (400 MHz, CD_3OD): δ = 7.53 (s, 1H), 7.07 (s, 1H), 6.80 (s, 1H), 2.35 (s, 3H), 1.97-1.93 (m, 1H), 1.42 (s, 6H), 1.08-1.02 (m, 4H). LCMS (m/z): 381.00 $[M+H]^+$; 98.60% (210 nm), 99.49% (254 nm). HPLC: 98.05% (210nm), 99.01% (254nm). HRMS calculated for $\text{C}_{16}\text{H}_{19}\text{N}_4\text{O}_5\text{S}_1$ $[M-H]^+$ 379.1082, found 379.1082.


N-((4,6-di-*tert*-butylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide




4,6-di-*tert*-butylpyrimidin-2-amine (0.15 g, 0.72 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. NaH (37 mg, 0.93 mmol) was added to aforementioned

solution and resulting mixture was stirred at 15 min under nitrogen atmosphere. Phenyl chloroformate (0.16 g, 1.08 mmol) was added dropwise to the aforementioned solution at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion of reaction (TLC, 10% ethyl acetate-hexanes, R_f , 0.5), the reaction mixture was concentrated *in vacuo*. The residue obtained was diluted with 10% IPA/ CHCl_3 , filtered through a celite pad and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 4% EtOAc-hexanes eluant to give phenyl (4,6-di-*tert*-butylpyrimidin-2-yl)carbamate (0.1 g, 43%) as a white solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.65 (s, 1H), 7.38 (m, 2H), 7.22 (m, 3H), 7.01 (s, 1H), 1.32 (s, 18H). LCMS (m/z): 327.80 $[\text{M}+\text{H}]^+$

4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (65 mg, 0.305 mmol) was dissolved in anhydrous THF (8 mL) and treated carefully with NaH (30 mg, 0.764 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 45 minutes and treated with a solution of phenyl (4,6-di-*tert*-butylpyrimidin-2-yl)carbamate (100 mg, 0.305 mmol) in THF (5 mL) dropwise under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 3 h. Upon completion of reaction, (TLC, 50% ethyl acetate-hexanes, R_f , 0.5), the reaction mixture was diluted with saturated NH_4Cl solution and extracted with EtOAc (2 x 20 mL). The combined organic extract was washed with water, brine dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give *N*-((4,6-di-*tert*-butylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (0.07 g, 52%) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 13.75 (s, 1H), 10.71 (s, 1H), 7.83 (s, 1H), 7.37 (s, 1H), 7.20 (s, 1H), 5.17 (s, 1H), 1.39 (s, 6H), 1.31 (s, 18H). LCMS (m/z): 439.55 $[\text{M}+\text{H}]^+$; 94.58% (210 nm), 97.94% (254 nm). HPLC: 98.51% (210nm), 99.27% (254nm). HRMS calculated for $\text{C}_{20}\text{H}_{29}\text{N}_4\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^+$ 437.1864, found 437.1846.


METHYL FURANS***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide**

4-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (52 mg, 51%).

***N*-((2,6-diisopropylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide**

2-Isocyanato-1,3-diisopropylbenzene (prepared using general method A1) and 4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide were used in general method C1 to give the titled compound as an off white solid (14 mg, 4%). ¹H NMR (400 MHz, CD₃OD): δ = 7.24 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 2H), 7.04 (s, 1H), 3.10 (sept., *J* = 6.8 Hz, 2H), 2.50 (s, 3H), 1.50 (s, 6H), 1.17 (d, *J* = 6.8 Hz, 12H).


DEUTERATED FURANS***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-1,1,1,3,3,3-*d*₆furan-2-sulfonamide**



N-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide can be synthesized using 4-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and *d*₆-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide in general method C1.

Alternatively, ethyl 2-methyl-5-sulfamoylfuran-3-carboxylate (0.4 g, 0.96 mmol) in anhydrous THF (30 mL) at -10 °C was treated with *d*₃-methyl magnesium iodide solution (1.0 M in Et₂O, 10 eq.) drop-wise over 10 minutes with vigorous stirring. The solution was then stirred at ambient temperature for 12 h then cooled to 0 °C and quenched drop-wise with a solution of sat. ammonium chloride. The aqueous solution was extracted using EtOAc (2 x 20 mL), the combined organics washed with brine (20 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC to give the titled compound as a white solid (5 mg, 1%). ¹H NMR (300 MHz, CD₃OD): δ = 7.50 (d, *J* = 1.2 Hz, 1H), 6.95 (d, *J* = 1.2 Hz, 1H), 6.89 (s, 1H), 2.83 (t, *J* = 7.2 Hz, 4H), 2.75 (t, *J* = 7.2 Hz, 4H), 2.02 (quin, *J* = 7.2 Hz, 4H).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-1,1,1,3,3,3-*d*₆-5-methylfuran-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and *d*₆-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide were


used in general method C1 to give the titled compound as a white solid (10 mg, 3%). ^1H NMR (400 MHz, CD_3OD) δ = 7.03 (s, 1H), 6.95 (s, 1H), 2.86 (t, J = 7.4 Hz, 4H), 2.73 (t, J = 7.4 Hz, 4H), 2.48 (s, 3H), 2.04 (p, J = 7.4 Hz, 4H).

4-(2-hydroxypropan-2-yl-1,1,1,3,3,3- d_6)-5-methyl-N-((3,5,6,7-tetrahydro-2H-indeno[5,6-*b*]furan-4-yl)carbamoyl)furan-2-sulfonamide




4-isocyanato-3,5,6,7-tetrahydro-2H-indeno[5,6-*b*]furan (prepared using general method A1) and d_6 -4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (20 mg, 5%). ^1H NMR (400 MHz, CD_3OD) δ = 7.13 (s, 1H), 6.52 (s, 1H), 4.51 (t, J = 8.6 Hz, 2H), 3.03 (t, J = 8.6 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.68 (t, J = 7.4 Hz, 2H), 2.50 (s, 3H), 2.05 (p, J = 7.4 Hz, 2H).


N-((4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-*b*]furan-8-yl)carbamoyl)-4-(2-hydroxypropan-2-yl-1,1,1,3,3,3- d_6)-5-methylfuran-2-sulfonamide



4-Bromo-8-isocyanato-3,5,6,7-tetrahydro-2H-indeno[5,6-*b*]furan (prepared using general method A1) and d_6 -4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (32 mg, 39%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.01 (s, 1H), 7.07 (s, 1H), 5.04 (s, 1H), 4.59 (t, J = 8.7 Hz, 2H), 3.14 (t, J = 8.7 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.43 (s, 3H), 1.98 (q, J = 7.4 Hz, 2H).

THIOPHENES***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)thiophene-2-sulfonamide**

4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and thiophene-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (11 mg, 11%). ^1H NMR (400 MHz, CD_3OD): δ = 7.79 (d, J = 4.0 Hz, 1H), 7.76 (d, J = 4.0 Hz, 1H), 7.73 (t, J = 4.0 Hz, 1H), 6.93 (s, 1H), 2.83 (t, J = 12 Hz, 4H), 2.66 (t, J = 12 Hz, 4H), 2.04-1.96 (m, 4H). ^{13}C NMR (100 MHz, CD_3OD): δ 143.5, 143.2, 137.8, 132.7, 132.2, 126.6, 126.4, 118.2, 110.3, 32.5, 29.9, 25.1; LCMS Purity: >95%; LCMS (m/z): 363 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_3\text{S}_2$ ($\text{M} + \text{H}$) $^+$, 363.0832, found 363.0819.


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-methylthiophene-2-sulfonamide**

4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) 5-methylthiophene-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (12 mg, 18%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.88 (s, 1H), 7.43 (d, J = 4.0 Hz, 1H), 6.89 (s, 1H), 6.82 (d, J = 4.0 Hz, 1H), 2.78 (t, J = 12 Hz, 4H), 2.61 (t, J = 12 Hz, 4H), 2.47 (s, 3H), 1.97-

1.89 (m, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 143.2, 142.9, 137.3, 130.6, 126.0, 125.6, 125.2, 117.5, 108.7, 32.69, 30.7, 25.5, 15.4; LCMS Purity: >95%; LCMS (m/z): 377 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_3\text{S}_2$, $(\text{M} + \text{H})^+$ 377.0988, found 377.0994.


THIAZOLES

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)thiazole-2-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and thiazole-2-sulfonamide were used in general method C2 to give the titled compound as a white solid (8 mg, 20%). ^1H NMR (400 MHz, CD_3OD): δ = 7.02 (d, 1H, J = 4.0 Hz), 6.99 (s, 1H), 6.60 (d, 1H, J = 4.0 Hz), 2.88 (t, 4H, J = 8.0 Hz), 2.76 (t, 4H, J = 8.0 Hz), 2.08-2.02 (m, 4H); ^{13}C NMR (100 MHz, CD_3OD): δ = 169.6, 144.2, 144.1, 137.7, 137.5, 132.4, 118.1, 106.9, 32.4, 29.9, 25.2.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-2-methylthiazole-5-sulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 2-methylthiazole-5-sulfonamide were used in general method C3 to give the titled compound as a white solid (35 mg, 65%); ^1H NMR (600

MHz, DMSO- d_6) δ = 7.73 (s, 1H), 7.53 (s, 1H), 6.78 (s, 1H), 2.75 (t, J = 7.4 Hz, 4H), 2.66 (t, J = 7.4 Hz, 4H), 2.59 (s, 3H), 1.93-1.88 (m, 4H); ^{13}C NMR (150 MHz, DMSO- d_6): 166.8, 158.3, 143.9, 142.0, 141.4, 136.6, 132.3, 115.5, 32.5, 30.4, 25.0, 18.6; LCMS Purity: >95%; LCMS (m/z): 378 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{17}\text{H}_{18}\text{N}_3\text{O}_3\text{S}_2$ $[\text{M}-\text{H}]^+$ 376.0795, found 376.0791.


TRIAZOLES

1-benzyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1*H*-1,2,4-triazole-3-sulfonamide




4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-benzyl-1*H*-1,2,4-triazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (40 mg, 15%) ^1H NMR (400 MHz, DMSO- d_6): δ = 8.9 (s, 1H), 8.0 (s, 1H), 7.35-7.28 (m, 5H), 6.90 (s, 1H), 5.48 (s, 2H), 2.77 (t, J = 7.2 Hz, 4H), 2.59 (t, J = 7.2 Hz, 4H), 1.95-1.90 (m, 4H). LCMS (m/z): 438.10 ($\text{M} + 1$) $^+$ 95.84% (210 nm), 97.84% (254 nm). HPLC: 95.99% (210nm), 95.31% (254nm).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4*H*-1,2,4-triazole-3-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4H-1,2,4-triazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (31 mg, 62%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 9.83 (bs, 1H), 7.99 (s, 1H), 7.62 (s, 1H), 6.77 (s, 1H), 2.73 (t, J = 7.4 Hz, 4H), 2.64 (t, J = 7.4 Hz, 4H), 1.91-1.86 (m, 4H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): 159.2, 149.8, 148.7, 142.5, 137.2, 132.8, 116.1, 33.0, 30.9, 25.6; LCMS Purity: >95%; LCMS (m/z): 348 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{15}\text{H}_{16}\text{N}_5\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 346.0979, found 346.0983.

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1*H*-1,2,3-triazole-4-sulfonamide**




1,2,3,5,6,7-hexahydro-s-indacen-4-amine, **7** (100 mg, 0.578 mmol) was dissolved in anhydrous THF (5 mL) and treated with Et_3N (70 mg, 0.693 mmol) at RT. The solution was treated with triphosgene (70 mg, 0.231 mmol) and resulting mixture was stirred at 70 $^\circ\text{C}$ for 3h. The reaction mixture was concentrated *in vacuo*. The residue obtained was stirred with n-pentane (20 mL) for 10 min and filtered through celite. The filtrate was concentrated *in vacuo* to give isocyanate as a white solid. In another 50 mL round bottom flask, 1-isopropyl-1*H*-1,2,3-triazole-4-sulfonamide (95 mg, 0.50 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (42 mg, 1.05 mmol) at 0 $^\circ\text{C}$ under nitrogen. It was stirred at RT for 45 minutes and treated with

aforementioned solution of isocyanate in THF under nitrogen. The resulting reaction mixture was stirred at RT for 5 h. Upon completion (TLC, 70% ethyl acetate-hexanes, R_f , 0.3), the reaction mixture was diluted with saturated NH_4Cl solution and extracted with EtOAc (2 x 25 mL). The combined organic extract was washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: Gemini NX C18 (21.5 mm x 150 mm particle size 5 μm); flow: 15 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/10, 2/20, 8/65]. The fractions were lyophilized to give N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1*H*-1,2,3-triazole-4-sulfonamide (25 mg, 12%), as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.75 (s, 1H), 7.91 (s, 1H), 6.89 (s, 1H), 4.9 (m, 1H), 2.79 (t, J = 7.2 Hz, 4H), 2.60 (t, J = 7.2 Hz, 4H), 1.96-1.89 (m, 4H), 1.5 (d, J = 6.8 Hz, 6H). LCMS (m/z): 390.10 $[\text{M}+\text{H}]^+$; 100% (210 nm), 100% (254 nm). HPLC: 96.05% (210nm), 96.13% (254nm). HRMS calculated for $\text{C}_{18}\text{H}_{22}\text{N}_5\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 388.1449, found 388.1457.

PYRAZOLES


N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1*H*-pyrazole-5-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 1-methyl-1*H*-pyrazole-5-sulfonamide were used in general method C2 to give the titled compound as a white solid (8 mg) 20%. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 7.95 (bs, 1H), 7.45 (s, 1H), 6.88 (s, 1H), 6.66 (s, 1H), 4.02 (s, 3H), 2.77 (t, J = 16 Hz, 4H), 2.60 (t, J = 16 Hz, 4H), 1.96-1.88


(m, 4H). ^{13}C NMR (150 MHz, DMSO- d_6): δ = 143.1, 142.9, 137.2, 125.2, 117.4, 110.0, 109.0, 108.7, 38.6, 33.0, 30.7, 25.5; LCMS Purity: >95%; LCMS (m/z): 361 $[\text{M} + \text{H}]^+$; HRMS calculated for $\text{C}_{17}\text{H}_{20}\text{N}_4\text{O}_3\text{S}$ ($\text{M} + \text{H}$) $^+$, 361.13289, found 361.13213.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-methyl-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-methyl-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as a white solid (40 mg, 8%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.8 (brs, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 6.92 (s, 1H), 6.69 (s, 1H), 3.91 (s, 3H), 2.80 (t, J = 7.2 Hz, 4H), 2.62 (t, J = 7.2 Hz, 4H), 1.96 (t, J = 7.2 Hz, 4H). LCMS (m/z): 383.10 ($\text{M} + \text{Na}$) $^+$; 96.00% (210 nm), 93.44% (254 nm). HPLC: 97.86% (210nm), 97.44% (254nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (5 mg, 1 %). ^1H NMR (400 MHz, CD_3OD) δ = 8.28 (d, J = 2.8 Hz, 1H), 6.96 (d, J = 2.8, 1H), 6.91 (s, 1H), 2.84 (t, J = 7.4 Hz, 4H), 2.75 (t, J = 7.4 Hz, 4H), 2.03 (m, J = 7.4 Hz,


4H).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-isopropyl-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as an off-white solid (40 mg, 9%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 10.92 (s, 1H), 8.02 (s, 1H), 8.0 (s, 1H), 6.94 (s, 1H), 6.74 (s, 1H), 4.67-4.59 (m, 1H), 2.78 (t, *J* = 7.2 Hz, 4H), 2.58 (t, *J* = 7.2 Hz, 4H), 1.95-1.91 (m, 4H), 1.44 (d, *J* = 6.8 Hz, 6H). LCMS (*m/z*): 387.1 (*M* - 1)⁻; 97.14% (210 nm), 95.11% (254 nm). HPLC: 95.57% (210 nm), 93.53% (254 nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-4-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-isopropyl-1*H*-pyrazole-4-sulfonamide were used in general method C3 to give the titled compound as a white solid (40 mg, 10%) ¹H NMR (400 MHz, DMSO-*d*₆): δ = 10.6 (s, 1H), 8.44 (s, 1H), 8.05 (s, 1H), 7.86 (s, 1H), 6.94 (s, 1H), 4.63-4.57 (m, 1H), 2.80 (t, *J* = 7.2 Hz, 4H), 2.57 (t, *J* = 7.6


Hz, 4H), 1.94-1.89 (m, 4H), 1.42 (d, $J = 6.8$ Hz 6H). LCMS (m/z): 389.20 ($M + 1$)⁺; 97.25% (210 nm), 94.22% (254 nm). HPLC: 97.13% (210nm), 95.06% (254nm).

1-cyclopropyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1*H*-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-cyclopropyl-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (20 mg, 6%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 7.83 (s, 1H), 7.8 (s, 1H), 6.84 (s, 1H), 6.48 (s, 1H), 3.81 – 3.71 (m, 1H), 2.77 (t, $J = 7.4$ Hz, 4H), 2.64 (t, $J = 7.4$ Hz, 4H), 2.02 – 1.86 (m, 4H), 1.09 – 0.93 (m, 4H).


1-(*tert*-butyl)-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1*H*-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-(*tert*-butyl)-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a pale yellow solid (120 mg, 51%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 10.85 (br.s., 1H), 7.95 (s, 1H), 7.88 (br.s., 1H), 6.88 (s, 1H), 6.63 (s, 1H), 2.79 (t, $J = 7.2$ Hz, 4H), 2.61 (t, $J = 7.2$


Hz, 4H), 1.96 (m, 4H), 1.55 (s, 9H). LCMS (m/z): 403.15 ($M+1$)⁺; 97.86% (210 nm), 96.50% (254 nm). HPLC: 96.45% (210nm), 95.89% (254nm).

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 1-cyclohexyl-1H-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (20 mg, 6%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.8 (s, 1H), 8.03 (s, 1H), 7.99 (d, J = 2.4, 1H), 6.95 (s, 1H), 6.75 (d, J = 2.4 Hz, 1H), 4.33 – 4.20 (m, 1H), 2.79 (t, J = 7.4 Hz, 4H), 2.58 (t, J = 7.4 Hz, 4H), 2.05 – 1.88 (m, 6H), 1.86 – 1.63 (m, 6H), 1.48 – 1.33 (m, 2H).


N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-phenyl-1H-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 1-phenyl-1H-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as an off-white solid (110 mg, 27%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 10.92 (s, 1H), 8.61 (d, J = 2.4 Hz,


1H), 7.95 (br.s., 1H), 7.86 (d, $J = 8.4$ Hz, 2H), 7.56 (t, $J = 7.6$ Hz, 2H), 7.41 (t, $J = 7.2$ Hz, 1H), 6.9 (d, $J = 2.0$ Hz, 1H), 6.86 (s, 1H), 2.77 (t, $J = 7.2$ Hz, 4H), 2.62 (t, $J = 7.2$ Hz, 4H), 1.91-1.83 (m, 4H). LCMS (m/z): 421.05 ($M - 1$)⁻; 96.62% (210 nm), 95.12% (254 nm). HPLC: 95.2% (210 nm), 95.77% (254 nm).

1-benzyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1*H*-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and , 1-benzyl-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (85 mg, 34%). ¹H NMR (400 MHz, DMSO- d_6): $\delta = 10.85$ (s, 1H), 8.05 (d, $J = 2.4$ Hz, 1H), 7.99 (s, 1H), 7.32-7.31 (m, 3H), 7.24-7.22(m, 2H), 6.93 (s, 1H), 6.78 (d, $J = 2.4$ Hz, 1H), 5.44 (s, 2H), 2.80 (t, $J = 7.6$ Hz, 4H), 2.57 (t, $J = 7.2$ Hz, 4H), 1.96 (m, 4H). LCMS (m/z): 437.15 ($M + 1$)⁺; 97.70% (210 nm), 96.86% (254 nm). HPLC: 98.05% (210 nm), 97.56% (254 nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-(1-phenylethyl)-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and , 1-(1-phenylethyl)-1*H*-pyrazole-3-sulfonamide were


used in general method C3 to give the titled compound as a white solid (0.13 g, 38%). ¹H NMR (400 MHz, DMSO-*d*₆) δ = 7.94 (d, *J* = 2.4 Hz, 1H), 7.80 (s, 1H), 7.34 – 7.18 (m, 5H), 6.85 (s, 1H), 6.62 (d, *J* = 2.3 Hz, 1H), 5.68 (q, *J* = 7.0 Hz, 1H), 2.76 (t, *J* = 7.4 Hz, 4H), 2.58 (t, *J* = 7.4 Hz, 4H), 1.90 (p, *J* = 7.4 Hz, 4H), 1.8 (d, *J* 7.1 Hz, 3H).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-(2-(piperidin-1-yl)ethyl)-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and , 1-(2-(piperidin-1-yl)ethyl)-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (110 mg, 25%). ¹H NMR (400 MHz, CD₃OD): δ = 7.76 (d, *J* = 2.4 Hz , 1H), 6.91 (s, 1H), 6.73 (d, *J* = 2.4 Hz 1H), 4.55 (t, *J* = 6.4 Hz, 2H), 3.41 (t, *J* = 6.0Hz, 2H), 3.02 (s, 4H), 2.86 (t, *J* = 7.2 Hz, 4H), 2.78 (t, *J* = 7.2 Hz, 4H), 2.06-1.99 (m, 4H), 1.74-1.70 (m, 4H), 1.51 (d, *J* = 5.2 Hz ,2H). LCMS (*m/z*): 458.20 (*M* + 1)⁺; 100% (210 nm), 100% (254 nm). HPLC: 98.70% (210nm), 98.31% (254nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1,5-dimethyl-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using


general method A1) and 1,5-dimethyl-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as a white solid (15 mg, 4 %). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 10.7 (br.s., 1H), 7.98 (s, 1H), 6.93 (s, 1H), 6.52 (s, 1H), 3.79 (s, 3H), 2.80 (t, *J* = 7.2 Hz, 4H), 2.62 (t, *J* = 7.6 Hz, 4H), 2.28 (s, 3H), 1.98-1.93 (m, 4H). LCMS (*m/z*): 397.10 (M+Na)⁺; 97.75% (210 nm), 88.23% (254 nm). HPLC: 94.42% (210nm), 95.19% (254nm).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (200 mg, 48%). ¹H NMR (400 MHz, CD₃OD): δ = 7.10 (s, 1H), 6.87 (s, 1H), 4.03 (s, 3H), 2.83 (t, *J* = 7.2 Hz, 4H), 2.74- (t, *J* = 7.2 Hz, 4H), 2.03-1.99 (m, 4H). LCMS(*m/z*): 429.10 (M + 1)⁺; 97.73% (210 nm), 95.71% (254 nm). HPLC: 94.95% (210nm), 93.52% (254nm).


***N*-((2,6-diisopropylphenyl)carbamoyl)-1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide**



2-Isocyanato-1,3-diisopropylbenzene (prepared using general method A1) and 1-methyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide were used in general


method C3 to give the titled compound as a white solid (70 mg, 39%). ^1H NMR (400 MHz, CD_3OD): δ = 7.18-7.16 (m, 1H), 7.10-7.08 (m, 3H), 4.03 (s, 3H), 3.17-3.13 (m, 2H), 1.03 (d, J = 6.0 Hz, 12H). LCMS (m/z): 433.15 ($M + 1$) $^+$; 99.73% (210 nm), 98.16% (254 nm). HPLC: 97.51% (210 nm), 95.47% (254 nm).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-1-isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-isopropyl-5-(trifluoromethyl)-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (15 mg, 12%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.54 (s, 1H), 6.90 (s, 1H), 6.77 (s, 1H), 4.62-4.56 (m, 1H), 2.76 (t, J = 7.2 Hz, 4H), 2.67 (t, J = 7.6 Hz, 4H), 1.92-1.84 (m, 4H), 1.44 (d, J = 6.4 Hz, 6H). LCMS (m/z): 455.05 ($M - 1$) $^-$; 96.13% (210 nm), 95.41% (254 nm). HPLC: 95.71% (210 nm), 95.12% (254 nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-isopropyl-1-methyl-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using


general method A1) and 5-isopropyl-1-methyl-1*H*-pyrazole-3-sulfonamide were used in general method C3 to give the titled compound as a white solid (10 mg, 17%). ¹H NMR (400 MHz, CD₃OD): δ = 6.88 (s, 1H), 6.50 (s, 1H), 3.82 (s, 3H), 3.08 – 3.03 (m, 1H), 2.83 (t, *J* = 7.2 Hz, 4H), 2.71 (t, *J* = 7.2 Hz, 4H), 2.04-1.96 (m, 4H), 1.21 (d, *J* = 6.8 Hz, 6H). LCMS(*m/z*): 403.20 (M + 1)⁺; 98.39% (210 nm), 94.19% (254 nm). HPLC: 95.62% (210nm), 93.00% (254nm).

***N*-((2,6-diisopropylphenyl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-methyl-1*H*-pyrazole-3-sulfonamide**



2-Isocyanato-1,3-diisopropylbenzene (prepared using general method A1) and 5-(2-hydroxypropan-2-yl)-1-methyl-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as a white solid (90 mg, 26%). ¹H NMR (400 MHz, CD₃OD): δ = 7.25-7.24 (m, 1H), 7.16-7.14 (m, 2H), 6.67(s, 1H), 4.13 (s, 3H), 3.11-3.08 (m, 2H), 1.61 (s, 6H), 1.16 (d, *J* = 6.8 Hz, 12H). LCMS (*m/z*): 423.20 (M + 1)⁺; 99.16% (210 nm), 97.19% (254 nm). HPLC: 98.16% (210nm), 97.09% (254nm).


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-methyl-1*H*-pyrazole-3-sulfonamide.**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 5-(2-hydroxypropan-2-yl)-1-methyl-1*H*-pyrazole-3-


sulfonamide were used in general method C1 to give the titled compound as a white solid (70 mg, 15%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.01 (s, 1H), 6.92 (s, 1H), 6.53 (s, 1H), 5.51 (s, 1H), 4.02 (s, 3H), 2.79 (t, $J = 7.4$ Hz, 4H), 2.62 (t, $J = 7.4$ Hz, 4H), 1.95 (p, $J = 7.4$ Hz, 4H), 1.50 (s, 6H).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-phenyl-1*H*-pyrazole-3-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 5-(2-hydroxypropan-2-yl)-1-phenyl-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as a white solid (10 mg, 2%). ^1H NMR (400 MHz, CD_3OD): δ = 7.54 (s, 5H), 6.59 (s, 1H), 6.91 (s, 1H), 2.86 (t, $J = 7.2$ Hz, 4H), 2.69 (t, $J = 7.2$ Hz, 4H), 2.05-1.96 (m, 4H), 1.44 (s, 6H). LCMS (m/z): 481.20 ($\text{M} - 1$) $^-$; 93.76% (210 nm), 93.24% (254 nm). HPLC: 95.86% (210 nm), 93.93% (254 nm).


1-benzyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1*H*-pyrazole-3-sulfonamide



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 1-benzyl-5-(2-hydroxypropan-2-yl)-1*H*-pyrazole-3-sulfonamide were used in general method C1 to give the titled compound as a


white solid (40 mg, 7%). ^1H NMR (400 MHz, CD_3OD): δ = 7.20-7.14 (m, 5H), 6.95 (s, 2H), 6.73 (s, 1H), 5.77 (s, 2H), 2.86 (t, J = 7.2 Hz, 4H), 2.68 (t, J = 7.6 Hz, 4H), 2.01-1.94 (m, 4H), 1.51 (s, 6H). LCMS (m/z): 494.7 ($M+1$) $^+$; 98.74% (210 nm), 96.05% (254 nm). HPLC: 95.11% (210 nm), 95.08% (254 nm).

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazole-3-sulfonamide**



5-chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and 5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazole-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (83 mg, 17%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 7.81 (s, 1H), 7.10 (s, 2H), 6.42 (s, 1H), 5.45 (s, 1H), 3.99 (s, 3H), 3.03 (hept, J = 7.0 Hz, 2H), 1.47 (s, 6H), 1.05 (d, J = 1.8 Hz, 12H). HRMS calculated for $\text{C}_{20}\text{H}_{28}\text{Cl}_1\text{N}_4\text{O}_4\text{S}_1$ $[\text{M}-\text{H}]^-$ 455.1525, found 455.1515.


***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-phenyl-1H-pyrazole-3-sulfonamide**



5-chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and 5-(2-hydroxypropan-2-yl)-1-phenyl-1H-pyrazole-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (168

mg, 31%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 7.87 (s, 1H), 7.52 (s, 5H), 7.10 (s, 2H), 6.71 (s, 1H), 5.42 (s, 1H), 3.10 – 2.92 (m, 2H), 1.31 (s, 6H), 1.02 (d, J = 7.0 Hz, 12H). HRMS calculated for $\text{C}_{25}\text{H}_{30}\text{Cl}_1\text{N}_4\text{O}_4\text{S}_1$ $[\text{M}-\text{H}]^-$ 517.1682, found 517.1671.

N-((4-chloro-2,6-dimethylphenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide




A solution of 4-chloro-2,6-dimethylaniline (50 mg, 0.321 mmol) in DCM (5 mL) was treated with Et_3N (50 mg, 0.48 mmol) and cooled to 0 °C, Phenyl chloroformate (60 mg, 0.39 mmol) was added dropwise at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with saturated NaHCO_3 solution, extracted with DCM (2 x 20 mL) and the combined organic extract washed with water, brine dried (Na_2SO_4) and concentrated *in vacuo*. The residue obtained was washed with n-pentane and dried *in vacuo* to give phenyl (4-chloro-2,6-dimethylphenyl)carbamate (75 mg, 85%) as a brown solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.46-7.37 (m, 4H), 7.26-7.20 (m, 2H), 7.12-7.11(m, 2H), 2.33(s, 6H). LCMS (m/z): 275.9 $[\text{M}+\text{H}]^+$.

1-isopropyl-1H-pyrazole-3-sulfonamide (150 mg, 0.79 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (80 mg, 1.98 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 30 min then treated with a solution of phenyl (4-chloro-2,6-dimethylphenyl)carbamate (240 mg, 0.87 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and

stirred for 3 h. Upon completion the reaction mixture was diluted with saturated NH_4Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract was washed with water, brine dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give *N*-((4-chloro-2,6-dimethylphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (90 mg, 31%) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 11.05 (s, 1H), 7.99 (d, J = 2.8 Hz, 1H), 7.93 (s, 1H), 7.13 (s, 2H), 6.73 (d, J = 2.4 Hz, 1H), 4.64-4.57 (m, 1H), 2.03 (s, 6H), 1.43 (d, J = 6.8 Hz, 6H). LCMS (m/z): 370.95 $[\text{M}+\text{H}]^+$; 97.62% (210 nm), 97.48% (254 nm). HPLC: 97.20% (210nm). HRMS calculated for $\text{C}_{15}\text{H}_{18}\text{Cl}_1\text{N}_4\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 369.0794, found 369.0785.


***N*-((4-chloro-2,6-dimethoxyphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide**



A solution of 4-chloro-2,6-dimethoxyaniline (200 mg, 1.06 mmol) in THF (8 mL) was cooled to 0 °C and treated with NaH (62 mg, 1.59 mmol) under nitrogen atmosphere. The resulting mixture was stirred for 15 min. before phenylchloroformate (330 mg, 2.13 mmol) was added dropwise at 0°C. The reaction mixture was warmed to RT and stirred for 12h. Upon completion, the reaction mixture was diluted with EtOAc and filtered through a celite pad and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 10% EtOAc-hexanes eluant to give phenyl (4-chloro-2,6-dimethoxyphenyl)carbamate (0.2 g, 61%) as a white solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.35-7.33 (m, 2H), 7.20-7.19 (m, 3H), 6.61 (s, 2H), 3.83 (s, 6H).

1-isopropyl-1*H*-pyrazole-3-sulfonamide (100 mg, 0.53 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (52 mg, 1.32 mmol) at 0 °C under nitrogen atmosphere.). The resulting mixture was stirred at RT for 40 min then treated with a solution of phenyl (4-chloro-2,6-dimethoxyphenyl)carbamate (180 mg, 0.58 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The combined organic extract was washed with water, brine, dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: Gemini NX C18 (21.2 mm x 150 mm particle size 5μm); flow: 20 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/20, 2/20, 8/70]. The fractions were lyophilized to give N-((4-chloro-2,6-dimethoxyphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (20 mg, 9%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.90 (d, *J* = 2.0 Hz, 1H), 7.28 (s, 1H), 6.72 (s, 2H), 6.63 (d, *J* = 2.0 Hz, 1H), 4.60-4.54 (m, 1H), 3.70 (s, 6H), 1.43(d, *J* = 6.8 Hz, 6H). LCMS (*m/z*): 403.0 [M+H]⁺.; 90.61% (210nm). HPLC: 91.63% (210nm). HRMS calculated for C₁₅H₁₈Cl₁N₄O₅S₁ [M-H]⁻ 401.0692, found 401.0684.


N-((4-chloro-2-methyl-6-(trifluoromethyl)phenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide



4-Chloro-2-methyl-6-(trifluoromethyl)aniline (50 mg, 0.24 mmol) was dissolved


in anhydrous THF (5 mL) and treated with Et₃N (30 mg, 0.29 mmol) at RT. The solution was treated with triphosgene (30 mg, 0.095 mmol) and resulting mixture was stirred at 60 °C for 4 h. The reaction mixture was concentrated *in vacuo*. The residue obtained was stirred with n-pentane (20 mL) for 10 min, filtered through a celite pad and concentrated *in vacuo* to give the corresponding isocyanate as a white solid. In another 50 mL round bottom flask, 1-isopropyl-1H-pyrazole-3-sulfonamide (40 mg, 0.212 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (22 mg, 0.529 mmol) at 0 °C under nitrogen atmosphere. It was stirred at RT for 30 minutes. The aforementioned solution of isocyanate was added in THF under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 2 h. Upon completion of reaction the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 25 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give N-((4-chloro-2-methyl-6-(trifluoromethyl)phenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide. This was triturated with diethyl ether and n-pentane to give N-((4-chloro-2-methyl-6-(trifluoromethyl)phenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide (35 mg, 35%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.05 (s, 1H), 8.09 (s, 1H), 7.96 (s, 1H), 7.70 (s, 1H), 7.61 (s, 1H), 6.67 (d, *J* = 0.4 Hz, 1H), 4.62 (m, 1H), 2.05 (s, 3H), 1.43 (d, *J* = 6.8 Hz, 6H). ¹⁹F NMR (400 MHz, DMSO-*d*₆): δ = -60.82. LCMS (m/z): 425.00 [M+H]⁺; 94.05% (210 nm). HPLC: 98.03% (210nm). HRMS calculated for C₁₅H₁₅ClF₃N₄O₃S₁ [M-H]⁻ 423.0511, found 423.0513.

N-((4-chloro-2-methoxy-6-(trifluoromethyl)phenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide



4-Chloro-2-methoxy-6-(trifluoromethyl)aniline (50 mg, 0.22 mmol) was dissolved in anhydrous THF (2 mL) and treated with Et₃N (27 mg, 0.27 mmol) at RT. The solution was treated with triphosgene (32 mg, 0.11 mmol) and resulting mixture was stirred at 70 °C for 3 h. The reaction mixture was concentrated *in vacuo* and the residue obtained stirred with 5% EtOAc-hexanes (20 mL) for 10 min, filtered through celite and concentrated *in vacuo* to give the desired isocyanate as a white solid. In another 50 mL round bottom flask, 1-isopropyl-1H-pyrazole-3-sulfonamide (42 mg, 0.22 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (18 mg, 0.44 mmol) at 0 °C under nitrogen atmosphere. The mixture was stirred at 0 °C for 20 minutes and treated with aforementioned solution of isocyanate in THF under nitrogen atmosphere. The resulting reaction mixture was stirred at 0-10 °C for 2 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 50% EtOAc-hexanes eluant to give N-((4-chloro-2-methoxy-6-(trifluoromethyl)phenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide (10 mg, 10%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.81 (s, 1H), 7.53 (d, *J* = 2.4 Hz, 1H), 7.22 (d, *J* = 1.6 Hz, 1H), 7.10 (s, 1H), 6.82 (d, *J* = 2.0 Hz, 1H), 4.64-4.57 (m, 1H), 3.84 (s, 3H), 1.54 (d, *J* = 6.8 Hz, 6H). ¹⁹F NMR (400 MHz, CDCl₃): δ = -61.55. LCMS (*m/z*): 441.05 [M+H]⁺; 94.58% (210 nm). HPLC: 92.16% (210nm). HRMS calculated for C₁₅H₁₅ClF₃N₄O₄S₁ [M-H]⁻ 439.0460, found 439.0478.

N-((4-chloro-2,6-diethylphenyl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide




A solution of 4-chloro-2,6-dicyclopropylaniline (100 mg, 0.546 mmol) in THF (5 mL) was cooled to 0 °C and treated with NaH (30 mg, 0.66 mmol) under nitrogen atmosphere and stirred for 15 min. Phenyl chloroformate (130 mg, 0.819 mmol) was added dropwise to the aforementioned solution at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion the mixture was diluted with EtOAc, filtered through a celite pad and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 10% EtOAc-hexanes to give phenyl (4-chloro-2,6-diethylphenyl)carbamate (0.15 g, 91%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.38-7.33 (m, 2H), 7.23-7.18 (m, 3H), 7.13 (m, 2H), 6.27 (s, 1H), 2.75-2.64 (m, 4H), 1.28-1.22 (m, 6H).

1-isopropyl-1H-pyrazole-3-sulfonamide (75 mg, 0.40 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (40 mg, 0.99 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 30 min then treated with a solution of phenyl (4-chloro-2,6-diethylphenyl)carbamate (130 mg, 0.44 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 4 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 30-40% EtOAc-hexanes eluant followed by trituration


with diethyl ether and n-pentane to give N-((4-chloro-2,6-diethylphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (40 mg, 24%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.05 (s, 1H), 7.99 (d, *J* = 2.4 Hz, 1H), 7.89 (s, 1H), 7.12 (s, 2H), 6.72 (d, *J* = 2.4 Hz, 1H), 4.62-4.59 (m, 1H), 2.42 (q, *J* = 7.6 Hz, 4H), 1.43 (d, *J* = 6.8 Hz, 6H), 1.02 (t, *J* = 7.6 Hz, 6H). LCMS (*m/z*): 399.0 [M+H]⁺, 96.72% (210nm). HPLC: 97.13% (210nm). HRMS calculated for C₁₇H₂₂ClN₄O₃S₁ [M-H]⁻ 397.1107, found 397.1090.

N-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and 1-isopropyl-1*H*-pyrazole-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (221 mg, 49%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 7.70 (d, *J* = 2.3 Hz, 1H), 7.49 (s, 1H), 7.00 (s, 2H), 6.36 (s, 1H), 4.62 – 4.29 (m, 1H), 3.11 (d, *J* = 6.4 Hz, 2H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.01 (d, *J* = 6.8 Hz, 12H). ¹³C NMR (151 MHz, DMSO) δ = 160.96, 156.43, 150.19, 135.25, 131.49, 128.53, 123.27, 105.21, 54.23, 28.80, 24.15, 23.55. HRMS calculated for C₁₉H₂₆ClN₄O₃S₁ [M-H]⁻ 425.1420, found 425.1409.

N-((4-chloro-2,6-dicyclo propylphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide




A solution of 4-chloro-2,6-dicyclopropylaniline (150 mg, 0.724 mmol) in THF (5 mL) was cooled to 0 °C. NaH (35 mg, 0.87 mmol) was added in portions to aforementioned solution and stirred for 20 min. Phenyl chloroformate (170 mg, 1.08 mmol) was added dropwise to the aforementioned solution at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion, the mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 15% EtOAc-hexanes eluant to give phenyl (4-chloro-2,6-dicyclopropylphenyl)carbamate (195 mg, 83%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.37-7.35 (m, 2H), 7.21-7.19 (m, 3H), 6.84-6.83 (m, 2H), 2.08-2.04 (m, 2H), 1.04-1.02 (m, 4H), 0.69-0.68 (m, 4H). LCMS (*m/z*): 328.2 [M+H]⁺.

1-isopropyl-1*H*-pyrazole-3-sulfonamide (100 mg, 0.53 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (53 mg, 1.32 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 30 min then treated with a solution of phenyl (4-chloro-2,6-dicyclopropylphenyl)carbamate (190 mg, 0.582 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The reaction mixture was warmed to RT and stirred for 4 h. Upon completion of reaction the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give N-((4-chloro-2,6-dicyclopropylphenyl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide. This

was triturated with diethyl ether and n-pentane to give (25 mg, 11%) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 11.05 (s, 1H), 8.01-7.98 (m, 2H), 6.74 (s, 3H), 4.59-4.56 (m, 1H), 1.77 -1.76 (m, 2H), 1.41 (d, J = 6.8 Hz, 6H), 0.77-0.75 (m, 4H), 0.56-0.55 (m, 4H). LCMS (m/z): 423.00 $[\text{M}+\text{H}]^+$; 93.58% (210 nm). HPLC: 92.87% (210nm). HRMS calculated for $\text{C}_{19}\text{H}_{22}\text{Cl}_1\text{N}_4\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 421.1107, found 421.1107.

***N*-((7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide**




7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-amine, **6** (70mg, 0.33 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. NaH (20 mg, 0.505 mmol) was added to the aforementioned solution under nitrogen atmosphere and stirred for 15 min before phenyl chloroformate (100 mg, 0.674 mmol) was added dropwise at 0°C. The reaction mixture was warmed to RT and stirred for 12h. Upon completion the reaction mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using, 10% EtOAc-hexanes eluent to give phenyl (7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamate (80 mg, 73%) as a brown solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.39-7.37 (m, 3H), 7.25-7.24 (m, 2H), 6.85(s, 1H), 3.0-2.94 (m, 4H), 2.12-2.10 (m, 2H), 1.34 (m, 1H), 0.96-0.95 (m, 2H), 0.59-0.57 (m, 2H). LCMS (m/z): 328.30 $[\text{M}+\text{H}]^+$.

1-isopropyl-1*H*-pyrazole-3-sulfonamide (41 mg, 0.219 mmol) was dissolved in anhydrous THF (3 mL) and treated carefully with NaH (21 mg, 0.549 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 30 min and was treated with a solution of phenyl (7-chloro-5-cyclopropyl-2,3-

dihydro-1*H*-inden-4-yl)carbamate (80 mg, 0.244 mmol) in THF (2 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 4 h. Upon completion the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract was washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: Gemini NX C18 (21.2 mm x 150 mm particle size 5µm); flow: 20 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/20, 2/30, 8/70]. The fractions were lyophilized to give N-((7-chloro-5-cyclopropyl-2,3-dihydro-1*H*-inden-4-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (20 mg, 20%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.95 (d, *J* = 2.4 Hz, 1H), 6.74 (s, 1H), 6.69(d, *J* = 2.4 Hz, 1H), 4.60-4.55 (m, 1H), 2.84 (t, *J* = 7.6 Hz, 2H), 2.66 (t, *J* = 7.6 Hz, 2H), 1.95-1.92 (m, 2H), 1.79-1.76 (m, 1H), 1.41(d, *J* = 6.4 Hz, 6H), 0.82-0.78 (m, 2H), 0.54-0.50 (m, 2H). LCMS (m/z): 421.15 [M-H]⁻; 94.19% (210 nm). HPLC: 95.46% (210nm). HRMS calculated for C₁₉H₂₂ClN₄O₃S₁ [M-H]⁻ 421.1107, found 421.1110.

5-chloro-3-cyclopropyl-2-(3-((1-isopropyl-1*H*-pyrazol-3-yl)sulfonyl)ureido)-N,N-dimethylbenzamide




2-amino-5-chloro-3-cyclopropyl-N,N-dimethylbenzamide (200 mg, 0.84 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (50 mg, 1.26 mmol) at 0 °C under nitrogen atmosphere. The resulting reaction mixture

was stirred for 15 min. then phenyl chloroformate (262 mg, 1.68 mmol) was added dropwise at 0 °C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion the reaction mixture was diluted with EtOAc, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 15% EtOAc-hexanes eluant to give phenyl (4-chloro-2-cyclopropyl-6-(dimethylcarbamoyl) phenyl)carbamate (0.14, 47%) as dark brown liquid. ¹H NMR (300 MHz, CDCl₃): δ = 7.39-7.34 (m, 2H), 7.23-7.15 (m, 3H), 7.08-7.02 (m, 2H), 3.09(s, 3H), 2.96 (s, 3H), 2.05-2.0 (m, 1H), 1.05-1.02 (m, 2H), 0.71-0.69 (m, 2H). LCMS (*m/z*): 358.60 [M+H]⁺.

1-isopropyl-1*H*-pyrazole-3-sulfonamide (57 mg, 0.30 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (18 mg, 0.451 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at RT for 45 min then treated with a solution of phenyl (4-chloro-2-cyclopropyl-6-(dimethylcarbamoyl) phenyl)carbamate (120 mg, 0.335 mmol) in THF (3 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 2 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 30 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC [column: Gemini NX C18 110A AXIA (21.2 mm x 150 mm particle size 5 μ m); flow: 18 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/20, 2/20, 10/60]. The fractions were lyophilized to give 5-chloro-3-cyclopropyl-2-(3-((1-isopropyl-1*H*-pyrazol-3-yl)sulfonyl)ureido)-*N,N*-dimethylbenzamide (10 mg, 7%) as a white solid. ¹H NMR (400 MHz, CD₃OD): δ = 7.77 (s, 1H), 7.11 (d, *J* = 2.4 Hz, 1H), 7.05 (d, *J* = 2.0 Hz, 1H), 6.76 (s, 1H), 4.62-4.53 (m, 1H), 2.96 (s, 3H), 2.84 (s, 3H), 1.88-1.87(m, 1H), 1.50 (d, *J* = 6.8 Hz, 6H), 0.90-0.88 (m, 2H), 0.63-0.61 (m, 2H). LCMS (*m/z*): 454.0 [M+H]⁺.; 97.52% (210 nm). HPLC: 92.05% (210nm). HRMS calculated for

$C_{19}H_{23}Cl_1N_5O_4S_1$ $[M-H]^-$ 452.1165, found 452.1180.

N-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide




A solution of 4,6-dimethylpyrimidin-2-amine (300 mg, 2.43 mmol) in THF (10 mL) was cooled to 0 °C and treated with NaH (140 mg, 3.64 mmol) under nitrogen atmosphere. The resulting mixture was stirred for 15 min then treated with phenyl chloroformate (0.6 mL, 4.87 mmol) at 0°C. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion, the reaction mixture was diluted with EtOAc (30 mL) filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 30% EtOAc-hexanes eluant to give phenyl (4,6-dimethylpyrimidin-2-yl)carbamate (250 mg, 42%) as a white solid. ^1H NMR (300 MHz, $CDCl_3$): δ = 8.14 (s, 1H), 7.45-7.34 (m, 2H), 7.25-7.18 (m, 3H), 6.78 (s, 1H), 2.46 (s, 6H). LCMS (m/z): 244.30 $[M+H]^+$.

1-isopropyl-1H-pyrazole-3-sulfonamide (75 mg, 0.396 mmol) was dissolved in anhydrous THF (50 mL) and treated carefully with NaH (40mg, 0.99 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was warmed to RT and stirred for 30 min. The reaction mixture was cooled to 0°C then treated with a solution of phenyl (4,6-dimethylpyrimidin-2-yl)carbamate (100 mg, 0.436 mmol) in THF (5 mL) under nitrogen atmosphere at 0 °C. The reaction mixture was warmed to RT and stirred for 3 h. Upon completion, the reaction mixture was diluted with saturated NH_4Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by reverse phase

preparative HPLC [column: Gemini NX-bridge (150 mm x 21.2 mm particle size 5 μ m); flow: 15 mL/min; eluent: 10 mM ammonium bicarbonate in water (A) & MeCN (B); gradient: T/% B= 0/10, 2/20, 10/60]. The fractions were lyophilized to give N-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (10 mg, 13%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 13.0 (s, 1H), 7.49-7.46 (m, 2H), 7.02 (d, J = 2.4 Hz, 1H), 6.74 (s, 1H), 4.62-4.57 (m, 1H), 2.45 (s, 6H), 1.53 (d, J = 6.8 Hz, 6H). LCMS (m/z): 339.10 $[\text{M}+\text{H}]^+$. 99.70% (210 nm), 100% (254 nm). HPLC: 97.22% (210nm). HRMS calculated for $\text{C}_{13}\text{H}_{17}\text{N}_6\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 337.1088, found 337.1099.

N-((4,6-di-*tert*-butylpyrimidin-2-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide




A solution of 4,6-di-*tert*-butylpyrimidin-2-amine (0.15 g, 0.72 mmol) in THF (5 mL) was cooled to 0 $^{\circ}\text{C}$ and treated with NaH (35 mg, 0.86 mmol) under nitrogen atmosphere. The resulting mixture was stirred for 15 min and phenyl chloroformate (0.17 g, 1.08 mmol) was added dropwise to the aforementioned solution at 0 $^{\circ}\text{C}$. The reaction mixture was warmed to RT and stirred for 12 h. Upon completion, the reaction mixture was concentrated *in vacuo* and the residue obtained diluted with ethyl acetate, filtered through celite and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 15% EtOAc-hexanes eluant to give phenyl (4,6-di-*tert*-butylpyrimidin-2-yl)carbamate (140 mg, 59%) as a white solid. ^1H NMR (400 MHz, CDCl_3): δ = 7.95 (s, 1H), 7.65-7.61 (m, 2H), 7.50-7.45 (m, 4H), 1.32 (s, 18H). LCMS (m/z): 328.40 $[\text{M}+\text{H}]^+$;

1-Isopropyl-1*H*-pyrazole-3-sulfonamide (50 mg, 0.264 mmol) was dissolved in

anhydrous THF (40 mL) and treated carefully with NaH (27 mg, 0.661 mmol) at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 30 minutes then treated with a solution of phenyl (4,6-di-*tert*-butylpyrimidin-2-yl)carbamate (95 mg, 0.29 mmol) in THF (5 mL) under nitrogen atmosphere at 0 °C. The resulting reaction mixture was warmed to RT and stirred for 4 h. Upon completion, the reaction mixture was diluted with saturated NH₄Cl solution, extracted with EtOAc (2 x 50 mL) and the combined organic extract washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel (60-120 mesh) using 40% EtOAc-hexanes eluant to give N-((4,6-di-*tert*-butylpyrimidin-2-yl)carbamoyl)-1-isopropyl-1*H*-pyrazole-3-sulfonamide (38 mg, 25%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 13.75 (s, 1H), 10.71 (s, 1H), 8.01 (d, *J* = 2.4 Hz, 1H), 7.18 (s, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 4.61-4.54 (m, 1H), 1.38(d, *J* = 6.8 Hz, 6H), 1.31 (s, 18H). LCMS (*m/z*): 423.50 [M+H]⁺; 99.88% (210 nm). HPLC: 98.49% (210nm). HRMS calculated for C₁₉H₂₉N₆O₃S₁ [M-H]⁻ 421.2027, found 421.2008.


PHENYL/BICYCLICS

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide




4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and phenylsulfonamide were used in general method C1 to give the titled compound as a white solid (50 mg, 13%). ¹H NMR (400 MHz, CD₃OD): δ = 8.05 (d, *J* = 7.6 Hz, 2H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.63 (t, *J* = 7.6 Hz, 2H), 6.96 (s, 1H), 2.84 (t, *J* = 7.2 Hz, 4H), 2.59 (t, *J* = 7.2 Hz, 4H), 2.00 (quin, *J* = 7.2 Hz, 4H).

5-(Dimethylamino)-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)naphthalene-1-sulfonamide



A solution of 5-(dimethylamino)naphthalene-1-sulfonamide (20 mg, 0.08 mmol) in THF (5.0 mL) was treated with DIPEA (17 μ L, 0.09 mmol), stirred at ambient temperature for 15 min, then a solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) (19 mg, 0.09 mmol) in THF (1.0 mL) was added drop wise. The reaction mixture was stirred at ambient temperature overnight then concentrated *in vacuo*. The crude product was purified by HPLC to give the titled compound as a pale-yellow solid (24 mg, 66%). ^1H NMR (400 MHz, CD_3OD) δ = 8.62 (d, J = 8.4 Hz, 1H), 8.36 (dd, J = 9.5, 8.1 Hz, 2H), 7.67 – 7.56 (m, 2H), 7.26 (d, J = 7.8 Hz, 1H), 6.91 (s, 1H), 2.91 (s, 6H), 2.79 (t, J = 7.4 Hz, 4H), 2.40 (t, J = 7.4 Hz, 4H), 1.92 (quin, J = 7.4 Hz, 4H). ^{13}C NMR (101 MHz, CD_3OD) δ = 152.5, 150.3, 144.4, 138.3, 131.9, 131.7, 131.1, 130.3, 130.1, 129.9, 128.9, 127.2, 123.6, 119.4, 119.1, 118.9, 115.7, 78.4, 78.0, 77.7, 49.6, 48.3, 45.6, 33.4, 33.2, 30.5, 29.3, 25.9, 25.8; HRMS (ESI) calcd. for $\text{C}_{25}\text{H}_{27}\text{N}_3\text{O}_3\text{S}$ [$\text{M}+\text{H}$] 450.1846, found 450.1859.


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-2,3-dihydro benzo[*b*]thiophene-6-sulfonamide 1,1-dioxide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 2,3-dihydrobenzo[*b*]thiophene-6-sulfonamide 1,1-dioxide were


used in general method C2 to give the titled compound as a white solid (33 mg, 28%). ^1H NMR (600 MHz, DMSO- d_6): δ = 8.17 (bs, 1H), 8.15 (s, 1H), 8.13 (d, J = 9 Hz, 1H), 7.73 (d, J = 12 Hz, 1H), 6.89 (s, 1H), 3.68 (t, J = 9 Hz, 2H), 3.43 (t, J = 6 Hz, 2H), 2.75 (t, J = 6 Hz, 4H), 2.55 (t, J = 6 Hz, 4H), 1.93-1.88 (m, 4H). ^{13}C NMR (150 MHz, DMSO- d_6): δ = 151.6, 143.3, 143.0, 142.7, 139.6, 137.6, 137.5, 132.2, 128.9, 120.1, 117.9, 50.9, 32.9, 30.6, 25.6, 25.4 LCMS (m/z): 447 $[\text{M} + \text{H}]^+$

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-2-methoxybenzenesulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 2-methoxybenzenesulfonamide were used in general method C6 to give the titled compound as a white solid (30 mg, 48%). ^1H NMR (400 MHz, CD_3OD) δ 7.96 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 8.3 Hz, 1H), 7.14 – 7.05 (m, 2H), 6.97 (s, 1H), 4.00 (s, 3H), 2.83 (t, J = 7.3 Hz, 4H), 2.56 (t, J = 7.3 Hz, 4H), 2.09 – 1.90 (m, 4H). ^{13}C NMR (101 MHz, CD_3OD) δ 155.9, 143.2, 136.6, 134.7, 129.5, 127.2, 126.6, 125.9, 119.5, 118.0, 111.6, 111.2, 55.3, 31.9, 29.3, 24.5. HRMS (ESI) calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$ $[\text{M} + \text{H}]$ 387.1373, found 387.1378.


***N*-(1,2,3,5,6,7-Hexahydros-indacen-4-ylcarbamoyl)-3-(trifluoromethyl)benzenesulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general


method A1) and 3-(trifluoromethyl)benzenesulfonamide were used in general method C4 to give the titled compound as a white solid (0.015 g, 12%); Off white sticky. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.01 (bs, 1H), 8.34 (s, 1H), 8.25-8.23 (m, 2H), 8.11 (d, J = 7.6 Hz, 1H), 7.90 (t, J = 8.0 Hz, 1H), 6.93 (s, 1H), 2.77 (t, J = 7.2 Hz, 4H), 2.50 (m, 4H), 1.90 (quin, J = 7.6 Hz, 4H). LCMS, Purity: 96.69%, m/z 425.1 ($M+H^+$). HRMS (FAB $^+$) calcd for $C_{20}H_{19}F_3N_2O_3S$ [$M+H$] $^+$: 425.1068, found: 425.1009.

***N*-(1,2,3,5,6,7-hexahydros-indacen-4-ylcarbamoyl)-3-methoxybenzenesulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 3-methoxybenzenesulfonamide were used in general method C4 to give the titled compound as an off-white solid (0.025 g, 23%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.77 (bs, 1H), 8.15 (s, 1H), 7.56-7.45 (m, 3H), 7.27 (d, J = 8.0 Hz, 1H), 6.93 (s, 1H), 3.82 (s, 3H), 2.77 (t, J = 7.2 Hz, 4H), 2.53 (t, J = 7.6 Hz, 4H), 1.92 (quin, J = 7.2 Hz, 4H). LCMS, Purity: 95.02%, tr = 3.77 min, m/z 387.28 ($M+H^+$). HRMS (FAB $^+$) calcd for $C_{20}H_{22}N_2O_4S$ [$M+H$] $^+$: 387.1300, found: 387.1301.


***N*-(1,2,3,5,6,7-Hexahydros-indacen-4-ylcarbamoyl)-3-(trifluoromethoxy)benzenesulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general


method A1) and 3-(trifluoromethoxy)benzenesulfonamide were used in general method C4 to give the titled compound as an off-white solid (0.045 g, 43%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ = 8.04 (d, J = 8.0 Hz, 1H), 7.95 (s, 1H), 7.72 (t, J = 8.4 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 2.82 (t, J = 7.6 Hz, 4H), 2.59 (t, J = 7.6 Hz, 4H), 1.99 (quin, J = 7.6 Hz, 4H). ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$): δ = 149.2, 147.9, 143.1, 142.2, 137.3, 131.5, 128.5, 126.4, 125.9, 121.2, 119.7, 118.6, 118.1, 32.5, 29.4, 25.0. ^{19}F NMR (233.33 MHz, $\text{DMSO-}d_6$): -57.10 (s, 3F). LCMS, Purity: 95.56%, m/z 441.20 ($M+H^+$). HRMS (FAB^+) calcd for $\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_4\text{S}$ [$M+H$] $^+$: 441.1018, found: 441.1015.

3-(difluoromethoxy)-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)benzenesulfonamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 3-(difluoromethoxy)benzenesulfonamide were used in general method C5 to give the titled compound as an off-white solid (0.056 g, 50%). ^1H NMR (600 MHz, Acetonitrile- d_3) δ = 7.85 (d, J = 8.0 Hz, 1H), 7.75 (t, J = 2.1 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.53 (s, 1H), 7.43 (dd, J = 8.0, 2.1 Hz, 1H), 6.95 (s, 1H), 2.81 (t, J = 7.5 Hz, 4H), 2.55 (t, J = 7.5 Hz, 4H), 1.95 (quin, J = 7.5 Hz, 4H).

***N*¹-(1,2,3,5,6,7-Hexahydros-indacen-4-ylcarbamoyl)benzene-1,3-disulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and benzene-1,3-disulfonamide were used in general method C4 to give the titled compound as a white solid (0.080 g, 12%). ^1H NMR (400 MHz, DMSO- d_6): δ = 11.02 (bs, 1H), 8.36 (s, 1H), 8.24 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 8.0 Hz, 1H), 7.63 (s, 2H), 6.93 (s, 1H), 2.77 (t, J = 7.2 Hz, 4H), 2.54 (t, J = 7.6 Hz, 4H), 1.92 (quin, J = 7.2 Hz, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 149.0, 144.9, 143.1, 140.9, 137.3, 130.4, 130.2, 128.5, 124.4, 118.1, 32.4, 30.0, 25.0. LCMS, Purity: 98.63%, m/z 436.03 ($M+H^+$). HRMS (FAB $^+$) calcd for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_5\text{S}_2$ [$M+H$] $^+$: 436.0923, found: 436.0919.

N^1 -((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)- N^3,N^3 -dimethylbenzene-1,3-disulfonamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and N^1,N^1 -dimethylbenzene-1,3-disulfonamide were used in general method C1 to give the titled compound as a white solid (0.019 g, 5%). ^1H NMR (400 MHz, CD_3OD) δ 8.41 (t, J = 1.4 Hz, 1H), 8.32 (dt, J = 7.9, 1.4 Hz, 1H), 8.08 (dt, J = 7.9, 1.4 Hz, 1H), 7.87 (t, J = 7.9 Hz, 1H), 6.95 (s, 1H), 2.84 (t, J = 7.4 Hz, 4H), 2.73 (s, 6H), 2.61 (t, J = 7.4 Hz, 4H), 2.00 (p, J = 7.4 Hz, 4H).

3-(N -((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)benzoic acid



Methyl 3-(*N*-(1, 2, 3, 5, 6, 7-hexahydro-*s*-indacen-4-ylcarbamoyl)sulfamoyl)benzoate (0.25 g, 0.603 mmol) was dissolved in a mixture of tetrahydrofuran:methanol:water (9 mL, 1:1:1) and the mixture was cooled to 0 °C. Lithium hydroxide monohydrate (0.75 g, 1.81 mmol, 3 eq) was added and the mixture stirred at ambient temperature for 3h. Upon completion, the reaction mixture was poured into chilled water and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated *in vacuo*. The product was purified by reverse phase preparative HPLC to afford the titled compound as a white solid (0.017 g, 3%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 13.26 (bs, 1H), 8.43 (s, 1H), 8.13-8.08 (m, 2H), 7.99 (bs, 1H), 7.67 (t, *J* = 8.0 Hz, 1H), 6.87 (s, 1H), 6.52 (s, 1H), 2.75 (t, *J* = 7.2 Hz, 4H), 2.55 (t, *J* = 7.6 Hz, 4H), 1.89 (quin, *J* = 7.6 Hz, 4H). LCMS, Purity: 96%, *m/z* 400.98 (*M*+*H*⁺). HRMS (FAB⁺) calcd for C₂₀H₂₀N₂O₅S [*M*+*H*]⁺: 401.1093, found: 401.4514.


3-(*N*-(1, 2, 3, 5, 6, 7-Hexahydro-*s*-indacen-4-ylcarbamoyl)sulfamoyl)benzamide



3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)benzoic acid (0.06 g, 0.074 mmol) was dissolved in anhydrous *N,N*-dimethylformamide (4 mL) and the solution cooled to 0 °C. Diisopropylethylamine (3.0 eq) and HATU (2.0 eq) were added and the mixture stirred at 0 °C for 15 min. Ammonium chloride (3.0 eq) was added and the mixture stirred at ambient temperature for 5 h. Upon completion the reaction mixture was poured into brine (20 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The

crude residue was purified by reverse phase preparative HPLC to afford the titled compound as a white solid (0.011 g, 37%). ^1H NMR (400 MHz, DMSO- d_6): δ = 8.23 (d, J = 9.2 Hz, 2H), 8.02 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.33 (s, 1H), 6.74 (s, 1H), 2.73 (t, J = 6.8 Hz, 4H), 2.62 (t, J = 6.8 Hz, 4H), 1.87 (quin, J = 7.6 Hz, 4H). LCMS, Purity: 93%, m/z 400.05 ($M+H^+$). HRMS (FAB $^+$) calcd for $C_{20}H_{21}N_3O_4S$ [$M+H$] $^+$: 400.1253, found: 400.1378.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) was added directly to methyl 3-sulfamoylbenzoate (0.447 g, 2.07 mmol, 1.20 equiv) at ambient temperature and the mixture was stirred overnight. The reaction mixture was poured into chilled water and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated *in vacuo*. The residue obtained was purified by column chromatography on silica gel using 0-10% gradient of methanol in dichloromethane to give methyl 3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)benzoate as a light-brown solid (0.36 g, 50%).

Methyl 3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)benzoate (0.06 g, 0.144 mmol) was dissolved in anhydrous THF and the solution cooled to 0 °C. Methyl magnesium bromide (3 M solution in diethyl ether, 0.14 mL, 0.42 mmol, 3.0 eq) was added and the mixture stirred at ambient temperature for 4 h. Upon completion, saturated aqueous ammonium chloride was added to the reaction mixture and extracted


with ethyl acetate. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated *in vacuo*. Purification of the crude residue by reverse phase preparative HPLC gave the titled compound as an off-white solid (0.015 g, 25%). ^1H NMR (400 MHz, DMSO-d_6): δ = 8.16 (s, 1H), 7.91 (s, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.59-7.48 (m, 2H), 7.32 (t, J = 7.6 Hz, 1H), 6.78 (s, 1H), 5.10 (s, 1H), 2.74 (t, J = 7.2 Hz, 4H), 2.60 (t, J = 6.8 Hz, 4H), 1.88 (quin, J = 7.6 Hz, 4H), 1.42 (s, 6H). LCMS, Purity: 91 %, m/z 415.05 ($\text{M}+\text{H}^+$).

3-Azido-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)benzenesulfonamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 3-azidobenzenesulfonamide were used in general method C6 to give the titled compound as an off white solid (70 mg, 50%). ^1H NMR (600 MHz, DMSO-d_6) δ = 8.22 (s, 1H), 7.72 (m, J = 5.2 Hz, H), 7.65 (t, J = 8.0 Hz, 1H), 7.59 (s, 1H), 7.46 – 7.42 (m, 1H), 6.93 (s, 1H), 2.77 (t, J = 7.4 Hz, 4H), 2.53 (t, J = 7.4 Hz, 4H), 1.92 (m, 4H). ^{13}C NMR (101 MHz, CD_3OD) δ 151.2, 144.9, 144.6, 142.9, 142.5, 138.9, 131.5, 131.4, 128.6, 124.9, 124.6, 124.6, 119.8, 119.2, 118.9, 111.9, 33.7, 33.6, 31.1, 29.7, 26.3. HRMS (ESI) calcd. for $\text{C}_{19}\text{H}_{20}\text{N}_5\text{O}_3\text{S}$ [$\text{M}+\text{H}$] 398.1281, found 398.1272.

***N*-((1,2,3,5,6,7-Hexahydro-*s*-indacen-4-yl)carbamoyl)-3-(4-phenyl-1*H*-1,2,3-triazol-1-yl) benzenesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 3-(4-phenyl-1*H*-1,2,3-triazol-1-yl)benzenesulfonamide were used in general method C6 to give the titled compound as a pale yellow solid (10 mg, 49%). ¹H NMR (400 MHz, CD₃OD) δ = 8.89 (s, 1H), 8.55 (s, 1H), 8.21 (d, *J* = 8.2 Hz, 1H), 8.13 (d, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 7.6 Hz, 2H), 7.79 (t, *J* = 8.0 Hz, 1H), 7.68 (s, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.39 (t, *J* = 7.4 Hz, 1H), 6.92 (s, 1H), 2.82 (t, *J* = 7.4 Hz, 4H), 2.70 – 2.63 (m, 4H), 1.98 (m, 4H). ¹³C NMR (151 MHz, CD₃OD) δ = 148.8, 143.9, 143.6, 137.7, 137.2, 137.0, 130.6, 130.3, 129.7, 129.6, 128.8, 128.5, 127.6, 127.4, 126.7, 125.6, 124.5, 124.0, 119.3, 118.7, 110.8, 32.7, 32.6, 30.2, 28.7, 25.3. HRMS (ESI) calcd. for C₂₇H₂₆N₅O₃S [M+H] 500.1751, found 500.1735.

***N*-(3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)pent-4-ynamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and *N*-(3-sulfamoylphenyl)pent-4-ynamide were used in general method C6 to give the titled compound as a white solid (116 mg, 61%). ¹H NMR (400 MHz, CD₃OD) δ = 8.18 (s, 1H), 7.81 (d, *J* = 8.3 Hz, 1H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.43 (dd, *J* = 8.3, 7.8 Hz, 1H), 6.87 (s, 1H), 2.79 (t, *J* = 7.2 Hz, 4H), 2.67 – 2.60 (m, 4H), 2.60 – 2.48 (m, 4H), 2.28 – 2.22 (m, 1H), 2.04 – 1.89 (m, 4H). ¹³C NMR (101 MHz, CD₃OD) δ = 170.9, 143.3, 143.0, 138.8, 137.7, 128.7, 128.3, 126.4, 122.8, 122.0, 117.9, 117.7, 82.0, 68.9, 35.4, 32.4, 29.9, 25.1, 13.9. HRMS (ESI) calcd. for C₂₄H₂₆N₃O₄S [M+H] 452.1639, found 452.1658.

3-(1-(3-aminopropyl)-1*H*-1,2,3-triazol-4-yl)-*N*-(3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)propanamide



N-(3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)pent-4-ynamide and 3-azidopropan-1-amine were used in general method F to give the titled compound as a white solid (6 mg, 43%). ^1H NMR (600 MHz, CD_3OD) δ = 7.85 (s, 1H), 7.55 (t, J = 3.8 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.29 (t, J = 7.9 Hz, 1H), 6.78 (s, 1H), 4.26 (t, J = 6.4 Hz, 2H), 3.00 (t, J = 6.6 Hz, 2H), 2.71 (t, J = 7.3 Hz, 4H), 2.64 – 2.50 (m, 8H), 1.94-2.02 (m, 2H), 1.92 – 1.83 (m, 4H). ^{13}C NMR (151 MHz, CD_3OD) δ = 173.0, 147.4, 146.8, 144.7, 144.6, 139.5, 139.2, 131.6, 130.0, 129.8, 124.2, 123.9, 123.2, 119.5, 118.6, 48.3, 37.7, 34.0, 31.6, 26.7, 26.6, 22.9. HRMS (ESI) calcd. for $\text{C}_{27}\text{H}_{34}\text{N}_7\text{O}_4\text{S}$ $[\text{M}+\text{H}]$ 552.2387, found 552.2368.

***N*-(3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)-3-(1-(3-((7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)propyl)-1H-1,2,3-triazol-4-yl)propanamide**




N-(2-Azidopropyl)-7-nitrobenzo[*c*][1,2,5]oxadiazol-4-amine was synthesized by the methods contained in Chun Li, Etienne Henry, Naresh Kumar Mani, Jie Tang, Jean-Claude Brochon, Eric Deprez, and Juan Xie *Eur. J. Org. Chem.* **2010**, 2395–2405. To a solution of 4-chloro-7-nitrobenzo[*c*][1,2,5]oxadiazole (300 mg, 1.5 mmol) in THF (10 mL) was added 3-azidopropyl amine (160 mg, 1.65 mmol) and Cs_2CO_3 (480 mg, 1.5 mmol). The reaction mixture was stirred

at 50 °C for 4 h. The reaction mixture was partitioned between EtOAc (50 mL) concentrated *in vacuo*. The residue was purified by column chromatography on silica gel using 30% EtOAc-petroleum ether eluent to afford *N*-(2-Azidopropyl)-7-nitrobenzo[*c*][1,2,5]oxadiazol-4-amine (240 mg, 76%). ¹H NMR (400 MHz, CDCl₃): δ = 8.50 (d, *J* = 8.8 Hz, 1 H), 6.57 (s, 1 H, NH), 6.23 (d, *J* = 8.8 Hz, 1 H), 3.66 (q, *J* = 6.8 Hz, 2 H), 3.59 (*J* = 6.0 Hz, 2 H), 2.00-2.16 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 144.2, 144.0, 143.8, 136.7, 123.7, 98.8, 49.1, 41.6, 27.6. HRMS (ESI): calcd. for C₉H₁₀N₇O₃ 264.0840; found 264.0711.

N-(3-(*N*-((1,2,3,5,6,7-Hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)pent-4-ynamide (10 mg, 0.022 mmol) and *N*-(2-azidopropyl)-7-nitrobenzo[*c*][1,2,5]oxadiazol-4-amine (7.0 mg, 0.026 mmol), 10 mol% THPTA, 5 mol% CuSO₄, 10 mol% sodium ascorbate in DMSO (500 uL) were stirred at room temperature for 12 h. The reaction mixture was subjected to purification using reverse phase (Reveleris flash column chromatography, 4 g, 18 mL/min., mobile phase; 10 mmol aqu. NH₄CO₃, MeCN) and freeze dried to give the product as a white solid (7.0 mg, 44 %). ¹H NMR (600 MHz, CD₃OD) δ = 8.46 (d, *J* = 8.7 Hz, 1H), 8.18 (s, 1H), 7.79 (d, *J* = 8.4 Hz, 1H), 7.67 (d, *J* = 7.9 Hz, 1H), 7.61 (s, 1H), 6.94 (s, 1H), 6.15 (d, *J* = 9.0 Hz, 1H), 4.46 (t, *J* = 6.7 Hz, 2H), 3.09 (t, *J* = 7.0 Hz, 2H), 2.82 (t, *J* = 7.4 Hz, 4H), 2.77 (t, *J* = 7.0 Hz, 2H), 2.70 – 2.56 (m, 6H), 2.37 – 2.26 (m, 2H), 1.99 (q, *J* = 7.3 Hz, 4H). ¹³C NMR (151 MHz, CD₃OD) δ = 172.9, 147.9, 145.4, 140.5, 139.0, 138.4, 130.6, 129.1, 128.0, 125.6, 124.2, 123.6, 120.3, 119.6, 112.4, 70.6, 48.9, 37.2, 34.3, 34.2, 31.7, 30.2, 26.8, 22.3; HRMS (ESI) calcd. for C₃₃H₃₄N₁₀O₇S [M-H] 713.2260, found 713.2290.

***N*-(3-(4-(3-((3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl) amino)-3-oxopropyl)-1*H*-1,2,3-triazol-1-yl)propyl)-5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide**




To a solution of biotin (0.4 g, 1.63 mmol) and 3-azidopropylamine (0.2 g, 1.96 mmol) in dry DMF (10.0 ml) was added HBTU (0.93 g, 2.45 mmol) followed by DIPEA (428 μ L, 2.45 mmol). The reaction mixture was stirred at RT for 12 h. The reaction was monitored by LCMS and after the completion of reaction, it was diluted with EtOAc (50 mL) washed with H₂O (25 mL), brine (25 mL). The organic layer was separated; dried (MgSO₄) and evaporated to give the crude product. The crude product was purified by column chromatography on silica gel using 50% EtOAc-Hexane eluent to isolate *N*-(3-azidopropyl)-5-((3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide as a white solid (0.13 g, 24%). ¹H NMR (400 MHz, CD₃OD) δ = 4.52 (dd, *J* = 7.9, 5.0 Hz, 1H), 4.32 (dd, *J* = 7.9, 4.5 Hz, 1H), 3.36 (t, *J* = 6.7 Hz, 2H), 3.28 (d, *J* = 6.8 Hz, 2H), 3.21 – 3.14 (m, 1H), 2.93 (dd, *J* = 12.8, 5.0 Hz, 1H), 2.75 (d, *J* = 12.8 Hz, 1H), 2.20 (t, *J* = 7.3 Hz, 2H), 1.78 (q, *J* = 6.8 Hz, 2H), 1.74 – 1.57 (m, 4H), 1.45 (q, *J* = 7.5 Hz, 2H). ¹³C NMR (101 MHz, CD₃OD) δ = 173.5, 163.4, 61.0, 59.3, 54.7, 48.2, 39.4, 35.8, 34.8, 27.7, 27.5, 27.2, 24.6.

N-(3-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)pent-4-ynamide (1.0 mmol) and *N*-(3-azidopropyl)-5-((3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide (2.0 mmol), 10 mol% THPTA, 5 mol% CuSO₄, 10 mol% sodium ascorbate in DMSO were stirred at room temperature for 12 h. The reaction mixture was purified using reverse phase column chromatography to give the titled compound as a white solid (8.0 mg, 31%); ¹H NMR (600 MHz, CD₃OD) δ

= 8.26 (s, 1H), 7.83 – 7.68 (m, 3H), 7.50 – 7.43 (m, 1H), 6.92 (s, 1H), 4.48 (dd, $J = 8.0, 4.8$ Hz, 1H), 4.41 – 4.22 (m, 3H), 3.18 (dd, $J = 6.9, 3.5$ Hz, 1H), 3.14 (td, $J = 6.7, 1.7$ Hz, 2H), 3.12 – 3.06 (m, 2H), 2.90 (dd, $J = 12.8, 4.9$ Hz, 1H), 2.81 (t, $J = 7.7$ Hz, 4H), 2.77 (d, $J = 7.1$ Hz, 1H), 2.71 (s, 1H), 2.62 (t, $J = 7.3$ Hz, 4H), 2.19 (td, $J = 7.4, 1.7$ Hz, 2H), 2.05 – 2.01 (m, 2H), 2.00 – 1.95 (m, 4H), 1.76 – 1.57 (m, 4H), 1.43 (q, $J = 7.6, 7.1$ Hz, 2H). ^{13}C NMR (151 MHz, CD_3OD) $\delta = 174.8, 174.8, 171.6, 171.5, 164.5, 146.2, 143.6, 139.1, 137.7, 129.1, 129.1, 128.7, 128.1, 126.5, 123.7, 122.9, 122.4, 122.2, 120.9, 118.4, 118.4, 118.3, 118.2, 118.2, 117.2, 110.5, 69.0, 61.9, 60.2, 55.6, 39.8, 36.1, 36.0, 35.8, 35.4, 35.4, 32.6, 32.6, 30.0, 29.7, 29.7, 28.6, 28.3, 28.0, 25.3, 25.2, 25.2, 20.9$. HRMS (ESI) calcd. for $\text{C}_{37}\text{H}_{48}\text{N}_9\text{O}_6\text{S}_2$ $[\text{M}+\text{H}]$ 778.3163, found 778.3145.

***N*-((1-(3-(*N*((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide**




5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)-*N*-((1-(3-sulfamoylphenyl)-1*H*-1,2,3-triazol-4-yl)methyl)pentanamide was synthesized using 5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)-*N*-(prop-2-yn-1-yl)pentanamide (1.0 mmol) and 3-azidobenzenesulfonamide (2.0 mmol), 10 mol% THPTA, 5 mol% CuSO_4 , 10 mol% NaAsc in DMSO were stirred at room temperature for 12 h. The formation of product was observed in LCMS. After completion of the reaction, the reaction mixture was subjected to HPLC purification (Reveleris flash column chromatography, 4 g, 18 mL/min., mobile phase; 10 mmol aq. NH_4CO_3 , MeCN) to isolate 5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)-*N*-((1-(3-sulfamoylphenyl)-1*H*-

1,2,3-triazol-4-yl)methyl)pentanamid as a white solid (24 mg, 47%) which was used directly.

To a solution of 5-((3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)-*N*-((1-(3-sulfamoylphenyl)-1*H*-1,2,3-triazol-4-yl)methyl)pentanamide (15 mg, 0.031 mmol) in THF (5.0 mL) under a nitrogen atmosphere was added DIPEA (605 μ L, 0.037 mmol). This mixture was stirred at room temperature for 15 min. A solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) (705 mg, 0.037 mmol) in THF was added drop-wise. The reaction mixture was stirred at room temperature overnight then the solvent was removed *in vacuo* to give crude compound which was purified by reversed phase column chromatography using 10 mM aq. (NH₄)₂CO₃ and MeCN mobile phase to isolate the titled compound as a white solid (5.2 mg, 24%). ¹H NMR (600 MHz, CD₃OD) δ = 8.53 (d, *J* = 2.4 Hz, 1H), 8.50 (d, *J* = 7.5 Hz, 1H), 8.22 – 8.11 (m, 2H), 7.86 – 7.78 (m, 1H), 6.99 (s, 1H), 4.62 (s, 2H), 4.57 – 4.49 (m, 1H), 4.38 – 4.31 (m, 1H), 3.27 – 3.20 (m, 1H), 3.00 – 2.84 (m, 4H), 2.78 – 2.70 (m, 4H), 2.36 (t, *J* = 7.2 Hz, 2H), 2.06 (q, *J* = 7.4 Hz, 4H), 1.83 – 1.73 (m, 3H), 1.71 – 1.63 (m, 1H), 1.54 – 1.43 (m, 3H). ¹³C NMR (151 MHz, CD₃OD) δ = 174.6, 164.5, 146.1, 145.4, 143.6, 137.7, 137.2, 130.5, 125.9, 123.4, 121.1, 117.8, 110.6, 61.8, 60.2, 55.5, 47.7, 47.6, 39.8, 3.2, 34.3, 32.6, 30.14, 28.2, 27.9, 25.3, 25.2. HRMS (ESI) calcd. for C₃₂H₃₉N₈O₅S₂ [M+H] 679.2479, found 679.2456.

***N*-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonamide**




Phenyl chloroformate (1 eq) was added to a solution of quinolin-6-amine (0.1 g, 0.69 mmol) in THF (50 mL) and triethylamine (1.5 eq.) to 0 °C. The solution was

diluted using water, extracted using ethyl acetate (x2), washed with water, brine then dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was triturated with pentane to give phenyl quinolin-6-ylcarbamate as an off-white solid which was used directly in the next reaction step.

3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide (0.185 g, 0.69 mmol) in THF (30 mL) at 0 °C was treated portion-wise with sodium hydride (3 eq.) and the suspension stirred for 30 minutes (until effervescence ceased). The crude phenyl quinolin-6-ylcarbamate was dissolved in THF (20 mL) then added slowly to the reaction and stirring continued at ambient temperature until completion, typically 2 h. The reaction was quenched with sat.aq. NH_4Cl , extracted with ethyl acetate (x2), washed with water (100 mL), brine (100 mL), dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was triturated using diethyl ether then pentane to give the titled compound, *N*-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide as a white solid (10 mg, 3%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.88 (s, 1H), 8.59 (d, J = 3.5 Hz, 1H), 8.11 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.70 – 7.60 (m, 2H), 7.56 (t, J = 7.8 Hz, 1H), 7.34 (dd, J = 8.3, 4.2 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H). ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -64.49.


***N*-(quinolin-5-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide**



N-(quinolin-5-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide was synthesised using modification of the procedures used to make *N*-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide but using quinolin-5-amine in place of quinolin-6-amine.


The titled compound was obtained as an off-white solid (10 mg, 3%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 8.79 (d, J = 4.1 Hz, 1H), 8.61 (s, 1H), 8.57 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 7.2 Hz, 1H), 7.70 (s, 1H), 7.59 – 7.50 (m, 2H), 7.40 (dd, J = 8.7, 4.1 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H). ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -64.51.

***N*-((6-methoxyquinolin-8-yl)carbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide**



N-((6-methoxyquinolin-8-yl)carbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide was synthesised using modification of the procedures used to make *N*-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide but using 6-methoxyquinolin-8-amine in place of quinolin-6-amine. The titled compound was obtained as an off-white solid (35 mg, 20%). ^1H NMR (400 MHz, CD_3OD) δ 8.64 (dd, J = 4.2, 1.6 Hz, 1H), 8.18 – 8.02 (m, 3H), 7.88 (s, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.50 – 7.36 (m, 2H), 6.79 (d, J = 2.6 Hz, 1H), 3.88 (s, 3H). ^{19}F NMR (376 MHz, CD_3OD) δ -67.04.


***N*-(quinolin-8-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide**



N-(Quinolin-8-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide was synthesised using modification of the procedures


used to make *N*-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonamide but using quinolin-8-amine in place of quinolin-6-amine. The titled compound was obtained as a white solid (20 mg, 16%). ¹H NMR (400 MHz, CD₃OD) δ = 8.82 (dd, *J* = 4.3, 1.6 Hz, 1H), 8.35 (dd, *J* = 7.4, 1.8 Hz, 1H), 8.21 (dd, *J* = 8.3, 1.7 Hz, 1H), 8.12 (d, *J* = 7.9 Hz, 1H), 7.88 (s, 1H), 7.59 (t, *J* = 7.9 Hz, 1H), 7.52 – 7.38 (m, 4H).

***N*-((2,3,6,7-tetrahydrobenzo[1,2-*b*:4,5-*b'*]difuran-4-yl)carbamoyl)-3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonamide**



4-isocyanato-2,3,6,7-tetrahydrobenzo[1,2-*b*:4,5-*b'*]difuran (prepared using general method A1) and 3-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzenesulfonamide were used in general method C1 to give the titled compound as a white solid (0.01 g, 2%). ¹H NMR (400 MHz, CD₃OD) δ = 8.06 (dt, *J* = 7.9, 1.3 Hz, 1H), 7.80 (s, 1H), 7.57 (t, *J* = 7.9 Hz, 1H), 7.44 (d, *J* = 7.9 Hz, 1H), 6.39 (s, 1H), 4.49 (t, *J* = 8.6 Hz, 2H), 4.42 (t, *J* = 8.6 Hz, 2H), 3.09 (t, *J* = 8.4 Hz, 2H), 3.02 (t, *J* = 8.6 Hz, 2H). ¹⁹F NMR (376 MHz, CD₃OD) δ -67.06.


4-chloro-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)benzenesulfonamide



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 4-chlorobenzenesulfonamide were used in general method C2 to give the titled compound as a white solid (48 mg, 43%). ¹H NMR (400 MHz,


DMSO- d_6): δ = 8.13 (s, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.68 (d, J = 12 Hz, 2H), 6.92 (s, 1H), 2.77 (t, J = 8.0 Hz, 4H), 2.54 (t, J = 8.0 Hz, 4H), 1.95-1.88 (m, 4H); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 150.1, 143.4, 139.9, 138.1, 137.6, 129.6, 129.4, 129.2, 32.8, 30.5, 25.9; LCMS purity: >95%; LCMS (m/z): 391 [$M + H$] $^+$; HRMS calculated for $\text{C}_{19}\text{H}_{19}\text{ClN}_2\text{O}_3\text{S}$ [$M + H$] $^+$: 391.0878, found: 391.0895.

***N*-(1,2,3,5,6,7-hexahydro-*s*-indacen-4-ylcarbamoyl)-4-methylbenzenesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 4-methylbenzenesulfonamide were used in general method C4 to give the titled compound as a white solid (0.045 g, 27%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.70 (br.s, 1H), 8.08 (s, 1H), 7.82 (d, J = 8 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 6.92 (s, 1H), 2.79-2.68 (m, 4H), 2.58-2.50 (m, 4H), 2.39 (s, 3H), 1.97-1.87 (m, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 149.0, 143.6, 143.0, 137.1, 129.4, 128.6, 127.3, 117.9, 32.4, 30.0, 25.0, 21.0. LCMS, Purity: 95.08%, m/z 371.07 ($M + H^+$). HRMS (FAB $^+$) calcd for $\text{C}_{20}\text{H}_{22}\text{N}_2\text{O}_3\text{S}$ [$M + H$] $^+$: 371.1351, found: 371.1419.

5-Chloro-*N*-(4-(*N*-(1,2,3,5,6,7-hexahydro-*s*-indacen-4-ylcarbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 5-chloro-2-methoxy-N-(4-sulfamoylphenethyl)benzamide were used in general method C4 to give the titled compound as a white solid (45 mg, 10%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.73 (s, 1H), 8.27 (t, J = 5.2 Hz, 1H), 8.09 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 2.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 2.4 Hz, 1H), 7.13 (d, J = 9.2 Hz, 1H), 6.92 (s, 1H), 3.78 (s, 3H), 3.54 (q, J = 6.4 Hz, 2H), 2.94 (t, J = 6.8 Hz, 2H), 2.75 (t, J = 7.2 Hz, 4H), 2.50 (m, 4H), 1.89 (quin, J = 7.6 Hz, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 163.6, 155.7, 145.3, 143.6, 143.0, 142.4, 142.1, 139.6, 137.1, 131.5, 129.5, 129.2, 127.4, 125.7, 124.8, 124.3, 117.9, 114.1, 108.3, 56.2, 34.7, 32.6, 32.4, 30.0, 28.9, 24.9. LCMS, Purity: 90.06%, t_r = 3.38 min, m/z 566.37 ($M-H^+$). HRMS (FAB $^+$) calcd for $\text{C}_{29}\text{H}_{30}\text{ClN}_3\text{O}_5\text{S}$ [$M+H$] $^+$: 568.1595, found: 568.1589.

***N*-(4-(*N*-(1,2,3,5,6,7-Hexahydros-indacen-4-ylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 5-methyl-N-(4-sulfamoylphenethyl)pyrazine-2-carboxamide were used in general method C4 to give the titled compound as an off-white solid (0.02 g, 4%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.71 (s, 1H), 9.02 (s, 1H), 8.96 (t, J = 6 Hz, 1H), 8.59 (s, 1H), 8.07 (s, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 6.92 (s, 1H), 3.57 (q, J = 6.8 Hz, 2H), 2.97 (t, J = 7.4 Hz, 2H), 2.82-2.73 (m, 4H), 2.53 (s, 3H), 2.57-2.50 (m, 4H), 1.97-1.84 (m, 4H). LCMS, Purity: 88.15%, m/z 520.28 ($M+H^+$). HRMS (FAB $^+$) calcd for $\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_4\text{S}$ [$M+H$] $^+$: 520.1940, found: 520.1977.

3-(4-(*N*-(1,2,3,5,6,7-Hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)-*N*-(prop-2-yn-1-yl)propanamide



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and *N*-(prop-2-yn-1-yl)-3-(4-sulfamoylphenyl)propanamide were used in general method C6 to give the titled compound as a white solid (120 mg, 68%). ^1H NMR (400 MHz, CD_3OD) δ = 7.91 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 6.98 (s, 1H), 3.95 (d, J = 2.9 Hz, 2H), 3.03 (t, J = 7.7 Hz, 2H), 2.85 (t, J = 7.4 Hz, 4H), 2.62 (t, J = 6.9 Hz, 4H), 2.55 – 2.46 (m, 2H), 2.25 (t, J = 2.6 Hz, 1H), 2.02 (m, 4H). ^{13}C NMR (101 MHz, CD_3OD) δ = 172.0, 147.2, 144.1, 143.8, 137.5, 129.0, 128.8, 128.1, 127.4, 126.5, 118.9, 79.2, 71.0, 36.8, 32.8, 32.8, 31.2, 30.7, 28.8, 28.7, 25.4, 25.3. HRMS (ESI) calcd. for $\text{C}_{25}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$ $[\text{M}+\text{H}]$ 466.1795, found 466.1794.


***N*-(4-(*N*-(1,2,3,5,6,7-Hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)-2-(methyl(7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)acetamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 2-(methyl(7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)-*N*-(4-sulfamoylphenethyl)acetamide were used in general method C4 to give the


titled compound as an orange solid (0.003 g, 1%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.74 (s, 1H), 8.51 (d, J = 8.8 Hz, 1H), 8.31 (t, J = 7.6 Hz, 1H), 8.09-7.96 (m, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 7.6 Hz, 2H), 6.89 (s, 1H), 6.42-6.32 (m, 1H), 4.74 (bs, 2H), 3.44-3.30 (m, 5H), 2.80 (t, J = 7.6 Hz, 2H), 2.73-2.69 (m, 4H), 2.61-2.50 (m, 4H), 1.92-1.88 (m, 4H). LCMS, Purity: 92.20%, m/z 632.35 ($M-H^+$).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-((7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)ethyl)benzenesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 4-(2-((7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino)ethyl)benzenesulfonamide were used in general method C4 to give the titled compound as a yellow solid (0.047 g, 15%). ^1H NMR (400 MHz, DMSO- d_6): δ = 10.69 (bs, 1H), 9.55 (s, 1H), 8.50 (d, J = 8.8 Hz, 1H), 8.09 (s, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 6.92 (s, 1H), 6.50 (d, J = 8.8 Hz, 1H), 3.76 (bs, 2H), 3.11 (t, J = 6.8 Hz, 2H), 2.76 (t, J = 7.6 Hz, 4H), 2.53 (t, J = 6.8 Hz, 4H), 1.90 (quin, J = 7.6 Hz, 4H). ^{13}C NMR (100 MHz, DMSO- d_6): δ = 149.1, 144.8, 144.3, 142.4, 138.3, 137.8, 137.1, 129.3, 128.6, 127.3, 125.7, 121.0, 117.9, 108.3, 99.5, 44.1, 33.2, 32.5, 30.1, 28.9, 25.0. LCMS, Purity: 96.50%, tr = 2.29 min, m/z 563.20 ($M+H^+$). HRMS (FAB $^+$) calcd for $\text{C}_{27}\text{H}_{26}\text{N}_6\text{O}_6\text{S}$ [$M+H$] $^+$: 563.1635, found: 563.1641.

2-(7-(Dimethylamino)-2-oxo-2*H*-chromen-4-yl)-*N*-(4-(*N*-(1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)acetamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A1) and 2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)-N-(4-sulfamoylphenethyl)acetamide were used in general method C4 to give the titled compound as a pale-yellow solid (0.008 g, 0.44%). ^1H NMR (400 MHz, DMSO- d_6): δ = 9.53 (s, 1H), 8.29 (t, J = 4.8 Hz, 1H), 8.22 (s, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H), 7.16 (d, J = 8.0 Hz, 2H), 6.74-6.70 (m, 2H), 6.54 (d J = 2.4 Hz, 1H), 5.99 (s, 1H), 3.56-3.52 (m, 2H), 3.48 (t, J = 6.0 Hz, 2H), 3.31-3.24 (m, 2H), 2.76-2.70 (m, 4H), 3.02 (s, 6H), 2.63 (t, J = 7.2 Hz, 4H), 1.88 (quin, J = 7.6 Hz, 4H). LCMS, Purity: 92.26%, m/z 629.40 (MH^+).

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzo[*d*][1,3]dioxole-5-sulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and benzo[*d*][1,3]dioxole-5-sulfonamide were used in general method C2 to give the titled compound as a white solid (28 mg, 27%). ^1H NMR (400 MHz, DMSO- d_6): δ = 8.04 (br.s., 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.09 (d, J = 4.0 Hz, 1H), 6.91 (s, 1H), 6.16 (s, 2H) 2.77 (t, J = 8.0 Hz, 4H), 2.56 (t, J = 8.0 Hz, 4H), 1.96-1.89 (m, 4H); LCMS Purity: >95%; LCMS (m/z): 401 [$\text{M} + \text{H}$] $^+$; HRMS calculated for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_5\text{S}$ [$\text{M} + \text{H}$] $^+$ 401.1166, found 401.1182.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonamide**




1,2,3,5,6,7-Hexahydro-*s*-indacen-4-amine (70 mg, 0.40 mmol) was dissolved in anhydrous THF (5 mL) and treated with Et₃N (49 mg, 0.49 mmol) at RT. The solution was treated with triphosgene (48 mg, 0.161 mmol) and resulting mixture was stirred at 70 °C for 2 h. The reaction mixture was concentrated *in vacuo*. The residue obtained was stirred with 5% EtOAc-hexanes (20 mL) for 10 min, filtered through a celite pad and concentrated *in vacuo* to give the corresponding isocyanate as a white solid. In a separate flask, 6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonamide (115 mg, 0.61 mmol) was dissolved in anhydrous THF (5 mL) and treated carefully with NaH (25 mg, 0.61 mmol) at 0 °C under nitrogen atmosphere and stirred for 20 minutes. The aforementioned isocyanate in THF was added to reaction mixture under nitrogen atmosphere. The reaction mixture was warmed to RT, stirred for 4 h then concentrated *in vacuo*. The residue obtained was diluted with 10 mM ammonium bicarbonate in water (20 mL), acetonitrile (20 mL), ethyl acetate (10 mL) and solid formed was removed by filtration and washed with diethyl ether to give *N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazole-2-sulfonamide (50 mg, 32%) as a white solid. ¹H NMR (400 MHz, CD₃OD): δ = 7.29 (s, 1H), 6.85 (s, 1H), 4.23(t, *J* = 7.2 Hz, 1H), 2.86-2.79 (m, 6H), 2.72 (t, *J* = 7.2 Hz, 4H), 2.65-2.60 (m, 2H), 2.02-1.95 (m, 4H). LCMS (*m/z*): 387.10 [M+H]⁺; 95.53% (210 nm). HPLC: 94.43% (210nm). HRMS calculated for C₁₉H₂₁N₄O₃S₁ [M-H]⁻ 385.1340, found 385.1331.

4-Acetyl-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-

yl)carbamoyl)benzenesulfonamide


4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4-acetylbenzenesulfonamide were used in general method C2 to give the titled compound as a white solid (31 mg, 16%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 11.03 (bs, 1H), 8.08 (d, J = 8.5 Hz, 2H), 7.99 (d, J = 8.5 Hz, 2H), 7.03 (bs, 1H), 6.87 (s, 1H), 2.75 (t, J = 7.4 Hz, 4H), 2.62 (s, 3H), 2.56 (t, J = 7.4 Hz, 4H), 1.90 (p, J = 7.4 Hz, 4H). HRMS calculated for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_4\text{S}_1$ $[\text{M}-\text{H}]^-$ 397.1128, found 397.1225.

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-nitrobenzenesulfonamide**




4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4-nitrobenzenesulfonamide were used in general method C2 to give the titled compound as a pale yellow solid (148 mg, 60%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 10.00 (bs, 1H), 8.21 (d, J = 9.0 Hz, 2H), 7.97 (d, J = 9.0 Hz, 2H), 7.45 (s, 1H), 6.75 (s, 1H), 2.73 (t, J = 7.4 Hz, 4H), 2.61 (t, J = 7.4 Hz, 4H), 1.87 (p, J = 7.4 Hz, 4H). HRMS calculated for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}_5\text{S}_1$ $[\text{M}-\text{H}]^-$ 400.0973, found 400.0979.

4-Amino-*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)benzenesulfonamide



N-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-nitrobenzenesulfonamide dissolved in a solution of ethyl acetate/ DMF (4:1, 25 mL/mmol) was stirred at room temperature for 1 h under hydrogen atmosphere with a catalytic amount of Pd/C (0.1 mol%) to afford the titled compound as a white solid (16 mg, 43%). ^1H NMR (600 MHz, DMSO- d_6) δ = 7.95 (s, 1H), 7.54 (d, J = 8.8 Hz, 2H), 6.91 (s, 1H), 6.59 (d, J = 8.8 Hz, 2H), 6.05 (s, 2H), 2.77 (t, J = 7.4 Hz, 4H), 2.55 (t, J = 7.4 Hz, 4H), 1.93 (q, J = 7.4 Hz, 4H). HRMS calculated for $\text{C}_{19}\text{H}_{20}\text{N}_3\text{O}_3\text{S}_1$ $[\text{M}-\text{H}]^-$ 370.1231, found 370.1225.


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-2,3-dihydro-1*H*-indene-5-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 2,3-dihydro-1*H*-indene-5-sulfonamide were used in general method C2 to give the titled compound as a white solid (48 mg, 12%). ^1H NMR (600 MHz, DMSO- d_6) δ = 10.68 (bs, 1H), 8.02 (s, 1H), 7.75 (d, J = 1.7 Hz, 1H), 7.68 (dd, J = 7.9, 1.7 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 6.90 (s, 1H),


2.91 (t, $J = 7.5$ Hz, 4H), 2.76 (t, $J = 7.4$ Hz, 4H), 2.53 (t, $J = 7.4$ Hz, 4H), 2.05 (p, $J = 7.5$ Hz, 2H), 1.91 (p, $J = 7.4$ Hz, 4H). HRMS calculated for $C_{22}H_{23}N_2O_3S_1$ $[M-H]^-$ 395.1435, found 395.1430.

***N*-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1*H*-indene-5-sulfonamide**



1-Chloro-4-isocyanatobenzene (prepared using general method B1) and 2,3-dihydro-1*H*-indene-5-sulfonamide were used in general method C2 to give the titled compound as a white solid (60 mg, 32%). ^1H NMR (600 MHz, DMSO- d_6) δ 10.90 (bs, 1H), 8.90 (s, 1H), 7.74 (d, $J = 1.8$ Hz, 1H) 7.68 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.41 – 7.35 (m, 3H), 7.26 (dt, 2H), 2.91 (m, 4H), 2.05 (p, $J = 7.5$ Hz, 2H). HRMS calculated for $C_{16}H_{14}ClN_2O_3S_1$ $[M-H]^-$ 349.0419, found HRMS 349.0418.


***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)quinoline-8-sulfonamide**



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and quinoline-8-sulfonamide were used in general method C3 to give the titled compound as a white solid (75 mg, 71%). ^1H NMR (600 MHz, CD_3OD): δ = 9.13 (dd, $J = 4.2, 1.6$ Hz, 1H), 8.57-8.49 (m, 2H), 8.26 (d, $J = 8.2$ Hz, 1H), 7.77-7.67 (m, 2H), 6.99 (s, 2H), 2.65-2.60, (m, 2H), 0.85 (d, 12H); ^{13}C NMR (150 MHz, CD_3OD) δ = 151.2, 149.0, 143.3, 136.8, 136.7, 133.8, 133.5, 132.3, 129.4, 129.1, 125.3, 123.0, 122.1, 109.1, 28.3, 22.5; LCMS Purity: >95%;


LCMS (m/z): 446 [M+H]⁺; HRMS calculated for C₂₂H₂₅Cl₁N₃O₃S₁ [M+H]⁺ 446.1300, found 446.1314.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)isoquinoline-5-sulfonamide**



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and isoquinoline-5-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (70 mg, 67%). ¹H NMR (600 MHz, CD₃OD): δ = 9.41 (s, 1H), 8.82 (s, 1H), 8.59 (d, *J* = 7.3 Hz, 2H), 8.35 (d, *J* = 8.2 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 6.96 (s, 2H), 2.74-2.70 (m, 2H), 0.96 (s, 6H), 0.85 (d, 12H); ¹³C NMR (150 MHz, CD₃OD) δ = 156.3, 152.5, 149.1, 143.8, 137.2, 133.9, 133.1, 132.6, 131.5, 130.4, 126.3, 124.8, 122.8, 122.1, 28.3, 22.4; LCMS Purity: >95%; LCMS (m/z): 446 [M+H]⁺; HRMS calculated for C₂₂H₂₅Cl₁N₃O₃S₁ [M+H]⁺ 446.1300, found 446.1319.


***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)quinoline-5-sulfonamide**



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and quinoline-5-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (31 mg, 60%). ¹H NMR (600 MHz, CD₃OD): δ = 9.53 (d, *J* = 8.9 Hz, 1H), 8.94 (d, *J* = 3.8 Hz, 1H), 8.35 (dd, *J* = 7.3, 1.2 Hz, 1H), 8.15 (d, *J* = 8.5 Hz, 1H), 7.79 (dd, *J* = 8.5, 7.3 Hz, 1H), 7.69 (dd, *J* = 8.7, 4.3 Hz, 1H), 2.81-2.76 (m, 2H), 0.85 (d,


12H); ^{13}C NMR (150 MHz, CD_3OD) δ = 161.4, 151.3, 150.7, 149.1, 142.2, 137.4, 134.0, 133.0, 132.8, 129.9, 129.4, 126.0, 124.1, 122.9, 29.6, 24.0; LCMS Purity: >95%; LCMS (m/z): 446 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{22}\text{H}_{25}\text{Cl}_1\text{N}_3\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 446.1300, found 446.1317.

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)quinoline-8-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and 4H-quinoline-8-sulfonamide were used in general method C3 to give the titled compound as a white solid (60 mg, 51%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 9.11 (d, J = 2.7 Hz, 1H), 8.56 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 7.4 Hz, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.17 (s, 1H), 7.76 (t, J = 7.7 Hz, 1H), 7.73 (dd, J = 8.4, 4.2 Hz, 1H), 6.82 (s, 1H), 2.67 (t, J = 7.4 Hz, 4H), 2.26 (t, J = 7.4 Hz, 4H), 1.79 (p, J = 7.5 Hz, 4H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 151.8, 151.7, 143.3, 143.2, 137.5, 137.1, 134.5, 133.4, 132.8, 129.9, 126.0, 122.8, 118.0, 108.7, 32.7, 30.2, 25.3. LCMS (m/z): 408 $[\text{M}+\text{H}]^+$. HRMS calculated for $\text{C}_{22}\text{H}_{22}\text{N}_3\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 408.1376, found 408.1371.


***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)quinoline-3-sulfonamide**



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and quinoline-3-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (30 mg,


57%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ 9.24 (s, 1H), 8.92 (s, 1H), 8.20 (d, $J = 8.3$ Hz, 1H), 8.12 (d, $J = 8.5$ Hz, 1H), 7.98 (s, 1H), 7.93 (t, $J = 7.7$ Hz, 1H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.02 (s, 2H), 2.81-2.78 (m, 2H), 0.84 (d, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 153.7, 149.3, 148.7, 147.6, 141.5, 136.8, 132.6, 132.4, 131.5, 129.9, 129.2, 128.4, 126.4, 123.3, 28.5, 23.5; LCMS Purity: >95%; LCMS (m/z): 446 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{22}\text{H}_{25}\text{Cl}_1\text{N}_3\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 446.1300, found 446.1315.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)quinoxaline-5-sulfonamide**



5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and quinoxaline-5-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (39 mg, 75%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 9.18 (d, $J = 3.7$ Hz, 2H), 8.46 (d, $J = 7.3$ Hz, 1H), 8.38 (dd, $J = 8.1, 2.7$ Hz, 1H), 8.04-7.95 (m, 1H), 7.83 (s, 1H), 6.99 (s, 2H), 2.55-2.49 (m, 2H), 0.74 (d, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): 149.2, 147.1, 146.8, 146.2, 142.7, 140.5, 138.5, 138.2, 134.2, 133.4, 132.6, 129.6, 123.4, 28.4, 22.7; LCMS Purity: >95%; LCMS (m/z): 447 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{21}\text{H}_{24}\text{Cl}_1\text{N}_4\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 447.1252, found 447.1266.


***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)naphthalene-2-sulfonamide**



5-chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and naphthalene-2-sulfonamide (prepared using general method E3) were


used in general method C3 to give the titled compound as a white solid (35 mg, 67%). ^1H NMR (600 MHz, CD_3OD): δ = 8.55 (s, 1H), 8.05-7.92 (m, 4H), 7.64-7.58 (m 2H), 6.99 (s, 2H), 2.94-2.89 (m, 2H), 0.94 (bs, 12H); ^{13}C NMR (150 MHz, CD_3OD) δ 159.9, 150.6, 142.2, 135.9, 134.0, 133.7, 132.6, 130.2, 129.5, 129.1, 128.8, 128.6, 128.1, 124.3, 124.2, 29.7, 24.0; LCMS Purity: >95%; LCMS (m/z): 445 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{23}\text{H}_{26}\text{Cl}_1\text{N}_2\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 445.1347, found 445.1349.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-6-methoxynaphthalene-2-sulfonamide**




5-chloro-2-isocyanato-1, 3-diisopropylbenzene (prepared using general method A2) and 6-methoxynaphthalene-2-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (39 mg, 70%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 8.23 (s, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.1, 6.4 Hz, 2H), 7.49 (s, 1H), 7.35 (d, J = 2.6 Hz, 1H), 7.20 (dd, J = 8.9, 2.6 Hz, 1H), 6.96 (s, 2H), 3.08-2.98 (m, 2H), 0.93 (bs, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 158.0, 149.6, 135.2, 134.4, 131.0, 130.5, 128.1, 127.5, 127.3, 126.5, 124.7, 124.6, 122.7, 119.4, 106.2, 55.7, 28.3, 23.4; LCMS Purity: >95%; LCMS (m/z): 475 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{24}\text{H}_{28}\text{Cl}_1\text{N}_2\text{O}_4\text{S}_1$ $[\text{M}+\text{H}]^+$ 475.1453, found 475.1474.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)naphthalene-2-sulfonamide**




5-Chloro-2-isocyanato-1, 3-diisopropylbenzene (prepared using general method A2) and 6-chloronaphthalene-2-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (34 mg, 61%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 8.30 (s, 1H), 8.06 (d, J = 2.2 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.93-7.85 (m, 2H), 7.55 (dd, J = 8.7, 2.2 Hz, 1H), 7.40 (s, 1H), 6.95 (s, 2H), 3.09-2.97 (m, 2H), 0.92 (bs, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 160.2, 149.6, 145.8, 134.8, 134.2, 131.7, 131.1, 130.8, 130.7, 127.2, 126.8, 126.6, 125.8, 125.7, 122.7, 28.3, 23.6; LCMS Purity: >95%; LCMS (m/z): 479 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{23}\text{H}_{25}\text{Cl}_2\text{N}_2\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 479.0957, found 479.0937.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide**




5-chloro-2-isocyanato-1, 3-diisopropylbenzene (prepared using general method A2) and 5,6,7,8-tetrahydronaphthalene-2-sulfonamide (prepared using general method E3) were used in general method C1 to give the titled compound as a white solid (8 mg, 38%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 7.85 (s, 1H), 7.58 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.08 (s, 2H), 2.85-2.81 (m, 2H), 2.78-2.74 (m, 4H), 1.74 (t, J = 3.3 Hz, 4H), 0.98 (bs, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 149.3, 137.7, 137.5, 132.4, 129.8, 129.5, 129.7, 126.3, 124.3, 123.4, 122.9, 29.3, 29.2, 28.5, 23.4, 22.8, 22.7; LCMS Purity: >95%; LCMS (m/z): 449 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{23}\text{H}_{30}\text{Cl}_1\text{N}_2\text{O}_3\text{S}_1$ $[\text{M}+\text{H}]^+$ 449.1660, found 449.1664.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)thieno[3,2-*b*]pyridine-6-sulfonamide**




5-chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and thieno[3,2-b]pyridine-6-sulfonamide were used in general method C3 to give the titled compound as a white solid (35 mg, 66%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 9.07 (d, J = 2.0 Hz, 1H), 9.05 (s, 1H), 8.45 (d, J = 5.5 Hz, 1H), 8.01 (s, 1H), 7.70 (d, J = 5.5 Hz, 1H), 7.05 (s, 2H), 2.79-2.75 (m, 2H), 0.87 (d, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 158.2, 152.7, 149.3, 145.8, 138.2, 132.7, 132.3, 132.2, 131.6, 131.1, 124.7, 123.4, 28.5, 22.9; LCMS Purity: >95%; LCMS (m/z): 452 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{20}\text{H}_{23}\text{Cl}_1\text{N}_3\text{O}_3\text{S}_2$ $[\text{M}+\text{H}]^+$ 452.0864, found 452.0884.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-3-ethylisoxazolo[5,4-b]pyridine-5-sulfonamide**




5-Chloro-2-isocyanato-1,3-diisopropylbenzene (prepared using general method A2) and thieno[3,2-b]pyridine-6-sulfonamide were used in general method C3 to give the titled compound as a white solid (38 mg, 64%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 9.11 (s, 1H), 8.98 (s, 1H), 8.14 (s, 1H), 7.08 (s, 2H), 3.09 (q, J = 7.5 Hz, 2H), 2.82-2.77 (m, 2H), 1.34 (t, J = 7.5 Hz, 3H), 1.02-0.90 (d, 12H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 170.2, 161.9, 150.5, 149.3, 134.3, 134.2, 132.8, 131.0, 123.5, 112.7, 109.9, 28.5, 23.0, 19.2, 11.9; LCMS Purity: >95%; LCMS (m/z): 465 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{21}\text{H}_{26}\text{Cl}_1\text{N}_4\text{O}_4\text{S}_1$ $[\text{M}+\text{H}]^+$ 465.1358, found 465.1354.

***N*-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzofuran-2-**


sulfonamide

4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (prepared using general method A2) and benzofuran-2-sulfonamide were used in general method C3 to give the titled compound as a white solid (60 mg, 52%); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.00 (bs, 1H), 7.77 (d, J = 8 Hz, 1H), 7.69 (d, J = 8 Hz, 1H), 7.51 (s, 1H), 7.49 (d, J = 8 Hz, 1H), 7.36 (t, J = 8 Hz, 1H), 7.08 (bs, 1H), 6.87 (s, 1H), 2.75 (t, J = 8 Hz, 4H), 2.59 (t, J = 8 Hz, 4H), 1.92-1.85 (m, 4H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 154.9, 143.2, 137.6, 130.3, 127.5, 126.7, 124.4, 123.3, 117.7, 112.3, 110.0, 109.4, 107.4, 32.9, 30.6, 25.5. LCMS (m/z): 397 $[\text{M}+\text{H}]^+$. HRMS calculated for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_4\text{S}_1$ $[\text{M}+\text{H}]^+$ 397.1217, found 397.1215.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)benzofuran-2-sulfonamide**


5-chloro-2-isocyanato-1, 3-diisopropylbenzene (prepared using general method A2) and benzofuran-2-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (25 mg, 49%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 7.85 (s, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.04 (s, 2H), 2.99-2.95 (m, 2H), 0.94 (bs, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ = 154.9, 149.5, 132.6, 132.3, 132.0, 127.2, 126.9, 126.8, 123.3, 123.2, 112.1, 112.0, 109.8, 28.5, 23.3; LCMS Purity: >95%; LCMS (m/z): 435 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{21}\text{H}_{24}\text{Cl}_1\text{N}_2\text{O}_4\text{S}_1$ $[\text{M}+\text{H}]^+$ 435.1140, found 435.1140.

***N*-((4-chloro-2,6-diisopropylphenyl)carbamoyl)benzo[*b*]thiophene-2-sulfonamide**



5-chloro-2-isocyanato-1, 3-diisopropylbenzene (prepared using general method A2) and benzo[*b*]thiophene-2-sulfonamide (prepared using general method E3) were used in general method C3 to give the titled compound as a white solid (38 mg, 72%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.03 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.80 (s, 1H), 7.46 (dt, J = 15.4, 7.0 Hz, 2H), 7.04 (s, 2H), 3.05–2.83 (m, 2H), 0.94 (bs, 12H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ 155.3, 149.5, 141.1, 138.0, 132.4, 132.0, 126.8, 125.7, 125.4, 123.1, 123.0, 122.9, 109.7, 28.5, 23.3; LCMS Purity: >95%; LCMS (m/z): 451 $[\text{M}+\text{H}]^+$; HRMS calculated for $\text{C}_{21}\text{H}_{24}\text{Cl}_1\text{N}_2\text{O}_3\text{S}_2$ $[\text{M}+\text{H}]^+$ 451.0911, found. 451.0900.


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)benzenesulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)benzenesulfonamide were used in general method C2 to give the titled compound as a white solid (85 mg, 52%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ = 10.72 (bs, 1H), 7.91 (s, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 2.9 Hz, 1H), 7.39 (d, J = 7.9


Hz, 2H), 7.29 (dd, $J = 8.7, 2.9$ Hz, 1H), 6.88 (s, 1H), 4.13 (t, $J = 7.5$ Hz, 2H), 3.83 (s, 3H), 2.93 (t, $J = 7.5$ Hz, 2H), 2.76 (t, $J = 7.4$ Hz, 4H), 2.55 (t, $J = 7.4$ Hz, 4H), 1.90 (p, $J = 7.4$ Hz, 4H), 1.42 (s, 6H). HRMS calculated for $C_{33}H_{34}N_3O_6S_1$ $[M-H]^-$ 600.2174, found 600.2183.

***N*-(4-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)-5-methylisoxazole-3-carboxamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 5-methyl-*N*-(4-sulfamoylphenethyl)isoxazole-3-carboxamide were used in general method C2 to give the titled compound as a white solid (14 mg, 62%). ^1H NMR (600 MHz, $DMSO-d_6$) δ 8.78 (t, $J = 5.8$ Hz, 1H), 7.80 (s, 1H), 7.74 (d, $J = 8.3$ Hz, 2H), 7.41 (d, $J = 8.3$ Hz, 2H), 6.85 (s, 1H), 6.50 (q, $J = 1.0$ Hz, 1H), 3.49 (m, 2H), 2.91 (t, $J = 7.0$ Hz, 2H), 2.75 (t, $J = 7.4$ Hz, 4H), 2.56 (t, $J = 7.4$ Hz, 4H), 2.45 (d, $J = 0.9$ Hz, 3H), 1.89 (p, $J = 7.4$ Hz, 4H). HRMS calculated for $C_{26}H_{27}N_4O_5S_1$ $[M-H]^-$ 507.1708, found 507.1709.


3-Ethyl-*N*-(4-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)-4-methyl-2-oxo-2,5-dihydro-1*H*-pyrrole-1-carboxamide



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 3-ethyl-4-methyl-2-oxo-*N*-(4-sulfamoylphenethyl)-2,5-

dihydro-1*H*-pyrrole-1-carboxamide were used in general method C2 to give the titled compound as a white solid (78 mg, 50%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 10.78 (bs, 1H), 8.38 (t, *J* = 7.6 Hz, 1H), 7.97 (s, 1H), 7.82 (d, *J* = 8.2 Hz, 2H), 7.42 (d, *J* = 8.2 Hz, 2H), 6.88 (s, 1H), 4.16 (s, 2H), 3.48 (q, *J* = 6.7 Hz, 2H), 2.88 (t, *J* = 7.2 Hz, 2H), 2.75 (t, *J* = 7.4 Hz, 4H), 2.53 (t, *J* = 7.4 Hz, 4H), 2.18 (q, *J* = 7.5 Hz, 2H), 2.01 (s, 3H), 1.90 (p, *J* = 7.4 Hz, 4H), 0.97 (t, *J* = 7.5 Hz, 3H). HRMS calculated for C₂₉H₃₃N₄O₅S₁ [M-H]⁻ 549.2177, found 549.2169.

5-Chloro-*N*-(4-(*N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide




4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 5-chloro-2-methoxy-*N*-(4-sulfamoylphenethyl)benzamide were used in general method C2 to give the titled compound as a white solid (325 mg, 70%). ¹H NMR (600 MHz, DMSO-*d*₆) δ = 10.83 (bs, 1H), 8.27 (t, *J* = 6.0 Hz, 1H), 7.96 (s, 1H), 7.84 (d, *J* = 8.0 Hz, 2H), 7.66 (d, *J* = 2.8 Hz, 1H), 7.50 (dd, *J* = 8.9 Hz, 2.8 Hz, 1H), 7.44 (t, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 8.9 Hz, 1H), 6.87 (s, 1H), 3.78 (s, 3H), 3.53 (q, *J* = 6.6 Hz, 2H), 2.91 (t, *J* = 7.2 Hz, 2H), 2.74 (t, *J* = 7.4 Hz, 4H), 2.53 (t, *J* = 7.4 Hz, 4H), 1.88 (p, *J* = 7.3 Hz, 4H). HRMS calculated for C₂₉H₂₉Cl₁N₃O₅S₁ [M-H]⁻ 566.1522, found 566.1543.

¹³C NMR (100 MHz, DMSO-*d*₆): δ = 163.6, 155.7, 145.3, 143.6, 143.0, 142.4, 142.1, 139.6, 137.1, 131.5, 129.5, 129.2, 127.4, 125.7, 124.8, 124.3, 117.9, 114.1, 108.3, 56.2, 34.7, 32.6, 32.4, 30.0, 28.9, 24.9. LCMS, Purity:

90.06%, $t_r = 3.38$ min, m/z 566.37 ($M-H^+$). HRMS (FAB⁺) calcd for $C_{29}H_{30}ClN_3O_5S$ [$M+H$]⁺ : 568.1595, found: 568.1589.

PYRIDINES

***N*-(1, 2, 3, 5, 6, 7-hexahydro-*s*-indacen-4-ylcarbamoyl)-4-(2-hydroxypropan-2-yl)pyridine-2-sulfonamide**




To a solution of 1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine (0.20 g, 1.15 mmol) in anhydrous THF (5 mL), triethylamine (0.35 g, 3.47 mmol, 3.0 eq) was added followed by triphosgene (0.265 g, 0.86 mmol, 0.5 eq) at 0 °C and the mixture was stirred at ambient temperature for 3 h. The mixture was cooled to 0 °C, methyl 2-sulfamoylisonicotinate (0.27 g, 1.27 mmol, 1.1 eq) added and stirring continued at ambient temperature overnight. Upon completion the reaction mixture was poured into brine and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using 20-50% gradient of EtOAc-hexanes eluent to give methyl 2-(*N*-(1, 2, 3, 5, 6, 7-hexahydro-*s*-indacen-4-ylcarbamoyl)sulfamoyl)isonicotinate as a light brown solid (0.31 g, 65%).

Methyl 2-(*N*-(1, 2, 3, 5, 6, 7-hexahydro-*s*-indacen-4-ylcarbamoyl)sulfamoyl)isonicotinate (0.30 g, 0.72 mmol) was dissolved in anhydrous THF (8 mL) and the solution cooled to 0 °C. Methyl magnesium bromide (3 M solution in diethyl ether, 0.96 mL, 2.88 mmol, 4.0 eq) was added at 0 °C under nitrogen atmosphere and stirring continued at ambient temperature for 3 h. Upon completion the reaction mixture was poured into saturated aqueous ammonium chloride and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (Na_2SO_4) and


concentrated *in vacuo*. The crude residue was purified by reverse phase prep HPLC to afford the titled compound as a white solid (0.016 g, 5%). ^1H NMR (400 MHz, CD_3OD): δ = 8.45 (br.s, 1H), 8.16 (s, 1H), 7.55 (br.s, 1H), 6.87 (s, 1H), 2.80 (t, J = 7.2 Hz, 4H), 2.66 (t, J = 7.2 Hz, 4H), 1.96 (quin, J = 7.6 Hz, 4H), 1.53 (s, 6H). LCMS, Purity: 98%, m/z 416.09 ($\text{M}+\text{H}^+$). HRMS (FAB^+) calcd for $\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}_4\text{S}$ [$\text{M}+\text{H}$] $^+$: 416.1566, found: 416.1556.

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-cyclopenta[*b*]pyridine-3-sulfonamide**



4-Isocyanato-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A2) and 6,7-dihydro-5H-cyclopenta[*b*]pyridine-3-sulfonamide were used in general method C2 to give the titled compound as a white solid (12 mg, 27%). ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ = 8.71 (s, 1H), 8.01 (s, 1H), 7.96 (bs, 1H), 6.87 (s, 1H), 2.97-2.93 (m, 4H), 2.75 (t, J = 6 Hz, 4H), 2.55 (t, J = 6 Hz, 4H), 2.11-2.07 (m, 2H), 1.93-1.88 (m, 4H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$): δ 169.6, 146.4, 144.9, 143.2, 137.4, 137.2, 131.0, 129.6, 117.7, 108.7, 34.0, 32.9, 30.6, 30.3, 25.4, 23.2. LCMS (m/z): 398 [$\text{M}+\text{H}$] $^+$.


***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)pyridine-2-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and pyridine-2-sulfonamide were used in general method


C1 to give the titled compound as a white solid (40 mg, 10%). ^1H NMR (400 MHz, DMSO- d_6): δ = 8.5 (d, J = 4.0 Hz, 1H), 7.88 (t, J = 7.6 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.4 (t, J = 5.8 Hz, 1H), 6.76 (s, 1H), 2.73 (t, J = 7.2 Hz, 4H), 2.61 (t, J = 7.2 Hz, 4H), 1.88 (quin, J = 7.2 Hz, 4H).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)pyridine-3-sulfonamide**




4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and pyridine-3-sulfonamide were used in general method C1 to give the titled compound as a white solid (12 mg, 3%). ^1H NMR (400 MHz, CD_3OD): δ = 9.08 (s, 1H), 8.65 (d, J = 4.4 Hz, 1H), 8.36 (d, J = 8.0 Hz, 1H), 7.56 (dd, J = 8.0, 4.8 Hz, 1H), 6.88 (s, 1H), 2.82 (t, J = 7.2 Hz, 4H), 2.69 (t, J = 7.2 Hz, 4H), 2.0 (quin, J = 7.2 Hz, 4H).

***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamoyl)-4-(trifluoromethyl)pyridine-2-sulfonamide**



4-Isocyanato-8-methyl-1,2,3,5,6,7-hexahydro-*s*-indacene (prepared using general method A1) and 4-(trifluoromethyl)pyridine-2-sulfonamide were used in general method C1 to give the titled compound as a white solid (16 mg, 3%). ^1H NMR (400 MHz, CD_3OD): δ = 8.47 (s, 1H), 8.22 (s, 1H), 7.42 (s, 1H), 6.98 (s, 1H), 2.82 (t, J = 7.2 Hz, 4H), 2.66 (t, J = 7.2 Hz, 4H), 1.95 (quin, J = 7.2 Hz, 4H); ^{19}F NMR (233.33 MHz, DMSO- d_6): -63.48 (s, 3F).

LINKER***N*-((1,2,3,5,6,7-hexahydro-*s*-indacen-4-yl)carbamothioyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide**

To a solution of 1,2,3,5,6,7-hexahydro-*s*-indacen-4-amine (0.10 g, 0.58 mmol) in anhydrous DCM (2.0 mL) was added 1,1'-thiocarbonyldiimidazole (1.1 eq) and the reaction stirred for 4 h at ambient temperature. The solvent was removed *in vacuo* then the residue taken up in acetone (2.0 mL) and potassium carbonate (2.5 eq) was added followed by 4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (1.2 eq). The reaction mixture was heated at reflux overnight, concentrated *in vacuo* then neutralized using 10 % citric acid (10 mL) and immediately extracted using ethyl acetate (2 x 10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified using column chromatography on silica with MeOH/DCM eluent followed by HPLC to give the titled compound as an off white solid (13 mg, 4%). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.0 (bs, 1H), 9.72(s, 1H), 7.88 (s, 1H), 7.43 (s, 1H), 7.01 (s, 1H), 5.15 (br.s., 1H), 2.81 (t, *J* = 6.8 Hz, 4H), 2.59 (t, *J* = 6.8 Hz, 4H), 1.95 (quin, *J* = 7.6 Hz, 4H), 1.39 (s, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 176.9, 143.1, 142.7, 138.7, 137.1, 130.4, 119.3, 117.7, 66.6, 32.4, 30.9, 29.9, 24.9. LCMS: Purity = 95.08%, *tr* = 3.45 min, *m/z* 421.30 (M+H⁺).

Biological Testing Methodology**NLRP3 inhibition assays**

The following assays can be used to determine inhibitory activity of test

compounds on the NLRP3 inflammasome using common stimuli such as adenosine triphosphate, nigericin, LeuLeu-OMe or monosodium urate crystals (MSU).

Cell culture

To generate HMDM, human monocytes are isolated from buffy coat blood using Ficoll-Plaque Plus (GE Healthcare) and density centrifugation. CD14⁺ cell selection is performed using MACS magnetic beads (Miltenyl Biotec). Isolated CD14⁺ monocytes are differentiated in culture for 7 days with 10 ng/ml human CSF-1 (Miltenyl Biotec) in Iscove's modified Dulbecco's medium (IMDM) containing L-glutamine supplemented with 10% FBS and 1% penicillin/streptomycin (Life Technologies) as described by Croker *et al* 2013 *Immunol Cell Biol* 91:625.

Mouse bone marrow-derived macrophages (BMDM) were derived from bone marrow progenitors isolated from the femurs and tibias of C57BL/6 mice. Bones were flushed with medium, and bone marrow cells were cultured for 7 days in RPMI 1640 medium supplemented with 10% heat inactivated FCS, 2 mM GlutaMAX (Life Technologies), 50 U/ml penicillin-streptomycin (Life Technologies) and 150 ng/ml recombinant human M-CSF (endotoxin-free, expressed and purified by The University of Queensland Protein Expression Facility).

NLRP3 inflammasome activation assays

HMDM are seeded at 1×10^5 /ml. The following day the overnight medium is replaced and cells are stimulated with *Escherichia coli* serotype 0111:B4 (Sigma Aldrich) for 3 h. Medium is removed and replaced with serum free medium (SFM) containing test compound 30 min prior to NLRP3 stimulation. Cells are then stimulated with: adenosine 5'-triphosphate disodium salt hydrate (5 mM 1 h), nigericin (10 μ M 1 h), LeuLeu-OMe (1 mM 2 h) or MSU (200 μ g/ml 15 h). ATP can be sourced from Sigma Aldrich, nigericin and MSU from

Invivogen and LeuLeu-Ome from Chem-Impex International.

BMDM are seeded at 1×10^5 /ml. The following day the overnight medium is replaced and cells are stimulated with Ultrapure lipopolysaccharide from Escherichia coli K12 strain (InvivoGen) for 3 h. Medium is removed and replaced with serum free medium (SFM) containing test compound 30 min prior to NLRP3 stimulation. Cells are then stimulated with: adenosine 5'-triphosphate disodium salt hydrate (1.25-5 mM 1 h), nigericin (5 μ M 1 h), LeuLeu-OME (1 mM 2 h) or MSU (200 μ g/ml 15 h). ATP can be sourced from Sigma Aldrich, nigericin and MSU from Invivogen and LeuLeu-Ome from Chem-Impex International.

Measurement of IL-1 β , IL-18, TNF α and cell death

For ELISA and cell death assays cells are seeded in 96 well plates. Supernatants are removed and analysed using ELISA kits according to the manufacturer's instructions (DuoSet® R&D Systems, ReadySetGo!® eBioscience, BD OptEIA™, or Perkin Elmer AlphaLISA®). Cell death is assessed by measurement of LDH release relative to a 100% cell lysis control using the CytoTox96® non-radioactive cytotoxicity assay (Promega).

Murine studies on compound levels in blood plasma and brain

General experimental: Carbutamide was purchased from Sigma Aldrich (Catalogue No. 381578). Acetonitrile was Chromasolv® HPLC grade (Sigma Aldrich, Sydney, Australia), the formic acid was AR grade 99%-100% Normapur (VWR International Pty Ltd, Brisbane, Australia), DMSO was ReagentPlus® grade (D5879, Sigma Aldrich, Sydney, Australia) and the H₂O Milli-Q was filtered. The HPLC vial and polypropylene inserts from Agilent Technologies (Melbourne, Australia), while the 1.5 mL Eppendorf tubes Protein LoBind Tubes were from VWR International Pty Ltd (Brisbane, Australia).

Preparation of precipitation solution: 100 mL ACN and 5 μ L of 10 mM

carbutamide in DMSO (ACN with 135 ng/mL carbutamide MS internal standard).

Preparation of standard curve in plasma: A 1 mg/mL of test compound in 10 mM NH_4HCO_3 was prepared and diluted 10-fold to give a 100,000 ng/mL stock solution. A series of 10-fold dilutions of the 100,000 ng/mL stock solution with 10 mM NH_4HCO_3 gave concentrations of 10,000, 1,000, 100 and 10 ng/mL. The 100,000 ng/mL stock solution was diluted to 3: 7 with 10 mM NH_4HCO_3 to give a concentration of 30,000 ng/mL and a series of 10-fold dilutions gave concentrations of 3,000, 300, 30 and 3 ng/mL.

20 μL of test compound-containing solution and 160 μL precipitation solution were added to 20 μL of mouse plasma in a low binding Eppendorf tube. The samples were vortexed, allowed to stand at 4 °C for 10 mins and centrifuged at $14,000 \times g$ for 8 min. 150 μL of the supernatant was transferred to an HPLC vial insert. The samples were stored at 4 °C until analysis.

Preparation of standard curve in brain homogenate: The sample solutions prepared for the plasma standard curve were used for the brain homogenate standard curve.

The mouse brain homogenate from the saline control was thawed and vortexed for 3 min or until homogenous, sonicated for 1 min. When the foam settled, 50 μL of mouse brain homogenate was transferred into an Eppendorf tube, followed by 50 μL of test compound in 10 mM NH_4HCO_3 , 150 μL of H_2O and 500 μL of ice cold precipitation solution with vortexing after every addition. The standards were allowed to stand at 4 °C for 10 mins and then centrifuged at $14,000 \times g$ for 8 min. 200 μL of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles were present and the samples stored at 4 °C until analysis.

Dosing of mice and transcardial perfusion

Dosing: Oral gavage at 20 mg/kg

Time point: 2 hour

Prepare stock compounds for dosing at 4 mg/ml in sterile PBS. Mice were weighed and dosed by oral gavage at 20 mg/kg for each compound. After 2 hours mice were anesthetized using a combination of Zoletil (50 mg/kg) and Xylazine (10 mg/kg) and blood was collected by cardiac puncture into tubes containing 20 μ L of 100 mM EDTA. The blood was centrifuged at 2000 $\times$ g for 15 minutes at 4 °C to collect plasma.

Preparation of plasma samples for analysis: 20 μ L of NH_4HCO_3 and 160 μ L precipitation solution were added to 20 μ L of mouse plasma in a low binding Eppendorf tube. The samples were vortexed, allowed to stand at 4 °C for 10 mins and centrifuged at 14,000 $\times$ g for 8 min. 150 μ L of the supernatant was transferred to an HPLC vial insert ensuring that no air bubbles were present. The samples were stored at 4 °C until analysis.

Brain homogenate preparation: The brains of mice were perfused with PBS for 5 minutes then dissected and weighed. Brain homogenate was prepared by homogenizing total brain (0.5 g) with 4 volumes (2 ml) of deionized water and stored at -20 °C before analysis. The homogenate was thawed, vortexed for 3 min or until homogenous, and sonicated for 1 min. When the foam settled, 50 μ L of mouse brain homogenate was transferred into an Eppendorf tube, followed by 50 μ L of 10 mM NH_4HCO_3 , 150 μ L of H_2O and 500 μ L of ice cold precipitation solution with vortexing after every addition. 200 μ L of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles were present and the samples stored at 4 °C until analysis.

Preparation of brain samples for analysis: 50 μ L of mouse brain was transferred into an Eppendorf tube, followed by 50 μ L of 10 mM NH_4HCO_3 , 150 μ L of H_2O and 500 μ L of ice cold precipitation solution with vortexing after every


addition. The solutions were allowed to stand at 4 °C for 10 mins and then centrifuged at 14,000 × g for 8 min. 200 µL of the supernatant was transferred to HPLC vial insert ensuring that no air bubbles were present and the samples stored at 4 °C until analysis.





LC-MS/MS: The samples were analysed on an AB Sciex 4000QTrap MS with 2 Shimadzu Nexera LC-30AD Solvent Delivery Units, Shimadzu Nexera SIL-30AC Auto-Sampler, Shimadzu Prominence DGU-20A₅ Degasser, Shimadzu Prominence CBM-20A System Controller and Shimadzu Prominence CTO-20A Column Oven. The column oven was set to 40 °C, while the Autosampler was set to 15 °C. 2 µL injections were made and MS analyses were undertaken in Selected Reaction Monitoring (SRM) mode using Turbo Spray (-)-ESI with Low Resolution Q1 and Low Resolution Q3. MS parameters: CUR: 30.00, IS: -4300.00, TEM: 500.00, GS1: 50.00, GS2: 50.00, ihe: ON, CAD: High, DP -60.00, EP -10.00, CXP -15.00. MCC950 SRM: Q1 403.2 to Q3 204.3 Da, dwell 150 msec, CE -27 and carbutamide (IS) SRM: Q1 270.0 to Q3 171.0 Da, dwell 100 msec, CE -25. HPLC Column: Waters Atlantis[®] T3 5 µm 2.1 × 50mm with Atlantis[®] T3 5 µm 2.1 × 10 mm guard column. Flow rates and solvent: 0.35 ml/min, solvent A: 0.1% formic acid in H₂O, solvent B: 0.1% formic acid in ACN; isocratic 2% B from 0→2 mins, gradient 2%→100% B from 2→5 mins, isocratic 100% from 5→9 mins, gradient 100%→2% B from 9→9.1 mins and isocratic 2% B from 9.1→13 mins. The peak areas from the SRM data for carbutamide and test compound were analysed using the AB Sciex's Analyst software using the Quantitation Wizard. The peak area was plotted against the ng/mL concentration in 20 µL 3 to 30,000 ng/mL test compound solutions and the lower and upper range of linear response was determined. These data were then plotted in Microsoft Excel and the linear response equation used to determine the test compound concentration in the 20 µL plasma solutions. Similarly, for the brain homogenate samples, the peak areas of the 50 µL 3 to 3,000 ng/mL test compound solutions were used to determine the test





compound concentration in the 50 μ L brain homogenate solutions.





RESULTS






The full series of tPSA and biological results are provided in the tables below, however select data is presented below for certain compounds of the invention.








SMILES	NAME	tPSA	MV
 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(C4CCCCC4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)cyclohexanesulfonamide	75	362
 <chem>O=C(NC1=C2CCCC2=CC3=C1CCC3)NS(C4CCCC4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)cyclopentanesulfonamide	75	348
 <chem>O=S(C1CCOCC1)(NC(NC2=C3CCCC3=C4C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydro-2H-pyran-4-sulfonamide	85	364
 <chem>O=C(NC1=C2CCCC2=CC3=C1CCC3)NS(C4COCC4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydrofuran-3-sulfonamide	85	350

 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(=O)(=O)c1ccoc1</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	85	346
 <chem>CC1=CC=C(S(=O)(=O)NC(=O)NC2=CC3=CC4=CC5=CC3CC4C2)O1</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylfuran-2-sulfonamide	85	360
<chem>CC1=CC=C(S(=O)(=O)NC(=O)NC2=CC3=CC4=CC5=CC3CC4C2)O1</chem>			
 <chem>CCC1=CC=C(S(=O)(=O)NC(=O)NC2=CC3=CC4=CC5=CC3CC4C2)O1</chem>	5-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	85	374
 <chem>O=S(=O)(NC(=O)NC1=CC2=CC3=CC4=CC5=CC3CC4C2)NC(C)CC1</chem>	5-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	88	403

 <chem>O=S(C1=CC(C(C)=C)=CO1)(NC(NC2=C(CCC3)C3=CC4=C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonamide	85	386
 <chem>O=C(NC1=C2CCCC2=CC3=C1CCC3)NS(C4=CC=CS4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonamide	75	362
 <chem>O=S(NC(NC1=C2C(CCC2)=CC3=C1CCC3)=O)(C4=CC=C(C)S4)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylthiophene-2-sulfonamide	75	376
 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(C4=NC=CS4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiazole-2-sulfonamide	88	363

 <chem>O=S(C1=CC=CC=C1)(NC(NC2=C(CCC3)C3=CC4=C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	75	356
 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(C4=C(OC)C=CC=C4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methoxybenzenesulfonamide	85	386
 <chem>FC(F)(F)C1=CC=CC(S(=O)(=O)NC(NC2=C3C(CCC3)=CC4=C2CCC4)=O)=O=C1</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(trifluoromethyl)benzenesulfonamide	75	424
 <chem>O=S(C1=CC(OC)=CC=C1)(NC(NC2=C(CCC3)C3=CC4=C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methoxybenzenesulfonamide	85	386
 <chem>O=S(C1=CC(OC(F)(F)F)=CC=C1)(NC(NC2=C(CCC3)C3=CC4=C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(trifluoromethoxy)benzenesulfonamide	85	440

 <chem>O=S(C1=CC(OC(F)F)=CC=C1)(NC(NC2=C(C(CCC3)=CC4=C2CCC4)=O)=O</chem>	3-(difluoromethoxy)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	85	422
 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(C4=CC=C(Cl)C=C4)(=O)=O</chem>	4-chloro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	75	391
 <chem>O=C(NC1=C2C(CCC2)=CC3=C1CCC3)NS(C4=CC=C(C)C=C4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonamide	75	370
 <chem>O=C(NC1=C2CCCC2=CC3=C1CCC3)NS(C4=CN=C5CCCC5=C4)(=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-sulfonamide	88	397
 <chem>O=S(C1=CC=CC=N1)(NC(NC2=C(CCC3)=CC4=C2CCC4)=O)=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-2-sulfonamide	88	357



 <chem>O=S(C1=CC=CN=C1)(NC(=O)NC2=CC=CC=C2)C3=CC4=C2CCCC4=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-3-sulfonamide	88	357
 <chem>O=S(C1=CC(C(F)(F)F)=CC=N1)(NC(=O)NC2=CC=CC=C2)C3=CC4=C2CCCC4=O</chem>	N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(trifluoromethyl)pyridine-2-sulfonamide	88	425

Table 1: Topological Polar Surface Area (tPSA) and molecular weight of select compounds.

Name	Chem Formula	HRMS formula	ESI+/-	HRMS Calc	HRMS found	Avg. IL-1 β IC50 Murine BMDM (nM)	Avg. IL-1 β IC50 HMDM (nM)	Avg. IL-1 β IC50 HMDM (nM)
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)cyclohexanesulfonamide	C19H26N2O3S	C19H27N2O3S	ESI+	363.1737	363.1729	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)cyclopentanesulfonamide	C18H24N2O3S	C18H25N2O3S	ESI+	349.158	349.1588	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydro-2H-pyran-4-sulfonamide	C18H24N2O4S	C18H25N2O4S	ESI+	365.153	365.1541	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)tetrahydrofuran-3-sulfonamide	C17H22N2O4S	C17H23N2O4S	ESI+	351.1373	351.1389	ND	++	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)morpholine-4-sulfonamide	C17H23N3O4S	C 17 H 24 N 3 O 4 S 1	ESI+	366.1482	366.14956	ND	++	ND
N-[1,2,3,5,6,7-hexahydro-s-indacen-4-yl]-N'-[(dimethylamino)sulfonyl]urea	C15H21N3O3S	C 15 H 22 N 3 O 3 S 1	ESI+	324.1376 4	324.13891	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	C17H18N2O4S	C 17 H 17 N 2 O 4 S 1	ESI-	345.0915	345.0906	+++	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylfuran-2-sulfonamide	C18H20N2O4S	C18H21N2O4S	ESI+	361.1216	361.1217	ND	++++	++++
5-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	C19H22N2O4S	C19H22N2O4S	ESI+	375.1373	375.1391	ND	+++	ND
5-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	C20H25N3O4S	C 20 H 26 N 3 O 4 S 1	ESI+	404.1639	404.1653	ND	++++	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₄ N ₂ O ₅ S	C ₂₀ H ₂₃ N ₂ O ₅ S 1	ESI-	403.1333	403.1351	++++	++++	++++
N-((8-bromo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₃ BrN ₂ O ₅ S	C ₂₀ H ₂₂ BrN ₂ O ₅ S 1	ESI-	481.0438	481.043 and 483.0392	++++	++++	ND
N-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₃ ClN ₂ O ₅ S	C ₂₀ H ₂₂ ClN ₂ O ₅ S 1	ESI-	437.0943	437.0941	++++	++++	ND
4-(2-hydroxypropan-2-yl)-N-((8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)furan-2-sulfonamide	C ₂₁ H ₂₆ N ₂ O ₅ S	C ₂₁ H ₂₅ N ₂ O ₅ S 1	ESI-	417.149	417.1499	++++	++++	ND
5-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)furan-3-carboxylic acid	C ₁₈ H ₁₈ N ₂ O ₆ S	C ₁₈ H ₁₇ N ₂ O ₆ S 1	ESI-	389.0813	389.0796	++	ND	ND

ethyl 5-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)furan-3-carboxylate	C20H22N2O6S	C 20 H 21 N 2 O 6 S 1	ESI-	417.1126	417.1117	+++	ND	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonamide	C20H22N2O4S	C 20 H 23 N 2 O 4 S 1	ESI+	387.1373	387.1379	+++	+++	ND
4-(2-hydroxypropan-2-yl)-N-((3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)carbamoyl)furan-2-sulfonamide	C19H22N2O6S	C 19 H 21 N 2 O 6 S 1	ESI-	405.1126	405.1113	++++	ND	ND
N-((4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C19H21BrN2O6S	C 19 H 20 Br 1 N 2 O 6 S 1	ESI-	483.0231	483.0232	++++	ND	ND
4-(2-hydroxypropan-2-yl)-N-((3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-4-yl)carbamoyl)furan-2-sulfonamide	C19H22N2O6S	C 19 H 21 N 2 O 6 S 1	ESI-	405.1126	405.1116	++++	ND	ND

4-(2-hydroxypropan-2-yl)-N-((2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)carbamoyl)furan-2-sulfonamide	C18H20N2O7S	C 18 H 19 N 2 O 7 S 1	ESI-	407.0918	407.0915	+++	ND	ND
N-(benzo[1,2-b:4,5-b']difuran-4-ylcarbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C18H16N2O7S	C 18 H 15 N 2 O 7 S 1	ESI-	403.0605	403.0604	++++	ND	ND
N-(anthracen-9-ylcarbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C22H20N2O5S	C 22 H 19 N 2 O 5 S 1	ESI-	423.102	423.1038	++	ND	ND
4-(2-hydroxypropan-2-yl)-N-(quinolin-8-ylcarbamoyl)furan-2-sulfonamide	C17H17N3O5S	C 17 H 16 N 3 O 5 S 1	ESI-	374.0816	374.0805	ND	++	ND
4-(2-hydroxypropan-2-yl)-N-((6-methoxyquinolin-8-yl)carbamoyl)furan-2-sulfonamide	C18H19N3O6S	C 18 H 18 N 3 O 6 S 1	ESI-	404.0922	404.0913	ND	++	ND

N-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)carbonyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C16H18N2O7S	C 16 H 17 N 2 O 7 S 1	ESI-	381.0762	381.078	++	ND	ND
N-((2,3-dihydrobenzofuran-7-yl)carbonyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C16H18N2O6S	C 16 H 17 N 2 O 6 S 1	ESI-	365.0813	365.0823	+	ND	ND
N-((2,4-bis(trifluoromethyl)phenyl)carbonyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C16H14F6N2O5S	C 16 H 13 F 6 N 2 O 5 S 1	ESI-	459.0455	459.0476	+++	++	ND
N-((2,5-bis(trifluoromethyl)phenyl)carbonyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C16H14F6N2O5S	C 16 H 13 F 6 N 2 O 5 S 1	ESI-	459.0455	459.0453	+++	++	ND
4-(2-hydroxypropan-2-yl)-N-((2-methoxyphenyl)carbonyl)furan-2-sulfonamide	C15H18N2O6S	C 15 H 17 N 2 O 6 S 1	ESI-	353.0813	353.0828	++	ND	ND

N-((2,5-dimethoxyphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C16H20N2O7S	C 16 H 19 N 2 O 7 S 1	ESI-	383.0918	383.0935	++	ND	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide	C21H26N2O5S	C 21 H 25 N 2 O 5 S 1	ESI-	417.149	417.1509	++++	ND	ND
N-((2,6-diisopropylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)-5-methylfuran-2-sulfonamide	C21H30N2O5S	C 21 H 29 N 2 O 5 S 1	ESI-	421.1803	421.18	ND	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-1,1,1,3,3,3-d6furan-2-sulfonamide	C20H18D6N2O5S	C 20 H 17 D 6 N 2 O 5 S 1	ESI-	409.171	409.1701	ND	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)-1,1,1,3,3,3-d6furan-2-sulfonamide	C21H20D6N2O5S	C 21 H 19 D 6 N 2 O 5 S 1	ESI-	423.1866	423.1878	ND	++++	ND

4-(2-hydroxypropan-2-yl-1,1,1,3,3,3-d6)-5-methyl-N-((3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-4-yl)carbamo-yl)furan-2-yl)sulfonamide	C20H18D6N2O6 S	C 20 H 17 D 6 N 2 O 6 S 1	ESI-	425.1659	425.1665	ND	++++	ND
N-((4-bromo-3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-8-yl)carbamo-yl)-4-(2-hydroxypropan-2-yl-1,1,1,3,3,3-d6)-5-methylfuran-2-sulfonamide	C20H17D6BrN2 O6S	C 20 H 16 Br 1 D 6 N 2 O 6 S 1	ESI-	503.0764	503.0748	ND	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)thiophene-2-sulfonamide	C17H18N2O3S2	C17H19N2O3S2	ESI+	363.0832	363.0819	ND	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-5-methylthiophene-2-sulfonamide	C18H20N2O3S2	C18H21N2O3S2	ESI+	377.0988	377.0994	ND	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)thiazole-2-sulfonamide	C16H17N3O3S2					ND	+	ND

1-benzyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1H-1,2,4-triazole-3-sulfonamide	C22H23N5O3S	C 22 H 22 N 5 O 3 S 1	ESI-	436.1449	436.1436	ND	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-5-sulfonamide	C17H20N4O3S	C 17 H 21 N 4 O 3 S 1	ESI+	361.1329	361.1321	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide	C17H20N4O3S	C 17 H 19 N 4 O 3 S 1	ESI-	359.1183	359.1176	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(trifluoromethyl)-1H-pyrazole-3-sulfonamide	C17H17F3N4O3S	C 17 H 18 F 3 N 4 O 3 S 1	ESI+	415.1046	415.1063	ND	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide	C19H24N4O3S	C 19 H 23 N 4 O 3 S 1	ESI-	387.1496	387.1514	ND	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-4-sulfonamide	C19H24N4O3S					ND	++++	++++

1-cyclopropyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1H-pyrazole-3-sulfonamide	C19H22N4O3S	C 19 H 23 N 4 O 3 S 1	ESI+	387.1485	387.1501	ND	++++	ND
1-(tert-butyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1H-pyrazole-3-sulfonamide	C20H26N4O3S	C20H27N4O3S1	ESI+	403.1798	403.1802	ND	++++	++++
1-cyclohexyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1H-pyrazole-3-sulfonamide	C22H28N4O3S	C 22 H 29 N 4 O 3 S 1	ESI+	429.1955	429.1968	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-phenyl-1H-pyrazole-3-sulfonamide	C22H22N4O3S	C 22 H 23 N 4 O 3 S 1	ESI+	423.1485	423.1474	ND	+++	ND
1-benzyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1H-pyrazole-3-sulfonamide	C23H24N4O3S	C 23 H 25 N 4 O 3 S 1	ESI+	437.1642	437.163	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-phenylethyl)-1H-pyrazole-3-sulfonamide	C24H26N4O3S	C 24 H 27 N 4 O 3 S 1	ESI+	451.1798	451.1811	ND	+++	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-1-(2-(piperidin-1-yl)ethyl)-1H-pyrazole-3-sulfonamide	C23H31N5O3S	C 23 H 30 N 5 O 3 S 1	ESI-	456.2075	456.2076	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-1,5-dimethyl-1H-pyrazole-3-sulfonamide	C18H22N4O3S	C 18 H 21 N 4 O 3 S 1	ESI-	373.134	373.1334	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-sulfonamide	C18H19F3N4O3S	C 18 H 18 F 3 N 4 O 3 S 1	ESI-	427.1057	427.1057	ND	+++	ND
N-((2,6-diisopropylphenyl)carbamo-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-sulfonamide	C18H23F3N4O3S	C 18 H 22 F 3 N 4 O 3 S 1	ESI-	431.137	431.1388	ND	++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-1-isopropyl-5-(trifluoromethyl)-1H-pyrazole-3-sulfonamide	C20H23F3N4O3S	C 20 H 24 F 3 N 4 O 3 S 1	ESI+	457.1516	457.1528	ND	+++	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-isopropyl-1-methyl-1H-pyrazole-3-sulfonamide	C20H26N4O3S	C 20 H 25 N 4 O 3 S 1	ESI-	401.1653	401.1637	ND	+++	ND
N-((2,6-diisopropylphenyl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazole-3-sulfonamide	C20H30N4O4S	C 20 H 29 N 4 O 4 S 1	ESI-	421.1915	421.1904	ND	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazole-3-sulfonamide	C20H26N4O4S	C 20 H 25 N 4 O 4 S 1	ESI-	417.1602	417.1603	++++	++++	++++
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1-phenyl-1H-pyrazole-3-sulfonamide	C25H28N4O4S	C 25 H 27 N 4 O 4 S 1	ESI-	479.1758	479.1758	++++	++++	++++
1-benzyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide	C26H30N4O4S	C 26 H 29 N 4 O 4 S 1	ESI-	493.1915	493.1912	ND	++++	++++

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)benzenesulfonamide	C19H20N2O3S	C 19 H 19 N 2 O 3 S 1	ESI-	355.1122	355.1139	ND	++++	ND
5-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)naphthalene-1-sulfonamide	C25H27N3O3S	C 25 H 28 N 3 O 3 S 1	ESI+	450.1846	450.1859	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)-2,3-dihydrobenzo[b]thiophene-6-sulfonamide 1,1-dioxide	C21H22N2O5S2	C 21 H 23 N 2 O 5 S 2	ESI+	447.1043	447.1034	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)-2-methoxybenzenesulfonamide	C20H22N2O4S	C 20 H 23 N 2 O 4 S 1	ESI+	387.1373	387.1378	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)-3-(trifluoromethyl)benzenesulfonamide	C20H19F3N2O3S	C 20 H 18 F 3 N 2 O 3 S 1	ESI-	423.0996	423.1009	+++	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyle)-3-methoxybenzenesulfonamide	C20H22N2O4S	C 20 H 21 N 2 O 4 S 1	ESI-	385.1228	385.1211	++++	++++	ND

3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)benzamide	C20H21N3O4S	C 20 H 20 N 3 O 4 S 1	ESI-	398.118	398.1167	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonamide	C22H26N2O4S	C 22 H 25 N 2 O 4 S 1	ESI-	413.1541	413.154	ND	++++	ND
3-azido-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	C19H19N5O3S	C 19 H 20 N 5 O 3 S 1	ESI+	398.1281	398.1272		+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(4-phenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide	C27H25N5O3S	C 27 H 26 N 5 O 3 S 1	ESI+	500.1751	500.1735	ND	++	ND
N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)pent-4-ynamide	C24H25N3O4S	C 24 H 26 N 3 O 4 S 1	ESI+	452.1639	452.1658	ND	+++	ND
3-(1-(3-aminopropyl)-1H-1,2,3-triazol-4-yl)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-	C27H33N7O4S	C 27 H 34 N 7 O 4 S 1	ESI+	552.2387	552.2368	ND	+++	ND

N-((1-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phe-nyl)-1H-1,2,3-triazol-4-yl)methyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide	C32H38N8O5S2	C32H39N8O5S2	ESI+	679.2479	679.2456	+	++	ND
N-(quinolin-6-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide	C18H12F3N5O3 S	C 18 H 11 F 3 N 5 O 3 S 1	ESI-	434.054	434.0558	>50 uM	>50 uM	ND
N-(quinolin-5-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide	C18H12F3N5O3 S	C 18 H 11 F 3 N 5 O 3 S 1	ESI-	434.054	434.0547	ND	+	ND
N-((6-methoxyquinolin-8-yl)carbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide	C19H14F3N5O4 S	C 19 H 13 F 3 N 5 O 4 S 1	ESI-	464.0646	464.0664	ND	+	ND
N-(quinolin-8-ylcarbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide	C18H12F3N5O3 S	C 18 H 11 F 3 N 5 O 3 S 1	ESI-	434.054	434.0551	ND	++	ND

N-((2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)carbamoyl)-3-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzenesulfonamide	C19H15F3N4O5 S	C 19 H 14 F 3 N 4 O 5 S 1	ESI-	467.0642	467.0627	ND	++	ND
4-chloro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	C19H19ClN2O3S	C19H19ClN2O3S	ESI+	391.0878	391.0895	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonamide	C20H22N2O3S	C 20 H 21 N 2 O 3 S 1	ESI-	369.1278	369.1296	+++	+++	ND
3-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)-N-(prop-2-yn-1-yl)propanamide	C25H27N3O4S	C 25 H 28 N 3 O 4 S 1	ESI+	466.1795	466.1794	ND	++++	ND
N-(4-(N-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phenyl)-2-(methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)acetamide	C30H34N7O7S					ND	++	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethyl)benzenesulfonamide	C27H26N6O6S	C 27 H 25 N 6 O 6 S 1	ESI-	561.1562	561.1579	+++	+++	ND
2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)-N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)acetamide	C34H36N4O6S					ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzo[d][1,3]dioxole-5-sulfonamide	C20H20N2O5S	C 20 H 21 N 2 O 5 S 1	ESI+	401.1166	401.1182	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)pyridine-2-sulfonamide	C21H25N3O4S	C 21 H 24 N 3 O 4 S 1	ESI-	414.1493	414.1497	ND	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-	C21H23N3O3S	C 21 H 24 N 3 O 3 S 1	ESI+	398.1533	398.1538	ND	++++	ND

N-((4-chloro-2-methyl-6-(trifluoromethyl)phenyl)carbamo-yl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₁₆ H ₁₆ ClF ₃ N ₂ O ₅ S	C ₁₆ H ₁₅ Cl ₁ F ₃ N ₂ O ₅ S ₁	ESI-	439.0348	439.0339	>10,000	ND	ND
sodium ((4-chloro-2,6-diisopropylphenyl)carbamo-yl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)amide	C ₂₀ H ₂₆ ClN ₂ NaO ₅ S	C ₂₀ H ₂₆ Cl ₁ N ₂ O ₅ S ₁	ESI-	441.1256	441.1264	ND	++++	ND
N-((4-chloro-2,6-dicyclopropylphenyl)carbamo-yl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₃ ClN ₂ O ₅ S	C ₂₀ H ₂₂ Cl ₁ N ₂ O ₅ S ₁	ESI-	437.0943	437.0945	++++	ND	ND
4-(2-hydroxypropan-2-yl)-N-((5-methoxy-2,3-dihydro-1H-inden-4-yl)carbamo-yl)furan-2-sulfonamide	C ₁₈ H ₂₂ N ₂ O ₆ S	C ₁₈ H ₂₁ N ₂ O ₆ S ₁	ESI-	393.1126	392.1113	+++	+++	ND
N-((7-chloro-5-cyclopropyl-2,3-dihydro-1H-inden-4-yl)carbamo-yl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₃ ClN ₂ O ₅ S	C ₂₀ H ₂₂ Cl ₁ N ₂ O ₅ S ₁	ESI-	437.0943	437.0927	++++	ND	ND

N-((3-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₄ N ₂ O ₆ S	C ₂₀ H ₂₃ N ₂ O ₆ S ₁	ESI-	419.1282	419.1263	ND	+++	ND
N-((1-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₂₀ H ₂₄ N ₂ O ₆ S	C ₂₀ H ₂₃ N ₂ O ₆ S ₁	ESI-	419.1282	419.1265	ND	++	ND
N-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₁₄ H ₁₈ N ₄ O ₅ S	C ₁₄ H ₁₇ N ₄ O ₅ S ₁	ESI-	353.0925	353.0921	>10,000	>50000	ND
N-((4,6-dimethylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₁₄ H ₁₈ N ₄ O ₅ S	C ₁₄ H ₁₇ N ₄ O ₅ S ₁	ESI-	353.0925	353.0923	>10,000	>50000	ND
N-((4-cyclopropyl-6-methylpyrimidin-2-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C ₁₆ H ₂₀ N ₄ O ₅ S	C ₁₆ H ₁₉ N ₄ O ₅ S ₁	ESI-	379.1082	379.1082	ND	+++	ND

N-((4,6-di-tert-butylpyrimidin-2-yl)carbamo-yl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide	C20H30N4O5S	C 20 H 29 N 4 O 5 S 1	ESI-	437.1864	437.1846	ND	+	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-2-methylthiazole-5-sulfonamide	C17H19N3O3S2	C 17 H 18 N 3 O 3 S 2	ESI-	376.0795	376.0791	++++	ND	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-4H-1,2,4-triazole-3-sulfonamide	C15H17N5O3S	C 15 H 16 N 5 O 3 S 1	ESI-	346.0979	346.0983	++++	ND	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamo-yl)-1-isopropyl-1H-1,2,3-triazole-4-sulfonamide	C18H23N5O3S	C 18 H 22 N 5 O 3 S 1	ESI-	388.1449	388.1457	+++	++++	ND
sodium ((4-chloro-2,6-diisopropylphenyl)carbamo-yl)((5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazol-3-yl)sulfonyl)amide	C20H28ClN4NaO4S	C 20 H 28 Cl 1 N 4 O 4 S 1	ESI-	455.1525	455.1515	ND	++++	ND
sodium ((4-chloro-2,6-diisopropylphenyl)carbamo-yl)((5-(2-hydroxypropan-2-yl)sulfonyl)amide	C25H30ClN4NaO4S	C 25 H 30 Cl 1 N 4 O 4 S 1	ESI-	517.1682	517.1671	ND	++++	ND

N-((4,6-di-tert-butylpyrimidin-2-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide	C19H30N6O3S	C 19 H 29 N 6 O 3 S 1	ESI-	421.2027	421.2008	>10,000	ND	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-sulfonamide	C19H22N4O3S	C 19 H 21 N 4 O 3 S 1	ESI-	385.1340	385.1331	+++	ND	ND
4-acetyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	C21H22N2O4S	C 21 H 21 N 2 O 4 S 1	ESI-	397.1228	397.1225	++++	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-nitrobenzenesulfonamide	C19H19N3O5S	C 19 H 18 N 3 O 5 S 1	ESI-	400.0973	400.0979	++++	ND	ND
4-amino-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide	C19H21N3O3S	C 19 H 20 N 3 O 3 S 1	ESI-	370.1231	370.1225	++++	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfonamide	C22H24N2O3S	C 22 H 23 N 2 O 3 S 1	ESI-	395.1435	395.143	++++	++	ND

N-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfonamide	C16H15ClN2O3S	C ₁₆ H ₁₄ Cl ₁ N ₂ O ₃ S ₁	ESI-	349.0419	349.0418	>10,000	>100,000	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo yl)quinoline-8-sulfonamide	C22H24ClN3O3S	C ₂₂ H ₂₅ Cl ₁ N ₃ O ₃ S ₁	ESI+	446.1300	446.1314	ND	++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo yl)isoquinoline-5-sulfonamide	C22H24ClN3O3S	C ₂₂ H ₂₅ Cl ₁ N ₃ O ₃ S ₁	ESI+	446.1300	446.1319	ND	+++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo yl)quinoline-3-sulfonamide	C22H24ClN3O3S	C ₂₂ H ₂₅ Cl ₁ N ₃ O ₃ S ₁	ESI+	446.1300	446.1315	ND	++++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo yl)quinoline-5-sulfonamide	C22H24ClN3O3S	C ₂₂ H ₂₅ Cl ₁ N ₃ O ₃ S ₁	ESI+	446.1300	446.1317	ND	+++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)quinoline-8-sulfonamide	C22H21N3O3S	C ₂₂ H ₂₂ N ₃ O ₃ S ₁	ESI+	408.1376	408.1371	ND	+++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo yl)quinoxaline-5-sulfonamide	C21H23ClN4O3S	C ₂₁ H ₂₄ Cl ₁ N ₄ O ₃ S ₁	ESI+	447.1252	447.1266	++++	ND	ND

N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)naphthalene-2-sulfonamide	C23H25ClN2O3S	C 23 H 26 Cl 1 N 2 O 3 S 1	ESI+	445.1347	445.1349	ND	++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)-6-methoxynaphthalene-2-sulfonamide	C24H27ClN2O4S	C 24 H 28 Cl 1 N 2 O 4 S 1	ESI+	475.1453	475.1474	++++	ND	ND
6-chloro-N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)naphthalene-2-sulfonamide	C23H24Cl2N2O3S	C 23 H 25 Cl 2 N 2 O 3 S 1	ESI+	479.0957	479.0937	++++	ND	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide	C23H29ClN2O3S	C 23 H 30 Cl 1 N 2 O 3 S 1	ESI+	449.1660	449.1664	++++	ND	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)-3-ethylisoxazolo[5,4-b]pyridine-5-sulfonamide	C21H25ClN4O4S	C 21 H 26 Cl 1 N 4 O 4 S 1	ESI+	465.1358	465.1354	++	ND	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamo-yl)thieno[3,2-b]pyridine-6-sulfonamide	C20H22ClN3O3S2	C 20 H 23 Cl 1 N 3 O 3 S 2	ESI+	452.0864	452.0884	+++	ND	ND

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzofuran-2-sulfonamide	C21H20N2O4S	C 21 H 21 N 2 O 4 S 1	ESI+	397.1217	397.1215	ND	+++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamoyl)benzofuran-2-sulfonamide	C21H23ClN2O4S	C 21 H 24 Cl 1 N 2 O 4 S 1	ESI+	435.1140	435.114	++++	++++	ND
N-((4-chloro-2,6-diisopropylphenyl)carbamoyl)benzo[b]thiophene-2-sulfonamide	C21H23ClN2O3S 2	C 21 H 24 Cl 1 N 2 O 3 S 2	ESI+	451.0911	451.09	+++	++++	ND
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)benzenesulfonamide	C33H35N3O6S	C 33 H 34 N 3 O 6 S 1	ESI-	600.2174	600.2183	+++	++	ND
N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phenethyl)-5-methylisoxazole-3-carboxamide	C26H28N4O5S	C 26 H 27 N 4 O 5 S 1	ESI-	507.1708	507.1709	+++	+++	ND

3-ethyl-N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phe-nethyl)-4-methyl-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide	C29H34N4O5S	C 29 H 33 N 4 O 5 S 1	ESI-	549.2177	549.2169	+++	+++	ND
5-chloro-N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phe-nethyl)-2-methoxybenzamide	C29H30ClN3O5S	C 29 H 29 Cl 1 N 3 O 5 S 1	ESI-	566.1522	566.1543	+++	+++	ND
4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)benzenesulfonamid-e	C20H22N2O5S	C 20 H 21 N 2 O 5 S 1	ESI-	401.1177	401.1174	>10,000	>200,000	ND
5-methyl-N-(4-sulfamoylphenethyl)isoxazole-3-carboxamide	C13H15N3O4S	C 13 H 14 N 3 O 4 S 1	ESI-	308.0711	308.0708	>10,000	ND	ND
N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)phe-nethyl)-5-methylpyrazine-2-	C27H29N5O4S	C 27 H 28 N 5 O 4 S 1	ESI-	518.1867	518.1858	ND	+++	ND



		
Brain Concentration (ng/g)*	184	1339
Plasma Concentration (ng/mL)	17490	66260
Brain/Plasma Ratio^a	0.0117	0.0203
tPSA	104.7	84.5

Table 4: Properties of sulfonylureas, including increased BBB penetration, with and without hydroxylalkyl group on furan ring.



Plasma Concentration Post-Dosing

A single dose pharmacokinetic study of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide (MCC7840 and being a compound of the first aspect) in comparison to N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (MCC950) using an iv dose of 4 mg/Kg and po dose of 20 mg/Kg clearly indicated an extended half-life, increased maximum concentration (C_{max}) and area under the curve (AUC) for the pyrazole derivative in comparison to the

furan. This is advantageous leading to comparatively lower doses or less frequent administration.

The procedure followed was: Male C57BL/6 mice were used at 7-9 weeks age with 3 animals per group. Mice were dosed with test compound using single intravenous bolus or oral gavage. Blood samples were taken via submandibular or saphenous vein for analysis of plasma concentrations of compound by LC-MS/MS at the following timepoints: IV (3 mice): 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dosing, PO (3 mice): 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dosing. LC-MS/MS method for the quantitative determination of test compound in corresponding biological matrix was developed. PK parameters were calculated using Phoenix WinNonlin 6.3. The results are shown graphically in FIGs 1A to 1C (MCC950) and FIGs 2A to 2C (MCC7840).

The relevant compound structures are shown below and tables 5-8 contain the relevant data:



Bioavailability of MCC_000950_016 in Mouse (ng/mL)							
MCC_000950_016							
IV							
IV Time (h)	M1	M2	M3	Mean IV		SD	CV (%)
0.0833	20200	17200	17700	18367	±	1607	8.75
0.250	16000	10200	12700	12967	±	2909	22.4
0.500	11700	9420	10500	10540	±	1141	10.8
1.00	9340	7730	8230	8433	±	824	9.77
2.00	7410	6000	5010	6140	±	1206	19.6
4.00	3280	2390	2130	2600	±	603	23.2
8.00	905	843	480	743	±	230	30.9
24.0	3.29	2.33	2.33	2.65	±	0.554	20.9
PK Parameters	M1	M2	M3	Mean IV		SD	CV (%)
Rsq_adj	1.000	0.998	0.999	--	±	--	--
No. points used for T _{1/2}	6.00	7.00	3.00	ND	±	--	--
C ₀ (ng/mL)	22695	22332	20894	21974	±	953	4.34
T _{1/2} (h)	2.00	1.97	2.05	2.00	±	0.0394	1.97
Vd _{ss} (L/kg)	0.265	0.339	0.313	0.306	±	0.0376	12.3
Cl (mL/min/kg)	1.59	1.99	2.17	1.92	±	0.295	15.4
T _{last} (h)	24.0	24.0	24.0	24.0	±	--	--
AUC _{0-last} (ng.h/mL)	41880	33489	30751	35373	±	5799	16.4
AUC _{0-inf} (ng.h/mL)	41889	33496	30758	35381	±	5800	16.4
MRT _{0-last} (h)	2.77	2.83	2.40	2.67	±	0.234	8.76
MRT _{0-inf} (h)	2.78	2.84	2.41	2.67	±	0.233	8.73
AUC _{Extra} (%)	0.0226	0.0198	0.0224	0.0216	±	0.00158	7.30
AUMC _{Extra} (%)	0.219	0.187	0.251	0.219	±	0.0318	14.6

Bioavailability of MCC_000950_016 in Mouse (ng/mL)							
MCC_000950_016							
PO							
PO Time (h)	M4	M5	M6	Mean PO	SD	CV (%)	
0.250	21900	29000	48900	33267	± 13997	42.1	
0.500	20400	34100	35800	30100	± 8443	28.1	
1.00	19300	33700	37000	30000	± 9412	31.4	
2.00	18500	22500	26200	22400	± 3851	17.2	
4.00	10200	13000	10500	11233	± 1537	13.7	
8.00	4330	2360	4670	3787	± 1247	32.9	
24.0	60.7	17.4	39.3	39.1	± 21.7	55.3	
PK Parameters	M4	M5	M6	Mean PO	SD	CV (%)	
Rsq_adj	0.999	0.996	0.996	--	± --	--	
No. points used for T _{1/2}	4.00	5.00	6.00	ND	± --	--	
C _{max} (ng/mL)	21900	34100	48900	34967	± 13521	38.7	
T _{max} (h)	0.250	0.500	0.250	0.333	± 0.144	43.3	
T _{1/2} (h)	2.67	2.11	2.37	2.39	± 0.282	11.8	
T _{last} (h)	24.0	24.0	24.0	24.0	± --	--	
AUC _{0-last} (ng·h/mL)	108135	123399	144734	125422	± 18383	14.7	
AUC _{0-inf} (ng·h/mL)	108369	123452	144868	125563	± 18341	14.6	
MRT _{0-last} (h)	4.26	3.07	3.47	3.60	± 0.603	16.8	
MRT _{0-inf} (h)	4.31	3.08	3.49	3.63	± 0.624	17.2	
AUC _{Extra} (%)	0.216	0.0429	0.0929	0.117	± 0.0892	76.0	
AUMC _{Extra} (%)	1.40	0.376	0.730	0.835	± 0.519	62.1	
Bioavailability (%) ^a	--	--	--	71.0	± --	--	

Tables 5 and 6: PK and bioavailability data for N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide (MCC950)

Bioavailability of MCC_007840_002 in Mouse (ng/mL)							
MCC_007840_002							
IV							
IV Time (h)	M1	M2	M3	Mean IV		SD	CV (%)
0.0833	47800	41900	38600	42767	±	4661	10.9
0.250	28100	29300	29300	28900	±	693	2.40
0.500	25200	25200	24500	24967	±	404	1.62
1.00	19900	18900	17200	18667	±	1365	7.31
2.00	13300	14700	19900	15967	±	3478	21.8
4.00	6520	8550	8590	7887	±	1184	15.0
8.00	3490	3360	4440	3763	±	590	15.7
24.0	149	122	130	134	±	13.9	10.4
PK Parameters	M1	M2	M3	Mean IV		SD	CV (%)
Rsq_adj	0.998	0.999	0.996	--	±	--	--
No. points used for $T_{1/2}$	3.00	3.00	3.00	3.00	±	--	--
C_0 (ng/mL)	62333	50100	44301	52245	±	9205	17.6
$T_{1/2}$ (h)	3.62	3.29	3.26	3.39	±	0.204	6.01
$V_{d_{ss}}$ (L/kg)	0.170	0.158	0.151	0.160	±	0.00989	6.20
Cl (mL/min/kg)	0.659	0.633	0.571	0.621	±	0.0455	7.33
T_{last} (h)	24.0	24.0	24.0	24.0	±	--	--
AUC_{0-last} (ng.h/mL)	100364	104705	116222	107097	±	8195	7.65
AUC_{0-inf} (ng.h/mL)	101143	105283	116833	107753	±	8132	7.55
MRT_{0-last} (h)	4.11	4.01	4.28	4.13	±	0.133	3.23
MRT_{0-inf} (h)	4.30	4.15	4.40	4.29	±	0.129	3.02
AUC_{Extra} (%)	0.770	0.549	0.523	0.614	±	0.136	22.1
$AUMC_{Extra}$ (%)	5.23	3.81	3.41	4.15	±	0.957	23.1

Bioavailability of MCC_007840_002 in Mouse (ng/mL)							
MCC_007840_002							
PO							
PO Time (h)	M4	M5	M6	Mean PO	SD	CV (%)	
0.250	84300	27400	69700	60467	± 29552	48.9	
0.500	70300	24000	56600	50300	± 23784	47.3	
1.00	60400	20900	45700	42333	± 19964	47.2	
2.00	54900	19100	53800	42600	± 20359	47.8	
4.00	32900	14100	32800	26600	± 10825	40.7	
8.00	14100	12800	29900	18933	± 9520	50.3	
24.0	660	2370	1370	1467	± 859	58.6	
PK Parameters	M4	M5	M6	Mean PO	SD	CV (%)	
Rsq_adj	0.999	0.984	0.968	--	± --	--	
No. points used for T _{1/2}	3.00	6.00	4.00	ND	± --	--	
C _{max} (ng/mL)	84300	27400	69700	60467	± 29552	48.9	
T _{max} (h)	0.250	0.250	0.250	0.250	± 0.000	0.0	
T _{1/2} (h)	3.57	7.31	4.18	5.02	± 2.01	40.1	
T _{last} (h)	24.0	24.0	24.0	24.0	± --	--	
AUC _{0-last} (ng·h/mL)	364947	226687	457808	349814	± 116301	33.2	
AUC _{0-inf} (ng·h/mL)	368345	251697	466063	362035	± 107323	29.6	
MRT _{0-last} (h)	4.80	8.07	6.41	6.43	± 1.64	25.4	
MRT _{0-inf} (h)	5.03	10.7	6.83	7.52	± 2.90	38.6	
AUC _{Extra} (%)	0.922	9.94	1.77	4.21	± 4.98	118	
AUMC _{Extra} (%)	5.35	32.1	7.78	15.1	± 14.8	98.1	
Bioavailability (%) ^a	--	--	--	67.2	± --	--	

Tables 7 and 8: PK and bioavailability data for N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide (MCC7840)

Common names	Structure	HMDM IC50 vs NLRP3	BMDM IC50 vs NLRP3	Common names	Structure	HMDM IC50 vs NLRP3	BMDM IC50 vs NLRP3
Glibenclamide (Glyburide)		6 μ M	22 μ M	Acetohexamide		>200 μ M	>200 μ M
Glibenclamide precursor		>200 μ M	>200 μ M	Tolazamide		>200 μ M	
Glipizide		>200 μ M	>200 μ M	Gliclazide		>200 μ M	>200 μ M
Glipizide precursor		>50 μ M		Tolbutamide		>200 μ M	>200 μ M




















Glimepiride		92 μM		Carbutamide		>200 μM	
Glimepiride precursor		>200 μM		Chlorpropamide		>200 μM	>200 μM
Gliquidone		32 μM		Glixoxepide			
Gliquidone precursor		>200 μM	>10 μM	Glixoxepide Precursor			>10,000
				Sulofenur		>100 μM	>10 μM

Table 9: Comparative IC₅₀ data for commercial compounds.

Structure	HMDM IC50 vs NLRP3	BMDM IC50 vs NLRP3	Structure	HMDM IC50 vs NLRP3	BMDM IC50 vs NLRP3
	0.14 μ M	0.24 μ M		0.31 μ M	0.036 μ M
		0.32 μ M		0.54 μ M	0.7 μ M
	0.65 μ M	0.22 μ M		0.31 μ M	0.014 μ M
	2.3 μ M	0.26 μ M		0.3 μ M	0.03 μ M
	0.19 μ M	0.28 μ M		1.46 μ M	0.05 μ M



					0.043 μ M
--	--	--	--	--	---------------

Table 10 –Biological Activity data for select compounds of the first aspect (sorted by hybrid BMDM)

CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:



Formula (I)


wherein

W is selected from O, S and Se;

J is selected from S and Se;

R₁ is selected from the group consisting of 5-membered and 6-membered heterocyclyl, all of which are optionally substituted, wherein any optional substituent is independently selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, hydroxyalkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆-C₁₂ aryl, aryloxy, heteroaryl, heterocyclyl, halo, hydroxyl, halogenated alkyl, amino, alkylamino, arylamino, acyl, amido, CN, NO₂, N₃, CH₂OH, CONH₂, CONR₂₄R₂₅, CO₂R₂₄, CH₂OR₂₄, NHCOR₂₄, NHCO₂R₂₄, C₁-C₃ alkylthio, sulfate, sulfonic acid, sulfonate esters, phosphonic acid, phosphate, phosphonate, mono-, di-, or triphosphate esters, trityl, monomethoxytrityl, R₂₄SO, R₂₄SO₂, CF₃S, CF₃SO₂, and trialkylsilyl, wherein R₂₄ and R₂₅ are each independently selected from H and C₁-C₁₀ alkyl;

R₂ is selected from a 2,6-dialkylphenyl, a 2,6-dialkyl-4-halophenyl, a 2,6-dicycloalkylphenyl, a 2,6-dicycloalkyl-4-halophenyl, and:




wherein each incidence of Y is independently selected from C, N, S and O, which are optionally substituted, wherein any optional substituent is independently selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, hydroxyalkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆-C₁₂ aryl, aryloxy, heteroaryl, heterocyclyl, halo, hydroxyl, halogenated alkyl, amino, alkylamino, arylamino, acyl, amido, CN, NO₂, N₃, CH₂OH, CONH₂, CONR₂₄R₂₅, CO₂R₂₄, CH₂OR₂₄, NHCOR₂₄, NHCO₂R₂₄, C₁-C₃ alkylthio, sulfate, sulfonic acid, sulfonate esters, phosphonic acid, phosphate, phosphonate, mono-, di-, or triphosphate esters, trityl, monomethoxytrityl, R₂₄SO, R₂₄SO₂, CF₃S, CF₃SO₂, and trialkylsilyl, wherein R₂₄ and R₂₅ are each independently selected from H and C₁-C₁₀ alkyl;

R₅ is selected from the group consisting of hydrogen, halo, cyano, amide, sulphonamide, acyl, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₅ cycloalkyl and C₁-C₆ alkoxy, all of which groups are optionally substituted with halo, cyano or C₁-C₆ alkoxy; and


both R₁ is directly bonded to J and R₂ is directly bonded to the adjacent nitrogen, via a carbon atom.

2. The compound of claim 1, wherein R₁ is a 6-membered heterocyclyl, all of which are optionally substituted as defined in claim 1.
3. The compound of any one of the preceding claims, wherein R₁ is a fully saturated heterocyclyl, all of which are optionally substituted as defined in claim 1.


4. The compound of any one of the preceding claims, wherein R_1 is a nitrogen heterocyclyl, all of which are optionally substituted as defined in claim 1.
5. The compound of any one of the preceding claims, wherein R_1 is selected from the group consisting of tetrahydrofuran, tetrahydropyran, pyran, pyrrolidine, morpholine, piperazine and piperidine, all of which are optionally substituted as defined in claim 1.
6. The compound of any one of the preceding claims, wherein R_1 is selected from the group consisting of tetrahydrofuran, tetrahydropyran, pyrrolidine, morpholine, piperazine and piperidine, all of which are optionally substituted as defined in claim 1.
7. The compound of any one of the preceding claims, wherein R_1 is selected from the group consisting of pyrrolidine, piperazine and piperidine, all of which are optionally substituted as defined in claim 1.
8. The compound of any one of the preceding claims, wherein R_1 is piperidine optionally substituted as defined in claim 1.
9. The compound of any one of claims 1, 2, 3, 5 or 6, wherein R_1 is selected from the group consisting of:



and in combination with each such R_1 group, R_2 is independently selected from the group consisting of:




10. The compound of any one of the preceding claims, wherein R_2 is selected from:



wherein Y and R_5 are as defined in any one of the preceding claims.

11. The compound of any one of the preceding claims, wherein R_2 is selected from:



wherein each incidence of Y is a carbon and R₅ is hydrogen or halo.


12. The compound of any one of the preceding claims, wherein R₂ is selected from a substituted or hydrogenated indacene, a 2,6-dialkylphenyl, a 2,6-dialkyl-4-halophenyl, a 2,6-dicycloalkylphenyl, and a 2,6-dicycloalkyl-4-halophenyl.

13. The compound of any one of the preceding claims, wherein R₂ is selected from hexahydroindacene, 2,6-diisopropylphenyl, 2,6-diisopropyl-4-chlorophenyl, 2,6-dicyclopropylphenyl and 2,6-dicyclopropyl-4-chlorophenyl.


14. The compound of any one of the preceding claims, wherein J is a sulphur atom.

15. The compound of any one of the preceding claims, wherein W is an oxygen atom.


16. The compound of any one of the preceding claims, wherein the compound is a compound of formula (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt or solvate thereof:



formula (Ia)




formula (Ib)



formula (Ic)

wherein R₁ is as defined in any one of the preceding claims.

17. The compound of any one of claims 1-3, 5-6 or 9-16, wherein the compound is selected from the group consisting of:



and pharmaceutically acceptable salts and solvates thereof.

18. The compound or the pharmaceutically acceptable salt or solvate of any one of the preceding claims, wherein the compound, or the pharmaceutically acceptable salt or solvate, is an inhibitor of the NLRP3 inflammasome.

19. A pharmaceutical composition comprising a compound of any one of claim 1 to claim 18, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.

20. The compound or the pharmaceutically acceptable salt or solvate of any one of claim 1 to claim 18, for use in medicine.

21. The compound or the pharmaceutically acceptable salt or solvate of any one of claim 1 to claim 18, for use in treating or preventing:

- (a) a disease, disorder or condition responsive to inhibition of activation of the NLRP3 inflammasome; and/or
- (b) a disease, disorder or condition responsive to modulation of one or more of IL-1 β , IL-17, IL-18, IL-1 α , IL-37, IL-33 and Th17 cells; and/or
- (c) a disease, disorder or condition of the immune system; and/or
- (d) an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition; and/or
- (e) a disease, disorder or condition of the skin; and/or
- (f) a disease, disorder or condition of the cardiovascular system; and/or
- (g) a cancer, tumour or other malignancy; and/or

- (h) a disease, disorder or condition of the renal system; and/or
- (i) a disease, disorder or condition of the gastro-intestinal tract; and/or
- (j) a disease, disorder or condition of the respiratory system; and/or
- (k) a disease, disorder or condition of the endocrine system; and/or
- (l) a disease, disorder or condition of the central nervous system (CNS); and/or
- (m) a disease, disorder or condition selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome and Schnitzler syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma, asbestosis, silicosis and cystic fibrosis; central nervous system diseases including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria and

brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudo-gout; ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy and diabetic nephropathy; liver disease including non-alcoholic steatohepatitis and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis; viral infections including alpha virus including Chikungunya and Ross River, and flavivirus including Dengue and Zika viruses, flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodysplastic syndrome, leukemia; polymyositis; stroke; myocardial infarction; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; pericarditis including Dressler's syndrome; ischaemia reperfusion injury; and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

22. The compound or the pharmaceutically acceptable salt or solvate of any one of claim 1 to claim 18, for use in diagnosing a disease, disorder or condition, wherein the compound or the pharmaceutically acceptable salt or solvate is a labelled compound of any one of claim 1 to claim 18, or a pharmaceutically acceptable salt or solvate thereof, or metal ion chelate complex thereof.

23. Use of the compound or the pharmaceutically acceptable salt or solvate of any one of claim 1 to claim 18, in the manufacture of a medicament for treating or preventing:

(a) a disease, disorder or condition of the immune system; and/or

- (b) an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition; and/or
- (c) a disease, disorder or condition of the skin; and/or
- (d) a disease, disorder or condition of the cardiovascular system; and/or
- (e) a cancer, tumour or other malignancy; and/or
- (f) a disease, disorder or condition of the renal system; and/or
- (g) a disease, disorder or condition of the gastro-intestinal tract; and/or
- (h) a disease, disorder or condition of the respiratory system; and/or
- (i) a disease, disorder or condition of the endocrine system; and/or
- (j) a disease, disorder or condition of the central nervous system (CNS); and/or
- (k) a disease, disorder or condition selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases

including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome and Schnitzler syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma, asbestosis, silicosis and cystic fibrosis; central nervous system diseases including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudo-gout; ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy and diabetic nephropathy; liver disease including non-alcoholic steatohepatitis and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis; viral infections including alpha virus including Chikungunya and Ross River, and flavivirus including Dengue and Zika viruses, flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodysplastic syndrome, leukemia; polymyositis; stroke; myocardial infarction; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; pericarditis including Dressler's syndrome; ischaemia reperfusion injury; and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

24. Use of the compound or the pharmaceutically acceptable salt or solvate of any one of claim 1 to claim 18, in the manufacture of a medicament for diagnosing a disease, disorder or condition, wherein the medicament comprises a labelled compound of any one of claim 1 to claim 18, or a

pharmaceutically acceptable salt or solvate thereof, or metal ion chelate complex thereof;

wherein the disease, disorder or condition is:

- (a) a disease, disorder or condition of the immune system; and/or
- (b) an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition; and/or
- (c) a disease, disorder or condition of the skin; and/or
- (d) a disease, disorder or condition of the cardiovascular system; and/or
- (e) a cancer, tumour or other malignancy; and/or
- (f) a disease, disorder or condition of the renal system; and/or
- (g) a disease, disorder or condition of the gastro-intestinal tract; and/or
- (h) a disease, disorder or condition of the respiratory system; and/or
- (i) a disease, disorder or condition of the endocrine system; and/or
- (j) a disease, disorder or condition of the central nervous system (CNS); and/or
- (k) a disease, disorder or condition selected from the group consisting of constitutive inflammation including the cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation,

antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases including multiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome and Schnitzler syndrome; respiratory diseases including chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma, asbestosis, silicosis and cystic fibrosis; central nervous system diseases including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases including Type 2 diabetes, atherosclerosis, obesity, gout, pseudo-gout; ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD), corneal infection, uveitis and dry eye; kidney disease including chronic kidney disease, oxalate nephropathy and diabetic nephropathy; liver disease including non-alcoholic steatohepatitis and alcoholic liver disease; inflammatory reactions in skin including contact hypersensitivity and sunburn; inflammatory reactions in the joints including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis; viral infections including alpha virus including Chikungunya and Ross River, and flavivirus including Dengue and Zika viruses, flu, HIV; hidradenitis suppurativa (HS) and other cyst-causing skin diseases; cancers including lung cancer metastasis, pancreatic cancers, gastric cancers, myelodysplastic syndrome, leukemia; polymyositis; stroke; myocardial infarction; Graft versus Host Disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurism; wound healing; depression, psychological stress; pericarditis including Dressler's syndrome; ischaemia reperfusion injury; and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.